WO2016156290A1 - Novel 5-substituted imidazole derivatives - Google Patents

Novel 5-substituted imidazole derivatives Download PDF

Info

Publication number
WO2016156290A1
WO2016156290A1 PCT/EP2016/056764 EP2016056764W WO2016156290A1 WO 2016156290 A1 WO2016156290 A1 WO 2016156290A1 EP 2016056764 W EP2016056764 W EP 2016056764W WO 2016156290 A1 WO2016156290 A1 WO 2016156290A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
alkyl
alkoxy
cyano
cycloalkyl
Prior art date
Application number
PCT/EP2016/056764
Other languages
French (fr)
Inventor
Sebastian Hoffmann
Hendrik Helmke
Peter Dahmen
Ulrike Wachendorff-Neumann
David Bernier
Ricarda MILLER
Pierre-Yves Coqueron
Pierre Genix
Sven WITTROCK
Jean-Pierre Vors
Philippe Kennel
Stephane Brunet
Sébastien NAUD
Ruth Meissner
Original Assignee
Bayer Cropscience Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112017021183A priority Critical patent/BR112017021183A2/en
Priority to JP2017551271A priority patent/JP2018516237A/en
Priority to EA201792151A priority patent/EA201792151A1/en
Priority to KR1020177031654A priority patent/KR20170132315A/en
Priority to AU2016239067A priority patent/AU2016239067A1/en
Priority to EP16711859.5A priority patent/EP3277666A1/en
Priority to CN201680027971.2A priority patent/CN107635968A/en
Priority to CR20170445A priority patent/CR20170445A/en
Application filed by Bayer Cropscience Aktiengesellschaft filed Critical Bayer Cropscience Aktiengesellschaft
Priority to MX2017012709A priority patent/MX2017012709A/en
Priority to CA2981379A priority patent/CA2981379A1/en
Priority to US15/563,414 priority patent/US10231453B2/en
Publication of WO2016156290A1 publication Critical patent/WO2016156290A1/en
Priority to IL254773A priority patent/IL254773A0/en
Priority to PH12017501808A priority patent/PH12017501808A1/en
Priority to CONC2017/0010006A priority patent/CO2017010006A2/en
Priority to ZA2017/07424A priority patent/ZA201707424B/en
Priority to US16/190,285 priority patent/US10568326B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to novel 5-substituted imidazolylmethyl derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.
  • WO-A 2013/076228 discloses the preparation and safening effect of certain imidazole metal salt complexes, wherein the imidazole ring may be unsubstituted or substituted by up to 3 methyl groups or halogen atoms.
  • WO-A 2014/076228 discloses microbiocides and their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants. The microbiocides may be based on a tetrazole, triazole, oxazole, thiazole, or imidazole structure.
  • R 1 represents hydrogen, in each case optionally branched Ci-Cs-alkyl, Ci-Cs-haloalkyl, C2-C7-alkenyl, C 2 -C7-haloalkenyl, C ⁇ -Cs-alkynyl, C ⁇ -Cs-haloalkynyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C 4 -haloalkyl-, Ci-C 4 -alkoxy-, Ci-C 4 -haloalkoxy-, Ci-C 4 -alkylthio- or Ci-C 4 -haloalkylthio- substituted C3-C7-cycloalkyl, optionally halogen-, cyano-, Ci-C 4 -alkyl-, Ci-C 4 -haloalkyl-, G-C 4 - alkoxy-, C i -C 4 -haloalkoxy- , Ci-C 4 -al
  • R 2 represents H, Ci-Cs-alkyi, -Si(R 6a )( R 6b )( R 6c ), -P(0)(OH) 2 , -CH 2 -0-P(0)(GH) 3 ⁇ 4 -C(0)-Ci-C 8 -alkyl, -C(0)-C 3 -C 7 -cycloalkyl, -C(0)NH-Ci-C 8 -alkyl; -C(0)N-di-Ci-C 8 -alkyl; -C(0)0-Ci-C 8 -aIkyl; wherein the -C(0)-Ci-C 8 -alkyi, -C(0)-C3-C 7 -cycloalkyl, -C(0)NH-Ci-C 8 -alkyl; -C(0)N-di-Ci- C 8 -alkyl or -C(0)0-Ci-C 8 -alkyl may be non-substituted or substituted by one or
  • R 6a , R 6b , R 6c represent independent from each other a phenyl or Ci-C 8 -alkyl;
  • R 3 represents halogen; hydroxyl; cyano; i so cyano; nitro; amino; sulfanyl; pentafluoro- 6 -suifanyl; carboxaldehyde, hydroxycarbonyl, Ci-Cs-alkyl; Ci-C 8 -haloalkyl; Ci-Cs-cyanoalkyl; Ci-C 8 - alkyloxy; Ci-C 8 -halogenalkyloxy; tri(Ci-C 8 -alkyl)siiyl; tri(Ci-C 8 -alkyl)silyl-Ci-C 8 -alkyl; C3-C7- cycloalkyl; C3-C7-halogencycloalkyl; C3-C7-cycloalkenyl; C3-C7-halogencycloalkenyl; C4-C10- cycloalkylalkyl; C4-C10- cycloalkylalkyl;
  • R 4 and R 5 may form together with the carbon atom to which they are attached an optionally halogen-,
  • Q represents a 6-membered aromatic represents CX 1 or N; wherein X 1 represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non-substituted carbaldehyde 0-(Ci-Cs-alkyi)oxime, pentaftuoro- 6 -suifenyl, substituted or non-substituted G-Cs-alkyl, substituted or non- substituted C3-Cs-cycloalkyl, substituted or non- substituted C3 - C?-halogency clo alky 1 having 1 to 5 halogen atoms; substituted or non-substituted C3-C7-cycloalkenyl; substituted or non-substituted Ci-Cs- halogenoalkyl having 1 to 5 halogen atoms, a substituted or non- substituted substituted or non-substituted C2-C8
  • U 4 represents CX 4 or N; wherein X * represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non- substituted carbaldehyde 0-(C i -Cs-alkyl)oxime, pentafluoro- 6 -sulfenyl group, substituted or non-substituted G-G-alkyl, substituted or non-substituted G-G- cycloalkyl, substituted or non-substituted C3-C7-halogencycloalkyl having 1 to 5 halogen atoms; substituted or non- substituted G-G-cycloalkenyl; substituted or non-substituted G- G-halogenoalkyl having 1 to 5 halogen atoms, a substituted or non-substituted G-G- alkenyi, substituted or non- substituted G-G-alkynyl
  • U 5 represents CX 5 or N; wherein X 3 represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non- substituted carbaldehyde 0-(G-Cs-alkyl)oxime, pentafluoro- 6 -sulfenyl group, substituted or non-substituted G-Cs-alkyl, substituted or non-substituted G-G- cycloaLkyl, substituted or non-substituted G-G-halogencycloalkyl having 1 to 5 halogen atoms; substituted or non- substituted G-G-cycloalkenyl; substituted or non-substituted G- G-halogenoalkyl having 1 to 5 halogen atoms, a substituted or non-substituted G-G- alkenyl, substituted or non- substituted G-G-alkynyl, substituted
  • U 1 and U 2 or U 2 and U 3 or U 3 and U 4 may form together an additional saturated or unsaturated 4 to 6-membered halogen- or Ci-Cs-alkyl-substituted or non-substituted ring; and its salts or N- oxides.
  • the salts or N-oxides of the imidazole derivatives of formula (I) also have fungicidal properties.
  • the formula (I) provides a general definition of the imidazole derivatives according to the invention. Preferred radical definitions for the formulae shown above and below are given below. These definitions apply to the end products of the formulae (I), (I-i), (I-l-Q-I-1), (I-l-Q-I-2) and (I-l-Q-I-3) and likewise to all intermediates.
  • R 1 preferably represents in each case optionally branched Ci-Cs-alkyl, Ci-Cg-haloalkyl, CVC7-alkenyl, C 2 -C7-haloalkenyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, C 1 -C4- haloalkoxy-, Ci-C4-alkylthio- or C 1 -C4-haloalkylthio-substituted C3-C7-cycloalkyl.
  • R ! more preferably represents in each case optionally branched Ci-C4-alkyl, Ci-C4-haloalkyl, C 2 -C5- alkenyl, C 2 -C5-haloalkenyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, C i-C4-haloalkoxy-, Ci-C4-alkoxy-, Ci-C4-alkylthio- or Ci-C4-haloalkylthio-substituted C3-C «-cycloalkyl.
  • R ' more preferably represents ieri-butyl, isopropyl, 1 -halocyclopropyl, l-(Ci-C4-alkyl)cyclopropyl, 1- (Ci-C4-alkoxy)cyciopropyi or l-(Ci-C4-alkylthio)cyclopropyl.
  • R 1 most preferably represents terf-butyl, isopropyl, 1-chlorocyclopropyL 1 -fluorocyclopropyl or 1- methylcyclopropyl.
  • R 2 preferably represents I I. Ci-Cs-alkyl, halogen- or Ci-Cs-alkoxy-substituted or non- substituted -
  • R more preferably represents I I. Ci-C-4-alkyl, non-substituted -C(0)-C i -C4-alkyl. R most preferably represents 1 1.
  • R 3 prel ' erahly represents halogen; hydroxyl; cyano; isocyano; nitro; carboxaldehyde, hydroxycarbonyl,
  • R ' more preferably represents halogen; cyano; carboxaldehyde, hydroxycarbonyl, Ci-Cs-alkyl; Ci-Cs- haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs-alkyloxy; C 1 -Cs-halogenalkyloxy ; C3-C7-cycloalkyl; C3-C7- halogencycloalkyl; C2-Cs-alkenyl; C2-Cs-alkynyl; Ci-Cs-alkylsulfanyl; Ci-Cs-halogenoalkylsulfanyl; Ci-Cs- alkylcarbonyl; C 1 -Cs-halogenoalkylcarbonyl; C 1 -Cs-alkoxy carbonyl; Ci-Cs-halogenoalkoxycarbonyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy
  • R ' most preferably represents represents halogen; cyano; carboxaldehyde, hydroxycarbonyl, C1-C4- alkyl; Ci-C4-haloalkyl; Ci-C4-cyanoalkyl; Ci-C -alkyloxy; Ci-C4-halogenalkyloxy; C3-C7-cycloalkyl; C3-C7- halogencycloalkyl; C 2 -Cs-alkenyi; C 2 -C5-alkynyl; C 1 -C 4 -alkylsulfanyl; C 1 -C 4 -halogenoalkylsulfanyl; C 1 -C 4 - alkylcarbonyl; C 1 -C4-halogenoalkylcarbonyl; Ci-C4-alkoxycarbonyl; Ci-C4-halogenoalkoxycarbonyl; benzyl; phenyl; furyl; pyrrolyl; thien
  • R 3 represents fluorine; chlorine; bromine; iodine; cyano; hydroxycarbonyl, carboxaldehyde, Ci-C4-alkyl; Ci-C4-haioalkyl; Ci-C4-cyanoalkyl; Ci-C4-alkyloxy; C3-C7- cycloalkyl; C 2 -Cs-alkynyl; C 1 -C4-aliylsulfanyl; C 1 -C 4 -alkylcarbonyl; C 1 -C4-alkoxycarbonyl; phenyl; or thienyl; wherein the phenyl, or thienyl may be optionally substituted by one or more group(s) selected from halogen; Ci-Cs-alkyl; Ci-Cs-haioalkyl; Ci-Cs-alkyloxy; C 1 -C s-halogenalkyloxy .
  • R 3 represents fluorine; chlorine; bromine; iodine; cyano; hydroxycarbonyl, carboxaldehyde, methyl; trifluoromethyl; cyanomethyl; methoxy; methylsulfanyl; cyclopropyl; ethinyl; methylcarbonyl (acetyl); carboxyl; methoxycarbonyl; ethoxycarbonyl; phenyl; or 2- thienyl.
  • R 3 represents fluorine; chlorine; bromine; iodine; or cyano.
  • R 3 represents chlorine or cyano.
  • R 4 prei ' erahlv represents hydrogen, fluorine, Ci-C4-alkyl.
  • R 4 more preferably represents hydrogen, fluorine, Ci-C3-alkyl.
  • R 4 even more preferably represents hydrogen, fluorine, methyl
  • R 5 preferably represents hydrogen, fluorine, Ci-C4-alkyl.
  • R 5 more preferably represents hydrogen, fluorine, Ci-Cs-alkyl.
  • R 5 even more prei ' erahlv represents hydrogen, fluorine, methyl
  • R 4 and R 5 may preferably form together with the carbon atom to which they are attached an optionally halogen-, C 1 -C 4 -a!kyl-substituted Cs-Ce-cycloalkyl ring.
  • R 4 and R 5 may more preferably form together with the carbon atom to which they are attached a Cs-Ce- cycloalkyi ring.
  • R 4 and R 5 may even more preferably form together with the carbon atom to which they are attached a cyclopropyl ring.
  • X 1 , X 2 , X 3 , X 4 or X 5 in the definitions for U 1 , U 2 , U 3 , U 4 or U 5 represent hydrogen or halogen.
  • Q preferably represents a substituted 6-membered aromatic heterocycle containing one or two nitrogen atoms or a substituted 6-membered aromatic carbocycle. Substituted means that the cycle of the given formula comprises at least one of X 1 , X 2 , X 3 , X 4 or X 5 not being hydrogen.
  • Q also preferably represents a, preferably substituted, 6-membered aromatic cycle of formula (Q-I-l)
  • X 1 , X 2 , X 3 , X 4 or X 5 have the same definition as given for formula (I) above.
  • X 1 , X 2 , X 3 , X 4 or X 5 preferably represent hydrogen or halogen.
  • Q more preferably represents a, preferably substituted, phenyl, 3-pyridyl or 4-pyridyl of formula (Q-I-
  • X ! , X 2 , X 3 , X 4 or X 5 have the same definition as given for formula (I) above.
  • X 1 , X 2 , X 3 , X 4 or X 5 preferably represent hydrogen or halogen.
  • Q most preferably represents a, preferably substituted, phenyl or 3-pyridyl of formula (Q-I-l) or (Q-I-
  • X 1 , X 2 , X 3 , X 4 or X 5 have the same definition as given for formula (I) above.
  • X 1 , X 2 , X 3 , X 4 or X 5 preferably represent hydrogen or halogen.
  • Q represents a, preferably substituted, phenyl or 3-pyridyl of formula (Q-l- 1 a) or (Q-I-2a)
  • X 1 , X 3 or X 5 have the same definition as given for formula (I) above.
  • X 1 , X 2 , X 3 , X 4 or X 5 preferably represent hydrogen or halogen.
  • X 2 and X 4 represent hydrogen and X ! , X" or X 5 represents hydrogen or halogen.
  • Musi preferably X 1 , X 2 and X 4 represent hydrogen and X 3 or X 5 represents hydrogen or halogen.
  • Preferred embodiments according to the present invention are compounds of formula (I), wherein R ' represents halogen or cyano; and
  • R R ' , R 4 and R 5 have the same definition as given for formula (I).
  • R 3 preferably represents fluorine; chlorine; bromine; iodine or cyano and Q, R ! , R , R 4 and R 5 have the same definition as given for formula
  • R 3 represents Ci-Cs-alkyl; Ci-Cs-haloalkyi; Ci-Cs-cyanoalkyl; Ci-Cs-alkyioxy; Ci-Cs- halogenalkyloxy; C3-C7-cycioalkyi; CVCT-halogencycloalkyl; C3-C7-cycloalkenyl; C3-C7- halogencycloalkenyl; C4-C 10- cy cloalkylalkyl; C4-C 1 o-halocy cloalkylalkyl; C6-C12- cycloalkylcycloalkyl; Ci-Cs-alkyi-C3-C7-cycloalkyi; Ci-Cs-alkoxy-C3-C7-cycloalkyl; C2-C8- alkenyl; C2-Cs-alkynyl; C2-Cs-alkenyloxy; C2-Cs-halogenalkenyloxy;
  • R R , R 4 and R 5 have the same definition as given for formula (I).
  • R ' preferably represents Ci-Cs-alkyl; Ci-Cs-haloalkyl; G-Cs-cyanoalkyl; G-Cs-alkyloxy; Ci-Cs- halogenalkyloxy;; C3-C7-cycloalkyl; G-G-halogencycloalkyl; G-Cs-alkenyl; C 2 -Cs-alkynyl; G-Cs- alkylsulfanyl; Ci-Cs-halogenoalkylsulfanyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy or phenyloxy wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; amino; sulfanyl; pen
  • R ' most preferably represents represents Ci-C4-alkyl; G-G-haloalkyl; Ci-C4-cyanoalkyi; C 1 -C4- alkyloxy; G-G-halogenalkyioxy; C3-C7-cycloalkyl; C3-C7-halogencycloalkyl; G-G-alkenyi; C2-C5- alkynyl; Ci-C4-alkylsulfanyl; C 1 -C4-halogenoalkylsulfanyl; benzyl; phenyl; furyl; pyrrolyl; thienyl; pyridyl; benzyloxy or phenyloxy; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; G- Cs-alkyl; Ci
  • R 3 even more preferably represents Ci-C4-alkyl; Ci-C4-haloalkyl; Ci-C4-cyanoalkyi; Ci-C4-alkyloxy; C3-C7-cycloalkyl; C 2 -C5-alkynyl; Ci-C4-alkylsulfanyl; phenyl; or thienyl; wherein the phenyl, or thienyl may be optionally substituted by one or more group(s) selected from halogen; Ci-Cs-alkyl; Ci-Cs-haloalkyl; Ci- C s-alky ioxy ; G-C s-halogenalkyloxy ; and Q, R 1 , R 2 , R 4 and R 5 have the same definition as given for formula (I) In such preferred embodiments according to the present invention
  • R ' even more preferably represents methyl; trifluoromethyl; cyanomethyl; methoxy; methylsulfanyl; cyclopropyl; ethinyl; phenyl; or 2-thienyl; and Q, R 1 , R 2 , R 4 and R 5 have the same definition as given for formula (I).
  • Other preferred embodiments according to the present invention are compounds of formula (I), wherein
  • R' represents carboxaldehyde, hydroxycarbonyl, C i -Cs-alkylcarbonyl; Ci-Cs-halogenoalkylcarbonyl; arylcarbonyl; C 3 -Cs-cycioalkylcarbonyl; C 3 -Cs-halogenocycloalkyicarbonyl; Ci-Cs-alkylcarbamoyl; di-Ci-Cs-alkylcarbamoyl; N-C i -Cs-alkyloxy carbamoyl; Ci-Cs-alkoxycarbamoyl; N-Ci-Cs-alkyl-Ci- Cs-alkoxycarbamoyl; C i -Cs-alkoxycarbonyl; C i -Cs-halogenoalkoxycarbonyl; C3-C8- cycloalkoxycarbonyl; Ci-Cs-alkoxyalkylcarbonyi; C 2
  • R 3 preferably represents carboxaldehyde, hydroxycarbonyl, Ci-Cs-alkylcarbonyl; Ci-Cs- halogenoalkylcarbonyl; arylcarbonyl; C 3 -Cs-cycloalkylcarbonyl; C 3 -Cs-halogenocycloalkylcarbonyl; Ci-Cs- alkoxycarbonyl; C 1 -Cs-halogenoalkoxycarbonyl; Cs-Cg- cycloalkoxycarbonyl; C 1 -Cs-alkylcarbonyloxy; Ci-Cs-haiogenoalkylcarbonyloxy; or C3-Cs-cycloalkylcarbonyloxy; and Q, R 1 , R , R 4 and R 5 have the same definition as given for formula (I).
  • R 3 more preferably represents carboxaldehyde, hydroxycarbonyl, C 1 -Cs-alkylcarbonyl; Ci-Cs- halogenoalkylcarbonyl; Ci-Cs-alkoxycarbonyl; or Ci-Cs-halogenoalkoxycarbonyl; and
  • R 3 most preferably represents carboxaldehyde, hydroxycarbonyl, C i-C4-alkylcarbonyl; C1-C4- halogenoalkylcarbonyl; Ci-C 4 -alkoxycarbonyl; or Ci-C 4 -halogenoalkoxycarbonyl; and
  • R 1 , R , R 4 and R 5 have the same definition as given for formula (I).
  • R 3 even more preferably represents carboxaldehyde, hydroxycarbonyl, Ci-C4-alkylcarbonyl; or C1-C4- alkoxycarbonyl; and Q, R 1 , R 2 , R 4 and R 5 have the same definition as given for formula (I).
  • R 3 even more preferably represents carboxaldehyde, hydroxycarbonyl, Ci-C4-alkylcarbonyl; or C1-C4- alkoxycarbonyl; and Q, R 1 , R 2 , R 4 and R 5 have the same definition as given for formula (I).
  • R 3 even more preferably represents carboxaldehyde, hydroxycarbonyl, methylcarbonyl (acetyl); carboxyl; methoxycarbonyl; or ethoxycarbonyl; and
  • R 1 , R , R 4 and R 3 have the same definition as given for formula (I).
  • a preferred embodiment of the present invention relates to compounds of the formula (1-1)
  • R 1 , R 2 , R R 4 , R 5 , U 3 , U 4 , X ! , X 2 and X 5 have the same definition as given for formula (I).
  • R 1 , R 2 , R 3 , R 4 , R ⁇ X 1 , X 2 , X 3 , X 4 and X 5 have the same definition as given for formula (I).
  • R , R ⁇ R , R , R , X 1 , X 2 , X 3 and X have the same definition as given for formula (I).
  • R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 , X 4 and X 5 have the same definition as given for formula (I).
  • radical definitions and explanations given above in general terms or stated within preferred ranges can, however, also be combined with one another as desired, i.e. including between the particular ranges and preferred ranges. They apply both to the end products and correspondingly to precursors and intermediates. In addition, individual definitions may not apply.
  • Ci-Cs-alkyl comprises the largest range defined here for an alkyl radical. Specifically, this definition comprises the meanings methyl, ethyl, n-, isopropyl, n-, iso-, sec-, tert-butyl, and also in each case all isomeric pentyls, hexyls, heptyls and octyls, such as methyl, ethyl, propyl, 1-methylethyl, butyl, 1- methylpropyl, 2-methylpropyl, 1 , 1 -dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1 ,2-dimethylpropyl, 1 , 1 -dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropy
  • Ci-C4-alkyl such as methyl, ethyl, n-, isopropyl, n-, iso-, sec-, tert-butyl.
  • Ci-C3-alkyl comprises methyl, ethyl, n-, isopropyl.
  • halogen comprises fluorine, chlorine, bromine and iodine.
  • Ci-Cs-haloalkyl - represents, for example, Ci-Cs-alkyl as defined above substituted by one or more halogen substituents which can be the same or different.
  • Ci-Cs- haloatkyi represents chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, tri fluoromethyl, chloro fluoromethyl, dichloro fluoromethyl, chlorodi fluoromethyl, 1-fluoroethyl, 2- fluoroethyl, 2,2-difluoroethyl, 2,2,2 -trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2- dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyi, 1 -fluoro- 1 -methylethyl, 2-fluoro- 1,1- dimethylethyl, 2-fluoro- 1 -fluoromethyl- 1 -methylethyl, 2-fluoro- 1 , 1 -di(fluoro)
  • Ci-C4-alkyl represents, for example, Ci-C4-a!kyl as defined above substituted by one or more fluorine substituent(s).
  • Preferably mono- or multiple fluorinated Ci-C4-alkyl represents fluoromethyl, difluoromethyl, tri fluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2- trifluoroethyl, pentafluoroethyi, 1 - fluoro- 1 -methylethyl, 2-fluoro- 1 , 1 -dimethylethyl, 2-fluoro- 1- fluoromethyl- 1 -methylethyl, 2-fluoro- 1 , 1 -di(fluoromethyl)-ethyl, 1 -methyl- 3 -trifluoromethylbutyl, 3- methyl- 1 -trifluoromethylbutyl.
  • C2-Cs-alkenyl comprises the largest range defined here for an alkenyl radical. Specifically, this definition comprises the meanings ethenyl, n-, isopropenyl, n-, iso-, sec-, tert-butenyl, and also in each case all isomeric pentenyls, hexenyls, heptenyls, octenyls, 1 -methyl- 1 -propenyl, 1 -ethyl- 1 -butenyl, 2,4- dimethyl- 1 -pentenyl, 2,4-dimethyl-2-pentenyi.
  • Halogen-substituted alkenyl - referred to as C2-C8- haloalkenyl - represents, for example, C2-Cs-alkenyl as defined above substituted by one or more halogen substituents which can be the same or different.
  • a preferred range is C2-C4-alkenyl, such as ethenyl, n-, isopropenyl, n-, iso-, sec- or tert-butenyl.
  • C2-Cs-alkynyl comprises the largest range defined here for an alkynyl radical. Specifically, this definition comprises the meanings ethynyl, 11-, isopropynyl, n-, iso-, sec-, tert-butynyl, and also in each case all isomeric pentynyls, hexynyls, heptynyls, octynyls.
  • Halogen-substituted alkynyl - referred to as C2- C8-haloalkynyl - represents, for example, C2-C8-alkynyl as defined above substituted by one or more halogen substituents which can be the same or different.
  • a preferred range is C2-C4-alkynyl, such as ethynyl, n-, isopropynyl, n-, iso-, sec- or tert-butynyl.
  • the definition C3-C?-cycloaIkyl comprises monocyclic saturated hydrocarbyl groups having 3 to 7 carbon ring members, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • halogen- sub stituted cycloalkyl and halocycloalkyl comprises monocyclic saturated hydrocarbyl groups having 3 to 7 carbon ring members, such as 1 - fluoro- cyclopropyl and 1-chloro- cyclopropyl.
  • the definition bicycloalkyl comprises spirocyclic alkyl wherein two substituents at the same carbon atom of a Cs-C T -cycloalkyl can form together with the carbon atom to which they are attached a C3-C7-cycloalkyl, this definition comprises for example the meaning spiro[2.2]pentyl.
  • the definition bicycloalkyl also comprises bicyclic alkyls wherein two substituents at different adjacent or non- adjacent carbon atoms of a C3-C7-cycloalkyl can form together with the carbon atoms to which they are attached a C3-C 6 -cycloalkyl, this definition comprises for example the meaning bicyclo[2.2.1 ]heptane-2-yl, bicyclo[2.2.1]heptane-7-yi, bicycio[4.1.0]heptane-2-yl, bicyclo[4.1.0]heptane-3-yl, bicyclo[4.1.0]heptane-7-yl
  • the definition bicycloalkyl also comprises bicyclic alky Is wherein two substituents at different adjacent or non- adjacent carbon atoms of a C3-C 6 -cycloalkyl can form an alkylene bridge between the carbon atoms to which they are attached, this definition comprises for example the meaning bicyclo[2.2.1 ]hept
  • aryl comprises aromatic, mono-, bi- or tricyclic ring, for example phenyl, naphthyl, anthracenyl (anthryl), phenanthracenyl (phenanthryl).
  • the definition hetaryl or heteroaryl comprises unsaturated, benzoannulated or not benzoannulated heterocyclic 5- to 10-membered ring containing up to 4 heteroatoms selected from N, O and S.
  • the definition hetaryl or heteroaryl comprises unsubstituted or substituted, unsaturated heterocyclic 5- to 7- membered ring containing up to 4 heteroatoms selected from N, O and S: for example 2- fury 1, 3-furyl, 2- thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrrolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 1-pyrazolyl, 1 11- imidazol-2-yl, 1 H-imidazol-4-yl, 1 H-imidazol-5-yl, 1 H-imidazol- 1 -yl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2- thiazoly
  • 5-membered heteroaryl comprises an unsaturated heterocyclic 5-membered ring containing up to 4 heteroatoms selected from N, O and S: for example 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrrolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 1-pyrazolyl, 1 H-imidazol-2-yl, lH-imidazol-4- yl, 1 H-imidazol-5-yl, 1 H-imidazol- 1 -yl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5- thiazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1H-1,2,3- triazol
  • the definition 6-membered heteroaryl comprises an unsaturated heterocyclic 6-membered ring containing up to 4 heteroatoms selected from N, O and S: for example 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3- pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, l,3,5-triazin-2-yl, l,2,4-triazin-3-yl, l,2,4-triazin-5-yl, l,2,4-triazin-6-yl.
  • heterocycloalkyl comprises saturated or partially unsaturated mono-, bi- or tricyclic ring systems consisting of C-atoms and containing up to 4 heteroatoms selected from N, O and S: for example aziridinyl, pyrrolidinyl, dihydropyridyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydrothiofuranyl, tetrahydropyranyl, pyranyl, isoxazolidinyl, isoxazolinyl, pyrazolinyl, dihydropyrrolyl, tetrahydropyridinyl, dioxolanyl, dioxanyl, oxathiolanyl, oxathianyl, dithhiolanyl, dithianyl.
  • partially unsaturated refers to ring systems that are neither saturated, i.e. comprising no double bound, nor fully unsaturated, i.e. comprising the maximum possible number of double bonds.
  • partially unsaturated ring systems comprise at least one double bond, but not the maximum possible number of double bonds.
  • Optionally substituted radicals may be mono- or polysubstituted, where in the case of polysubstitution, the substituents may be identical or different.
  • a group or a substituent which is substituted according to the invention preferably can be substituted by one or more group(s) selected from the list consisting of halogen; Si l; nitro; hydroxy!; cyano; amino; sulfanyl; pentafluoro- 6 -sulfanyl; formyl; formyloxy; formylamino; carbamoyl; N- hydroxycarbamoyl; carbamate; (hydroxyimino)-C i-C «-alkyl; Ci-Cs-aikyl; Ci-Cg-halogenalkyl; Ci-Cg- alkyloxy; G-Cs-halogenalkyloxy; Ci-Cs-alkylthio; C i -Cs-halogenalkylthio ; tri(Ci-Cs-alkyl)silyl; tri(Ci-Cs- alkyl)silyl-Ci-C8-alkyl; C3
  • the compounds according to the invention can be present as mixtures of different possible isomeric forms, in particular of stereoisomers, such as, for example, E and Z, threo and erythro, and also optical isomers, and, if appropriate, also of tautomers.
  • stereoisomers such as, for example, E and Z, threo and erythro, and also optical isomers, and, if appropriate, also of tautomers.
  • the compounds of the present invention can exist in one or more optical or chiral isomer forms depending on the number of asymmetric centres in the compound.
  • the invention thus relates equally to all the optical isomers and to their racemic or scalemic mixtures (the term "scalemic” denotes a mixture of enantiomers in different proportions) and to the mixtures of all the possible stereoisomers, in all proportions.
  • the diastereoisomers and/or the optical isomers can be separated according to the methods which are known per se by the man ordinary skilled in the art.
  • the compounds of the present invention can also exist in one or more geometric isomer forms depending on the number of double bonds in the compound.
  • the invention thus relates equally to all geometric isomers and to all possible mixtures, in all proportions.
  • the geometric isomers can be separated according to general methods, which are known per se by the man ordinary skilled in the art.
  • the compounds of the present invention can also exist in one or more geometric isomer forms depending on the relative position (syn/anti or cis/trans) of the substituents of ring B.
  • the invention thus relates equally to all syn/anti (or cis/trans) isomers and to all possible syn/anti (or cis/trans) mixtures, in all proportions.
  • the syn/anti (or cis/trans) isomers can be separated according to general methods, which are known per se by the man ordinary skilled in the art.
  • the present invention furthermore related to processes for preparing compounds of formula (I ).
  • the present invention furthermore relates to intermediates such as compounds of formula (XVII) and the preparation thereof.
  • the compounds (I ) can be obtained by various routes in analogy to prior art processes known (see e.g. EP-A 461 502, DE-A 40 27 608, DE-A 32 35 935 and references therein) and by synthesis routes shown schematically below and in the experimental part of this application.
  • the radicals Q, R 1 , R ' , R 3 , R 4 and R 5 have the meanings given above for the compounds of formula (I). These definitions apply not only to the end products of the formul a (I) but likewise to all intermediates.
  • R a is aryl, G-Cs-alkyl or C3-C7-cycloalkyl
  • R b is Ci-Cs-alkyl or Ci-Cs-alkyloxy, preferably - NMe3 ⁇ 4 -NMeOMe; or heterocyclic leaving groups, such as imidazole, triazole and hydroxybenzotriazole.
  • the compounds (lla) (Scheme 1) can be converted by means of methods described in the literature to the corresponding compounds (I II ) and subsequently to compounds (V). In a first process, for example, compounds ( lla) are halogenated.
  • the compounds (lla) can be halogenated e.g. with Bromo- or Chlorosuccinimide (see e.g. WO-A 2011/012622, WO-A 2008/003622, WO-A 2005/1 11003; Synthesis, 18, 2008, 2996 and references cited therein), preferably in the presence of a radical initiator such as Azobisisobutyronitrile or dibenzoyl peroxide and in the presence of an organic solvent, e.g. a chlorinated organic solvent such as tetrachloromethane.
  • a radical initiator such as Azobisisobutyronitrile or dibenzoyl peroxide
  • an organic solvent e.g. a chlorinated organic solvent such as tetrachloromethane.
  • compounds ( lla) undergo side-chain halogenation in the presence of bromine or chlorine (see e.g.
  • the compounds (III ) can subsequently be reacted with compounds (IV) or (VI ) wherein A and E represent a replaceable group such as halide, -OR, NHR a or NR a R b , preferably chloro, -O-methyl, -O-ethyl, - Me2 or - NMeOMe.
  • a and E represent a replaceable group such as halide, -OR, NHR a or NR a R b , preferably chloro, -O-methyl, -O-ethyl, - Me2 or - NMeOMe.
  • compounds (III ) are reacted in a first step with e.g. Zink, Magnesium or isopropylmagnesium chloride, followed by a carbonyl compound ( IV) or (VI) preferably under anhydrous conditions and optionally in the presence of a metal catalyst, such as palladium- or nickel-based catalysts.
  • the metal catalyst can be used such as (Ph 3 P) 2 PdCl 2 (e.g. WO-A 2012/087784, EP-A 461 502), PEPPSI-IPr (Chem. Eur. J. 2006, 12, 4743 - 4748) or prepared in- situ by the mixing of a metals salt (e.g. Pd(OAc) 2 ) and a ligand (such as e.g. PPhi, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (S-Phos)).
  • a metals salt e.g. Pd(OAc) 2
  • a ligand such as e.g. PPhi, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (S-Phos)
  • the Insertion of the metal can be enhanced by the addition of ionic salts, such as Li Br, LiCl, Lil, Cul, Zn(OPiv) 2 , MgCl3 ⁇ 4 CuCN (see e.g. Dissertation Albrecht Metzer 2010 (University Kunststoff); Angew. Chem. Int. Ed. 201 1, 50, 9205 -9209), or by activation of the metal using halogenated alkanes ( 1 ,2-dibromoethane) or halogenated alkylsilanes (TMSC1). Alternatively this sequence may be carried out in a one-pot fashion (see e.g. Beller et al, Chem. Asian J., 2011, 7(1) 40-44).
  • ionic salts such as Li Br, LiCl, Lil, Cul, Zn(OPiv) 2 , MgCl3 ⁇ 4 CuCN (see e.g. Dissertation Albrecht Metzer 2010 (University Kunststoff); Angew.
  • the reaction is preferably performed at temperatures between room temperature and re fluxing temperature of the solvent.
  • the solvent all common solvents inert under the reaction conditions, such as for example ethers (such as e.g. tetrahydrofurane, diethyl ether) can be used and the reaction can be effected in mixtures of two or more of these solvents.
  • A halogen, preferably CI
  • E -O-Ci-Cs-alkyl, preferably -O-methyl, -O-ethyl; -0-aryl; -S-Ci-Cs-alkyl; -S-aryl; -NHR a ; -NR a R b ;
  • R" is aryl, Ci-Cg-alkyl or C3-C7-cycloalkyl
  • R b is Ci-Cs-alkyl or Ci-Cs-alkyioxy, preferably - Me2, -NMeOMe; or heterocyclic leaving groups, such as imidazole, triazole and hydroxybenzotriazole.
  • a and E are, for example, halide, -OR. NHR" or NR a R b , preferably chloro, -O-methyl, -O-ethyl, - NMe2 or -NMeOMe, etc., which can act as appropriate leaving groups to form the desired ketones ( V) under suitable reaction conditions (Scheme 2).
  • halogen preferably CI or Br
  • halogen, hydroxy! preferably CI or Br
  • metal based catalysts which are either used directly or being in situ prepared from a metal precursor (e.g. Pd2dba3, Pd(OAc)?) and a ligand (e.g. phosphine based ligands like Xanthphos, 2-(dicyciohexylphosphino)-2'-methylbiphenyl, 2-Diphenylphosphino-2'-(N,N- dimethylamino)biphenyl, tri-t-butylphosphine, Tri-o-tolylphosphine) (see e.g. WO-A 2008/147544, WO-A 2005/027837).
  • a metal precursor e.g. Pd2dba3, Pd(OAc)
  • a ligand e.g. phosphine based ligands like Xanthphos, 2-(dicyciohexylphosphino)-2'-methylbiphen
  • bases various organic and inorganic bases can be used such as potassium phosphate, base, e.g. sodium amide, sodium hydride or sodium tert-butoxide.
  • base e.g. sodium amide, sodium hydride or sodium tert-butoxide.
  • silicon containing bases can be used (e.g. NaHMDS, KHMDS, LiHMDS).
  • the compounds (V) (Scheme 4) can be converted by means of methods described in the literature to the corresponding compounds (XII ) (see e.g. EP-A 461 502, DE-A 33 15 681, H - A 291 797, Bioorganic & Medicinal Chemistry Letters (1996), 6(16), 2031-2036).
  • Intermediates (V) are preferably reacted with trimethylsulfoxonium- or trimethylsulfonium-salts, preferably trimethylsulfoxonium halides, trimethylsulfonium halides, trimethylsulfoxonium methylsulfates or trimethylsulfonium methylsulfates, preferably in the presence of a base such as sodium hydride.
  • compounds (V) can be first converted to the corresponding olefins (XIII ). followed by epoxidation to obtain epoxides (XII ) (see e.g. EP-A 291 797).
  • A halogen, 0-S0 2 -Ci-C 8 -alkyi or O-SC -aryi, preferably CI or Br
  • a compound having the general formula (XII ) can be synthesized analogously to methods described in the literature by a coupling reaction of a compound having the corresponding general formula ( lie) with a substrate of the general formula (XIV) (see e.g. DE-A 40 27 608, WO-A 93/02086, WO-A 93/12121, Journal of Organic Chemistry, 2001, 2149-2153 and references cited therein).
  • G stands for halogen, preferably chloride or bromide
  • compounds (lie) are first transformed into Grignard reagents by the reaction with magnesium or with halogen/metal exchange reagents such as isopropylmagnesium halides and subsequently reacted with ketones (XIV) preferably under anhydrous conditions to obtain compounds of the general formula (XII) (see e.g. DE4027608).
  • the halides (lie) can be converted to the corresponding zinc reagents and subsequently reacted with ketones (XIV) (e.g. ChemComm, 2008, 5824-5826; Journal of Organic Chemistry, 2004, 908- 914 and references cited therein).
  • the possible groups for A are, for example, halides which can act as appropriate leaving groups to form the desired compounds (XII) under suitable reaction conditions.
  • A halogen, 0-S0 2 -Ci-C 8 -alkyl or 0-S0 2 -aryl, preferably CI or Br
  • a compound having the general formula (XV) can be synthesized analogously to methods described in the literature by a coupling reaction of a compound having the corresponding general formula (He) with a substrate of the general formula (XIV) (see e.g. DE-A 40 27 608, WO-A 93/02086, WO- A 93/12121, Journal of Organic Chemistry, 2001, 2149-2153).
  • G stands for halogen, preferably chloride or bromide
  • compounds (lie) are first transformed into Grignard reagents by the reaction with magnesium or with halogen/metal exchange reagents, such as isopropylmagnesium halides, and subsequently reacted with ketones (XIV ) preferably under anhydrous conditions to obtain compounds of the general formula (XV) (see e.g. DE-A 4027608).
  • the halides (He) can be converted to the corresponding zinc reagents and subsequently reacted with ketones (XIV) (e.g. ChemComm, 2008, 5824-5826; Journal of Organic Chemistry, 2004, 908- 914 and references cited therein).
  • the possible groups for A are, for example, halides which can act as appropriate leaving groups to form the desired compounds (XV) under suitable reaction conditions.
  • the compounds (XII ) obtained according to Process D, E or F can be converted by means of methods described in the literature to the corresponding compounds (la) (see e.g. DE-A 40 27 608, EP-A 461 502, DE-A 33 15 681, EP-A 291 797, WO9529901, EP0291797,).
  • the starting materials (XII) can be reacted with an imidazole of formula (XVI) which are commercially available or can be obtained by means of methods described in the literature, optionally in the presence of a base, such as potassium carbonate and/or potassium iert-butoxide, optionally in the presence of a Lewis acid, such as magnesium dichloride or BFj/Et20.
  • organomagnesium bases such as MeMgCl, TMPMgCl or analogues may also be employed (see Org. Lett, 2016, 18 (1), pp 16-19 DOI: 10.1021/'acs.orglett.5b02994).
  • nitriles such as e.g. acetonitrile, propionitrile
  • the reaction can be effected in mixtures of two or more of these solvents.
  • A halogen, 0-S0 2 -Ci-C 8 -aIkyl or 0-S0 2 -aryl, preferably CI or Br
  • the compounds (XV) obtained according to Process G can be converted by means of methods described in the literature to the corresponding compounds ( la) (see e.g. DE-A 40 27 608).
  • the starting materials (XV) can be reacted with an imidazole of formula ( XV I ) which are commercially available or can be obtained by means of methods described in the literature, optionally in the presence of a base, such as potassium carbonate and'or potassium iert-butoxide, optionally in the presence of a Lewis acid, such as magnesium dichloride or Alternatively, organomagnesium bases such as MeMgCl, TMPMgCi or analogues may also be employed (see Org. Lett, 2016, 18 (1), pp 16-19 DOI: 10.1021/acs.orglett.5b02994).
  • nitriles such as e.g. acetonitrile, propionitrile
  • the reaction can be effected in mixtures of two or more of these solvents.
  • halogen 0-S0 2 -Ci-C 8 -aIkyl or 0-S0 2 -aryl, preferably CI or Br
  • the imidazoles of formula (XVI ) which are commercially available or can be obtained by means of methods described in the literature can be alkylated by compounds of formula (XIV) by means of methods described in the literature to the corresponding ketones (XVII) (see e.g Chemical Biology & Drug Design (2010), 75(1), 68-90, Acta Chemica Scandinavica (1990), 44(1), 1050-1057).
  • the reaction is optionally in the presence of a base, such as potassium carbonate, triethylamine, and/or potassium tert-butoxide, optionally in the presence of a Lewis acid, such as magnesium dichloride or BFiiEW, optionally in the presence of a metal oxide, such as zinc oxide or barium oxide.
  • a base such as potassium carbonate, triethylamine, and/or potassium tert-butoxide
  • a Lewis acid such as magnesium dichloride or BFiiEW
  • a metal oxide such as zinc oxide or barium oxide.
  • organomagnesium bases such as MeMgCl, TMPMgCi or analogues may also be employed (see Org. Lett., 2016, 18 (1), pp 16-19 DOI: 10.1021/acs.orglett.5b02994).
  • nitriles such as e.g. acetonitrile, propionitrile
  • the reaction can be effected in mixtures of two or more of these solvents.
  • PG formyl; Ci-Cs-alkyl; Ci-Cs-halogenalkyl; tri(Ci-C 8 -alkyl)silyl; tri(Ci-C 8 -alkyl)silyl-Ci-C 8 -alkyl; C 2 -C 8 -alkenyl; C 2 -C 8 -alkynyl, C i -Cs-a kylsulfonyl; Ci-Cs-alkylcarbonyl; Ci-Cs-halogenoalkylcarbonyi; C 3 - C8-cycloalkylcarbonyl; Ci-Cs-alkylcarbamoyl; di-Ci-Cs-alkylcarbamoyl; N-Ci-Cs-alkyioxycarbamoyl; Ci- Cg-alkoxycarbamoyl; N-C l-Cs-alkyl-C 1 -Cs-alkoxycarbamo
  • the imidazoles of formula (XVI ) which are commercially available or can be obtained by means of methods described in the literature can be converted into imidazoles of formula (XX) by means of methods described in the literature (see e.g "Protective groups in organic synthesis", Wiley Interscience, 1999; 3 rd edition, T. Greene & P. Wuts , p.615-632 and references cited therein, Journal of organic chemistry (2013), 78, 12220- 12223).
  • the reaction is optionally in the presence of a base, such as potassium carbonate, triethylamine, and/or potassium tert-butoxide,, optionally in the presence of a Lewis acid, such as magnesium dichloride or ⁇ 3 / ⁇ 3 ⁇ 40, optionally in the presence of a metal oxide, such as zinc oxide or barium oxide.
  • a base such as potassium carbonate, triethylamine, and/or potassium tert-butoxide
  • a Lewis acid such as magnesium dichloride or ⁇ 3 / ⁇ 3 ⁇ 40
  • a metal oxide such as zinc oxide or barium oxide.
  • the imidazoles of formula (XX) can consequently be converted into imidazolium salts of formula (XXI) by means of methods described in the literature (see e.g "Protective groups in organic synthesis", Wiley Interscience, 1999; 3 rd edition, T. Greene & P. Wuts , p.615-632 and references cited therein, Journal of organic chemistry (2013), 78, 12220-12223).
  • the reaction is optionally in the presence of a base, such as potassium carbonate, triethylamine, and/or potassium tert-butoxide,, optionally in the presence of a Lewis acid, such as magnesium dichloride or BF 3 /Et 2 0, optionally in the presence of a metal oxide, such as zinc oxide or barium oxide.
  • a base such as potassium carbonate, triethylamine, and/or potassium tert-butoxide
  • a Lewis acid such as magnesium dichloride or BF 3 /Et 2
  • a metal oxide such as zinc oxide or barium oxide.
  • imidazolium salts of formula (XXI) can be converted into ketones of formula (XVII) by means of methods described in the literature (see e.g "Protective groups in organic synthesis", Wiley Interscience, 1999; 3 rd edition, T. Greene & P. Wuts , p.615-632 and references cited therein, Journal of organic chemistry (2013), 78, 12220-12223).
  • solvent all common solvents inert under the reaction conditions, such as for example nitriles (such as e.g. acetonitrile, propionitrile) or alcohols (such as e.g. methanol, ethanol), can be used and the reaction can be effected in mixtures of two or more of these solvents.
  • nitriles such as e.g. acetonitrile, propionitrile
  • alcohols such as e.g. methanol, ethanol
  • R 3a halogen, O-SC -Ci-Cs-alkyl or 0-S0 2 -aryl, preferably Br or I
  • R 3b cyano; amino; hydro xycarbonyl, Ci-Cs-alkyl; Ci-Cs-haloalkyi; Ci-Cs-cyanoalkyl; Ci-Cs- alkyloxy; Ci-Cs-halogenalkyloxy ; tri(Ci-Cs-alkyl)silyl-Ci-C8-alkyl; Cs-CT-cycloalkyl; C3-C7- halogenocycloalkyl; C3-C7-cycloalkenyl; C3-C7-halogencycloalkenyl; C4-C 10-cycloalkylalkyl; C4-C10- halocycloalkyialkyl; C «-C 12-cycloalkylcycloalkyl; C 1 -Cs-alkyl-Cs-C?- cy cloalkyl; Ci-Cg-alkoxy-Cs-C?- cycloalkyl; tri(Ci-C
  • ketones of formula (W'lla) obtained according to Processes J or K can be converted by means of methods described in the literature to the corresponding compounds (XVIIb) (see e.g "Palladium in heterocyclic chemistry", Pergamon Press, 2000; l st edition, J. Li & G.
  • Gribble via a coupling reaction, optionally in the presence of a catalyst, preferably a transition metal catalyst, such as copper salts, palladium salts or complexes for example palladium (II) chloride, palladium (II) acetate, tetrakis-(triphenylphosphine) palladium(O), bis-(triphenylphosphine) palladium dichloride (II), tris(dibenzylideneacetone) dipalladium(O), bis(dibenzylideneacetone) palladium(O), or 1 , 1 , -bis(diphenylphosphino)ferrocene-palladium (II) chloride.
  • a catalyst preferably a transition metal catalyst, such as copper salts, palladium salts or complexes for example palladium (II) chloride, palladium (II) acetate, tetrakis-(triphenylphosphine) palla
  • the palladium complex is directly generated in the reaction mixture by separately adding to the reaction mixture a palladium salt and a complex ligand such as a phosphine, for example triethylphosphine, tri-tert-butylphosphine, tricyclohexylphosphine, 2-(dicyclohexylphosphine)biphenyl, 2-(di-tert- butylpho sphin)biphenyl, 2-(dicyclohexylphosphine)-2'-(N,N-dimethylamino)-biphenyl, triphenylphosphine, tris-(o-tolyl)phosphine, sodium 3 -(diphenylphosphino)benzolsulfonate, tris-2-(methoxyphenyl)phosphine, 2,2'-bis-(diphenylphosphine)- 1 , 1 '-binaphthyl
  • Such coupling reactions are optionally performed in the presence of a base such as an inorganic or an organic base; preferably an alkaline earth metal or alkali metal hydride, hydroxide, amide, alcoholate, acetate, carbonate or hydrogen carbonate, such as sodium hydride, sodium amide, lithiium diisopropylamide, sodium methanolate, sodium ethanolate, potassium tert-butanolate, sodium acetate, potassium acetate, calcium acetate, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, potassium bicarbonate, sodium bicarbonate, cesium carbonate or ammonium carbonate; and also tertiary amine, such as trimethylamine, triethylamine (TEA), tributylamine, N,N-dimethylaniline, N,N-dimethyl-benzylamine, N,N- diisopropyl-ethylamine (DIPEA), pyridine, N-methylpiperidine, N-methyl
  • a compound of formula (XVIla) is reacted with a cyanide reagent such as a metallic cyanide for example sodium cyanide, potassium cyanide, zinc cyanide; a metallo ' idic cyanide, an organo-metallic cyanide for example di-Ci-Ce-alkylaluminum cyanide notably di-ethylaluminum cyanide; an organo- metallo ' idic cyanide for example tri-Ci-Ce-alkyisilylcyanide notably tri-methylsilylcyanide in order to yield a compound of formula (XVI lb) wherein R 3b represents a cyano.
  • a metallic cyanide for example sodium cyanide, potassium cyanide, zinc cyanide
  • a metallo ' idic cyanide an organo-metallic cyanide for example di-Ci-Ce-alkylaluminum cyanide notably di-ethylaluminum
  • ketones of formula (XVII ) obtained according to Processes J to L are reacted with derivatives (li ), wherein G stands for halogen or hydrogen. If G stands for halogen, compounds (lie) are first transformed into Grignard reagents by the reaction with magnesium or with transmetallation reagents such as isopropylmagenesium halides and subsequently reacted with ketone (XVU ), preferably under anhydrous conditions to obtain compounds (la).
  • compounds ( lie) can be reacted with an organolithium reagent such as methyllithium or n-butyllithium preferably under anhydrous conditions to obtain a lithiated species.
  • an organolithium reagent such as methyllithium or n-butyllithium preferably under anhydrous conditions
  • a base such as lithiumdiisopropylamide or lithium bis(trimethylsilyl)amide
  • the obtained intermediates are subsequently reacted with ketones (XVU), preferably under anhydrous conditions to obtain compounds of the general formula ( la).
  • the compounds (XVII) (Scheme 14) can be converted by means of methods described in the literature to the corresponding compounds (XVIII ) (see e.g. DE-A 31 1 1 238, DE-A 33 07 217).
  • Compounds of the general formula (XVI I) are preferably reacted with trimethylsulfoxonium halides, trimethylsulfonium halides, trimethylsulfoxonium methylsulfates or trimethylsulfonium methylsulfates, preferably in the presence of a base, such as sodium hydroxide, to obtain compounds (XVIII).
  • compounds (Ic) can be obtained by the reaction of (XVIII) with (XIX).
  • G stands for halogen, preferably chloride or bromide
  • compounds (XIX) are first transformed into Grignard reagents by the reaction with magnesium or with transmetallation reagents such as isopropylmagnesium halides and subsequently reacted with epoxides (XVIII) preferably under anhydrous conditions.
  • compounds (XIX) (G hydrogen or halogen) are reacted with compounds (XVIII) preferably in the presence of a base.
  • the compounds (la) obtained according to Processes 1 1, 1, M or N can be converted by means of methods described in the literature to the corresponding compounds ( lb) (see e.g. DE-A 3202604, JP-A 02101067, EP-A 225 739, CN-A 101824002, FR-A 2802772; WO-A 2012/175119, Bioorganic & Medicinal Chemistry Letters, 7207-7213, 2012; Journal of the American Chemical Society, 19358-19361, 2012, Journal of Organic Chemistry, 9458-9472, 2012; Organic Letters, 554-557, 2013; Journal of the American Chemical Society, 15556, 2012).
  • benzyl phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; amino; sulfanyl; pentafluoro- ⁇ v 6 -sulfanyl; carboxalde
  • Gribble via a coupling reaction, optionally in the presence of a catalyst, preferably a transition metal catalyst, such as copper salts, palladium salts or complexes for example palladium (II) chloride, palladium (II) acetate, tetrakis-(triphenylphosphine) palladium(O), bis-(triphenylphosphine) palladium di chloride (II), tris(dibenzylideneacetone) dipalladium(O), bis(dibenzylideneacetone) palladium(O), or 1,1'- bis(diphenylphosphino)ferrocene-palladiurn (II) chloride.
  • a catalyst preferably a transition metal catalyst, such as copper salts, palladium salts or complexes for example palladium (II) chloride, palladium (II) acetate, tetrakis-(triphenylphosphine) palladium
  • the palladium complex is directly generated in the reaction mixture by separately adding to the reaction mixture a palladium salt and a complex ligand such as a phosphine, for example triethylphosphine, tri-tert-butylphosphine, tricyclohexylphosphine, 2-(dicyclohexylphosphine)biphenyl, 2-(di-tert-butylphosphin)biphenyl, 2- (dicyclohexylphosphine)-2'-(N,N-dimethylamino)-biphenyl, triphenylphosphine, tris-(o-tolyl)phosphine, sodium 3-(diphenylphosphino)benzolsulfonate, tris-2-(methoxyphenyl)phosphine, 2,2 -bis- (diphenylpho sphine) - 1 , 1 '-binaphthyl,
  • Such coupling reactions are optionally performed in the presence of a base such as an inorganic or an organic base; preferably an alkaline earth metal or alkali metal hydride, hydroxide, amide, alcoholate, acetate, carbonate or hydrogen carbonate, such as sodium hydride, sodium amide, lithiium diisopropylamide, sodium methanolate, sodium ethanolate, potassium tert-butanolate, sodium acetate, potassium acetate, calcium acetate, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, potassium bicarbonate, sodium bicarbonate, cesium carbonate or ammonium carbonate; and also tertiary amine, such as trimethylamine, triethylamine (TEA), tributylamine, ⁇ , ⁇ -dimethylaniline, N,N-dimethyl-benzylamine, N,N- diisopropyl-ethylamine (DIPEA), pyridine, N-methylpiperidine, N-
  • the preferred compounds of the formulae (I-I), (I-l-Q-I-1), (I-l-Q-I-2) and (I-l-Q-I-3) can also be obtained according to the processes A to P according to the invention.
  • the radicals R 1 , R , R R 4 , R 5 and Q have the meanings given above for the compounds of formulae (I-I), (I-l-Q-I-1), ( i- ! -Q-l- 2) and ( I- l -Q-I-3).
  • Useful reaction auxiliaries are, as appropriate, inorganic or organic bases or acid acceptors. These preferably include alkali metal or alkaline earth metal acetates, amides, carbonates, hydrogencarbonates, hydrides, hydroxides or alkoxides, for example sodium acetate, potassium acetate or calcium acetate, lithium amide, sodium amide, potassium amide or calcium amide, sodium carbonate, potassium carbonate or calcium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate or calcium hydrogencarbonate, lithium hydride, sodium hydride, potassium hydride or calcium hydride, lithium hydroxide, sodium hydroxide, potassium hydroxide or calcium hydroxide, n-butyllithium, sec-butyllithium, tert-butyllithium, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium methoxide, ethoxide, n- or i-propoxide, n-, i-, s- or t-butoxid
  • Useful reaction auxiliaries are, as appropriate, inorganic or organic acids. These preferably include inorganic acids, for example hydrogen fluoride, hydrogen chloride, hydrogen bromide and hydrogen iodide, sulphuric acid, phosphoric acid and nitric acid, and acidic salts such as NaHSC>4 and KI ISOj, or organic acids, for example, formic acid, carbonic acid and alkanoic acids such as acetic acid, trifluoroacetic acid, trichloroacetic acid and propionic acid, and also glycolic acid, thiocyanic acid, lactic acid, succinic acid, citric acid, benzoic acid, cinnamic acid, oxalic acid, saturated or mono- or diunsaturated C6-C20 fatty acids, alkylsulphuric monoesters, alkylsulphonic acids (sulphonic acids having straight- chain or branched alkyl radicals having 1 to 20 carbon atoms), arylsulphonic acids or
  • the processes A to P according to the invention are optionally performed using one or more diluents.
  • Useful diluents are virtually all inert organic solvents. Unless otherwise indicated for the above described processes A to P, these preferably include aliphatic and aromatic, optionally halogenated hydrocarbons, such as pentane, hexane, heptane, cyclohexane, petroleum ether, benzine, ligroin, benzene, toluene, xylene, methylene chloride, ethylene chloride, chloroform, carbon tetrachloride, chlorobenzene and o- dichlorobenzene, ethers such as diethyl ether, dibutyl ether and methyl tert-butyl ether, glycol dimethyl ether and diglycol dimethyl ether, tetrahydrofuran and dioxane, ketones such as acetone, methyl ethyl ketone
  • reaction temperatures can be varied within a relatively wide range.
  • the temperatures employed are between -78°C and 250°C, preferably temperatures between -78°C and 150°C.
  • the reaction time varies as a function of the scale of the reaction and of the reaction temperature, but is generally between a few minutes and 48 hours.
  • the processes according to the invention are generally performed under standard pressure. However, it is also possible to work under elevated or reduced pressure.
  • the starting materials required in each case are generally used in approximately equimolar amounts. However, it is also possible to use one of the components used in each case in a relatively large excess.
  • the compounds are optionally separated from the reaction mixture by one of the customary separation techniques. If necessary, the compounds are purified by recrystallization or chromatography.
  • the invention further relates to novel intermediates of the compounds of formula (I), which form part of the invention.
  • Novel intermediates according to the present invention are novel compounds of formula (XVII)
  • R represents hydrogen, in each case optionally branched Ci-Cs-alkyl, Ci-Cs-haloalkyl, C 2 -C 6 -alkenyl, C 2 -C7-haloalkenyl, C 2 -Cs-alkynyl, Ci-Cg-haloalkynyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, C i - C4-haloalkoxy- , Ci-C4-alkylthio- or C i -C4-haloalkylthio- substituted C3-C7-cycloalkyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, C 1 -C4- alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-alkylthi
  • R ' represents halogen; hydroxyl; cyano; isocyano; nitro; amino; sulfanyl; pentafluoro- 6 -sulfanyl; carboxaldehyde, Ci-Cralkyl; Ci-Cs-haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs-alkyloxy; Ci-Cs- halogenalkyloxy; tri(Ci-C 8 -aIkyl)silyl; tri(CrC 8 -alkyl)silyl-Ci-Cs-alkyi; C 3 -C 7 -cycloalkyl; C3-C7- halogencycloalkyl; C3-C7-cycloalkenyl; C3-C7-halogencycloalkenyl; C4-C 10- cycloalkylalkyl; C4- Cio-halocycloalkylalkyl; C «-Ci2-cycloalkylcycl
  • ⁇ V preferably represents in each case optionally branched Ci-Cs-alkyl, Ci-Cs-haloalkyl, C2-C?-alkenyl, CyC 7 -haloalkenyl, optionally halogen-, cyano-, Ci-C4-alkyl-, C i-Ct-haloalkyl- , Ci-C4-alkoxy-, C 1 -C4- haloalkoxy-, Ci-C4-alkylthio- or Ci-C4-haloalkyithio-substituted C3-C7-cycloaLkyl;
  • R 1 more preferably represents in each case optionally branched Ci-C4-alkyl, Ci-C4-haloalkyl, C2-C5- alkenyi, C ⁇ -Cs-haloalkenyl, optionally halogen-, cyano-, Ci-Cvalkyl-, Ci-C4-haloaLkyl-, C i-C4-haloalkoxy-, Ci-C4-alkoxy-, Ci-C " 4-alkylthio- or Ci-C4-haloalkylthio-substituted C3-C «-cycloaltyl.
  • R 1 most preferably represents ieri-butyl, isopropyl, 1 -halocyclopropyl, l-(Ci-C4-alkyl)cyciopropyi, 1- (Ci-C4-alkoxy)cyclopropyl or l-(Ci-C4-alkyithio)cyclopropyi.
  • R ' represents feri-butyi, isopropyl, 1 -chlorocyclopropyl, 1 -fluorocyclopropyl or 1 -methylcy clopropyl.
  • R ' preferably represents halogen; hydroxyl; cyano; isocyano; nitro; carboxaldehyde, Ci-Cs-alkyl; Ci- Cs-haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs-alkyloxy; C 1 -Cs-halogenalkyloxy ; C3-C7-cycloalkyl; C3-C7- halogencycloalkyl; C2-Cs-aUcenyl; C2-Cralkynyl; C2-Cs-alkenyloxy; C2-Cs-halogenauienyloxy; C3-C8- alkynyloxy; Cs-Cs-halogenoalkynyloxy; Ci-Cs-alkylsulfanyl; Ci-Cs-halogenoalkylsulfanyl; Ci-Cs- alkylcarbonyl; Ci-Cg-halogenoalkylcarbonyl; arylcarbon
  • R ' more preferably represents halogen; cyano; carboxaldehyde, Ci-Cs-alkyl; Ci-Cs-haloalkyl; Ci-Cs- cyanoaltyl; Ci-Cs-alkyloxy; Ci-Cs-halogenalkyloxy; C3-C7-cycloalkyl; C3 -C7-halogencycloalkyl; C2-C8- alkenyl; C 2 -Cs-alkynyl; Ci-Cs-alkylsulfanyl; Ci-Cs-halogenoalkylsulfanyi; Ci-Cg-alkylcarbonyl; Ci-Cs- halogenoalkylcarbonyl; C 2 -Cs-alkoxycarbonyl; C 1 -Cs-halogenoalkoxy carbonyl; benzyl; phenyl; 5- membered heteroaryl; 6-membered heteroaryl; benzyloxy; or phenyl
  • R ' most preferably represents represents halogen; cyano; carboxaldehyde, Ci-C4-alkyl; C1-C4- haloalkyl; Ci-C4-cyanoalkyl; Ci-C4-alkyloxy; C 1 -C4-halogenalky loxy ; C3-C7-cycloalkyl; C3-C7- halogencycloalkyl; C 2 -Cs-alkenyl; C 2 -C5-alkynyl; C 1 -C4-alk 'lsulfanyl; C 1 -Ct-halogenoalkylsulfanyl; C 1 -C4- alkylcarbonyl; C i -C4-halogenoalkylcarbonyl; C2-C4-alkoxycarbonyl; Ci-C4-halogenoalkoxycarbonyl; benzyl; phenyl; futyl; pyrrolyl; thien
  • R ' represents fluorine; chlorine; bromine; iodine; cyano; carboxaldehyde, Ci-C4-alkyl; G-G-haloalkyl; Ci-C4-cyanoalkyl; Ci-C4-alkyloxy; G-G-cycloalkyl; C2-C5- alkynyl; C 1 -C4-aLkylsulfanyl; G-G-alkyicarbonyl; C2-C4-alkoxycarbonyl; phenyl; or thienyl; wherein the phenyl, or thienyl may be optionally substituted by one or more group(s) selected from halogen; G-Cs-alkyl; Ci-CVhaloalkyl; G-Cs-alkyloxy; G-Cs-halogenalkyloxy.
  • R 3 represents fluorine; chlorine; bromine; iodine; cyano; carboxaldehyde, methyl; trifluoromethyl; cyanomethyl; methoxy; methylsulfanyl; cyclopropyl; ethinyl; methylcarbonyl (acetyl); carboxyl; ethoxycarbonyl; phenyl; or 2-thienyl.
  • Preferred embodiments according to the present invention are compounds of formula (XVII), wherein R ' represents halogen or cyano;
  • R 1 has the same definition as given for formula (XVII).
  • R' preferably represents fluorine; chlorine; bromine; iodine or cyano
  • R 1 has the same definition as given for formula (XVII).
  • R 3 represents Ci-Cs-alkyl; G-Cs-haloalkyl; G-Cs-cyanoalkyl; Ci-Cs-alkyloxy; G-Cs- halogenalkyloxy; G-G-cycloalkyl; C3-C7-halogencycloalkyl; C3-C7-cycloalkenyl; C3-C7- halogencycloalkenyl; C4-C 10- cy cloalkylalkyl; C4-C 1 o-halocycloalkylalkyl; Ce- n- cycloalkylcycloalkyl; Ci-Cs-alkyl-C3-C7-cycloalkyl; Ci-Cs-alkoxy-C3-C7-cycloalkyl; G-G- alkenyl; C2-Cs-alkynyl; C2-Cs-alkenyloxy
  • R 1 has the same definition as given for formula (XVII).
  • R 3 preferably represents G-Cs-alkyl; Ci-Cs-haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs-alkyloxy; Ci-Cs- halogenalkyloxy ; ; C3-C 6 -cycloalkyl; Cs-C T -halogencycloalkyl; C 2 -Cs-alkenyl; C 2 -Cs-alkynyl; Ci-Cs- alkylsulfanyl; Ci-Cs-halogenoalkylsulfanyl; benzyl; phenyl; 5-menibered heteroaryl; 6-membered heteroaryl; benzyloxy or phenyloxy wherein the benzyl, phenyl, 5-rnembered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen
  • R 3 most preferably represents represents Ci-C4-alkyl; G-G-haloalkyl; Ci-C4-cyanoalkyl; C1-C4- alkyloxy; G-C4-halogenalkyloxy; G-G-cycloalkyl; G-Crhalogencycloalkyl; G-G-alkenyl; C 2 -C5- alkynyl; Ci-C4-alkylsulfanyl; C 1 -C 4 -halogenoalkylsulfanyl; benzyl; phenyl; furyl; pyrrolyl; thienyl; pyridyl; benzyloxy or phenyloxy; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; G- Cs-aikyi; G-
  • R ' even more preferably represents G-C4-alkyl; Ci-C4-haloalkyl; Ci-C4-cyanoalkyl; Ci-C4-alkyloxy; C 3 -C7-cycloalkyl; C 2 -C5-alkynyl; Ci-C 4 -alkylsulfanyl; phenyl; or thienyl; wherein the phenyl, or thienyl may be optionally substituted by one or more group(s) selected from halogen; G-Cs-alkyl; Ci-Cs-haloalkyl; Ci-
  • R 3 even more preferably represents methyl; trifluoromethyl; cyanomethyl; methoxy; methylsulfanyl; cyclopropyl; ethinyl; phenyl; or 2-thienyl; and R 1 has the same definition as given for formula (XVII).
  • R ' represents carboxaldehyde, G-Cs-alkyicarbonyi; Ci-Cs-halogenoalkylcarbonyl; arylcarbonyl; C 3 - Cs-cycloalkylcarbonyl; Cs-Cs-halogenocycloalkylcarbonyl; Ci-Cs-alkylcarbamoyl; di-Ci-Cs- alkylcarbamoyl; N-Ci-Cs-alkyloxycarbamoyl; Ci-Cg-alkoxycarbamoyl; N-Ci-Cs-alkyl-Ci-Cg- alkoxycarbamoyl; C2-C5-alkoxycarbonyl; Ci-Cs-halogenoalkoxycarbonyl; Cs-Cs- cycloaLkoxycarbonyl; C2-Cs-alkoxyalkylcarbonyl; C2-C8-halogenoalkoxyalkylcarbonyl; C3
  • R ' preferably represents carboxaldehyde, C 2 -Cg-alk;ylcarbonyi; C 1 -Cs-halogenoalkylcarbonyl; arylcarbonyl; Ci-Cs-cycloalkylcarbonyl; C3 -Cs-halogenocycloalkylcarbonyl; C2-Cs-alkoxycarbonyl; Ci-Cs- halogenoalkoxycarbonyl; C3 -C 8- cy clo altoxy carbonyl; Ci-Cs-alkyicarbonyloxy; Ci-Cs- halogenoalkylcarbonyloxy; or C3-Cs-cycloalkylcarbonyloxy; and and R 1 has the same definition as given for formula (XVII).
  • R 3 more preferably represents carboxaldehyde, Ci-Cs-alkylcarbonyl; C 1 -Cs-halogenoalkylcarbonyl; C2-
  • R ' most preferably represents carboxaldehyde, C 1 -C4-alkylcarbonyl; Ci-C4-halogenoalkylcarbonyl; C2- C 4 -alkoxycarbonyi; or Ci-C 4 -haiogenoalkoxycarbonyi; and and R 1 has the same definition as given for formula (XVII).
  • R 3 even more preferably represents carboxaldehyde, Ci-C 4 -alkylcarbonyl; or C 2 -C 4 -alkoxycarbonyl; and and R 1 has the same definition as given for formula (XVII).
  • R 3 even more preferably represents carboxaldehyde, methylcarbonyl (acetyl); carboxyl; or ethoxycarbonyl; and and R 1 has the same definition as given for formula (XVII).
  • the compounds of the formula (I) according to the invention can be converted into physiologically acceptable salts, e.g. as acid addition salts or metal salt complexes.
  • the compounds of the formula (I) have acidic or basic properties and can form salts, if appropriate also inner salts, or adducts with inorganic or organic acids or with bases or with metal ions. If the compounds of the formula (I) carry amino, alkylamino or other groups which induce basic properties, these compounds can be reacted with acids to give salts, or they are directly obtained as salts in the synthesis. If the compounds of the formula (I) carries hydroxyl, carboxyl or other groups which induce acidic properties, these compounds can be reacted with bases to give salts.
  • Suitable bases are, for example, hydroxides, carbonates, bicarbonates of the alkali metals and alkaline earth metals, in particular those of sodium, potassium, magnesium and calcium, furthermore ammonia, primary, secondary and tertiary amines having (Ci-C4)-alkyl groups, mono-, di- and trialkanolamines of (C1-C4)- alkanols, choline and also chloro choline.
  • the salts obtainable in this manner also have fungicidal properties.
  • inorganic acids examples include hydrohalic acids, such as hydrogen fluoride, hydrogen chloride, hydrogen bromide and hydrogen iodide, sulphuric acid, phosphoric acid and nitric acid, and acidic salts, such as NaHS(>4 and KHSO4.
  • Suitable organic acids are, for example, formic acid, carbonic acid and alkanoic acids, such as acetic acid, trifluoroacetic acid, trichloroacetic acid and propionic acid, and also glycolic acid, thio cyanic acid, lactic acid, succinic acid, citric acid, benzoic acid, cinnamic acid, maleic acid, fumaric acid, tartaric acid, sorbic acid oxalic acid, alky Isulphonic acids (sulphonic acids having straight- chain or branched alkyl radicals of 1 to 20 carbon atoms), ary Isulphonic acids or aryldisulphonic acids (aromatic radicals, such as phenyl and naphthyl, which carry one or two sulphonic acid groups), alkylphosphonic acids (phosphonic acids having straight- chain or branched alkyl radicals of 1 to 20 carbon atoms), arylphosphonic acids or aryldiphosphonic acids (aromatic radicals, such
  • Suitable metal ions are in particular the ions of the elements of the second main group, in particular calcium and magnesium, of the third and fourth main group, in particular aluminium, tin and lead, and also of the first to eighth transition group, in particular chromium, manganese, iron, cobalt, nickel, copper, zinc and others. Particular preference is given to the metal ions of the elements of the fourth period.
  • the metals can be present in various valencies that they can assume.
  • the acid addition salts of the compounds of the formula (I) can be obtained in a simple manner by customary methods for forming salts, for example by dissolving a compound of the formula (I) in a suitable inert solvent and adding the acid, for example hydrochloric acid, and be isolated in a known manner, for example by filtration, and, if required, be purified by washing with an inert organic solvent.
  • Suitable anions of the salts are those which are preferably derived from the following acids: hydrohalic acids, such as, for example, hydrochloric acid and hydrobromic acid, furthermore phosphoric acid, nitric acid and sulphuric acid.
  • the metal salt complexes of compounds of the formula (I) can be obtained in a simple manner by customary processes, for example by dissolving the metal salt in alcohol, for example ethanol, and adding the solution to the compound of the formula (I).
  • Metal salt complexes can be isolated in a known manner, for example by filtration, and, if required, be purified by recrystallization.
  • Salts of the intermediates can also be prepared according to the processes mentioned above for the salts of compounds of formula (I).
  • N-oxides of compounds of the formula (I) or intermediates thereof can be obtained in a simple manner by customary processes, for example by N-oxidation with hydrogen peroxide (H2O2), peracids, for example peroxy sulfuric acid or peroxy carboxylic acids, such as meta-chloroperoxybenzoic acid or peroxymonosulfuric acid (Caro's acid).
  • H2O2 hydrogen peroxide
  • peracids for example peroxy sulfuric acid or peroxy carboxylic acids, such as meta-chloroperoxybenzoic acid or peroxymonosulfuric acid (Caro's acid).
  • the invention also relates to a method for controlling unwanted microorganisms, characterized in that the compounds of the formula (I) are applied to the microorganisms and/or in their habitat.
  • the invention further relates to seed which has been treated with at least one compound of the formula (I).
  • the invention finally provides a method for protecting seed against unwanted microorganisms by using seed treated with at least one compound of the formula (I).
  • the compounds of the formula (I) have potent microbicidal activity and can be used for control of unwanted microorganisms, such as fungi and bacteria, in crop protection and in the protection of materials.
  • the compounds of the formula (I) have very good fungicidal properties and can be used in crop protection, for example for control of Plasmodiophoromycetes, Oomycetes, Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes and Deuteromycetes.
  • Bactericides can be used in crop protection, for example, for control of Pseudomonadaceae, Rhizobiaceae, Enterobacteriaceae, Corynebacteriaceae and Streptomycetaceae.
  • the compounds of the formula (I) can be used for curative or protective control of phytopathogenic fungi.
  • the invention therefore also relates to curative and protective methods for controlling phytopathogenic fungi by the use of the inventive active ingredients or compositions, which are applied to the seed, the plant or plant parts, the fruit or the soil in which the plants grow. Plants
  • Plants are understood here to mean all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants).
  • Crop plants may be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant cultivars which are protectable and non- pro tectable by plant breeders' rights.
  • Plant parts are understood to mean all parts and organs of plants above and below the ground, such as shoot, leaf, flower and root, examples of which include leaves, needles, stalks, stems, flowers, fruit bodies, fruits and seeds, and also roots, tubers and rhizomes.
  • the plant parts also include harvested material and vegetative and generative propagation material, for example cuttings, tubers, rhizomes, slips and seeds.
  • Plants which can be treated in accordance with the invention include the following: cotton, flax, grapevine, fruit, vegetables, such as Rosaceae sp. (for example pome fruits such as apples and pears, but also stone fruits such as apricots, cherries, almonds and peaches, and soft fruits such as strawberries), Ribesioidae sp., Juglandaceae sp. , Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp., Actinidaceae sp., Lauraceae sp., Musaceae sp.
  • Rosaceae sp. for example pome fruits such as apples and pears, but also stone fruits such as apricots, cherries, almonds and peaches, and soft fruits such as strawberries
  • Rosaceae sp. for example pome fruits such as apples and pears, but also stone fruits
  • Rubiaceae sp. for example coffee
  • Theaceae sp. Sterculiceae sp.
  • Rutaceae sp. for example lemons, oranges and grapefruit
  • Solanaceae sp. for example tomatoes
  • Liliaceae sp. Asteraceae sp.
  • Umbelliferae sp. for example lettuce
  • Umbelliferae sp. for example lettuce
  • Cicurbitaceae sp. for example cucumber
  • Alliaceae sp. for example leek, onion
  • peas for example peas
  • major crop plants such as Gramineae sp. (for example maize, turf, cereals such as wheat, rye, rice, barley, oats, millet and triticale), Asteraceae sp. (for example sunflower), Brassicaceae sp. (for example white cabbage, red cabbage, broccoli, cauliflower, Brussels sprouts, pak choi, kohlrabi, radishes, and oilseed rape, mustard, horseradish and cress), Fabacae sp. (for example bean, peanuts), Papilionaceae sp. (for example soya bean), Solanaceae sp. (for example potatoes), Chenopodiaceae sp. (for example sugar beet, fodder beet, swiss chard, beetroot); useful plants and ornamental plants for gardens and wooded areas; and genetically modified varieties of each of these plants.
  • Non-limiting examples of pathogens of fungal diseases which can be treated in accordance with the invention include: diseases caused by powdery mildew pathogens, for example Blumeria species, for example Blumeria graminis; Podosphaera species, for example Podosphaera leucotricha; Sphaerotheca species, for example Sphaerotheca fuliginea; Uncinula species, for example Uncinula necator; diseases caused by rust disease pathogens, for example Gymnosporangium species, for example Gymnosporangium sabinae; Hemileia species, for example Hemileia vastatrix; Phakopsora species, for example Phakopsora pachyrhizi or Phakopsora meibomiae; Puccinia species, for example Puccinia recondita, Puccinia graminis oder Puccinia striiformis; Uromyces species, for example Uromyces appendicular
  • Phytophthora species for example Phytophthora infestans
  • Plasmopara species for example Plasmopara viticola
  • Pseudoperonospora species for example Pseudoperono spora humuli or Pseudoperonospora cubensis
  • Pythium species for example Pythium ultimum
  • Cercospora species for example Cercospora beticola
  • Cladiosporium species for example Cladiosporium cucumerinum
  • Cochliobolus species for example Cochliobolus sativus (conidial form: Drechslera, syn: Helminthosporium) or Cochliobolus miyabeanus
  • CoUetotrichum species for example Colletotrichum lindemuthan
  • Fungal diseases on roots and the stem base caused, for example, by black root rot (Calonectria crotalariae), charcoal rot (Macrophomina phaseolina), fusarium blight or wilt, root rot, and pod and collar rot (Fusarium oxysporum, Fusarium orthoceras, Fusarium semitectum, Fusarium equiseti), mycoleptodiscus root rot (Mycoleptodiscus terrestris), neocosmospora ( eo co smo spora vasinfecta), pod and stem blight (Diaporthe phaseolorum), stem canker (Diaporthe phaseolorum var.
  • phytophthora rot (Phytophthora megasperma), brown stem rot (Phialophora gregata), pythium rot (Pythium aphanidermatum, Pythium irregulare, Pythium debaryanum, Pythium myriotylum, Pythium ultimum), rhizoctonia root rot, stem decay, and damping-off (Rhizoctonia solani), sclerotinia stem decay (Sclerotinia sclerotiorum), sclerotinia southern blight (Sclerotinia rolfsii), thielaviopsis root rot (Thielaviopsis basicola).
  • the compounds of the formula (I) can, at particular concentrations or application rates, also be used as growth regulators or agents to improve plant properties, or as microbicides, for example as fungicides, antimycotics, bactericides, viricides (including compositions against viroids) or as compositions against MLO (Mycoplasma-like organisms) and RLO (Rickettsia-like organisms).
  • Plant growth regulators may exert various effects on plants. The effect of the substances depends essentially on the time of application in relation to the developmental stage of the plant, and also on the amounts of active ingredient applied to the plants or their environment and on the type of application. In each case, growth regulators should have a particular desired effect on the crop plants.
  • Growth regulating effects comprise earlier germination, better emergence, more developed root system and/or improved root growth, increased ability of tillering, more productive tillers, earlier flowering, increased plant height and/or biomass, shorting of stems, improvements in shoot growth, number of kernels/ear, number of ears/m 2 , number of stolons and/or number of flowers, enhanced harvest index, bigger leaves, less dead basal leaves, improved phyllotaxy, earlier maturation /' earlier fruit finish, homogenous riping, increased duration of grain filling, better fruit finish, bigger fruit-Vegetable size, sprouting resistance and reduced lodging.
  • Increased or improved yield is referring to total biomass per hectare, yield per hectare, kernel/'fruit weight, seed size and/or hectolitre weight as well as to improved product quality, comprising: improved processability relating to size distribution (kernel, fruit, etc.), homogenous riping, grain moisture, better milling, better vinification, better brewing, increased juice yield, harvestability, digestibility, sedimentation value, falling number, pod stability, storage stability, improved fiber length/'strength/uniformity, increase of milk and/or meet quality of silage fed animals, adaption to cooking and frying; further comprising improved marketability relating to improved fruit grain quality, size distribution (kernel, fruit, etc.), increased storage / shelf-life, firmness / softness, taste (aroma, texture, etc.), grade (size, shape, number of berries, etc.), number of berries/fruits per bunch, crispness, freshness, coverage with wax, frequency of physiological disorders, colour, etc.; further comprising increased desired ingredients such as
  • protein content protein content, fatty acids, oil content, oil quality, aminoacid composition, sugar content, acid content (pH), sugar/acid ratio (Brix), polyphenols, starch content, nutritional quality, gluten content index, energy content, taste, etc.; and further comprising decreased undesired ingredients such as e.g. less mycotoxines, less aflatoxines, geosmin level, phenolic aromas, lacchase, polyphenol oxidases and peroxidases, nitrate content etc.
  • decreased undesired ingredients such as e.g. less mycotoxines, less aflatoxines, geosmin level, phenolic aromas, lacchase, polyphenol oxidases and peroxidases, nitrate content etc.
  • Plant growth-regulating compounds can be used, for example, to slow down the vegetative growth of the plants.
  • Such growth depression is of economic interest, for example, in the case of grasses, since it is thus possible to reduce the frequency of grass cutting in ornamental gardens, parks and sport facilities, on roadsides, at airports or in fruit crops.
  • Also of significance is the inhibition of the growth of herbaceous and woody plants on roadsides and in the vicinity of pipelines or overhead cables, or quite generally in areas where vigorous plant growth is unwanted.
  • growth regulators for inhibition of the longitudinal growth of cereal. This reduces or completely eliminates the risk of lodging of the plants prior to harvest.
  • growth regulators in the case of cereals can strengthen the culm, which also counteracts lodging.
  • the employment of growth regulators for shortening and strengthening culms allows the deployment of higher fertilizer volumes to increase the yield, without any risk of lodging of the cereal crop.
  • vegetative growth depression allows denser planting, and it is thus possible to achieve higher yields based on the soil surface.
  • Another advantage of the smaller plants obtained in this way is that the crop is easier to cultivate and harvest.
  • Reduction of the vegetative plant growth may also lead to increased or improved yields because the nutrients and assimilates are of more benefit to flower and fruit formation than to the vegetative parts of the plants.
  • growth regul ators can also be used to promote vegetative growth. This is of great benefit when harvesting the vegetative plant parts. However, promoting vegetative growth may also promote generative growth in that more assimilates are formed, resulting in more or larger fruits.
  • beneficial effects on growth or yield can be achieved through improved nutrient use efficiency, especially nitrogen (N)-use efficiency, phosphours (P)-use efficiency, water use efficiency, improved transpiration, respiration and/or C02 assimilation rate, better nodulation, improved Ca-metabolism etc.
  • nitrogen (N)-use efficiency especially nitrogen (N)-use efficiency, phosphours (P)-use efficiency, water use efficiency, improved transpiration, respiration and/or C02 assimilation rate, better nodulation, improved Ca-metabolism etc.
  • growth regulators can be used to alter the composition of the plants, which in turn may result in an improvement in quality of the harvested products. Under the influence of growth regulators, parthenocarpic fruits may be formed. In addition, it is possible to influence the sex of the flowers. It is also possible to produce sterile pollen, which is of great importance in the breeding and production of hybrid seed.
  • growth regulators can control the branching of the plants.
  • by breaking apical dominance it is possible to promote the development of side shoots, which may be highly desirable particularly in the cultivation of ornamental plants, also in combination with an inhibition of growth.
  • side shoots which may be highly desirable particularly in the cultivation of ornamental plants, also in combination with an inhibition of growth.
  • the amount of leaves on the plants can be controlled such that defoliation of the plants is achieved at a desired time.
  • defoliation plays a major role in the mechanical harvesting of cotton, but is also of interest for facilitating harvesting in other crops, for example in viticulture.
  • Defoliation of the plants can also be undertaken to lower the transpiration of the plants before they are transplanted.
  • growth regulators can modulate plant senescence, which may result in prolonged green leaf area duration, a longer grain filling phase, improved yield quality, etc. Growth regulators can likewise be used to regulate fruit dehiscence. On the one hand, it is possible to prevent premature fruit dehiscence. On the other hand, it is also possible to promote fruit dehiscence or even flower abortion to achieve a desired mass ("thinning"). In addition it is possible to use growth regulators at the time of harvest to reduce the forces required to detach the fruits, in order to allow mechanical harvesting or to facilitate manual harvesting.
  • Growth regulators can also be used to achieve faster or else delayed ripening of the harvested material before or after harvest. This is particularly advantageous as it allows optimal adjustment to the requirements of the market. Moreover, growth regulators in some cases can improve the fruit colour. In addition, growth regulators can also be used to synchronize maturation within a certain period of time. This establishes the prerequisites for complete mechanical or manual harvesting in a single operation, for example in the case of tobacco, tomatoes or coffee.
  • growth regulators By using growth regulators, it is additionally possible to influence the resting of seed or buds of the plants, such that plants such as pineapple or ornamental plants in nurseries, for example, germinate, sprout or flower at a time when they are normally not inclined to do so. In areas where there is a risk of frost, it may be desirable to delay budding or germination of seeds with the aid of growth regulators, in order to avoid damage resulting from late frosts.
  • growth regulators can induce resistance of the plants to frost, drought or high salinity of the soil. This allows the cultivation of plants in regions which are normally unsuitable for this purpose.
  • the compounds of the formula (I) also exhibit a potent strengthening effect in plants. Accordingly, they can be used for mobilizing the defences of the plant against attack by undesirable microorganisms.
  • Plant- strengthening (resistance-inducing) substances in the present context are substances capable of stimulating the defence system of plants in such a way that the treated plants, when subsequently inoculated with undesirable microorganisms, develop a high degree of resistance to these microorganisms.
  • plant physiology effects comprise the following:
  • Abiotic stress tolerance comprising tolerance to high or low temperatures, drought tolerance and recovery after drought stress, water use efficiency (correlating to reduced water consumption), flood tolerance, ozone stress and UV tolerance, tolerance towards chemicals like heavy metals, salts, pesticides etc.
  • Biotic stress tolerance comprising increased fungal resistance and increased resistance against nematodes, viruses and bacteria.
  • biotic stress tolerance preferably comprises increased fungal resistance and increased resistance against nematodes.
  • Increased plant vigor comprising plant health / plant quality and seed vigor, reduced stand failure, improved appearance, increased recovery after periods of stress, improved pigmentation (e.g. chlorophyll content, stay-green effects, etc.) and improved photosynthetic efficiency.
  • Mycotoxins include particularly, but not exclusively, the following: deoxynivalenol (DON), nivalenol, 15-Ac-DON, 3-Ac-DON, T2- and HT2-toxin, fumonisins, zearalenon, moniliformin, fusarin, diaceotoxyscirpenol (DAS), beauvericin, enniatin, fusaroproliferin, fusarenol, ochratoxins, patulin, ergot alkaloids and aflatoxins which can be produced, for example, by the following fungi: Fusarium spec, such as F.
  • verticillioides etc. and also by Aspergillus spec, such as A. flavus, A. parasiticus, A. nomius, A. ochraceus, A. clavatus, A. terreus, A. versicolor, Penicillium spec, such as P. verrucosum, P. viridicatum, P. citrinum, P. expansum, P. claviforme, P. roqueforti, Claviceps spec, such as C. purpurea, C. fusiformis, C. paspali, C. africana, Stachybotrys spec, and others.
  • Aspergillus spec such as A. flavus, A. parasiticus, A. nomius, A. ochraceus, A. clavatus, A. terreus, A. versicolor, Penicillium spec, such as P. verrucosum, P. viridicatum, P. citrinum,
  • the compounds of the formula (I) can also be used in the protection of materials, for protection of industrial materials against attack and destruction by phytopathogenic fungi.
  • the compounds of the formula (I) can be used as antifouling compositions, alone or in combinations with other active ingredients.
  • Industrial materials in the present context are understood to mean inanimate materials which have been prepared for use in industry.
  • industrial materials which are to be protected by inventive compositions from microbial alteration or destruction may be adhesives, glues, paper, wallpaper and board/cardboard, textiles, carpets, leather, wood, fibers and tissues, paints and plastic articles, cooling lubricants and other materials which can be infected with or destroyed by microorganisms.
  • Parts of production plants and buildings, for example cooling-water circuits, cooling and heating systems and ventilation and air-conditioning units, which may be impaired by the proliferation of microorganisms may also be mentioned within the scope of the materials to be protected.
  • Industrial materials within the scope of the present invention preferably include adhesives, sizes, paper and card, leather, wood, paints, cooling lubricants and heat transfer fluids, more preferably wood.
  • the compounds of the formula (I) may prevent adverse effects, such as rotting, decay, discoloration, decoloration or formation of mould.
  • the compounds of the formula (I) may also be used against fungal diseases liable to grow on or inside timber.
  • the term "timber" means all types of species of wood, and all types of working of this wood intended for construction, for example solid wood, high-density wood, laminated wood, and plywood.
  • the method for treating timber according to the invention mainly consists in contacting a composition according to the invention; this includes for example direct application, spraying, dipping, injection or any other suitable means.
  • the compounds of the formula (I) can be used to protect objects which come into contact with saltwater or brackish water, especially hulls, screens, nets, buildings, moorings and signalling systems, from fouling.
  • Storage goods are understood to mean natural substances of vegetable or animal origin or processed products thereof which are of natural origin, and for which long-term protection is desired.
  • Storage goods of vegetable origin for example plants or plant parts, such as stems, leaves, tubers, seeds, fruits, grains, can be protected freshly harvested or after processing by (pre)drying, moistening, comminuting, grinding, pressing or roasting.
  • Storage goods also include timber, both unprocessed, such as construction timber, electricity poles and barriers, or in the form of finished products, such as furniture.
  • Storage goods of animal origin are, for example, hides, leather, furs and hairs.
  • the inventive compositions may prevent adverse effects, such as rotting, decay, discoloration, decoloration or formation of mould.
  • Microorganisms capable of degrading or altering the industrial materials include, for example, bacteria, fungi, yeasts, algae and slime organisms.
  • the compounds of the formula (I) preferably act against fungi, especially moulds, wood-discoloring and wood-destroying fungi (Ascomycetes, Basidiomycetes, D enter omycetes and Zygomycetes), and against slime organisms and algae.
  • microorganisms of the following genera Alternaria, such as Alternaria tenuis; Aspergillus, such as Aspergillus niger; Chaetomium, such as Chaetomium glohosum; Coniophora, such as Coniophora puetana; Lentinus, such as Lentinus tigrinus; Penicillium, such as Penicillium glaucum; Polyporus, such as Polyporus versicolor; Aureobasidium, such as Aureobasidium pullulans; Sclerophoma, such as Sclerophoma pityophila; Trichoderma, such as Trichoderma viride; Ophiostoma spp., Ceratocystis spp., Humicola spp., Petriella spp., Trichurus spp., Coriolus spp., Gloeophyllum spp., Pleurotus spp., Poria
  • the present invention further relates to a composition for controlling unwanted microorganisms, comprising at least one of the compounds of the formula (I).
  • fungicidal compositions which comprise agriculturally suitable auxiliaries, solvents, carriers, surfactants or extenders.
  • a carrier is a natural or synthetic, organic or inorganic substance with which the active ingredients are mixed or combined for better applicability, in particular for application to plants or plant parts or seed.
  • the carrier which may be solid or liquid, is generally inert and should be suitable for use in agriculture.
  • Useful solid carriers include: for example ammonium salts and natural rock flours, such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and synthetic rock flours, such as finely divided silica, alumina and silicates; useful solid carriers for granules include: for example, crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite and dolomite, and also synthetic granules of inorganic and organic flours, and granules of organic material such as paper, sawdust, coconut shells, maize cobs and tobacco stalks; useful emulsifiers and/or foam-formers include: for example nonionic and anionic emulsifiers, such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, for example alkylaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, aryl
  • oligo- or polymers for example those derived from vinylic monomers, from acrylic acid, from EO and/or PO alone or in combination with, for example, (poly)alcohols or (poly)amines. It is also possible to use lignin and its sulphonic acid derivatives, unmodified and modified celluloses, aromatic and/or aliphatic sulphonic acids and also their adducts with formaldehyde.
  • the active ingredients can be converted to the customary formulations, such as solutions, emulsions, wettable powders, water- and oil-based suspensions, powders, dusts, pastes, soluble powders, soluble granules, granules for broadcasting, suspoemulsion concentrates, natural products impregnated with active ingredient, synthetic substances impregnated with active ingredient, fertilizers and also microencapsulations in polymeric substances.
  • customary formulations such as solutions, emulsions, wettable powders, water- and oil-based suspensions, powders, dusts, pastes, soluble powders, soluble granules, granules for broadcasting, suspoemulsion concentrates, natural products impregnated with active ingredient, synthetic substances impregnated with active ingredient, fertilizers and also microencapsulations in polymeric substances.
  • the active ingredients can be applied as such, in the form of their formulations or the use forms prepared therefrom, such as ready-to-use solutions, emulsions, water- or oil-based suspensions, powders, wettable powders, pastes, soluble powders, dusts, soluble granules, granules for broadcasting, suspoemulsion concentrates, natural products impregnated with active ingredient, synthetic substances impregnated with active ingredient, fertilizers and also microencapsulations in polymeric substances.
  • Application is accomplished in a customary manner, for example by watering, spraying, atomizing, broadcasting, dusting, foaming, spreading-on and the like. It is also possible to deploy the active ingredients by the ultra-low volume method or to inject the active ingredient preparation/the active ingredient itself into the soil. It is also possible to treat the seed of the plants.
  • the formulations mentioned can be prepared in a manner known per se, for example by mixing the active ingredients with at least one customary extender, solvent or diluent, emulsifier, dispersant and/or binder or fixing agent, wetting agent, a water repellent, if appropriate siccatives and UV stabilizers and if appropriate dyes and pigments, antifoams, preservatives, secondary thickeners, stickers, gibberellins and also other processing auxiliaries.
  • the present invention includes not only formulations which are already ready for use and can be deployed with a suitable apparatus to the plant or the seed, but also commercial concentrates which have to be diluted with water prior to use.
  • the compounds of the formula (I) may be present as such or in their (commercial) formulations and in the use forms prepared from these formulations as a mixture with other (known) active ingredients, such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators, herbicides, fertilizers, safeners and/or semiochemicals.
  • active ingredients such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators, herbicides, fertilizers, safeners and/or semiochemicals.
  • auxiliaries used may be those substances which are suitable for imparting particular properties to the composition itself or and/or to preparations derived therefrom (for example spray liquors, seed dressings), such as certain technical properties and/or also particular biological properties.
  • Typical auxiliaries include: extenders, solvents and carriers.
  • Suitable extenders are, for example, water, polar and nonpolar organic chemical liquids, for example from the classes of the aromatic and nonaromatic hydrocarbons (such as paraffins, alkylbenzenes, alkylnaphthalenes, chlorobenzenes), the alcohols and polyols (which may optionally also be substituted, etherified and/or esterified), the ketones (such as acetone, cyclohexanone), esters (including fats and oils) and (poly)ethers, the unsubstituted and substituted amines, amides, lactams (such as N-alkylpyrrolidones) and lactones, the sulphones and sulphoxides (such as dimethyl sulphoxide).
  • aromatic and nonaromatic hydrocarbons such as paraffins, alkylbenzenes, alkylnaphthalenes, chlorobenzenes
  • the alcohols and polyols which may optionally also
  • Liquefied gaseous extenders or carriers are understood to mean liquids which are gaseous at standard temperature and under standard pressure, for example aerosol propellants such as halohydrocarbons, or else butane, propane, nitrogen and carbon dioxide.
  • tackifiers such as carboxymethylcellulose, natural and synthetic polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or else natural phospholipids such as cephalitis and lecithins and synthetic phospholipids.
  • Further additives may be mineral and vegetable oils. If the extender used is water, it is also possible to use, for example, organic solvents as auxiliary solvents.
  • Useful liquid solvents are essentially: aromatics such as xylene, toluene or alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example petroleum fractions, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethylformamide and dimethyl sulphoxide, or else water.
  • aromatics such as xylene, toluene or alkylnaphthalenes
  • chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride
  • aliphatic hydrocarbons such as
  • compositions comprising compounds of the formula (I) may additionally comprise further components, for example surfactants.
  • surfactants are emulsifiers and/or foam formers, dispersants or wetting agents having ionic or nonionic properties, or mixtures of these surfactants.
  • Examples thereof are salts of polyacrylic acid, salts of lignosulphonic acid, salts of phenolsulphonic acid or naphthalenesulphonic acid, polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines, substituted phenols (preferably alkylphenols or arylphenols), salts of sulphosuccinic esters, taurine derivatives (preferably alkyl taurates), phosphoric esters of polyethoxylated alcohols or phenols, fatty esters of polyoLs, and derivatives of the compounds containing sulphates, sulphonates and phosphates, for example alkyiaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, arylsulphonates, protein hydrolysates, lignosulphite waste liquors and methylcellulose.
  • the presence of a surfactant is necessary if one of the active ingredients and/or one of the iner
  • dyes such as inorganic pigments, for example iron oxide, titanium oxide and Prussian Blue, and organic dyes such as alizarin dyes, azo dyes and metal phthalocyanine dyes, and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.
  • Further additives may be perfumes, mineral or vegetable, optionally modified oils, waxes and nutrients (including trace nutrients), such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.
  • Additional components may be stabilizers, such as cold stabilizers, preservatives, antioxidants, light stabilizers, or other agents which improve chemical and/or physical stability.
  • the active ingredients can be combined with any solid or liquid additive commonly used for formulation purposes.
  • the formulations contain generally between 0.05 and 99% by weight, 0.01 and 98% by weight, preferably between 0.1 and 95% by weight, more preferably between 0.5 and 90% of active ingredient, most preferably between 10 and 70 per cent by weight.
  • compositions described above can be used for controlling unwanted microorganisms, in which the compositions comprising compounds of the formula (I) are applied to the microorganisms and/or in their habitat.
  • Compounds of the formula (I) can be used as such or in formulations thereof and can be mixed with known fungicides, bactericides, acaricides, nematicides or insecticides, in order thus to broaden, for example, the activity spectrum or to prevent development of resistance.
  • Useful mixing partners include, for example, known fungicides, insecticides, acaricides, nematicides or else bactericides (see also Pesticide Manual, 14th ed.).
  • the invention furthermore includes a method for treating seed.
  • a further aspect of the present invention relates in particular to seeds (dormant, primed, pregerminated or even with emerged roots and leaves) treated with at least one of the compounds of the formula (I).
  • the inventive seeds are used in methods for protection of seeds and emerged plants from the seeds from phytopathogenic harmful fungi. In these methods, seed treated with at least one inventive active ingredient is used.
  • the compounds of the formula (I) are also suitable for the treatment of seeds and young seedlings.
  • a large part of the damage to crop plants caused by harmful organisms is triggered by the infection of the seeds before sowing or after germination of the plant. This phase is particularly critical since the roots and shoots of the growing plant are particularly sensitive, and even small damage may result in the death of the plant. Accordingly, there is great interest in protecting the seed and the germinating plant by using appropriate compositions.
  • the present invention therefore also relates to a method for protecting seeds, germinating plants and emerged seedlings against attack by animal pests and/or phytopathogenic harmful microorganisms by treating the seeds with an inventive composition.
  • the invention also relates to the use of the compositions according to the invention for treating seeds for protecting the seeds, the germinating plants and emerged seedlings against animal pests and/or phytopathogenic microorganisms.
  • the invention further relates to seeds which has been treated with an inventive composition for protection from animal pests and/or phytopathogenic microorganisms.
  • One of the advantages of the present invention is that the treatment of the seeds with these compositions not only protects the seed itself, but also the resulting plants after emergence, from animal pests and/or phytopathogenic harmful microorganisms. In this way, the immediate treatment of the crop at the time of sowing or shortly thereafter protect plants as well as seed treatment in prior to sowing.
  • the inventive active ingredients or compositions can be used especially also for transgenic seed, in which case the plant which grows from this seed is capable of expressing a protein which acts against pests, herbicidal damage or abiotic stress.
  • the treatment of such seeds with the inventive active ingredients or compositions for example an insecticidal protein, can result in control of certain pests. Surprisingly, a further synergistic effect can be observed in this case, which additionally increases the effectiveness for protection against attack by pests., microorganisms, weeds or abiotic stress.
  • the compounds of the formula (I) are suitable for protection of seed of any plant variety which is used in agriculture, in the greenhouse, in forests or in horticulture. More particularly, the seed is that of cereals (such as wheat, barley, rye, millet and oats), oilseed rape, maize, cotton, soybeen, rice, potatoes, sunflower, beans, coffee, beet (e.g. sugar beet and fodder beet), peanut, vegetables (such as tomato, cucumber, onions and lettuce), lawns and ornamental plants. Of particular significance is the treatment of the seed ofwheat, soybean, oilseed rape, maize and rice.
  • transgenic seed As also described below, the treatment of transgenic seed with the inventive active ingredients or compositions is of particular significance.
  • These heterologous genes in transgenic seeds may originate, for example, from microorganisms of the species Bacillus, Rhizobium, Pseudomonas, Serratia, Trichoderma, Clavibacter, Glomus or Gliocladium.
  • These heterologous genes preferably originates from Bacillus sp., in which case the gene product is effective against the European corn borer and/or the Western corn rootworm.
  • the heterologous genes originate from Bacillus thuringiensis.
  • the inventive composition is applied to seeds either alone or in a suitable formulation.
  • the seed is treated in a state in which it is sufficiently stable for no damage to occur in the course of treatment.
  • seeds can be treated at any time between harvest and some time after sowing. It is customary to use seed which has been separated from the plant and freed from cobs, shells, stalks, coats, hairs or the flesh of the fruits. For example, it is possible to use seed which has been harvested, cleaned and dried down to a moisture content of less than 15% by weight.
  • seed which, after drying, for example, has been treated with water and then dried again or seeds just after priming, or seeds stored in primed conditions or pre-germinated seeds, or seeds sown on nursery trays, tapes or paper.
  • the amount of the inventive composition applied to the seed and/or the amount of further additives is selected such that the germination of the seed is not impaired, or that the resulting plant is not damaged. This must be ensured particularly in the case of active ingredients which can exhibit phytotoxic effects at certain application rates.
  • the compounds of the formula (I) can be applied directly, i.e. without containing any other components and without having been diluted. In general, it is preferable to apply the compositions to the seed in the form of a suitable formulation. Suitable formulations and methods for seed treatment are known to those skilled in the art.
  • the compounds of the formula (I) can be converted to the customary formulations relevant to on- seed applications, such as solutions, emulsions, suspensions, powders, foams, slurries or combined with other coating compositions for seed, such as film forming materials, pelleting materials, fine iron or other metal powders, granules, coating material for inactivated seeds, and also ULV formulations.
  • These formulations are prepared in a known manner, by mixing the active ingredients or active ingredient combinations with customary additives, for example customary extenders and solvents or diluents, dyes, wetting agents, dispersants, emulsifiers, antifoams, preservatives, secondary thickeners, adhesives, gibberellins, and also water.
  • Useful dyes which may be present in the seed dressing formulations usable in accordance with the invention are all dyes which are customary for such purposes. It is possible to use either pigments, which are sparingly soluble in water, or dyes, which are soluble in water. Examples include the dyes known by the names Rhodamine B, C.I. Pigment Red 112 and C.I. Solvent Red 1.
  • Useful wetting agents which may be present in the seed dressing formulations usable in accordance with the invention are all substances which promote wetting and which are conventionally used for the formulation of active agrochemical ingredients.
  • Usable with preference are alkylnaphthalenesulphonates, such as diisopropyl- or diisobutylnaphthalenesulphonates.
  • Useful dispersants and/or emulsifiers which may be present in the seed dressing formulations usable in accordance with the invention are all nonionic, anionic and cationic dispersants conventionally used for the formulation of active agrochemical ingredients. Usable with preference are nonionic or anionic dispersants or mixtures of nonionic or anionic dispersants.
  • Useful nonionic dispersants include especially ethylene oxide/propylene oxide block polymers, alkylphenol polyglycol ethers and tristryrylphenol polyglycol ether, and the phosphated or sulphated derivatives thereof.
  • Suitable anionic dispersants are especially lignosulphonates, polyacrylic acid salts and arylsulphonate/ formaldehyde condensates.
  • Antifoams which may be present in the seed dressing formulations usable in accordance with the invention are all foam-inhibiting substances conventionally used for the formulation of active agrochemical ingredients. Silicone antifoams and magnesium stearate can be used with preference.
  • Preservatives which may be present in the seed dressing formulations usable in accordance with the invention are all substances usable for such purposes in agrochemical compositions. Examples include dichlorophene and benzyl alcohol hemiformal.
  • Secondary thickeners which may be present in the seed dressing formulations usable in accordance with the invention are all substances usable for such purposes in agrochemical compositions.
  • Preferred examples include cellulose derivatives, acrylic acid derivatives, xanthan, modified clays and finely divided silica.
  • Adhesives which may be present in the seed dressing formulations usable in accordance with the invention are all customary binders usable in seed dressing products.
  • Preferred examples include polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol and tylose.
  • the formulations for on- seed applications usable in accordance with the invention can be used to treat a wide variety of different kinds of seed either directly or after prior dilution with water.
  • the concentrates or the preparations obtainable therefrom by dilution with water can be used to dress the seed of cereals, such as wheat, barley, rye, oats, and triticale, and also seeds of maize, soybean, rice, oilseed rape, peas, beans, cotton, sunflowers, and beets, or else a wide variety of different vegetable seeds.
  • the formulations usable in accordance with the invention, or the dilute preparations thereof can also be used for seeds of transgenic plants. In this case, additional synergistic effects may also occur in interaction with the substances formed by expression.
  • the application rate of the formulations usable in accordance with the invention can be varied within a relatively wide range. It is guided by the particular content of the active ingredients in the formulations and by the seeds.
  • the application rates of each single active ingredient is generally between 0.001 and 15 g per kilogram of seed, preferably between 0.01 and 5 g per kilogram of seed.
  • the compounds of the formula (I) also have very good antimycotic effects. They have a very broad antimycotic activity spectrum, especially against dermatophytes and yeasts, moulds and diphasic fungi (for example against Candida species, such as Candida albicans, Candida glabrata), and Epidermophyton fioccosum, Aspergillus species, such as Aspergillus niger and Aspergillus fumigatus, Trichophyton species, such as Trichophyton mentagrophytes, Microsporon species such as Microsporon canis and audouinii. The enumeration of these fungi by no means constitutes a restriction of the mycotic spectrum covered, and is merely of illustrative character.
  • the compounds can be used also to control important fungal pathogens in fish and Crustacea farming, e.g. saprolegnia diclina in trouts, saprolegnia parasitica in crayfish.
  • the compounds of the formula (I) can therefore be used both in medical and in non-medical applications.
  • the compounds of the formula (I) can be used as such, in the form of their formulations or the use forms prepared therefrom, such as ready-to-use solutions, suspensions, wettable powders, pastes, soluble powders, dusts and granules.
  • Application is accomplished in a customary manner, for example by watering, spraying, atomizing, broadcasting, dusting, foaming, spreading-on and the like. It is also possible to deploy the active ingredients by the ultra-low volume method or to inject the active ingredient preparation/the active ingredient itself into the soil. It is also possible to treat the seed of the plants.
  • GMO GMO
  • wild plant species and plant cultivars or those obtained by conventional biological breeding methods, such as crossing or protoplast fusion, and also parts thereof, are treated.
  • transgenic plants and plant cultivars obtained by genetic engineering methods if appropriate in combination with conventional methods (Genetically Modified Organisms), and parts thereof are treated.
  • the terms "parts” or “parts of plants” or “plant parts” have been explained above. More preferably, plants of the plant cultivars which are commercially available or are in use are treated in accordance with the invention.
  • Plant cultivars are understood to mean plants which have new properties ("traits") and have been obtained by conventional breeding, by mutagenesis or by recombinant DNA techniques. They can be cultivars, varieties, bio- or genotypes.
  • the method of treatment according to the invention can be used in the treatment of genetically modified organisms (GMOs), e.g. plants or seeds.
  • GMOs genetically modified organisms
  • Genetically modified plants are plants of which a heterologous gene has been stably integrated into genome.
  • the expression "heterologous gene” essentially means a gene which is provided or assembled outside the plant and when introduced in the nuclear, chloroplastic or mitochondrial genome gives the transformed plant new or improved agronomic or other properties by expressing a protein or polypeptide of interest or by downregulating or silencing other gene(s) which are present in the plant (using for example, antisense technology, cosuppression technology, RNA interference - RNAi - technology or microR A - miRNA - technology).
  • a heterologous gene that is located in the genome is also called a transgene.
  • a transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event.
  • Plants and plant cultivars which are preferably to be treated according to the invention include all plants which have genetic material which impart particularly advantageous, useful traits to these plants (whether obtained by breeding and/or biotechnological means).
  • Plants and plant cultivars which are also preferably to be treated according to the invention are resistant against one or more biotic stresses, i.e. said plants show a better defense against animal and microbial pests, such as against nematodes, insects, mites, phytopathogenic fungi, bacteria, viruses and/or viroids.
  • Plants and plant cultivars which may also be treated according to the invention are those plants which are resistant to one or more abiotic stresses.
  • Abiotic stress conditions may include, for example, drought, cold temperature exposure, heat exposure, osmotic stress, flooding, increased soil salinity, increased mineral exposure, ozone exposure, high light exposure, limited availability of nitrogen nutrients, limited availability of phosphorus nutrients, shade avoidance.
  • Plants and plant cultivars which may also be treated according to the invention are those plants characterized by enhanced yield characteristics.
  • Increased yield in said plants can be the result of, for example, improved plant physiology, growth and development, such as water use efficiency, water retention efficiency, improved nitrogen use, enhanced carbon assimilation, improved photosynthesis, increased germination efficiency and accelerated maturation.
  • Yield can furthermore be affected by improved plant architecture (under stress and non- stress conditions), including but not limited to, early flowering, flowering control for hybrid seed production, seedling vigor, plant size, internode number and distance, root growth, seed size, fruit size, pod size, pod or ear number, seed number per pod or ear, seed mass, enhanced seed filling, reduced seed dispersal, reduced pod dehiscence and lodging resistance.
  • Further yield traits include seed composition, such as carbohydrate content and composition for example cotton or starch, protein content, oil content and composition, nutritional value, reduction in anti-nutritional compounds, improved processability and better storage stability.
  • Plants that may be treated according to the invention are hybrid plants that already express the characteristic of heterosis or hybrid vigor which results in generally higher yield, vigor, health and resistance towards biotic and abiotic stresses).
  • Plants or plant cultivars which may be treated according to the invention are herbicide-tolerant plants, i.e. plants made tolerant to one or more given herbicides. Such plants can be obtained either by genetic transformation, or by selection of plants containing a mutation imparting such herbicide tolerance.
  • Plants or plant cultivars which may also be treated according to the invention are insect-resistant transgenic plants, i.e. plants made resistant to attack by certain target insects. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such insect resistance.
  • Plants or plant cultivars obtained by plant biotechnology methods such as genetic engineering which may also be treated according to the invention are tolerant to abiotic stresses. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such stress resistance.
  • Plants or plant cultivars obtained by plant biotechnology methods such as genetic engineering which may also be treated according to the invention show altered quantity, quality and/or storage- stability of the harvested product and/or altered properties of specific ingredients of the harvested product.
  • Plants or plant cultivars which may also be treated according to the invention are plants, such as cotton plants, with altered fiber characteristics. Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered fiber characteristics.
  • Plants or plant cultivars which may also be treated according to the invention are plants, such as oilseed rape or related Brassica plants, with altered oil profile characteristics. Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered oil profile characteristics.
  • Plants or plant cultivars which may also be treated according to the invention are plants, such as oilseed rape or related Brassica plants, with altered seed shattering characteristics.
  • Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered seed shattering characteristics and include plants such as oilseed rape plants with delayed or reduced seed shattering.
  • Plants or plant cultivars which may also be treated according to the invention are plants, such as Tobacco plants, with altered post- translational protein modification patterns.
  • the application rates can be varied within a relatively wide range, depending on the kind of application.
  • the application rate of the inventive active ingredients is
  • leaves from 0.1 to 10 000 g/ha, preferably from 10 to 1000 g/ha, more preferably from 50 to 300 g ha (in the case of application by watering or dripping, it is even possible to reduce the application rate, especially when inert substrates such as rockwool or perlite are used);
  • Step 1 Preparation of l-allvl-4-chloro-lH-imidazole
  • reaction mixture was diluted with water (1 L), extracted with dichloromethane (2 x 1 L), the combined organic layers were dried (MgS(>4) and concentrated in vacuo, to provide 290 g of a mixture of regioisomers (80% purity, 93% yield), which were separated by distillation at reduced pressure (0.1 mbar).
  • Step 3 Preparation of l-(l-chlorocvclopropvl)-2-(5-chloro-lH-imidazol-l-yl)ethanone (XVII-l )
  • reaction mixture was diluted with water (1 L), extracted with dichloromethane (2 x 1 L), the combined organic layers were dried (MgS04) and concentrated in vacuo, to provide 163 g of a 75:25 mixture of regioisomers (80% purity, 96% yield), which were separated by distillation at reduced pressure (0.1-0.2 mbar).
  • M LogP value is determined by measurement of LC-UV, in an acidic range, with 0.1% formic acid in water and acetonitrile as eluent (linear gradient from 10% acetonitrile to 95% acetonitrile).
  • ⁇ LogP value is determined by measurement of LC-UV, in a neutral range, with 0.001 molar ammonium acetate solution in water and acetonitrile as eluent (linear gradient from 10% acetonitrile to 95% acetonitrile).
  • i LogP value is determined by measurement of LC-UV, in an acidic range, with 0.1% phosphoric acid and acetonitrile as eluent (linear gradient from 10% acetonitrile to 95% acetonitrile).
  • IH-NMR data of selected examples are written in form of lH-NMR-peak lists. To each signal peak are listed the ⁇ -value in ppm and the signal intensity in round brackets. Between the ⁇ -value - signal intensity pairs are semicolons as delimiters.
  • the peak list of an example has therefore the form: ⁇ (intensity i); 62 (intensitV2); ; ⁇ ; (intensit i); ; ⁇ ⁇ (intensity n )
  • Intensity of sharp signals correlates with the height of the signals in a printed example of a NMR spectrum in cm and shows the real relations of signal intensities. From broad signals several peaks or the middle of the signal and their relative intensity in comparison to the most intensive signal in the spectrum can be shown.
  • tetramethylsilane For calibrating chemical shift for 1 1 1 1 spectra, we use tetramethylsilane and/or the chemical shift of the solvent used, especially in the case of spectra measured in DM SO. Therefore in NMR peak lists, tetramethylsilane peak can occur but not necessarily.
  • the IH-NMR peak lists are similar to classical IH-NMR prints and contains therefore usually all peaks, which are listed at classical NMR-interpretation.
  • peaks of solvents for example peaks of DMSO in DMSO-De and the peak of water are shown in our I H-NMR peak lists and have usually on average a high intensity .
  • the peaks of stereoisomers of the target compounds and/or peaks of impurities have usually on average a lower intensity than the peaks of target compounds (for example with a purity >90%).
  • Such stereoisomers and/or impurities can be typical for the specific preparation process. Therefore their peaks can help to recognize the reproduction of our preparation process via "side-products-fing ⁇ rints".
  • An expert who calculates the peaks of the target compounds with known methods (MestreC, ACD- simulation, but also with empirically evaluated expectation values) can isolate the peaks of the target compounds as needed optionally using additional intensity filters. This isolation would be similar to relevant peak picking at classical 1H-NMR interpretation.

Abstract

The present invention relates to novel 5-substituted imidazolylmethyl derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.

Description

Novel 5-suhstitiited imidazole derivatives
The present invention relates to novel 5-substituted imidazolylmethyl derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.
It is already known that particular 2-iodo-substituted imidazole derivatives can be used in crop protection as fungicides (cf. WO-A 2013/076228). Moreover, US-A 4,085,209 discloses the preparation and safening effect of certain imidazole metal salt complexes, wherein the imidazole ring may be unsubstituted or substituted by up to 3 methyl groups or halogen atoms. WO-A 2014/076228 discloses microbiocides and their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants. The microbiocides may be based on a tetrazole, triazole, oxazole, thiazole, or imidazole structure.
Since the ecological and economic demands made on modern active ingredients, for example fungicides, are increasing constantly, for example with respect to activity spectrum, toxicity, selectivity, application rate, formation of residues and favourable manufacture, and there can also be problems, for example, with resistances, there is a constant need to develop novel fungicidal compounds and compositions which have advantages over the known compounds and compositions at least in some areas.
Accordingly, the present invention provides novel imidazole derivatives of the formula (I)
Figure imgf000002_0001
wherein
R1 represents hydrogen, in each case optionally branched Ci-Cs-alkyl, Ci-Cs-haloalkyl, C2-C7-alkenyl, C2-C7-haloalkenyl, C^-Cs-alkynyl, C^-Cs-haloalkynyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-alkylthio- or Ci-C4-haloalkylthio- substituted C3-C7-cycloalkyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, G-C4- alkoxy-, C i -C4-haloalkoxy- , Ci-C4-alkylthio- or C i -C4-haloalkylthio-substituted bicycloalkyl, optionally halogen-, cyano-, G-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, Ci- C4-alkylthio- or Ci-C4-haloalkylthio-substituted C3-Cs-cycloalkylalkyl; optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, C i - C4-halo alkoxy-, Ci-C4-alkylthio- or Ci- C4-haloalkylthio-substituted C3-C7-halocycloalkyl-Ci-C4-alkyl; optionally halogen-, cyano-, Ci-C4- alkyl-, C i-C4-haloalkyl-, Ci-C4-alkoxy-, C i -C4-haloalkoxy- , Ci-C4-alkylthio- or Ci-C4- haioalkylthio-substituted C3-C7-halocycloalkyl-Ci-C4-haloalkyl; optionally halogen-, cyano-, C1-C4- alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-alkylthio- or C1-C4- haloalkylthio- substituted C3-C7-cycloalkyl-Ci-C4-haloalkyl; optionally halogen-, cyano-, C1-C4- alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-alkylthio- or C1-C4- haloalkylthio- substituted C3-C7-cycloalkyl- C3-C7-cycloalkyl; optionally halogen-, cyano-, C1-C4- alkyl-, C i-C4-haloalkyl-, Ci-C4-alkoxy-, C 1 -C4-haloalkoxy- , Ci-C4-alkyithio- or C1-C4- haloalkylthio- substituted Cs-CT-cycloalkenyl, optionally halogen-, cyano-, Ci-C4-alkyl-, C1-C4- haloalkyl-, Ci-C4-alkoxy-, C i-C4-haloalkoxy-, Ci-C4-alkylthio- or Ci-C4-haloalkylthio-substituted tri(Ci-C8-alkyl)silyl-Ci-C4-alkyl; optionally halogen-, cyano-, Ci-C4-alkyl-, C 1 -C4-haloalkyl-, Ci- C4-alkoxy-, C 1 -C4-haloalkoxy-, Ci-C4-alkylthio- or Ci-C4-haioalkylthio-substituted tri(Ci-Cs- alkyl)silyl-C3-C7-cycloalkyl;
R2 represents H, Ci-Cs-alkyi, -Si(R6a)( R6b)( R6c), -P(0)(OH)2, -CH2-0-P(0)(GH)¾ -C(0)-Ci-C8-alkyl, -C(0)-C3-C7-cycloalkyl, -C(0)NH-Ci-C8-alkyl; -C(0)N-di-Ci-C8-alkyl; -C(0)0-Ci-C8-aIkyl; wherein the -C(0)-Ci-C8-alkyi, -C(0)-C3-C7-cycloalkyl, -C(0)NH-Ci-C8-alkyl; -C(0)N-di-Ci- C8-alkyl or -C(0)0-Ci-C8-alkyl may be non-substituted or substituted by one or more group(s) selected from halogen or Ci-Cs-alkoxy; wherein
R6a, R6b, R6c represent independent from each other a phenyl or Ci-C8-alkyl;
R3 represents halogen; hydroxyl; cyano; i so cyano; nitro; amino; sulfanyl; pentafluoro- 6-suifanyl; carboxaldehyde, hydroxycarbonyl, Ci-Cs-alkyl; Ci-C8-haloalkyl; Ci-Cs-cyanoalkyl; Ci-C8- alkyloxy; Ci-C8-halogenalkyloxy; tri(Ci-C8-alkyl)siiyl; tri(Ci-C8-alkyl)silyl-Ci-C8-alkyl; C3-C7- cycloalkyl; C3-C7-halogencycloalkyl; C3-C7-cycloalkenyl; C3-C7-halogencycloalkenyl; C4-C10- cycloalkylalkyl; C4-C 1 o-halocycloalkylalkyl; Ce-C 12-cycloalkylcycloalkyl; Ci-Cs-alkyl-Cs-C?- cycloalkyl; Ci-C8-alkoxy-C3-C7-cycloalkyl; tri(Ci-C8-alkyl)silyl-C3-C7-cycloalkyl; C2-C8-alkenyl; C2-C8-alkynyl; C2-C8-alkenyloxy; C2-C8-halogenalkenyloxy; Cs-Cs-alkynyloxy; C3-C8- halogenoalkynyloxy; Ci-C8-alkylamino; Ci-C8-halogenalkylamino; C 1 - C8- cy anoalkoxy ; C4-C8- cycloalkylalkoxy; Cs-Ce-cycloallioxy; C 1 -Cs-alkylsulfanyl; Ci-C8-halogenoalkylsulfanyl; Ci-C8- alkylcarbonyl; Ci-C8-halogenoalkylcarbonyl; arylcarbonyl; C3-C8-cycioalkylcarbonyl; C3-C8- halogenocycloalkylcarbonyl; Ci-C8-alkylcarbamoyl; di-Ci-C8-alkylcarbamoyl; N-Ci-C8- alkyloxycarbamoyl; Ci-C8-alkoxycarbamoyi; N-Ci-C8-alkyl-Ci-C8-alkoxycarbamoyl; Ci-C8- alkoxycarbonyl; Ci-C8-halogenoalkoxycarbonyl; Cs-Cs-cycloalkoxycarbonyl; C2-C8- alkoxyalkylcarbonyl; C2-C8-halogenoalkoxyalkylcarbonyl; Cj-Cio-cycloalkoxyalkylcarbonyl; Ci- C8-alkylaminocarbonyi; di-C 1 -C8-alkylaminocarbonyl; C3-C8-cycloalkylaminocarbonyl; Ci-C8- alkylcarbonyloxy; C 1 -C8-halogenoalkylcarbonyloxy ; C3-C8-cycloalkylcarbonyloxy; Ci-C8- alkylcarbonylamino; Ci-C8-halogenoalkylcarbonylamino; C 1 -Cs-alkylaminocarbonyloxy ; di-Ci-Cs- alkylaminocarbonyloxy; C 1 -Cs-alkyloxycarbonyloxy ; C 1 -Cs-alkylsulfinyl; Ci-Cs- halogenoalkylsulfinyl; Ci-Cs-alkylsulfonyl; C 1 -Cs-halogenoalkylsulfonyl; C 1 -Cg-alkylsulfonyloxy ; Ci-Cs-halogenoalkylsulfonyloxy ; Ci-Cs-alkylaminosulfamoyl; di-Ci-Cs-alkylaminosulfamoyl; (Ci- C8-alkoxyimino)-Ci-C8-alkyl; (C3-C7-cycloalkoxyirruno)-Ci-Cs-alkyl; hydroxyimino-Ci-Cs-alkyl; (Ci-C8-aLkoxyimino)-C3-C7-cycloalkyl; hydroxyimino-C3-C7-cycloalkyl; (Ci-C8-alkylimino)-oxy; (Ci-Cs-alkylimino)-oxy-Ci-C8-alkyl; (C3-C7-cycloalkylimino)-oxy-Ci-Cs-alkyl; (G-Ce- allcylimino)-oxy-C3-C7-cycloalkyl; (Ci -C8-aIkenyloxyimino)-Ci-Cs-alkyl; (G-Cr alkynyloxyimino)-Ci-Cs-alkyl; (benzyloxyimino)-Ci-C8-alkyl; G-Cs-aikoxyalkyl; Ci-Cs- alkyithioalkyl; G-Cs-alkoxyalkoxyalkyl; Ci-Cs-halogenoalkoxyalkyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; amino; sulfanyl; pentafluoro- 6-sulfanyl; carboxaldehyde, hydroxycarbonyl, Ci-Cs-alkyl; Ci-Cs-haloalkyl; G-Cg-cyanoalkyl; G-Cs-alkyioxy; Ci-Cs- halogenalkyloxy; tri(Ci-Cs-alkyl)silyl; tri(Ci-Cs-alkyl)silyi-Ci-C8-alkyl; C3-C7-cycloalkyl; C3-C7- halogencycloalkyl; C3-C7-cycloalkenyl; C3-C7-halogencycloalkenyl; C4-Cio-cycloalkylalkyl; C4- Cio-halocycloalkylalkyl; Ce-Cn-cycloalkyicycioalkyl; Ci-Cs-alkyl-C3-C7-cycloalkyl; G-Cs- alkoxy-C3 - C7- cy cloalkyl; tri(C 1 -C8-alkyl)silyl- -C7-cycloalkyl; G-G-alkenyl; G-G-alkynyi; G- G-alkenyloxy; G-Cs-halogenalkenyloxy; C3 -G-alkynyloxy ; G-G-halogenoalkynyloxy; G-G- alkylamino; G-G-halogenalkylamino; G-G-cyanoalkoxy; G-Crcycloalkylalkoxy; G-G- cycloalkoxy; G-G-alkylsulfanyl; C 1-Cs-halogenoalkylsulfanyl; G-G-alkylcarbonyl; Ci-Cs- halogenoalkylcarbonyl; arylcarbonyl; G-Cs-cycloalkylcarbonyl; G-G- halogenocycloalkylcarbonyl; G-G-alkylcarbamoyl; di-Ci-Cg-alkylcarbamoyl; N-G-G- alkyloxycarbamoyl; G-Cs-alkoxycarbamoyl; N-C 1 -G-alkyl-C 1 -C alkoxy carbamoyl; G-G- alkoxycarbonyl; G-G-halogenoalkoxycarbonyl; G-G-cycioalkoxycarbonyi; G-G- alkoxyalkylcarbonyl; G-G-halogenoaikoxyaikylcarbonyl; C3-Cio-cycloalkoxyalkylcarbonyl; Ci- Cs-alkylaminocarbonyl; di-Ci-Cs-alkylaminocarbonyl; G-G-cycioalkylaminocarbonyl; G-G- alkylcarbonyloxy; G-G-halogenoalkylcarbonyloxy; G-G-cycloalkylcarbonyloxy; G-G- alkylcarbonylamino; G-G-halogenoalkylcarbonylamino; Ci-Cg-alkylaminocarbonyloxy; di-G-G- alkylaminocarbonyloxy; C 1 -G-alkyloxycarbonyloxy ; C 1 -G-alkylsulfinyl; G-G- halogenoalkylsulfinyl; C 1-Cs-alkylsulfonyl; Ci-Cs-halogenoalkyisulfonyl; C 1-Cs-alkylsulfonyloxy; C 1 -G-halogenoalkylsulfonyloxy ; Ci-Cs-alkylaminosulfamoyl; di-C 1 -G-alkylaminosulfamoyl; (G- C8-alkoxyimino)-Ci-Cralkyl; (G-G-cycloalkoxyimino)-CrCralkyl; hydroxyimino-G-G-alkyi; (Ci-C8-alkoxyimino)-C3-C7-cycioalkyl; hydroxyimino-C3-C7-cycloalkyl; (Ci-Cs-alkylimino)-oxy; (G-G-alkylimino)-oxy-G-G-alkyl; (G-G-cycloalkylimino)-oxy-G-C8-alkyl; (G-G- alkyhmino)-oxy-C3-C7-cycloalkyl; (C 1 -G-aIkenyloxyimino)-C 1-Cs-alkyl; (G-G- alkynyioxyimino)-Ci-C8-alkyl; (benzyloxyimino)-Ci-C8-alkyl; Ci-Cs-alkoxyalkyl; G-G- alkylthioalkyl; C 1-Cs-alkoxyalkoxyalkyl; G-G-halogenoalkoxyalkyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino; represents hydrogen, fluorine, G-G-alkyl, G-G-haloalkyl or G-G-alkyloxy; R5 represents hydrogen, fluorine, Ci-Cs-alkyl, Ci-Cs-haloalkyl or Ci-Cs-alkyloxy;
R4 and R5 may form together with the carbon atom to which they are attached an optionally halogen-,
Ci -Chalky 1-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, Ci -C4-haloalkoxy-, Ci-C4-alkylthio- or C1-C4- haloalkylthio- substituted C3-C7-cycloalkyl ring;
Q represents a 6-membered aromatic represents CX1 or N; wherein X1 represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non-substituted carbaldehyde 0-(Ci-Cs-alkyi)oxime, pentaftuoro- 6-suifenyl, substituted or non-substituted G-Cs-alkyl, substituted or non- substituted C3-Cs-cycloalkyl, substituted or non- substituted C3 - C?-halogency clo alky 1 having 1 to 5 halogen atoms; substituted or non-substituted C3-C7-cycloalkenyl; substituted or non-substituted Ci-Cs- halogenoalkyl having 1 to 5 halogen atoms, a substituted or non- substituted
Figure imgf000005_0002
substituted or non-substituted C2-C8-alkynyl, substituted or non-substituted Ci-Cs-alkoxy, substituted or non-substituted Ci-Cs-halogenoalkoxy having 1 to 5 halogen atoms, substituted or non-substituted Ci-Cs-alkylsulfenyl, substituted or non-substituted C2-C8- alkenyloxy, substituted or non- substituted C3-Cs-alkynyloxy, substituted or non-substituted C3-Ce- cy cloalkoxy , substituted or non-substituted N-(Ci-C8-alkoxy)-Ci-Cs-alkanimidoyl, substituted or non-substituted N-(Ci-C8-alkoxy)-Ci-C8-halogenoalkanimidoyl having 1 to 5 halogen atoms, Ci-Cs-alkyiaminocarbonyl; di-Ci-Cs-alkylaminocarbonyl, substituted or non- substituted Ci-Cs-alkoxycarbonyl, substituted or non-substituted Ci-Cg- alkylcarbonyloxy, substituted or non-substituted C 1 -Cs-alkylsulfinyl, substituted or non- substituted Ci-Cralkylsulfonyl, substituted or non-substituted (C 1 -Cs-alkoxyimino)-C 1-Cs- alkyl; substituted or non-substituted (C3-C7-cycloalkoxyimino)-Ci-Cs-alkyl; substituted or non- substituted hydroxyimino-C 1 -Cs-alkyl, substituted or non-substituted phenyloxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(Ci-Cs-alkyl)-silyloxy, substituted or non- substituted tri(Ci-Cs-alkyl)-silyl, substituted or non- substituted heterocyclyl, substituted or non- substituted heterocyclyloxy; represents CX2 or N; wherein X represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non- substituted carbaldehyde 0-(Ci-Cs-alkyl)oxime, pentafluoro- 6-sulfenyl group, substituted or non-substituted G-Cs-alkyl, substituted or non-substituted C3-C8- cycloalkyl, substituted or non-substituted C3-C7-halogencycloalkyl having 1 to 5 halogen atoms; substituted or non- substituted C3-C7-cycloalkenyl; substituted or non-substituted G- Cg-halogenoalkyl having 1 to 5 halogen atoms, a substituted or non-substituted G-G- alkenyl, substituted or non- substituted G-Cs-alkynyl, substituted or non- substituted G-G- alkoxy, substituted or non- substituted C 1 -G-halogeno alkoxy having 1 to 5 halogen atoms, substituted or non-substituted G-G-alkylsulfenyl, substituted or non-substituted G-G- alkenyloxy, substituted or non- substituted C3-Cs-alkynyloxy, substituted or non-substituted G - G- cy cloalkoxy , substituted or non-substituted N-(Ci-Cs-alkoxy)-Ci-C8-alkanimidoyl, substituted or non-substituted N-(Ci-Cs-alkoxy)-Ci-C8-halogenoalkanimidoyl having 1 to 5 halogen atoms, Ci-Cs-alkylaminocarbonyl; di-G-G-alkylaminocarbonyl, substituted or non- substituted G-G-alkoxycarbonyl, substituted or non-substituted G-G- alkylcarbonyloxy, substituted or non-substituted G-G-alkylsulfinyl, substituted or non- substituted G-G-alkylsulfonyi, substituted or non-substituted (G-G-alkoxyirnino)-G-G- alkyl; substituted or non-substituted (G-G-cycloalkoxyimino)-G-G-alkyl; substituted or non-substituted hydroxyimino-C 1 -G-alkyl, substituted or non-substituted phenyloxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(Ci-Cs-alkyl)-silyloxy, substituted or non-substituted tri(Ci-C8-alkyi)-silyl, substituted or non-substituted heterocyclyl, substituted or non- substituted heterocyclyloxy; represents CX3 or N; wherein X3 represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non- substituted carbaldehyde 0-(Ci-Cs-alkyl)oxime, pentafluoro- 6-sulfenyl group, substituted or non-substituted G-G-alkyl, substituted or non-substituted G-G- cycloalkyl, substituted or non-substituted C3-C7-halogencycloalkyl having 1 to 5 halogen atoms; substituted or non- substituted G-G-cyeloalkenyi; substituted or non-substituted G- Cs-halogenoalkyl having 1 to 5 halogen atoms, a substituted or non-substituted C2-C8- alkenyl, substituted or non-substituted C2-Cs-alkynyl, substituted or non-substituted Ci-Cs- alkoxy, substituted or non-substituted G-Cs-halogenoalkoxy having 1 to 5 halogen atoms, substituted or non-substituted G-Cs-alkylsuifenyl, substituted or non-substituted C2-C8- alkenyloxy, substituted or non- substituted C3-Cs-alkynyloxy, substituted or non-substituted C3 - Ce- cy cloalkoxy , substituted or non-substituted N-(Ci-C8-alkoxy)-Ci-Cs-alkanimidoyl, substituted or non-substituted N-(Ci-C8-alkoxy)-Ci-C8-halogenoalkanimidoyl having 1 to 5 halogen atoms, Ci-Cs-alkylaminocarbonyl; di-C i-Cs-alkylaminocarbonyl, substituted or non- substituted Ci-Cs-alkoxycarbonyl, substituted or non-substituted G-Cs- alkylcarbonyloxy, substituted or non-substituted G-Cs-alkylsulfinyl, substituted or non- substituted Ci-Cs-alkylsulfonyi, substituted or non-substituted (C 1 -Cs-alkoxyimino) -C 1 -Cs- alkyl; substituted or non-substituted (C3-C7-cycloalkoxyimino)-G-C8-alkyl; substituted or non- substituted hydroxyimino-C i -G-alkyl, substituted or non-substituted phenyloxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(Ci-Cs-alkyi)-siryloxy, substituted or non- substituted tri(Ci-Cs-alkyi)-silyl, substituted or non- substituted heterocyclyl, substituted or non- substituted heterocyclyloxy;
U4 represents CX4 or N; wherein X * represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non- substituted carbaldehyde 0-(C i -Cs-alkyl)oxime, pentafluoro- 6-sulfenyl group, substituted or non-substituted G-G-alkyl, substituted or non-substituted G-G- cycloalkyl, substituted or non-substituted C3-C7-halogencycloalkyl having 1 to 5 halogen atoms; substituted or non- substituted G-G-cycloalkenyl; substituted or non-substituted G- G-halogenoalkyl having 1 to 5 halogen atoms, a substituted or non-substituted G-G- alkenyi, substituted or non- substituted G-G-alkynyl, substituted or non- substituted G-G- alkoxy, substituted or non- substituted C 1 -C 8-halogeno alkoxy having 1 to 5 halogen atoms, substituted or non-substituted G-G-alkyisulfenyl, substituted or non-substituted G-G- alkenyloxy, substituted or non- substituted C3-Cs-alkynyloxy, substituted or non-substituted G - G- cy cloalkoxy , substituted or non-substituted N-(Ci-C8-alkoxy)-Ci-Cs-alkanimidoyl, substituted or non-substituted N-(CrC8-alkoxy)-G-Cs-haiogenoalkanimidoyl having 1 to 5 halogen atoms, Ci-Cs-alkylaminocarbonyl; di-Ci-Cs-a kylaminocarbonyl, substituted or non- substituted Ci-Cs-alkoxycarbonyl, substituted or non-substituted G-G- alkylcarbonyloxy, substituted or non-substituted C 1 -Cs-alkylsulfinyl, substituted or non- substituted C 1 -C8-alkylsulfonyl, substituted or non-substituted (G-Cs-alkoxyimino)-G-C8- alkyl; substituted or non-substituted (C3-C7-cycloalkoxyimino)-Ci-C8-alkyl; substituted or non- substituted hydroxyimino-C 1 -G-alkyl, substituted or non-substituted phenyloxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(G-Cs-alkyi)-siiyloxy, substituted or non-substituted tri(G-Cs-alkyl)-silyl, substituted or non- substituted heterocyclyl, substituted or non- substituted heterocyclyloxy;
U5 represents CX5 or N; wherein X3 represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non- substituted carbaldehyde 0-(G-Cs-alkyl)oxime, pentafluoro- 6-sulfenyl group, substituted or non-substituted G-Cs-alkyl, substituted or non-substituted G-G- cycloaLkyl, substituted or non-substituted G-G-halogencycloalkyl having 1 to 5 halogen atoms; substituted or non- substituted G-G-cycloalkenyl; substituted or non-substituted G- G-halogenoalkyl having 1 to 5 halogen atoms, a substituted or non-substituted G-G- alkenyl, substituted or non- substituted G-G-alkynyl, substituted or non- substituted G-Cs- alkoxy, substituted or non- substituted C 1 -C 8-halogeno alkoxy having 1 to 5 halogen atoms, substituted or non-substituted G-Cs-alkylsulfenyl, substituted or non-substituted C2-C8- alkenyloxy, substituted or non-substituted Cs-Cs-alkynyloxy, substituted or non-substituted C3 - Ce- cy cloalkoxy , substituted or non-substituted N-(Ci-C8-alkoxy)-Ci-C8-alkanimidoyl, substituted or non-substituted N-(Ci-C8-alkoxy)-Ci-C8-halogenoalkanimidoyl having 1 to 5 halogen atoms, CrCs-alkylaminocarbonyi; di-Ci-Cs-alkylaminocarbonyl, substituted or non- substituted G-Cs-alkoxycarbonyl, substituted or non-substituted G-Cr alkylcarbonyloxy, substituted or non-substituted C 1 -Cs-alkylsulfinyl, substituted or non- substituted C 1 -Cg-alkylsulfonyl, substituted or non-substituted (Ci-Cralkoxyimmo)-Ci-Cr alkyl; substituted or non-substituted (C3-C7-cycloalkoxyimino)-Ci-Cs-alkyi; substituted or non- substituted hydroxyimino-C 1 -Cs-alkyl, substituted or non-substituted phenyloxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(CrCs-alkyl)-silyloxy, substituted or non-substituted tri(Ci-C8-alkyl)-silyl, substituted or non- substituted heterocyclyl, substituted or non- substituted heterocyclyloxy; and wherein at most two of U1, U2, UJ, U4 or U5 can represent N; or
U1 and U2 or U2 and U3 or U3 and U4 may form together an additional saturated or unsaturated 4 to 6-membered halogen- or Ci-Cs-alkyl-substituted or non-substituted ring; and its salts or N- oxides. The salts or N-oxides of the imidazole derivatives of formula (I) also have fungicidal properties.
The formula (I) provides a general definition of the imidazole derivatives according to the invention. Preferred radical definitions for the formulae shown above and below are given below. These definitions apply to the end products of the formulae (I), (I-i), (I-l-Q-I-1), (I-l-Q-I-2) and (I-l-Q-I-3) and likewise to all intermediates. R1 preferably represents in each case optionally branched Ci-Cs-alkyl, Ci-Cg-haloalkyl, CVC7-alkenyl, C2-C7-haloalkenyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, C1-C4- haloalkoxy-, Ci-C4-alkylthio- or C 1 -C4-haloalkylthio-substituted C3-C7-cycloalkyl.
R! more preferably represents in each case optionally branched Ci-C4-alkyl, Ci-C4-haloalkyl, C2-C5- alkenyl, C2-C5-haloalkenyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, C i-C4-haloalkoxy-, Ci-C4-alkoxy-, Ci-C4-alkylthio- or Ci-C4-haloalkylthio-substituted C3-C«-cycloalkyl.
R ' more preferably represents ieri-butyl, isopropyl, 1 -halocyclopropyl, l-(Ci-C4-alkyl)cyclopropyl, 1- (Ci-C4-alkoxy)cyciopropyi or l-(Ci-C4-alkylthio)cyclopropyl. R1 most preferably represents terf-butyl, isopropyl, 1-chlorocyclopropyL 1 -fluorocyclopropyl or 1- methylcyclopropyl.
R2 preferably represents I I. Ci-Cs-alkyl, halogen- or Ci-Cs-alkoxy-substituted or non- substituted -
C(0)-Ci-C8-alkyi.
R more preferably represents I I. Ci-C-4-alkyl, non-substituted -C(0)-C i -C4-alkyl. R most preferably represents 1 1.
R3 prel'erahly represents halogen; hydroxyl; cyano; isocyano; nitro; carboxaldehyde, hydroxycarbonyl,
Ci-Cs-alkyl; Ci-Cs-haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs-alkyioxy; Ci-Cs-halogenalkyloxy; C3-C7-cycloalkyl; C3-C7-halogencycloalkyi; C2-Cg-alkenyl; Cs-Cs-alkynyl; C^-Cs-alkenyloxy; C2-C8-halogenalkenyioxy; C3- Cg-alkynyloxy; Cs-Cs-halogenoalkynyloxy; Ci-Cs-alkylsulfanyl; Ci-Cs-halogenoalkylsulfanyl; G-Cs- alkylcarbonyl; Ci-Cg-halogenoalkylcarbonyl; arylcarbonyl; aryl-Ci-Ce-alkylcarbonyl; C -Cg- cycloalkylcarbonyl; C3-Cs-halogenocycloalkylcarbonyi; aminothiocarbonyl; Ci-Cs-alkoxycarbonyl; Ci-Cs- halogenoaUcoxycarbonyl; C3 -C s- cy clo alkoxy carbonyl; Ci-Cs-alkyicarbonyloxy; Ci-Cg- halogenoalkylcarbonyloxy; Cs-Cs-cycloalkylcarbonyloxy; benzyl; phenyl; 5-membered heteroaryl; 6- membered heteroaryl; benzyloxy; or phenyloxy; wherein the benzyl, phenyl, 5-membered heteroaryl, 6- membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; isocyano; amino; sulfanyl; pentafluoro- 6-sulfanyl; Ci-Cs-alkyl; Ci-Cs-haloalkyi; Ci-Cg-alkyloxy; Ci-Cs-haiogenaltyioxy; tri(C i-C alkyl)silyl; C3-C7-cycloalkyi; C2-C8- alkenyl; C2-C8-alkynyl.
R ' more preferably represents halogen; cyano; carboxaldehyde, hydroxycarbonyl, Ci-Cs-alkyl; Ci-Cs- haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs-alkyloxy; C 1 -Cs-halogenalkyloxy ; C3-C7-cycloalkyl; C3-C7- halogencycloalkyl; C2-Cs-alkenyl; C2-Cs-alkynyl; Ci-Cs-alkylsulfanyl; Ci-Cs-halogenoalkylsulfanyl; Ci-Cs- alkylcarbonyl; C 1 -Cs-halogenoalkylcarbonyl; C 1 -Cs-alkoxy carbonyl; Ci-Cs-halogenoalkoxycarbonyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; or phenyloxy; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; amino; sulfanyl; pentafluoro- 6-suifanyl; G-Cg-alkyl; Ci-Cs-haloalkyi; Ci-Cg-alkyloxy; Ci-Cs-halogenalkyloxy; tri(Ci-Cs-alkyl)silyl; C3- C7-cycloalkyl; C2-Cs-alkenyl; C2-Cs-alkynyl.
R ' most preferably represents represents halogen; cyano; carboxaldehyde, hydroxycarbonyl, C1-C4- alkyl; Ci-C4-haloalkyl; Ci-C4-cyanoalkyl; Ci-C -alkyloxy; Ci-C4-halogenalkyloxy; C3-C7-cycloalkyl; C3-C7- halogencycloalkyl; C2-Cs-alkenyi; C2-C5-alkynyl; C 1 -C4-alkylsulfanyl; C 1 -C4-halogenoalkylsulfanyl; C1-C4- alkylcarbonyl; C 1 -C4-halogenoalkylcarbonyl; Ci-C4-alkoxycarbonyl; Ci-C4-halogenoalkoxycarbonyl; benzyl; phenyl; furyl; pyrrolyl; thienyl; pyridyl; benzyloxy; or phenyloxy; wherein the benzyl, phenyl, 5- membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; Ci-Cs-alkyl; Ci-Cs-haloalkyl; Ci-Cs-alkyloxy; Ci-Cs- halogenalkyloxy.
In preferred embodiments of the present invention R3 represents fluorine; chlorine; bromine; iodine; cyano; hydroxycarbonyl, carboxaldehyde, Ci-C4-alkyl; Ci-C4-haioalkyl; Ci-C4-cyanoalkyl; Ci-C4-alkyloxy; C3-C7- cycloalkyl; C2-Cs-alkynyl; C 1 -C4-aliylsulfanyl; C 1 -C4-alkylcarbonyl; C 1 -C4-alkoxycarbonyl; phenyl; or thienyl; wherein the phenyl, or thienyl may be optionally substituted by one or more group(s) selected from halogen; Ci-Cs-alkyl; Ci-Cs-haioalkyl; Ci-Cs-alkyloxy; C 1 -C s-halogenalkyloxy .
In further preferred embodiments of the present invention R3 represents fluorine; chlorine; bromine; iodine; cyano; hydroxycarbonyl, carboxaldehyde, methyl; trifluoromethyl; cyanomethyl; methoxy; methylsulfanyl; cyclopropyl; ethinyl; methylcarbonyl (acetyl); carboxyl; methoxycarbonyl; ethoxycarbonyl; phenyl; or 2- thienyl.
In even further preferred embodiments of the present invention R3 represents fluorine; chlorine; bromine; iodine; or cyano.
In further preferred embodiments of the present invention R3 represents chlorine or cyano.
R4 prei'erahlv represents hydrogen, fluorine, Ci-C4-alkyl.
R4 more preferably represents hydrogen, fluorine, Ci-C3-alkyl.
R4 even more preferably represents hydrogen, fluorine, methyl
R5 preferably represents hydrogen, fluorine, Ci-C4-alkyl.
R5 more preferably represents hydrogen, fluorine, Ci-Cs-alkyl.
R5 even more prei'erahlv represents hydrogen, fluorine, methyl
R4 and R5 may preferably form together with the carbon atom to which they are attached an optionally halogen-, C 1 -C4-a!kyl-substituted Cs-Ce-cycloalkyl ring.
R4 and R5 may more preferably form together with the carbon atom to which they are attached a Cs-Ce- cycloalkyi ring.
R4 and R5 may even more preferably form together with the carbon atom to which they are attached a cyclopropyl ring.
In preferred embodiments X1, X2, X3, X4 or X5 in the definitions for U1, U2, U3, U4 or U5 represent hydrogen or halogen. Q preferably represents a substituted 6-membered aromatic heterocycle containing one or two nitrogen atoms or a substituted 6-membered aromatic carbocycle. Substituted means that the cycle of the given formula comprises at least one of X1, X2, X3, X4 or X5 not being hydrogen.
Q also preferably represents a, preferably substituted, 6-membered aromatic cycle of formula (Q-I-l)
Figure imgf000011_0001
wherein X1, X2, X3, X4 or X5 have the same definition as given for formula (I) above. X1, X2, X3, X4 or X5 preferably represent hydrogen or halogen.
Q more preferably represents a, preferably substituted, phenyl, 3-pyridyl or 4-pyridyl of formula (Q-I-
Figure imgf000011_0002
wherein X!, X2, X3, X4 or X5 have the same definition as given for formula (I) above. X1, X2, X3, X4 or X5 preferably represent hydrogen or halogen.
Q most preferably represents a, preferably substituted, phenyl or 3-pyridyl of formula (Q-I-l) or (Q-I-
2)
Figure imgf000012_0001
wherein X1, X2, X3, X4 or X5 have the same definition as given for formula (I) above. X1, X2, X3, X4 or X5 preferably represent hydrogen or halogen.
In preferred embodiments of the present invention Q represents a, preferably substituted, phenyl or 3-pyridyl of formula (Q-l- 1 a) or (Q-I-2a)
Figure imgf000012_0002
wherein X1, X3 or X5 have the same definition as given for formula (I) above. X1, X2, X3, X4 or X5 preferably represent hydrogen or halogen.
More preferably X2 and X4 represent hydrogen and X ! , X" or X5 represents hydrogen or halogen. Musi preferably X1, X2 and X4 represent hydrogen and X3 or X5 represents hydrogen or halogen. Preferred embodiments according to the present invention are compounds of formula (I), wherein R ' represents halogen or cyano; and
Q, R R', R4 and R5 have the same definition as given for formula (I).
In such preferred embodiments according to the present invention R3 preferably represents fluorine; chlorine; bromine; iodine or cyano and Q, R!, R , R4 and R5 have the same definition as given for formula
(I).
Other preferred embodiments according to the present invention are compounds of formula (I), wherein
R3 represents Ci-Cs-alkyl; Ci-Cs-haloalkyi; Ci-Cs-cyanoalkyl; Ci-Cs-alkyioxy; Ci-Cs- halogenalkyloxy; C3-C7-cycioalkyi; CVCT-halogencycloalkyl; C3-C7-cycloalkenyl; C3-C7- halogencycloalkenyl; C4-C 10- cy cloalkylalkyl; C4-C 1 o-halocy cloalkylalkyl; C6-C12- cycloalkylcycloalkyl; Ci-Cs-alkyi-C3-C7-cycloalkyi; Ci-Cs-alkoxy-C3-C7-cycloalkyl; C2-C8- alkenyl; C2-Cs-alkynyl; C2-Cs-alkenyloxy; C2-Cs-halogenalkenyloxy; C3-Cs-alkynyloxy; C3-C8- halogenoaliynyloxy; C -Cs-cycloalkylalkoxy; C3-C6-cycloaltoxy; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy or phenyloxy; wherein the benzyl, phenyl, 5- membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydro xyl; cyano; amino; sulfanyl; pentaftuoro- 6-sulfanyl; G-Cs-alkyl; G-Cs-haloalkyl; G-Cs-alkyloxy; G -Cs-halogenalkyloxy; tri(Ci-Cs-alkyl)siiyl; G-Crcycloalkyl; G-Cs-alkenyl; G-G-alkynyl; and
Q, R R , R4 and R5 have the same definition as given for formula (I).
In such preferred embodiments according to the present invention
R ' preferably represents Ci-Cs-alkyl; Ci-Cs-haloalkyl; G-Cs-cyanoalkyl; G-Cs-alkyloxy; Ci-Cs- halogenalkyloxy;; C3-C7-cycloalkyl; G-G-halogencycloalkyl; G-Cs-alkenyl; C2-Cs-alkynyl; G-Cs- alkylsulfanyl; Ci-Cs-halogenoalkylsulfanyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy or phenyloxy wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; amino; sulfanyl; pentafluoro- 6-sulfanyl; Ci-Cs-alkyl; G-Cs-haloalkyl; G-Cs- alkyloxy; C i -Cs-halogenalkyloxy ; tri(Ci-Cs-alkyl)silyl; G-G-cycloalkyl; C2-Cs-alkenyl; C2-Cs-alkynyl; and Q, R1, R2, R4 and R5 have the same definition as given for formula (I).
In such preferred embodiments according to the present invention
R ' most preferably represents represents Ci-C4-alkyl; G-G-haloalkyl; Ci-C4-cyanoalkyi; C1-C4- alkyloxy; G-G-halogenalkyioxy; C3-C7-cycloalkyl; C3-C7-halogencycloalkyl; G-G-alkenyi; C2-C5- alkynyl; Ci-C4-alkylsulfanyl; C 1 -C4-halogenoalkylsulfanyl; benzyl; phenyl; furyl; pyrrolyl; thienyl; pyridyl; benzyloxy or phenyloxy; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; G- Cs-alkyl; Ci-Cs-haloalkyl; Ci-Cs-alkyloxy; C 1 -Cs-halogenalkyloxy; and Q, R!, R2, R4 and R5 have the same definition as given for formula (I)
In such preferred embodiments according to the present invention
R3 even more preferably represents Ci-C4-alkyl; Ci-C4-haloalkyl; Ci-C4-cyanoalkyi; Ci-C4-alkyloxy; C3-C7-cycloalkyl; C2-C5-alkynyl; Ci-C4-alkylsulfanyl; phenyl; or thienyl; wherein the phenyl, or thienyl may be optionally substituted by one or more group(s) selected from halogen; Ci-Cs-alkyl; Ci-Cs-haloalkyl; Ci- C s-alky ioxy ; G-C s-halogenalkyloxy ; and Q, R1, R2, R4 and R5 have the same definition as given for formula (I) In such preferred embodiments according to the present invention
R ' even more preferably represents methyl; trifluoromethyl; cyanomethyl; methoxy; methylsulfanyl; cyclopropyl; ethinyl; phenyl; or 2-thienyl; and Q, R1, R2, R4 and R5 have the same definition as given for formula (I). Other preferred embodiments according to the present invention are compounds of formula (I), wherein
R' represents carboxaldehyde, hydroxycarbonyl, C i -Cs-alkylcarbonyl; Ci-Cs-halogenoalkylcarbonyl; arylcarbonyl; C3-Cs-cycioalkylcarbonyl; C3-Cs-halogenocycloalkyicarbonyl; Ci-Cs-alkylcarbamoyl; di-Ci-Cs-alkylcarbamoyl; N-C i -Cs-alkyloxy carbamoyl; Ci-Cs-alkoxycarbamoyl; N-Ci-Cs-alkyl-Ci- Cs-alkoxycarbamoyl; C i -Cs-alkoxycarbonyl; C i -Cs-halogenoalkoxycarbonyl; C3-C8- cycloalkoxycarbonyl; Ci-Cs-alkoxyalkylcarbonyi; C2-Cs-halogenoalkoxyalkylcarbonyl; C3-C10- cycloalkoxyalkylcarbonyl; C 1 -Cs-alkylaminocarbonyl; di-Ci-Cs-alkylaminocarbonyl; CVCs- cycloalkylaminocarbonyl; Ci-Cs-alkylcarbonyloxy; Ci-Cs-halogenoalkylcarbonyloxy; CrCs- cycloalkylcarbonyloxy; Ci-Cs-alkylcarbonylarmno; Ci-Cs-halogenoalkylearbonylaniino; Ci-Cs- alkylaminocarbonyloxy; di-Ci-Cs-alkylaminocarbonyloxy; Ci-Cs-alkyloxycarbonyloxy; Ci-Cs- alkylsulfinyl; Ci-Cs-halogenoalkylsulfmyl; C 1 -Cs-aliylsul fonyl; C 1 -Cg-halogenoalkylsulfonyl; Ci- Cs-alkylsulfonyloxy; C 1 -Cs-halogenoalkylsulfonyloxy ; C 1 -Cs-alkylaminosulfamoyl or di-Ci-Cs- alkylaminosulfamoyl; and
Q, R1, R2, R4 and R3 have the same definition as given for formula (I). In such preferred embodiments according to the present invention
R3 preferably represents carboxaldehyde, hydroxycarbonyl, Ci-Cs-alkylcarbonyl; Ci-Cs- halogenoalkylcarbonyl; arylcarbonyl; C3-Cs-cycloalkylcarbonyl; C3-Cs-halogenocycloalkylcarbonyl; Ci-Cs- alkoxycarbonyl; C 1 -Cs-halogenoalkoxycarbonyl; Cs-Cg- cycloalkoxycarbonyl; C 1 -Cs-alkylcarbonyloxy; Ci-Cs-haiogenoalkylcarbonyloxy; or C3-Cs-cycloalkylcarbonyloxy; and Q, R1, R , R4 and R5 have the same definition as given for formula (I).
In such preferred embodiments according to the present invention
R3 more preferably represents carboxaldehyde, hydroxycarbonyl, C 1 -Cs-alkylcarbonyl; Ci-Cs- halogenoalkylcarbonyl; Ci-Cs-alkoxycarbonyl; or Ci-Cs-halogenoalkoxycarbonyl; and
Q, R', R , R4 and R5 have the same definition as given for formula (I). In such preferred embodiments according to the present invention
R3 most preferably represents carboxaldehyde, hydroxycarbonyl, C i-C4-alkylcarbonyl; C1-C4- halogenoalkylcarbonyl; Ci-C4-alkoxycarbonyl; or Ci-C4-halogenoalkoxycarbonyl; and
Q, R1, R , R4 and R5 have the same definition as given for formula (I).
In such preferred embodiments according to the present invention R3 even more preferably represents carboxaldehyde, hydroxycarbonyl, Ci-C4-alkylcarbonyl; or C1-C4- alkoxycarbonyl; and Q, R1, R2, R4 and R5 have the same definition as given for formula (I). In such preferred embodiments according to the present invention
R3 even more preferably represents carboxaldehyde, hydroxycarbonyl, methylcarbonyl (acetyl); carboxyl; methoxycarbonyl; or ethoxycarbonyl; and
Q, R1, R , R4 and R3 have the same definition as given for formula (I).
A preferred embodiment of the present invention relates to compounds of the formula (1-1)
Figure imgf000015_0001
wherein R1, R2, R R4, R5, U3, U4, X!, X2 and X5 have the same definition as given for formula (I).
In a further preferred embo compounds of the formula (I-l-Q-I-1)
Figure imgf000015_0002
I-l-Q-I-1)
wherein R1, R2, R3, R4, R\ X1, X2, X3, X4 and X5 have the same definition as given for formula (I).
In a further preferred embodiment of the present invention relates to compounds of the formula (I-l-Q-I-2)
Figure imgf000015_0003
wherein R , R\ R , R , R , X1, X2, X3 and X have the same definition as given for formula (I).
In a further preferred embodiment of the present invention relates to compounds of the formula (I-l-Q-I-3)
Figure imgf000016_0001
wherein R1, R2, R3, R4, R5, X1, X2, X4 and X5 have the same definition as given for formula (I).
The radical definitions and explanations given above in general terms or stated within preferred ranges can, however, also be combined with one another as desired, i.e. including between the particular ranges and preferred ranges. They apply both to the end products and correspondingly to precursors and intermediates. In addition, individual definitions may not apply.
Preference is given to those compounds of the formula (I) in which each of the radicals have the abovementioned preferred definitions.
Particular preference is given to those compounds of the formula (I) in which each of the radicals have the abovementioned more preferred definitions.
Very particular preference is given to those compounds of the formula (I) in which each of the radicals have the above mentioned most preferred definitions.
In the definitions of the symbols given in the above formulae, collective terms were used which are generally representative of the following substituents: The definition Ci-Cs-alkyl comprises the largest range defined here for an alkyl radical. Specifically, this definition comprises the meanings methyl, ethyl, n-, isopropyl, n-, iso-, sec-, tert-butyl, and also in each case all isomeric pentyls, hexyls, heptyls and octyls, such as methyl, ethyl, propyl, 1-methylethyl, butyl, 1- methylpropyl, 2-methylpropyl, 1 , 1 -dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1 ,2-dimethylpropyl, 1 , 1 -dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyi, 1-methylpentyl, 2- methylpentyl, 3-methylpentyl, 4-methylpentyl, 1 ,2-dimethylbutyl, 1,3-dimethylbutyl, 2 , 3 -dimethy lbutyl, 1,1- dimethylbutyl, 2 ,2-dimethylbutyl, 3,3-dimethylbutyl, 1 , 1 ,2-trimethylpropyl, 1 ,2,2-trimethylpropyl, 1- ethylbutyl, 2-ethylbutyl, 1 -ethyl-3 -methylpropyl, n-heptyl, 1 -methylhexyl, 1 -ethylpentyl, 2-ethylpentyl, 1- propylbutyl, octyl, 1 -methylheptyl, 2-methylheptyl, 1 -ethylhexyl, 2-ethylhexyl, 1-propylpentyl and 2- propylpentyl, in particular propyl, 1-methylethyl, butyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1- dimethylethyl, 1 ,2-dimethylbutyl, 1 ,3 -dimethylbutyl, pentyl, 1 -methylbutyl, 1-ethylpropyl, hexyl, 3- methylpentyl, heptyl, 1 -methylhexyl, 1 -ethyl-3-methylbutyl, 1 -methylheptyl, 1 ,2-dimethylhexyl, 1,3- dimethyloctyl, 4-methyloctyl, 1 ,2,2,3 -tetramethylbutyl, 1,3,3 -trimethy lbutyl, 1,2,3 -trimethy lbutyl, 1,3- dimethylpentyl, 1,3-dimethylhexyl, 5 -methyl- 3 -hexyl, 2-methyl-4-heptyl and 1 -methyl-2-cyclopropylethyl. A preferred range is Ci-C4-alkyl, such as methyl, ethyl, n-, isopropyl, n-, iso-, sec-, tert-butyl. The definition Ci-C3-alkyl comprises methyl, ethyl, n-, isopropyl. The definition halogen comprises fluorine, chlorine, bromine and iodine.
Halogen-substituted alkyl - referred to as Ci-Cs-haloalkyl - represents, for example, Ci-Cs-alkyl as defined above substituted by one or more halogen substituents which can be the same or different. Preferably Ci-Cs- haloatkyi represents chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, tri fluoromethyl, chloro fluoromethyl, dichloro fluoromethyl, chlorodi fluoromethyl, 1-fluoroethyl, 2- fluoroethyl, 2,2-difluoroethyl, 2,2,2 -trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2- dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyi, 1 -fluoro- 1 -methylethyl, 2-fluoro- 1,1- dimethylethyl, 2-fluoro- 1 -fluoromethyl- 1 -methylethyl, 2-fluoro- 1 , 1 -di(fluoromethyl)-ethyl, 3-chloro- 1 - methylbutyl, 2- chloro- 1 -methylbutyl, 1-chlorobutyl, 3 ,3 -dichloro- 1 -methylbutyl, 3-chloro- 1 -methylbutyl, 1- methyl- 3 -trifluoromethylbutyl, 3-methyl- 1 -trifluoromethylbutyl.
Mono- or multiple fluorinated Ci-C4-alkyl represents, for example, Ci-C4-a!kyl as defined above substituted by one or more fluorine substituent(s). Preferably mono- or multiple fluorinated Ci-C4-alkyl represents fluoromethyl, difluoromethyl, tri fluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2- trifluoroethyl, pentafluoroethyi, 1 - fluoro- 1 -methylethyl, 2-fluoro- 1 , 1 -dimethylethyl, 2-fluoro- 1- fluoromethyl- 1 -methylethyl, 2-fluoro- 1 , 1 -di(fluoromethyl)-ethyl, 1 -methyl- 3 -trifluoromethylbutyl, 3- methyl- 1 -trifluoromethylbutyl.
The definition C2-Cs-alkenyl comprises the largest range defined here for an alkenyl radical. Specifically, this definition comprises the meanings ethenyl, n-, isopropenyl, n-, iso-, sec-, tert-butenyl, and also in each case all isomeric pentenyls, hexenyls, heptenyls, octenyls, 1 -methyl- 1 -propenyl, 1 -ethyl- 1 -butenyl, 2,4- dimethyl- 1 -pentenyl, 2,4-dimethyl-2-pentenyi. Halogen-substituted alkenyl - referred to as C2-C8- haloalkenyl - represents, for example, C2-Cs-alkenyl as defined above substituted by one or more halogen substituents which can be the same or different. A preferred range is C2-C4-alkenyl, such as ethenyl, n-, isopropenyl, n-, iso-, sec- or tert-butenyl.
The definition C2-Cs-alkynyl comprises the largest range defined here for an alkynyl radical. Specifically, this definition comprises the meanings ethynyl, 11-, isopropynyl, n-, iso-, sec-, tert-butynyl, and also in each case all isomeric pentynyls, hexynyls, heptynyls, octynyls. Halogen-substituted alkynyl - referred to as C2- C8-haloalkynyl - represents, for example, C2-C8-alkynyl as defined above substituted by one or more halogen substituents which can be the same or different. A preferred range is C2-C4-alkynyl, such as ethynyl, n-, isopropynyl, n-, iso-, sec- or tert-butynyl. The definition C3-C?-cycloaIkyl comprises monocyclic saturated hydrocarbyl groups having 3 to 7 carbon ring members, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
The definition halogen- sub stituted cycloalkyl and halocycloalkyl comprises monocyclic saturated hydrocarbyl groups having 3 to 7 carbon ring members, such as 1 - fluoro- cyclopropyl and 1-chloro- cyclopropyl. The definition bicycloalkyl comprises spirocyclic alkyl wherein two substituents at the same carbon atom of a Cs-CT-cycloalkyl can form together with the carbon atom to which they are attached a C3-C7-cycloalkyl, this definition comprises for example the meaning spiro[2.2]pentyl. The definition bicycloalkyl also comprises bicyclic alkyls wherein two substituents at different adjacent or non- adjacent carbon atoms of a C3-C7-cycloalkyl can form together with the carbon atoms to which they are attached a C3-C6-cycloalkyl, this definition comprises for example the meaning bicyclo[2.2.1 ]heptane-2-yl, bicyclo[2.2.1]heptane-7-yi, bicycio[4.1.0]heptane-2-yl, bicyclo[4.1.0]heptane-3-yl, bicyclo[4.1.0]heptane-7-yl The definition bicycloalkyl also comprises bicyclic alky Is wherein two substituents at different adjacent or non- adjacent carbon atoms of a C3-C6-cycloalkyl can form an alkylene bridge between the carbon atoms to which they are attached, this definition comprises for example the meaning bicyclo[2.2.1 ]hept-2-ene-2-yl, bicyclo[2.2. l]hept-2-ene-5-yl, bicyclo[2.2. l]hept-2-ene-7-yl.
The definition aryl comprises aromatic, mono-, bi- or tricyclic ring, for example phenyl, naphthyl, anthracenyl (anthryl), phenanthracenyl (phenanthryl).
The definition hetaryl or heteroaryl comprises unsaturated, benzoannulated or not benzoannulated heterocyclic 5- to 10-membered ring containing up to 4 heteroatoms selected from N, O and S. Preferably The definition hetaryl or heteroaryl comprises unsubstituted or substituted, unsaturated heterocyclic 5- to 7- membered ring containing up to 4 heteroatoms selected from N, O and S: for example 2- fury 1, 3-furyl, 2- thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrrolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 1-pyrazolyl, 1 11- imidazol-2-yl, 1 H-imidazol-4-yl, 1 H-imidazol-5-yl, 1 H-imidazol- 1 -yl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2- thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-isothiazolyl, 4-isothiazolyl, 5- isothiazolyl, lH-l,2,3-triazol-l-yl, lH-l,2,3-triazol-4-yl, lH-l,2,3-triazol-5-yl, 2H-l,2,3-triazol-2-yl, 211- l,2,3-triazol-4-yl, lH-l,2,4-triazol-3-yl, lH-l,2,4-triazol-5-yl, lH-l,2,4-triazol-l-yl, 4H-l,2,4-triazol-3-yl, 4H-l,2,4-triazol-4-yl, lH-tetrazol-l-yl, lH-tetrazol-5-yl, 2H-tetrazol-2-yl, 2H-tetrazol-5-yl, 1,2,4-oxadiazol- 3-yl, l,2,4-oxadiazoi-5-yl, 1 ,2,4-thiadiazol-3 -yl, 1 ,2,4-thiadiazol-5-yl, l,3,4-oxadiazol-2-yl, 1,3,4-thiadiazol- 2-yl, l,2,3-oxadiazol-4-yl, l,2,3-oxadiazol-5-yl, l,2,3-thiadiazol-4-yl, l,2,3-thiadiazol-5-yl, 1,2,5-oxadiazol-
3- yl, l,2,5-thiadiazol-3-yl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl,
4- pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, l,3,5-triazin-2-yL l,2,4-triazin-3-yl, l,2,4-triazin-5-yl, 1,2,4- triazin-6-yl.
The definition 5-membered heteroaryl comprises an unsaturated heterocyclic 5-membered ring containing up to 4 heteroatoms selected from N, O and S: for example 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrrolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 1-pyrazolyl, 1 H-imidazol-2-yl, lH-imidazol-4- yl, 1 H-imidazol-5-yl, 1 H-imidazol- 1 -yl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5- thiazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1H-1,2,3- triazol-l-yl, lH-l,2,3-triazol-4-yl, lH-l,2,3-triazol-5-yl, 2H-l,2,3-triazol-2-yl, 2H-l,2,3-triazol-4-yl, I I I- l,2,4-triazol-3-yl, lH-l,2,4-triazol-5-yl, lH-l,2,4-triazol-l-yl, 4H-l,2,4-triazol-3-yl, 4H-l,2,4-triazol-4-yl, lH-tetrazol-l-yl, lH-tetrazol-5-yl, 2H-tetrazol-2-yl, 2H-tetrazol-5-yl, 1 ,2,4-oxadiazol-3 -yl, 1,2,4-oxadiazol-
5- yl, 1 ,2,4-thiadiazol-3 -yl, l,2,4-thiadiazol-5-yl, l,3,4-oxadiazol-2-yl, 1 ,3,4-thiadiazol-2-yl, 1,2,3-oxadiazol- 4-yl, 1 ,2,3 -oxadiazol-5 -yl, l,2,3-thiadiazol-4-yl, l,2,3-thiadiazol-5-yl, l,2,5-oxadiazol-3-yl, 1,2,5-thiadiazol-
3-yl.
The definition 6-membered heteroaryl comprises an unsaturated heterocyclic 6-membered ring containing up to 4 heteroatoms selected from N, O and S: for example 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3- pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, l,3,5-triazin-2-yl, l,2,4-triazin-3-yl, l,2,4-triazin-5-yl, l,2,4-triazin-6-yl.
The definition heterocycloalkyl comprises saturated or partially unsaturated mono-, bi- or tricyclic ring systems consisting of C-atoms and containing up to 4 heteroatoms selected from N, O and S: for example aziridinyl, pyrrolidinyl, dihydropyridyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydrothiofuranyl, tetrahydropyranyl, pyranyl, isoxazolidinyl, isoxazolinyl, pyrazolinyl, dihydropyrrolyl, tetrahydropyridinyl, dioxolanyl, dioxanyl, oxathiolanyl, oxathianyl, dithhiolanyl, dithianyl. The term partially unsaturated refers to ring systems that are neither saturated, i.e. comprising no double bound, nor fully unsaturated, i.e. comprising the maximum possible number of double bonds. In other words, partially unsaturated ring systems comprise at least one double bond, but not the maximum possible number of double bonds.
Optionally substituted radicals may be mono- or polysubstituted, where in the case of polysubstitution, the substituents may be identical or different.
Unless indicated otherwise, a group or a substituent which is substituted according to the invention preferably can be substituted by one or more group(s) selected from the list consisting of halogen; Si l; nitro; hydroxy!; cyano; amino; sulfanyl; pentafluoro- 6-sulfanyl; formyl; formyloxy; formylamino; carbamoyl; N- hydroxycarbamoyl; carbamate; (hydroxyimino)-C i-C«-alkyl; Ci-Cs-aikyl; Ci-Cg-halogenalkyl; Ci-Cg- alkyloxy; G-Cs-halogenalkyloxy; Ci-Cs-alkylthio; C i -Cs-halogenalkylthio ; tri(Ci-Cs-alkyl)silyl; tri(Ci-Cs- alkyl)silyl-Ci-C8-alkyl; C3-C7-cycloalkyl; C3-C7-halocycloalkyl; Cs-CT-cycloalkenyl; C3-C7- halocycloalkenyl; C4-Cio-cycloaIkylalkyl; C4-Cio-halocycloalkylalkyl; Ce-Cn-cycloalkylcycloalkyl; tri(Ci- Cs-alkyl)silyl-C3-C7-cycloalk;yl; C 1 -Cs-halogenoalkyl; C3-C7-halogenocycloalkyl; C2-Cs-alkenyl; C2-C8- alkynyl; C2-Cs-alkenyloxy; C2-Crhalogenalkenyloxy; C2-Cs-alkynyloxy; Ci-Cs-alkylarnino; di-Ci-Cs- alkylamino; C 1 -Cs-halogenalkylamino ; di-Ci-Cg-halogenalkylamino; Ci-Cs-alkylaminoalkyl; di-Ci-Cs- alkylaminoaliyl; Ci-Cs-alkoxy; C 1 -C s-halogenoalkoxy ; Ci-Cg-cyanoalkoxy; C4-Crcycloalkylalkoxy; Cs-Ce-cycloalkoxy; C2-Cs-alkoxyalkoxy; C 1 -Cg-alkylcarbonylalkoxy ; Ci-Cs-alkylsulfanyl; Ci-Cs- halogenoalkylsulfanyl; C2-Cs-alkenyloxy; C2-Cs-halogenoalkenyloxy; C3-Cs-alkynyloxy; C3-C8- halogenoalkynyloxy; Ci-Cs-alkylcarbonyl; Ci-Cg-halogenoalkylcarbonyi; Cs-Cs-cycloalkylcarbonyl; C3-C8- halogenocycloalkylcarbonyl; Ci-Cs-alkylcarbamoyl; di-Ci-Cs-alkylcarbamoyl; N-Ci-Cs-alkyloxycarbamoyl; Ci-Cs-allioxycarbamoyl; N-Ci-Cs-alkyl-Ci-Cralkoxycarbamoyl; Ci-Cs-alkoxycarbonyi; Ci-Cs- halogenoalkoxycarbonyl; C3 -C s- cy cloalkoxy carbonyl; C2-C8-alkoxyaliylcarbonyl; C2-C8- halogenoalkoxyalkylcarbonyl; C3- C 10- cy clo alkoxy alky lcarbonyl; Ci-Cg-alkylaminocarbonyl; di-Ci-Cs- alkylaminocarbonyl; C3-Cs-cycioalkylaminocarbonyl; C 1 -Cr alkylcarbonyloxy ; Ci-Cg- halogenoalkylcarbonyloxy; Cs-Cs-cycloalkylcarbonyioxy; C 1 -Cs-alkylcarbonylamino ; Ci-Cs- halogenoalkylcarbonylamino; Ci-Cs-alkylaminocarbonyloxy; di-Ci-Cs-alkylaminocarbonyloxy; Ci-Cs- alkyloxycarbonyloxy; Ci-Cs-alkylsulfmyl; Ci-Cg-haiogenoalkylsulfmyl; C i -Cg-alkylsulfonyl; Ci-Cs- halogenoalkylsulfonyl; Ci-Cs-alkylsulfonyloxy; Ci-Cs-halogenoalkyisulfonyloxy; G-Cs- alkylaminosulfamoyl; di-CrCs-alkylaminosulfamoyl; (Ci-Cs-alkoxyirnino)-Ci-C8-alkyl; (C3-C7- cycloalkoxyimino)-Ci-C8-alkyl; hydroxyimino-C 1 -Cs-alkyl; (CrCs-a]koxyimino)-C3-Crcycloalkyl; hydroxyimino-C3-C7-cycloalk>i; (Ci-Cs-alkylimino)-oxy; (Ci-Cs-alkylimino)-oxy-Ci-Cralkyl; (C3-C7- cycloalkylimino)-oxy-Ci-C8-alkyl; (CrC6-alkylimino)-oxy-C3-C7-cycloalky4; (Ci-Cs-alkenyloxyimino)- Ci-Ce-alkyl; (Ci-Cs-alkynyloxyimino)-Ci-Cralkyl; 2-oxopyrrolidin- 1 -yl, (benzyloxyimino)-C i-Cs-alkyl; Ci-Cs-alkoxyalkyi; Ci-Cs-alkylthioalkyl; C 1 -Cs-alkoxyalkoxyalkyl; CrCs-halogenoalkoxyalkyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenoxy; phenylsulfanyl; or phenylamino; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from the aforementioned list.
Depending on the nature of the substituents, the compounds according to the invention can be present as mixtures of different possible isomeric forms, in particular of stereoisomers, such as, for example, E and Z, threo and erythro, and also optical isomers, and, if appropriate, also of tautomers. What is claimed are both the E and the Z isomers, and also the threo and erythro, and the optical isomers, any mixtures of these isomers, and the possible tautomeric forms.
Depending on the nature of the substituents, the compounds of the present invention can exist in one or more optical or chiral isomer forms depending on the number of asymmetric centres in the compound. The invention thus relates equally to all the optical isomers and to their racemic or scalemic mixtures (the term "scalemic" denotes a mixture of enantiomers in different proportions) and to the mixtures of all the possible stereoisomers, in all proportions. The diastereoisomers and/or the optical isomers can be separated according to the methods which are known per se by the man ordinary skilled in the art. Depending on the nature of the substituents, the compounds of the present invention can also exist in one or more geometric isomer forms depending on the number of double bonds in the compound. The invention thus relates equally to all geometric isomers and to all possible mixtures, in all proportions. The geometric isomers can be separated according to general methods, which are known per se by the man ordinary skilled in the art. Depending on the nature of the substituents, the compounds of the present invention can also exist in one or more geometric isomer forms depending on the relative position (syn/anti or cis/trans) of the substituents of ring B. The invention thus relates equally to all syn/anti (or cis/trans) isomers and to all possible syn/anti (or cis/trans) mixtures, in all proportions. The syn/anti (or cis/trans) isomers can be separated according to general methods, which are known per se by the man ordinary skilled in the art. The compounds of formula (I) wherein Q is substituted by a hydroxy, a sulfanyl or an amino substituent may be found in its tautomeric form resulting from the shift of the proton of said hydroxy, sulfanyl or amino group. All tautomeric forms of such compounds of the present invention) wherein Q is substituted by a hydroxy, a sulfanyl or an amino substituent are also part of the present invention.
Illustration of the processes and intermediates
The present invention furthermore related to processes for preparing compounds of formula (I ). The present invention furthermore relates to intermediates such as compounds of formula (XVII) and the preparation thereof.
The compounds (I ) can be obtained by various routes in analogy to prior art processes known (see e.g. EP-A 461 502, DE-A 40 27 608, DE-A 32 35 935 and references therein) and by synthesis routes shown schematically below and in the experimental part of this application. Unless indicated otherwise, the radicals Q, R1, R' , R3, R4 and R5 have the meanings given above for the compounds of formula (I). These definitions apply not only to the end products of the formul a (I) but likewise to all intermediates.
Process A (Scheme I ):
Scheme 1: Process A - Preparation of Ketones (V).
Figure imgf000021_0001
= -I I or -OH
= halogen, -OS02-Ci-C8-alkyl, -OS02-aryi, -OP(0)(0-Ci-C8-alkyi)2 or -OP(0)(0-aryl)2, preferably -CI or -Br
= halogen, preferably -CI
= -O-Ci-Cg-alkyl, preferably -O-methyl, -O-ethyl; -O-aryl; -S-Ci-Cs-alkyl; -S-aryl; -NHR"; -NRaRb; Ra: is aryl, G-Cs-alkyl or C3-C7-cycloalkyl, Rb: is Ci-Cs-alkyl or Ci-Cs-alkyloxy, preferably - NMe¾ -NMeOMe; or heterocyclic leaving groups, such as imidazole, triazole and hydroxybenzotriazole. Compounds ( Ha) and/or (III ) are either commercially available or producible by processes described in the literature (see, for example, "Comprehensive Heterocyclic Chemistry III", Pergamon Press, 2008; vol. 7, pages 101-169; 217-308 & vol. 7, pages 1-331 and references cited therein; , "Comprehensive Heterocyclic Chemistry II", Pergamon Press, 1996; vol. 5, pages 37-243 & vol. 6, pages 1-278 and references cited therein; "Comprehensive Heterocyclic Chemistry I", Pergamon Press, 1984; vol. 2, pages 395-510 & vol. 3, pages 1-197 and references cited therein; "Comprehensive Heterocyclic Chemistry III", Pergamon Press, 2008; vol. 3, pages 45-388 & vol. 4, pages 1-364 and references cited therein; , "Comprehensive Heterocyclic Chemistry Π", Pergamon Press, 1996; vol. 2, pages 39-257 & vol. 3, pages 1-220 and references cited therein; "Comprehensive Heterocyclic Chemistry I", Pergamon Press, 1984; vol. 4, pages 155-376 & vol. 5, pages 167-498 and references cited therein).
The compounds (lla) (Scheme 1) can be converted by means of methods described in the literature to the corresponding compounds (I II ) and subsequently to compounds (V). In a first process, for example, compounds ( lla) are halogenated.
In case Y stands for hydrogen, the compounds (lla) can be halogenated e.g. with Bromo- or Chlorosuccinimide (see e.g. WO-A 2011/012622, WO-A 2008/003622, WO-A 2005/1 11003; Synthesis, 18, 2008, 2996 and references cited therein), preferably in the presence of a radical initiator such as Azobisisobutyronitrile or dibenzoyl peroxide and in the presence of an organic solvent, e.g. a chlorinated organic solvent such as tetrachloromethane. Alternatively, compounds ( lla) undergo side-chain halogenation in the presence of bromine or chlorine (see e.g. EP 557967) to obtain compounds (III ). Optionally, a radical initiator such as Azobisisobutyronitrile or dibenzoyl peroxide can be used. Alternatively, compounds ( lla) are reacted with a base, e.g. methyl lithium, and subsequently with a halogen source such as Magnesiumbromide to obtain compounds (III ) (see e.g. WO-A 2012/087784) Compounds (lla) where Y stands for OH are reacted with halogenating agents, such as PBr=, PCI3 or thionyl chloride, to obtain compounds (III) (see e.g. WO-A 2009/153554, Bioorganic & Medicinal Chemistry Letters, 22, 2012, 901-906, WO-A 2010/132999 and references cited therein). Alternatively, compounds ( lla) can be reacted with sulfonyl halides, such as e.g. Mesylchloride or Tosylchloride, or with phosphonic acid halides, such as e.g. diphenylphosphoryl chloride, to obtain the respective sulfonates and phosphates (see e.g. J. Org. Chem. 1992,57, 5425-5431 and references cited therein)
The compounds (III ) can subsequently be reacted with compounds (IV) or (VI ) wherein A and E represent a replaceable group such as halide, -OR, NHRa or NRaRb, preferably chloro, -O-methyl, -O-ethyl, - Me2 or - NMeOMe. To obtain compounds (V), compounds (III ) are reacted in a first step with e.g. Zink, Magnesium or isopropylmagnesium chloride, followed by a carbonyl compound ( IV) or (VI) preferably under anhydrous conditions and optionally in the presence of a metal catalyst, such as palladium- or nickel-based catalysts. The metal catalyst can be used such as (Ph3P)2PdCl2 (e.g. WO-A 2012/087784, EP-A 461 502), PEPPSI-IPr (Chem. Eur. J. 2006, 12, 4743 - 4748) or prepared in- situ by the mixing of a metals salt (e.g. Pd(OAc)2) and a ligand (such as e.g. PPhi, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (S-Phos)). The Insertion of the metal can be enhanced by the addition of ionic salts, such as Li Br, LiCl, Lil, Cul, Zn(OPiv)2, MgCl¾ CuCN (see e.g. Dissertation Albrecht Metzer 2010 (University Munich); Angew. Chem. Int. Ed. 201 1, 50, 9205 -9209), or by activation of the metal using halogenated alkanes ( 1 ,2-dibromoethane) or halogenated alkylsilanes (TMSC1). Alternatively this sequence may be carried out in a one-pot fashion (see e.g. Beller et al, Chem. Asian J., 2011, 7(1) 40-44).
The reaction is preferably performed at temperatures between room temperature and re fluxing temperature of the solvent. As the solvent, all common solvents inert under the reaction conditions, such as for example ethers (such as e.g. tetrahydrofurane, diethyl ether) can be used and the reaction can be effected in mixtures of two or more of these solvents.
Process B (Scheme 2):
Scheme 2: Process B - Preparation of Ketones (V)
Figure imgf000023_0001
A = halogen, preferably CI
E = -O-Ci-Cs-alkyl, preferably -O-methyl, -O-ethyl; -0-aryl; -S-Ci-Cs-alkyl; -S-aryl; -NHRa; -NRaRb;
R": is aryl, Ci-Cg-alkyl or C3-C7-cycloalkyl, Rb: is Ci-Cs-alkyl or Ci-Cs-alkyioxy, preferably - Me2, -NMeOMe; or heterocyclic leaving groups, such as imidazole, triazole and hydroxybenzotriazole.
Compounds (lib) are either commercially available or producible by processes described in the literature
(see, for example, "Comprehensive Heterocyclic Chemistry III", Pergamon Press, 2008; vol. 7, pages 101- 169; 217-308 & vol. 7, pages 1-331 and references cited therein; , "Comprehensive Heterocyclic Chemistry
Π", Pergamon Press, 1996; vol. 5, pages 37-243 & vol. 6, pages 1-278 and references cited therein;
"Comprehensive Heterocyclic Chemistry I", Pergamon Press, 1984; vol. 2, pages 395-510 & vol. 3, pages 1-
197 and references cited therein; "Comprehensive Heterocyclic Chemistry III", Pergamon Press, 2008; vol.
3, pages 45-388 & vol. 4, pages 1-364 and references cited therein; , "Comprehensive Heterocyclic Chemistry II", Pergamon Press, 1996; vol. 2, pages 39-257 & vol. 3, pages 1-220 and references cited therein; "Comprehensive Heterocyclic Chemistry I", Pergamon Press, 1984; vol. 4, pages 155-376 & vol. 5, pages 167-498 and references cited therein).
There are numerous literature methods for the preparation of ketones (see e.g. WO-A 2012/055942, WO-A 2012/100342, WO-A 2012/087784, WO-A 2012/087833, US-A 2012/0010190, Dalton Transaction, 2011, 2366-2374, Journal of the American Chemical Society, 1955, 3858-3860, Journal of the American Chemical Society, 1937, 1494-1497, W -A 2012/085815, WO-A 2011/042389, WO-A 2003/026663, Heterocycles, 1998, 2103-2109, Bioorganic & Medicinal Chemistry Letters, 2010, 2634-2640).
In general, it is possible to prepare compounds of the formula (V) from corresponding compounds (lib) and ( IV) and/or from corresponding compounds (lib) and (VI ) with suitable groups A and E (see Scheme 2, process B). Compounds (lib) are optionally reacted sequentially with a base, e.g. n-butyllithium, lithium- diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide sodium amide, potassium amide, potassium tert-butoxide, methyl lithium, TMP2Zn · 2MgCb · 2LiCl (see e.g. Dissertation Albrecht Metzer 2010, University Munich), followed by compounds (IV) or (VI), preferably under anhydrous conditions. Optionally, the reaction of compounds (lib) and compounds (IV) or (VI ) is carried out in the presence of a base in a one-pot fashion. The possible groups for A and E are, for example, halide, -OR. NHR" or NRaRb, preferably chloro, -O-methyl, -O-ethyl, - NMe2 or -NMeOMe, etc., which can act as appropriate leaving groups to form the desired ketones ( V) under suitable reaction conditions (Scheme 2).
In an alternative route compounds (lib) are reacted with compounds (VII ) in the presence of a base, e.g. phenyl lithium or methyl lithium, to obtain compounds (V) (see e.g. Journal of the American Chemical Society, 2011, 11194-11204; Journal of Medicinal Chemistry 1963, 205-207 and references cited therein).
Process C (Scheme 3):
•erne 3: Process C - Preparation of Ketones (V)
Figure imgf000024_0001
halogen, preferably CI or Br
O or l
Li, MgZM, ZnZM, Si(Ci-C8-alkyl)3, Sn(Ci-C8-alkyl)3
halogen, hydroxy! preferably CI or Br
One means of preparin compounds of the formula ( V) from corresponding compounds (VIII) with the compounds (IX) or (X) is shown in Scheme 3 (Process Q. Compounds (X) include compounds (Xa), (Xb) and (Xc)
Compounds (VIII ) are either commercially available or producible by processes described in the literature (see, for example, "Comprehensive Heterocyclic Chemistry III", Pergamon Press, 2008; vol. 7, pages 101- 169; 217-308 & vol. 7, pages 1-331 and references cited therein; , "Comprehensive Heterocyclic Chemistry II", Pergamon Press, 1996; vol. 5, pages 37-243 & vol. 6, pages 1-278 and references cited therein; "Comprehensive Heterocyclic Chemistry I", Pergamon Press, 1984; vol. 2, pages 395-510 & vol. 3, pages 1- 197 and references cited therein; "Comprehensive Heterocyclic Chemistry III", Pergamon Press, 2008; vol. 3, pages 45-388 & vol. 4, pages 1-364 and references cited therein; , "Comprehensive Heterocyclic Chemistry II", Pergamon Press, 1996; vol. 2, pages 39-257 & vol. 3, pages 1-220 and references cited therein; "Comprehensive Heterocyclic Chemistry I", Pergamon Press, 1984; vol. 4, pages 155-376 & vol. 5, pages 167-498 and references cited therein).
Compounds ( IX) and (X) are either commercially available or producible by processes described in the literature (see, for example, WO-A 2010/029066; Chemische Berichte, 1986, 2995-3026 and references cited therein). A compound having the general formula (V) can be synthesized analogously to methods described in the literature (see, for example Organic letters, 2009, 1773-1775; European Journal of Organic Chemistry, 2011, 1570-1574), by a coupling reaction of a compound with the corresponding general formula (VIII) with a substrate of the general formula (IX) or (X) where Z is halogen, preferably chlorine or bromine.
Compounds (VIII) are reacted with compounds of the general structure (IX) or (X) to obtain compounds ( V) analogously to methods described in the literature (e.g. Organic letters, 2009, 1773-1775, European Journal of Organic Chemistry, 2011, 1570-1574, Chemical & Pharmaceutical Bulletin, 1970, 1457- 1464, Chemical & Pharmaceutical Bulletin, 1980, 337-342, WO-A 2005/044785). Those reactions can be optionally carried out in the presence of a catalyst and a base.
As catalysts for the reaction various metal based catalysts can be used which are either used directly or being in situ prepared from a metal precursor (e.g. Pd2dba3, Pd(OAc)?) and a ligand (e.g. phosphine based ligands like Xanthphos, 2-(dicyciohexylphosphino)-2'-methylbiphenyl, 2-Diphenylphosphino-2'-(N,N- dimethylamino)biphenyl, tri-t-butylphosphine, Tri-o-tolylphosphine) (see e.g. WO-A 2008/147544, WO-A 2005/027837).
As bases various organic and inorganic bases can be used such as potassium phosphate, base, e.g. sodium amide, sodium hydride or sodium tert-butoxide. Alternatively, silicon containing bases can be used (e.g. NaHMDS, KHMDS, LiHMDS).
Figure imgf000025_0001
The compounds (V) (Scheme 4) can be converted by means of methods described in the literature to the corresponding compounds (XII ) (see e.g. EP-A 461 502, DE-A 33 15 681, H - A 291 797, Bioorganic & Medicinal Chemistry Letters (1996), 6(16), 2031-2036). Intermediates (V) are preferably reacted with trimethylsulfoxonium- or trimethylsulfonium-salts, preferably trimethylsulfoxonium halides, trimethylsulfonium halides, trimethylsulfoxonium methylsulfates or trimethylsulfonium methylsulfates, preferably in the presence of a base such as sodium hydride.
Process E (Scheme 5):
Figure imgf000026_0001
Alternatively, compounds (V) can be first converted to the corresponding olefins (XIII ). followed by epoxidation to obtain epoxides (XII ) (see e.g. EP-A 291 797).
Process F (Scheme 6):
Scheme 6: Process F - Preparation of Epoxides (XII).
Figure imgf000026_0002
G = halogen or hydrogen
A = halogen, 0-S02-Ci-C8-alkyi or O-SC -aryi, preferably CI or Br
Alternatively, a compound having the general formula (XII ) can be synthesized analogously to methods described in the literature by a coupling reaction of a compound having the corresponding general formula ( lie) with a substrate of the general formula (XIV) (see e.g. DE-A 40 27 608, WO-A 93/02086, WO-A 93/12121, Journal of Organic Chemistry, 2001, 2149-2153 and references cited therein).
Compounds ( lie) are either commercially available or producible by processes described in the literature (see, for example, "Comprehensive Heterocyclic Chemistry III", Pergamon Press, 2008; vol. 7, pages 101- 169; 217-308 & vol. 7, pages 1-331 and references cited therein; , "Comprehensive Heterocyclic Chemistry Π", Pergamon Press, 1996; vol. 5, pages 37-243 & vol. 6, pages 1-278 and references cited therein; "Comprehensive Heterocyclic Chemistry I", Pergamon Press, 1984; vol. 2, pages 395-510 & vol. 3, pages 1- 197 and references cited therein; "Comprehensive Heterocyclic Chemistry III", Pergamon Press, 2008; vol. 3, pages 45-388 & vol. 4, pages 1-364 and references cited therein; , "Comprehensive Heterocyclic Chemistry II", Pergamon Press, 1996; vol. 2, pages 39-257 & vol. 3, pages 1-220 and references cited therein; "Comprehensive Heterocyclic Chemistry I", Pergamon Press, 1984; vol. 4, pages 155-376 & vol. 5, pages 167-498 and references cited therein).
If G stands for halogen, preferably chloride or bromide, compounds (lie) are first transformed into Grignard reagents by the reaction with magnesium or with halogen/metal exchange reagents such as isopropylmagnesium halides and subsequently reacted with ketones (XIV) preferably under anhydrous conditions to obtain compounds of the general formula (XII) (see e.g. DE4027608). Alternatively, if G stands for halogen, the halides (lie) can be converted to the corresponding zinc reagents and subsequently reacted with ketones (XIV) (e.g. ChemComm, 2008, 5824-5826; Journal of Organic Chemistry, 2004, 908- 914 and references cited therein).
In an alternative route compounds (lie) (G=hydrogen) are reacted with compounds (XIV) preferably in the presence of a base. Compounds (lie) (G=hydrogen) are optionally reacted with a base upfront, e.g. n- butyllithium, lithium-diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide sodium amide, potassium amide, potassium tert-butoxide, methyl lithium, T M P : Z i r 2 M 1 y 2 L i C I (see e.g. Dissertation Albrecht Metzer 2010, University Munich), followed by compounds of the general structure (XIV) preferably under anhydrous conditions. The possible groups for A are, for example, halides which can act as appropriate leaving groups to form the desired compounds (XII) under suitable reaction conditions.
Process G (Scheme 7):
- Preparation of Alcohol (XV).
Figure imgf000027_0001
A = halogen, 0-S02-Ci-C8-alkyl or 0-S02-aryl, preferably CI or Br
A compound having the general formula (XV) can be synthesized analogously to methods described in the literature by a coupling reaction of a compound having the corresponding general formula (He) with a substrate of the general formula (XIV) (see e.g. DE-A 40 27 608, WO-A 93/02086, WO- A 93/12121, Journal of Organic Chemistry, 2001, 2149-2153).
If G stands for halogen, preferably chloride or bromide, compounds (lie) are first transformed into Grignard reagents by the reaction with magnesium or with halogen/metal exchange reagents, such as isopropylmagnesium halides, and subsequently reacted with ketones (XIV ) preferably under anhydrous conditions to obtain compounds of the general formula (XV) (see e.g. DE-A 4027608). Alternatively, if G stands for halogen, the halides (He) can be converted to the corresponding zinc reagents and subsequently reacted with ketones (XIV) (e.g. ChemComm, 2008, 5824-5826; Journal of Organic Chemistry, 2004, 908- 914 and references cited therein).
In an alternative route compounds (He) (G=hydrogen) are reacted with compounds (XIV) preferably in the presence of a base. Compounds (He) (G=hydrogen) are optionally reacted with a base upfront, e.g. n- butyllithium, lithium-di-isopropylamide, lithium bis(trimethylsilyl)amide, methyl lithium, followed by compounds of the general structure (XIV) preferably under anhydrous conditions. The possible groups for A are, for example, halides which can act as appropriate leaving groups to form the desired compounds (XV) under suitable reaction conditions.
Process H (Scheme 8):
Scheme 8: Process II Pre aration of compounds (la).
Figure imgf000028_0001
The compounds (XII ) obtained according to Process D, E or F can be converted by means of methods described in the literature to the corresponding compounds (la) (see e.g. DE-A 40 27 608, EP-A 461 502, DE-A 33 15 681, EP-A 291 797, WO9529901, EP0291797,). The starting materials (XII) can be reacted with an imidazole of formula (XVI) which are commercially available or can be obtained by means of methods described in the literature, optionally in the presence of a base, such as potassium carbonate and/or potassium iert-butoxide, optionally in the presence of a Lewis acid, such as magnesium dichloride or BFj/Et20. Alternatively, organomagnesium bases such as MeMgCl, TMPMgCl or analogues may also be employed (see Org. Lett, 2016, 18 (1), pp 16-19 DOI: 10.1021/'acs.orglett.5b02994).
As the solvent, all common solvents inert under the reaction conditions, such as for example nitriles (such as e.g. acetonitrile, propionitrile) can be used and the reaction can be effected in mixtures of two or more of these solvents.
Process I (Scheme 9):
Scheme 9: Process I Pre aration of compounds (la).
Figure imgf000028_0002
A = halogen, 0-S02-Ci-C8-aIkyl or 0-S02-aryl, preferably CI or Br
The compounds (XV) obtained according to Process G can be converted by means of methods described in the literature to the corresponding compounds ( la) (see e.g. DE-A 40 27 608). The starting materials (XV) can be reacted with an imidazole of formula ( XV I ) which are commercially available or can be obtained by means of methods described in the literature, optionally in the presence of a base, such as potassium carbonate and'or potassium iert-butoxide, optionally in the presence of a Lewis acid, such as magnesium dichloride or
Figure imgf000029_0001
Alternatively, organomagnesium bases such as MeMgCl, TMPMgCi or analogues may also be employed (see Org. Lett, 2016, 18 (1), pp 16-19 DOI: 10.1021/acs.orglett.5b02994).
As the solvent, all common solvents inert under the reaction conditions, such as for example nitriles (such as e.g. acetonitrile, propionitrile) can be used and the reaction can be effected in mixtures of two or more of these solvents.
Process J (Scheme 10):
Scheme 10: Process J - Preparation of ketones (XVII).
Figure imgf000029_0002
: halogen, 0-S02-Ci-C8-aIkyl or 0-S02-aryl, preferably CI or Br
The imidazoles of formula (XVI ) which are commercially available or can be obtained by means of methods described in the literature can be alkylated by compounds of formula (XIV) by means of methods described in the literature to the corresponding ketones (XVII) (see e.g Chemical Biology & Drug Design (2010), 75(1), 68-90, Acta Chemica Scandinavica (1990), 44(1), 1050-1057). The reaction is optionally in the presence of a base, such as potassium carbonate, triethylamine, and/or potassium tert-butoxide,, optionally in the presence of a Lewis acid, such as magnesium dichloride or BFiiEW, optionally in the presence of a metal oxide, such as zinc oxide or barium oxide. Alternatively, organomagnesium bases such as MeMgCl, TMPMgCi or analogues may also be employed (see Org. Lett., 2016, 18 (1), pp 16-19 DOI: 10.1021/acs.orglett.5b02994).
As the solvent, all common solvents inert under the reaction conditions, such as for example nitriles (such as e.g. acetonitrile, propionitrile) can be used and the reaction can be effected in mixtures of two or more of these solvents.
Process K (Scheme 11):
Scheme 11: Process K- Preparation of ketones (XVII).
Figure imgf000029_0003
(XVI) fxx-, R R3
(ΛΑ) (XXI) (XVII) A = halogen, 0-S02-Ci-C8-alkyl or 0-S02-aryl, preferably CI or Br
PG = formyl; Ci-Cs-alkyl; Ci-Cs-halogenalkyl; tri(Ci-C8-alkyl)silyl; tri(Ci-C8-alkyl)silyl-Ci-C8-alkyl; C2-C8-alkenyl; C2-C8-alkynyl, C i -Cs-a kylsulfonyl; Ci-Cs-alkylcarbonyl; Ci-Cs-halogenoalkylcarbonyi; C3- C8-cycloalkylcarbonyl; Ci-Cs-alkylcarbamoyl; di-Ci-Cs-alkylcarbamoyl; N-Ci-Cs-alkyioxycarbamoyl; Ci- Cg-alkoxycarbamoyl; N-C l-Cs-alkyl-C 1 -Cs-alkoxycarbamoyl; Ci-Cs-alkoxycarbonyl; Ci-Cs- halogenoalkoxycarbonyl; C3 -C cy cloalkoxy carbonyl; Ci-Cs-alkoxyalkylcarbonyl; C2-C8- halogenoalkoxyalkylcarbonyl; C3- C 10- cy clo alkoxy alky lcarbonyl; Ci-Cs-alkylaminocarbonyi; di-Ci-Cs- alkylaminocarbonyl; Cs-Cg-cycloalkylaminocarbonyl; C 1 -Cs-alkoxyalkyl; Ci-Cg-alkylthioalkyl; Ci-Cs- alkoxyalkoxyalkyl; Ci-Cs-halogenoalkoxyalkyl; aryl; arylalkyl; arylalkenyl; arylalkynyl; arylsulfonyl; phenoxyalkyl; heterocycloalkyl; heterocycloalkyl-C 1 -Cs-alkyl, ; 5-membered heteroaryl; 6-membered heteroaryl; wherein aryl; arylalkyl; arylalkenyl; arylalkynyl; arylsulfonyl; phenoxyalkyl; heterocycloalkyl; heterocycloalkyl-Ci-Cs-alkyl,; 5-membered heteroaryl; 6-membered heteroaryl may be optionally substituted by halogen, Ci-Cs-alkyl, Ci-Cs-alkoxy, nitro.
The imidazoles of formula (XVI ) which are commercially available or can be obtained by means of methods described in the literature can be converted into imidazoles of formula (XX) by means of methods described in the literature (see e.g "Protective groups in organic synthesis", Wiley Interscience, 1999; 3rdedition, T. Greene & P. Wuts , p.615-632 and references cited therein, Journal of organic chemistry (2013), 78, 12220- 12223). The reaction is optionally in the presence of a base, such as potassium carbonate, triethylamine, and/or potassium tert-butoxide,, optionally in the presence of a Lewis acid, such as magnesium dichloride or ΒΡ3/Τ¾0, optionally in the presence of a metal oxide, such as zinc oxide or barium oxide.
The imidazoles of formula (XX) can consequently be converted into imidazolium salts of formula (XXI) by means of methods described in the literature (see e.g "Protective groups in organic synthesis", Wiley Interscience, 1999; 3rdedition, T. Greene & P. Wuts , p.615-632 and references cited therein, Journal of organic chemistry (2013), 78, 12220-12223). The reaction is optionally in the presence of a base, such as potassium carbonate, triethylamine, and/or potassium tert-butoxide,, optionally in the presence of a Lewis acid, such as magnesium dichloride or BF3/Et20, optionally in the presence of a metal oxide, such as zinc oxide or barium oxide.
Finally, imidazolium salts of formula (XXI) can be converted into ketones of formula (XVII) by means of methods described in the literature (see e.g "Protective groups in organic synthesis", Wiley Interscience, 1999; 3rdedition, T. Greene & P. Wuts , p.615-632 and references cited therein, Journal of organic chemistry (2013), 78, 12220-12223).
As the solvent, all common solvents inert under the reaction conditions, such as for example nitriles (such as e.g. acetonitrile, propionitrile) or alcohols ( such as e.g. methanol, ethanol), can be used and the reaction can be effected in mixtures of two or more of these solvents.
Process L (Scheme 12):
Figure imgf000031_0001
(XVIIa) (XVIIb)
R3a = halogen, O-SC -Ci-Cs-alkyl or 0-S02-aryl, preferably Br or I
R3b = cyano; amino; hydro xycarbonyl, Ci-Cs-alkyl; Ci-Cs-haloalkyi; Ci-Cs-cyanoalkyl; Ci-Cs- alkyloxy; Ci-Cs-halogenalkyloxy ; tri(Ci-Cs-alkyl)silyl-Ci-C8-alkyl; Cs-CT-cycloalkyl; C3-C7- halogenocycloalkyl; C3-C7-cycloalkenyl; C3-C7-halogencycloalkenyl; C4-C 10-cycloalkylalkyl; C4-C10- halocycloalkyialkyl; C«-C 12-cycloalkylcycloalkyl; C 1 -Cs-alkyl-Cs-C?- cy cloalkyl; Ci-Cg-alkoxy-Cs-C?- cycloalkyl; tri(Ci-Cs-alkyl)silyl-C3-C7-cycloalkyi; C2-Cs-alkenyl; C^-Cs-alkynyl; C2-Cs-alkenyloxy; C2-C8- halogenalkenyloxy; C3-Cs-alkynyloxy; Cs-Cs-halogenoalkynyloxy; Ci-Cs-alkylamino; Ci-Cs- halogenalkyl amino; Ci-Cs-cyanoalkoxy; C4-Cs-cycloalkylalkoxy; C3-C6-cycloalkoxy; Ci-Cs- alkylcarbonyl; Ci-Cs-halogenoalkylcarbonyl; arylcarbonyl; C3-Cs-cycloalkylcarbonyl; Cs-Cs- halogenocycloalkylcarbonyl; Ci-Cs-alkylcarbamoyl; di-Ci-Cs-alkylcarbamoyl; N-Ci-Cs-alkyloxycarbamoyl; Ci-Cg-alkoxycarbamoyl; N-Ci-Cs-alkyl-Ci-Cg-alkoxycarbamoyl; C 1-Cs-alko xycarbonyl; Ci-Cs- halogenoalkoxycarbonyl; C3-Cs- cy cloalkoxy carbonyl; C2-C8-alkoxyalkylcarbonyl; C2-C8- halogenoalkoxyalkylcarbonyl; C3-Cio-cycloalkoxyalkylcarbonyl; Ci-Cs-alkylaminocarbonyl; di-Ci-Cs- alkylaminocarbonyl; Cs-Cs-cycloalkylaminocarbonyl; (Ci-C8-alkoxyimino)-Ci-Cs-alkyl; (C3-C7- cycloalkoxyimino)-Ci-C8-alkyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; amino; sulfanyl; pentafluoro- 6-sulfanyl; carboxaldehyde, hydroxycarbonyl, Ci-Cs-alkyl; Ci-Cs-haioalkyl; Ci-Cs-cyanoalkyl; Ci-Cs- alkyloxy; Ci-Cs-halogenalkyloxy; tri(Ci-Cs-alkyi)silyl; tri(Ci-C8-alkyl)silyl-Ci-Cs-alkyl; C3-C7-cycloalkyl; C3-C7-halogencycloalkyl; C3-C7-cycloalkenyl; C3-C7-halogencycloalkenyl; C4-Cio-cycloalkylalkyi; C4-C10- halocycloalkylalkyl; Ce-C 12-cycloalkylcycloalkyl; C 1 -Cs-alkyl-C3-C7- cy cloalkyl; C 1 -Cs-alkoxy-C3-C7- cycloalkyl; tri(Ci-Cs-alkyl)silyl-C3-C7-cycloalkyi; C2-Cs-alkenyl; C2-Cs-alkynyl; C2-Cs-alkenyloxy; C2-C8- halogenalkenyloxy; C3-Cs-alkynyioxy; C3-Cs-halogenoalkynyloxy; Ci-Cs-alkylamino; G-Cs- halogenalkylamino; Ci-Cs-cyanoalkoxy; G^-Cs-cycloalkylalkoxy; C3-Ce-cycloalkoxy; Ci-Cs-alkylsulfanyl; C 1 -C8-halogenoalkylsulfanyl; Ci-Cs-alkyicarbonyl; Ci-Cs-halogenoalkylcarbonyl; arylcarbonyl; C3-C8- cycloalkylcarbonyl; Cs-Cs-halogenocycloalkylcarbonyl; Ci-Cs-alkyicarbamoyi; di-Ci-Cg-alkylcarbamoyl; N-Ci-Cs-alkyloxycarbamoyl; Ci-Cs-alkoxycarbamoyl; N-Ci-Cs-aikyl-Ci-Cs-alkoxycarbamoyl; Ci-Cs- alkoxycarbonyl; Ci-Cs-halogenoalkoxycarbonyl; Cs-Cs-cycloalkoxycarbonyl; C2-Cs-alkoxyalkylcarbonyl; C2-C8-halogenoalkoxyalkylcarbonyl; C3-C 10-cycloalkoxyalkyicarbonyl; C 1 -Cg-alkylaminocarbonyl; di-C 1 - Cs-alkylaminocarbonyl; Cs-Cs-cycloalkylaminocarbonyl; Ci-Cs-alkylcarbonyloxy; Ci-Cs- halogenoalkylcarbonyloxy; Cs-Crcycloalkylcarbonyloxy; Ci-Cs-alkylcarbonylamino; Ci-Cs- halogenoalkylcarbonylamino; Ci-Cs-alkylaminocarbonyloxy; di-Ci-Cs-alkylaminocarbonyloxy; Ci-Cs- alkyloxycarbonyloxy; Ci-Cs-alkylsulfinyl; Ci-Cs-halogenoalkylsulfmyl; C i -Cs-alkylsulfonyl; Ci-Cs- halogenoalkylsulfonyl; Ci-Cs-alkylsulfonyloxy; C i -Cs-halogenoalkylsulfonyloxy ; Ci-Cs- alkylaminosulfamoyl; di-Ci-Cs-alkylaminosulfamoyl; (Ci-Cralkoxyimino)-Ci-C8-alkyl; (C3-C7- cycloalkoxyimmo)-Ci-Cs-alkyi; hydroxyimino-C 1 -Cs-alkyl; (Ci-Cs-alkoxyimino)-C3-C7-cycloalkyl; hydroxyimino-C3-C7-cycloalkyl; (Ci-Cs-allcylimino)-oxy; (Ci-Cs-alkylimmo)-oxy-Ci-Cralkyl; (C3-C7- cycloalkylimino)-oxy-Ci-C8-alkyl; (Ci-C6-alkyUrruno)-oxy-C3-C7-cycloalkyl; (Ci-Cs-alkenyloxyimino)- Ci-C8-alkyl; (C 1 -C8-alkynyloxyimino)-C 1 -Cs-alkyl; (benzyloxyimino)-C i-Cs-alkyl; Ci-Cs-alkoxyalkyl; Ci- Cg-alkylthioalkyl; Ci-Cs-alkoxyalkoxyalkyl; Ci-Cs-halogenoalkoxyalkyl; benzyl; phenyl; 5-niembered heteroaryl; 6-membered heteroaryl; benzyloxv; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino.
The ketones of formula (W'lla) obtained according to Processes J or K can be converted by means of methods described in the literature to the corresponding compounds (XVIIb) (see e.g "Palladium in heterocyclic chemistry", Pergamon Press, 2000; lstedition, J. Li & G. Gribble) via a coupling reaction, optionally in the presence of a catalyst, preferably a transition metal catalyst, such as copper salts, palladium salts or complexes for example palladium (II) chloride, palladium (II) acetate, tetrakis-(triphenylphosphine) palladium(O), bis-(triphenylphosphine) palladium dichloride (II), tris(dibenzylideneacetone) dipalladium(O), bis(dibenzylideneacetone) palladium(O), or 1 , 1 ,-bis(diphenylphosphino)ferrocene-palladium (II) chloride. As an alternative the palladium complex is directly generated in the reaction mixture by separately adding to the reaction mixture a palladium salt and a complex ligand such as a phosphine, for example triethylphosphine, tri-tert-butylphosphine, tricyclohexylphosphine, 2-(dicyclohexylphosphine)biphenyl, 2-(di-tert- butylpho sphin)biphenyl, 2-(dicyclohexylphosphine)-2'-(N,N-dimethylamino)-biphenyl, triphenylphosphine, tris-(o-tolyl)phosphine, sodium 3 -(diphenylphosphino)benzolsulfonate, tris-2-(methoxyphenyl)phosphine, 2,2'-bis-(diphenylphosphine)- 1 , 1 '-binaphthyl, 1 ,4-bis-(diphenylphosphine)butane, 1 ,2-bis-
(diphenylphosphine)ethane, 1 ,4-bis-(dicyclohexylphosphine)butane, 1 ,2-bis-(dicyclohexylphosphine)ethane, 2-(dicyciohexylphosphine)-2'-(N,N-dimethylamino)-biphenyl, bis(diphenylphosphino)ferrocene, tris-(2,4- tert-butylphenyl)-phosphite, (R)-(-)-l-[(S)-2-(diphenylphosphino)ferrocenyl]ethyldi-tert-butylphosphine, (S)-(+)-l-[(R)-2-(diphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine, (R)-(-)-l-[(S)-2- (diphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine, (S)-(+)-l-[(R)-2- (diphenylphosphino)ferrocenyl]ethyldi-t-butylphosphine.
Such coupling reactions are optionally performed in the presence of a base such as an inorganic or an organic base; preferably an alkaline earth metal or alkali metal hydride, hydroxide, amide, alcoholate, acetate, carbonate or hydrogen carbonate, such as sodium hydride, sodium amide, lithiium diisopropylamide, sodium methanolate, sodium ethanolate, potassium tert-butanolate, sodium acetate, potassium acetate, calcium acetate, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, potassium bicarbonate, sodium bicarbonate, cesium carbonate or ammonium carbonate; and also tertiary amine, such as trimethylamine, triethylamine (TEA), tributylamine, N,N-dimethylaniline, N,N-dimethyl-benzylamine, N,N- diisopropyl-ethylamine (DIPEA), pyridine, N-methylpiperidine, N-methylmorpholine, N,N- dimethylaminopyridine, diazabicyclooctane (DABCO), diazabicyclononene (DBN) or diazabicycloundecene (DBU),
For example, a compound of formula (XVIla) is reacted with a cyanide reagent such as a metallic cyanide for example sodium cyanide, potassium cyanide, zinc cyanide; a metallo'idic cyanide, an organo-metallic cyanide for example di-Ci-Ce-alkylaluminum cyanide notably di-ethylaluminum cyanide; an organo- metallo'idic cyanide for example tri-Ci-Ce-alkyisilylcyanide notably tri-methylsilylcyanide in order to yield a compound of formula (XVI lb) wherein R3b represents a cyano.
Process M (Scheme 13):
Figure imgf000033_0001
In a process according to Scheme 13, the ketones of formula (XVII ) obtained according to Processes J to L are reacted with derivatives (li ), wherein G stands for halogen or hydrogen. If G stands for halogen, compounds (lie) are first transformed into Grignard reagents by the reaction with magnesium or with transmetallation reagents such as isopropylmagenesium halides and subsequently reacted with ketone (XVU ), preferably under anhydrous conditions to obtain compounds (la).
In case G stands for hydrogen, compounds ( lie) can be reacted with an organolithium reagent such as methyllithium or n-butyllithium preferably under anhydrous conditions to obtain a lithiated species. Optionally, a base such as lithiumdiisopropylamide or lithium bis(trimethylsilyl)amide, can be used. The obtained intermediates are subsequently reacted with ketones (XVU), preferably under anhydrous conditions to obtain compounds of the general formula ( la).
Process N (Scheme 14): Scheme 14: Process N Preparation of compounds (Ic).
Figure imgf000034_0001
G = halogen or hydrogen
The compounds (XVII) (Scheme 14) can be converted by means of methods described in the literature to the corresponding compounds (XVIII ) (see e.g. DE-A 31 1 1 238, DE-A 33 07 217). Compounds of the general formula (XVI I) are preferably reacted with trimethylsulfoxonium halides, trimethylsulfonium halides, trimethylsulfoxonium methylsulfates or trimethylsulfonium methylsulfates, preferably in the presence of a base, such as sodium hydroxide, to obtain compounds (XVIII).
Compounds (XIX) are either commercially available or producible by processes described in the literature (see, for example, "Comprehensive Heterocyclic Chemistry III", Perg anion Press, 2008; vol. 7, pages 101- 169; 217-308 & vol. 7, pages 1-331 and references cited therein; , "Comprehensive Heterocyclic Chemistry Π", Pergamon Press, 1996; vol. 5, pages 37-243 & vol. 6, pages 1-278 and references cited therein; "Comprehensive Heterocyclic Chemistry I", Pergamon Press, 1984; vol. 2, pages 395-510 & vol. 3, pages 1- 197 and references cited therein; "Comprehensive Heterocyclic Chemistry III", Pergamon Press, 2008; vol. 3, pages 45-388 & vol. 4, pages 1-364 and references cited therein; , "Comprehensive Heterocyclic Chemistry II", Pergamon Press, 1996; vol. 2, pages 39-257 & vol. 3, pages 1-220 and references cited therein; "Comprehensive Heterocyclic Chemistry I", Pergamon Press, 1984; vol. 4, pages 155-376 & vol. 5, pages 167-498 and references cited therein).
Subsequently, compounds (Ic) can be obtained by the reaction of (XVIII) with (XIX). If G stands for halogen, preferably chloride or bromide, compounds (XIX) are first transformed into Grignard reagents by the reaction with magnesium or with transmetallation reagents such as isopropylmagnesium halides and subsequently reacted with epoxides (XVIII) preferably under anhydrous conditions. In an alternative route compounds (XIX) (G = hydrogen or halogen) are reacted with compounds (XVIII) preferably in the presence of a base. Compounds (XIX) (G=hydrogen or halogen) are optionally reacted with a base upfront, e.g. n-butyllithium, lithium-di-isopropylamide, lithium bis(trimethylsilyl)amide, methyl lithium, followed by compounds of the general structure (XV I II ) preferably under anhydrous conditions to form the desired compounds (Ic). Process (Scheme 15):
Figure imgf000035_0001
The compounds (la) obtained according to Processes 1 1, 1, M or N can be converted by means of methods described in the literature to the corresponding compounds ( lb) (see e.g. DE-A 3202604, JP-A 02101067, EP-A 225 739, CN-A 101824002, FR-A 2802772; WO-A 2012/175119, Bioorganic & Medicinal Chemistry Letters, 7207-7213, 2012; Journal of the American Chemical Society, 19358-19361, 2012, Journal of Organic Chemistry, 9458-9472, 2012; Organic Letters, 554-557, 2013; Journal of the American Chemical Society, 15556, 2012). Compounds of the general structure (la) are preferably reacted with alkylhalides, dialiylsulfates, anhydrides, acid chlorides, phosphorylchloride, alkylisocyanate, carbamoyl chlorides, carbono chloridates or imidocarbonates preferably in the presence of a base to obtain compounds (lb).
Process P (Scheme 16):
Figure imgf000035_0002
a!kylaminocarbonyl; C3-Cs-cycloalkylaminocarbonyl; (Ci-Cs-alkoxyimino)-Ci-C8-alkyl; (C3-C7- cycloa!koxyimino)-Ci-C8-a!kyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; amino; sulfanyl; pentafluoro-■v6-sulfanyl; carboxaldehyde, hydroxycarbonyl, Ci-Cs-alkyl; Ci-Cg-haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs- alkyloxy; Ci-Cs-halogenalkyloxy; tri(C 1 -Cs-alkyl)silyl; tri(Ci-C8-alkyl)silyi-Ci-Cs-alkyl; C3-C?-cycloalkyl; C3-C7-haiogencycloalkyl; C3-C7-cycloalkenyl; C3-C7-haiogencycloalkenyl; C4-Cio-cycloalkylalkyl; C4-C10- halocycloalkylalkyl; C«-C 12-cycloalkylcycloalkyl; C 1 -Cg-alkyl-Cs-C?- cy cloalkyl; Ci-Cs-alkoxy-Cs-C?- cycloalkyl; tri(Ci-Cs-alkyl)siiyi-C3-C7-cycloalkyl; C2-Cs-alkenyl; C2-Cs-alkynyl; Ci-Cs-aikenyloxy; C2-C8- halogenalkenyloxy; C3-Cs-alkynyloxy; Cs-Cs-halogenoalkynyloxy; Ci-Cs-alkylamino; Ci-Cs- halogenalkylamino; Ci-Cs-cyanoalkoxy; Gi-Cg-cycloalkylalkoxy; Cs-Ce-cycloalkoxy; Ci-Cs-a kylsulfanyl; Ci-Cs-halogenoalkylsulfanyl; Ci-Cs-alkylcarbonyl; Ci-Cs-halogenoalkylcarbonyl; arylcarbonyl; C3-C8- cycloalkylcarbonyl; C3-Cs-halogenocycloalkylcarbonyl; Ci-Cs-alkyicarbamoyl; di-Ci-Cg-alkylcarbamoyl; N-Ci-Cs-alkyloxycarbamoyl; C 1 -Cs-alkoxy carbamoyl; N-Ci-Cs-alkyl-Ci-Cs-alkoxycarbamoyl; Ci-Cg- alkoxycarbonyl; Ci-Cs-halogenoalkoxycarbonyl; CVCs-cycloalkoxycarbonyl; C2-C8-alkoxyalkylcarbonyl; C2-C8-haiogenoalkoxyalkylcarbonyl; C3-C 10-cycloalkoxyalkylcarbonyl; C 1 -Cs-alkylaminocarbonyi; di-C 1 - C8-alkylaminocarbonyl; C3-Cs-cycloalkylaminocarbonyl; C 1 -Cs-alkylcarbonyloxy ; Ci-Cs- halogenoalkylcarbonyloxy; C3 -C cy cloalkylcarbonyloxy ; Ci-Cs-alkylcarbonylamino; Ci-Cs- halogenoalkylcarbonylamino; C 1 -Cs-alkylaminocarbonyloxy ; di-Ci-Cs-alkylaminocarbonyloxy; Ci-Cg- alkyloxycarbonyloxy; Ci-Cs-alkylsulfinyl; Ci-Cs-halogenoalkylsulfmyl; C 1 -Cs-alkylsulfonyl; Ci-Cs- halogenoalkylsulfonyl; Ci-Cg-alkylsulfonyloxy; C 1 -Cs-halogenoalkylsulfonyloxy ; Ci-Cs- alkylaminosulfamoyl; di-C 1 -Cg-alkylaminosulfamoyl; (Ci-C8-alkoxyimino)-Ci-Cs-alkyl; (C3-C7- cycioalkoxyimino)-Ci-C8-alkyl; hydroxyimino-C 1 -Cs-a kyl; (Ci-Cs-alkoxyimino)-C3-C7-cycloalkyl; hydroxyimino-C3-C7-cycloalkyl; (Ci-Cs-alkyUmino)-oxy; (Ci-Cs-alkylimino)-oxy-Ci-C8-alkyl; (C3-C7- cycloalkylimino)-oxy-Ci-C8-alkyl; (Ci-C«-alkylimino)-oxy-C3-C7-cycloalkyl; (Ci-Cs-alkenyloxyimino)- Ci-C8-alkyl; (C 1 -C8-alkynyloxyimino)-C 1 -Cs-alkyl; (benzyloxyimino)-C i-Cs-alkyl; Ci-Cs-alkoxyalkyl; Ci- Cs-alkylthioalkyl; Ci-Cs-alkoxyalkoxyalkyi; Ci-Cs-halogenoalkoxyalkyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino.
The compounds ( la) obtained according to Processes i l, I, M, N or P wherein R' represents halogen, O-SO2- Ci-Cs-alkyl or O-SC -aryl, preferably Br or I are in Scheme 16 and process P referred to as compounds ( Id). Such compounds ( Id) can be converted by means of methods described in the literature to the corresponding compounds (le) (see e.g "Palladium in heterocyclic chemistry", Pergamon Press, 2000; lstedition, J. Li & G. Gribble) via a coupling reaction, optionally in the presence of a catalyst, preferably a transition metal catalyst, such as copper salts, palladium salts or complexes for example palladium (II) chloride, palladium (II) acetate, tetrakis-(triphenylphosphine) palladium(O), bis-(triphenylphosphine) palladium di chloride (II), tris(dibenzylideneacetone) dipalladium(O), bis(dibenzylideneacetone) palladium(O), or 1,1'- bis(diphenylphosphino)ferrocene-palladiurn (II) chloride. As an alternative the palladium complex is directly generated in the reaction mixture by separately adding to the reaction mixture a palladium salt and a complex ligand such as a phosphine, for example triethylphosphine, tri-tert-butylphosphine, tricyclohexylphosphine, 2-(dicyclohexylphosphine)biphenyl, 2-(di-tert-butylphosphin)biphenyl, 2- (dicyclohexylphosphine)-2'-(N,N-dimethylamino)-biphenyl, triphenylphosphine, tris-(o-tolyl)phosphine, sodium 3-(diphenylphosphino)benzolsulfonate, tris-2-(methoxyphenyl)phosphine, 2,2 -bis- (diphenylpho sphine) - 1 , 1 '-binaphthyl, 1 ,4-bis-(diphenylphosphine)butane, 1 ,2-bis-
(diphenylphosphine)ethane, 1 ,4-bis-(dicyclohexylphosphine)butane, 1 ,2-bis-(dicyclohexylphosphine)ethane, 2-(dicyclohexylphosphine)-2'-(N,N-dimethylamino)-biphenyl, bis(diphenylphosphino)ferrocene, tris-(2,4- tert-butylphenyl)-phosphite, (R)-(-)-l-[(S)-2-(diphenylphosphino)ferrocenyl]ethyldi-tert-butylphosphine, (S)-(+)-l-[(R)-2-(diphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine, (R)-(-)-l-[(S)-2- (diphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine, (S)-(+)-l-[(R)-2- (diphenylphosphino)ferrocenyl]ethyldi-t-butylphosphine. Such coupling reactions are optionally performed in the presence of a base such as an inorganic or an organic base; preferably an alkaline earth metal or alkali metal hydride, hydroxide, amide, alcoholate, acetate, carbonate or hydrogen carbonate, such as sodium hydride, sodium amide, lithiium diisopropylamide, sodium methanolate, sodium ethanolate, potassium tert-butanolate, sodium acetate, potassium acetate, calcium acetate, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, potassium bicarbonate, sodium bicarbonate, cesium carbonate or ammonium carbonate; and also tertiary amine, such as trimethylamine, triethylamine (TEA), tributylamine, Ν,Ν-dimethylaniline, N,N-dimethyl-benzylamine, N,N- diisopropyl-ethylamine (DIPEA), pyridine, N-methylpiperidine, N-methylmorpholine, N,N- dimethylaminopyridine, diazabicyclooctane (DABCO), diazabicyclononene (DBN) or diazabicycloundecene (DBU), For example, a compound of formula (Id) is reacted with a cyanide reagent such as a metallic cyanide for example sodium cyanide, potassium cyanide, zinc cyanide; a metallo'idic cyanide, an organo-metallic cyanide for example di-Ci-Ce-alkyialuminum cyanide notably di-ethylaluminum cyanide; an organo- metallo'idic cyanide for example tri-Ci-C6-alkylsilylcyanide notably tri-methylsilylcyanide in order to yield a compound of formula (le) wherein R '° represents a cyano. The preferred compounds of the formulae (I-I), (I-l-Q-I-1), (I-l-Q-I-2) and (I-l-Q-I-3) can also be obtained according to the processes A to P according to the invention. Unless indicated otherwise, the radicals R1, R , R R4, R5 and Q have the meanings given above for the compounds of formulae (I-I), (I-l-Q-I-1), ( i- ! -Q-l- 2) and ( I- l -Q-I-3). These definitions apply not only to the end products of the formulae (I-I), (I-l-Q-I-1), (I- 1 -Q- 1-2) and ( l- l -Q- I-3 ) but likewise to all intermediates. General The processes A to P according to the invention for preparing compounds of the formula (I) are optionally performed using one or more reaction auxiliaries.
Useful reaction auxiliaries are, as appropriate, inorganic or organic bases or acid acceptors. These preferably include alkali metal or alkaline earth metal acetates, amides, carbonates, hydrogencarbonates, hydrides, hydroxides or alkoxides, for example sodium acetate, potassium acetate or calcium acetate, lithium amide, sodium amide, potassium amide or calcium amide, sodium carbonate, potassium carbonate or calcium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate or calcium hydrogencarbonate, lithium hydride, sodium hydride, potassium hydride or calcium hydride, lithium hydroxide, sodium hydroxide, potassium hydroxide or calcium hydroxide, n-butyllithium, sec-butyllithium, tert-butyllithium, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium methoxide, ethoxide, n- or i-propoxide, n-, i-, s- or t-butoxide or potassium methoxide, ethoxide, n- or i-propoxide, n-, i-, s- or t-butoxide; and also basic organic nitrogen compounds, for example trimethylamine, triethylamine, tripropylamine, tributylamine, ethyldiisopropylamine, N,N-dimethylcyclohexylamine, dicyclohexylamine, ethyldicyclohexylamine, N,N- dimethylaniline, N,N-dimethylbenzylamine, pyridine, 2 -methyl-, 3 -methyl-, 4-methyl-, 2,4-dimethyl-, 2,6- dimethyl-, 3,4-dimethyl- and 3,5-dimethylpyridine, 5-ethyl-2-methylpyridine, 4-dimethylaminopyridine, N- methylpiperidine, l,4-diazabicyclo[2.2.2]-octane (DABCO), l,5-diazabicyclo[4.3.0]-non-5-ene (DBN) or l,8-diazabicyclo[5.4.0]-undec-7-ene (DBU).
Useful reaction auxiliaries are, as appropriate, inorganic or organic acids. These preferably include inorganic acids, for example hydrogen fluoride, hydrogen chloride, hydrogen bromide and hydrogen iodide, sulphuric acid, phosphoric acid and nitric acid, and acidic salts such as NaHSC>4 and KI ISOj, or organic acids, for example, formic acid, carbonic acid and alkanoic acids such as acetic acid, trifluoroacetic acid, trichloroacetic acid and propionic acid, and also glycolic acid, thiocyanic acid, lactic acid, succinic acid, citric acid, benzoic acid, cinnamic acid, oxalic acid, saturated or mono- or diunsaturated C6-C20 fatty acids, alkylsulphuric monoesters, alkylsulphonic acids (sulphonic acids having straight- chain or branched alkyl radicals having 1 to 20 carbon atoms), arylsulphonic acids or aryldisulphonic acids (aromatic radicals, such as phenyl and naphthyl, which bear one or two sulphonic acid groups), alkylphosphonic acids (phosphonic acids having straight- chain or branched alkyl radicals having 1 to 20 carbon atoms), arylphosphonic acids or aryldiphosphonic acids (aromatic radicals, such as phenyl and naphthyl, which bear one or two phosphonic acid radicals), where the alkyl and aryl radicals may bear further substituents, for example p- toluenesulphonic acid, salicylic acid, p-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, etc.
The processes A to P according to the invention are optionally performed using one or more diluents. Useful diluents are virtually all inert organic solvents. Unless otherwise indicated for the above described processes A to P, these preferably include aliphatic and aromatic, optionally halogenated hydrocarbons, such as pentane, hexane, heptane, cyclohexane, petroleum ether, benzine, ligroin, benzene, toluene, xylene, methylene chloride, ethylene chloride, chloroform, carbon tetrachloride, chlorobenzene and o- dichlorobenzene, ethers such as diethyl ether, dibutyl ether and methyl tert-butyl ether, glycol dimethyl ether and diglycol dimethyl ether, tetrahydrofuran and dioxane, ketones such as acetone, methyl ethyl ketone, methyl isopropyl ketone and methyl isobutyl ketone, esters, such as methyl acetate and ethyl acetate, nitriles, for example acetonitrile and propionitrile, amides, for example dimethylformamide, dimethylacetamide and N-methylpyrrolidone, and also dimethyl sulphoxide, tetramethylenesulphone and hexamethylphosphoramide and DMPU.
In the processes according to the invention, the reaction temperatures can be varied within a relatively wide range. In general, the temperatures employed are between -78°C and 250°C, preferably temperatures between -78°C and 150°C.
The reaction time varies as a function of the scale of the reaction and of the reaction temperature, but is generally between a few minutes and 48 hours.
The processes according to the invention are generally performed under standard pressure. However, it is also possible to work under elevated or reduced pressure.
For performance of the processes according to the invention, the starting materials required in each case are generally used in approximately equimolar amounts. However, it is also possible to use one of the components used in each case in a relatively large excess.
After a reaction has ended, the compounds are optionally separated from the reaction mixture by one of the customary separation techniques. If necessary, the compounds are purified by recrystallization or chromatography.
If appropriate, in the processes A to P according to the invention also salts and'or N-oxides of the starting compounds can be used.
The invention further relates to novel intermediates of the compounds of formula (I), which form part of the invention.
Novel intermediates according to the present invention are novel compounds of formula (XVII)
Figure imgf000039_0001
(XVII)
wherein
R represents hydrogen, in each case optionally branched Ci-Cs-alkyl, Ci-Cs-haloalkyl, C2-C6-alkenyl, C2-C7-haloalkenyl, C2-Cs-alkynyl, Ci-Cg-haloalkynyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, C i - C4-haloalkoxy- , Ci-C4-alkylthio- or C i -C4-haloalkylthio- substituted C3-C7-cycloalkyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, C1-C4- alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-alkylthio- or C 1 -C4-haloalkylthio-substituted bicycloalkyl, optionally halogen-, cyano-, Ci-CValkyl-, Ci-CU-haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, Ci- C4-alkylthio- or Ci-C4-haloalkylthio-substituted C3-Cs-cycloalkylalkyl; optionally halogen-, cyano-, G-C -alkyl-, Ci-C4-haloalkyi-, Ci-CValkoxy-, Ci-C -haloalkoxy-, Ci-C4-alkylthio- or Ci- C4-haloalkylthio-substituted C3-C7-halocycloalkyl-Ci-C4-alkyl; optionally halogen-, cyano-, C1-C4- alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, C1 -C4-haloalkoxy- , Ci-C4-alkylthio- or C1-C4- haloalkylthio- substituted C3-C7-halocycloalkyl-Ci-C4-haloalkyl; optionally halogen-, cyano-, C1-C4- alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, C1 -C4-haloalkoxy- , C1 -C4-alkylthio- or C1-C4- haloalkylthio- substituted C3-C7-cycioalkyl-Ci-C4-haloalkyl; optionally halogen-, cyano-, C1-C4- alkyi-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, C 1 -C4-alkylthio- or C1-C4- haloalkylthio- substituted C3-C7-cycloalkyl- C3-C7-cycloalkyl; optionally halogen-, cyano-, C1-C4- alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-alkylthio- or C1-C4- haloalkylthio- substituted C3-C7-cycloalkenyl, optionally halogen-, cyano-, Ci-C4-alkyl-, C1-C4- haloalkyi-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-alkylthio- or Ci-C4-haloaIkylthio-substituted tri(Ci-Cs-alkyi)silyl-Ci-C4-alkyl; optionally halogen-, cyano-, Ci-CValkyl-, Ci-C4-haloalkyl-, Ci- C4-alkoxy-, C 1 -C4-haloalkoxy-, Ci-C4-alkylthio- or Ci-C4-haloalkyithio-substituted tri(Ci-Cs- alkyl)silyl-C3-C7-cycloalkyl;
R ' represents halogen; hydroxyl; cyano; isocyano; nitro; amino; sulfanyl; pentafluoro- 6-sulfanyl; carboxaldehyde, Ci-Cralkyl; Ci-Cs-haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs-alkyloxy; Ci-Cs- halogenalkyloxy; tri(Ci-C8-aIkyl)silyl; tri(CrC8-alkyl)silyl-Ci-Cs-alkyi; C3-C7-cycloalkyl; C3-C7- halogencycloalkyl; C3-C7-cycloalkenyl; C3-C7-halogencycloalkenyl; C4-C 10- cycloalkylalkyl; C4- Cio-halocycloalkylalkyl; C«-Ci2-cycloalkylcycloalkyl; Ci-Cs-alkyl-C3-C7-cycloalkyl; Ci-Cs- alkoxy-Cs - C7- cy cloalkyl; tri(C1 -Cs-alkyl)silyl-C3 -C7-cycloalkyl; C2-Cs-alkenyl; C2-Cralkynyl; C2- Cs-alkenyloxy; C2-Cs-halogenalkenyloxy; C3-Cs-alkynyloxy; C3-Cs-halogenoalkynyloxy; Ci-Cs- alkylamino; Ci-Cg-halogenalkylamino; Ci-Cg-cyanoalkoxy; C4-Cs-cycloalkylalkoxy; C3-C6- cycloalkoxy; Ci-Cs-alkylsulfanyi; Ci-Cs-halogenoalkylsulfanyl; Ci-Cs-alkylcarbonyi; Ci-Cs- halogenoalkylcarbonyl; arylcarbonyl; aryl-C 1 -C6-alkylcarbonyl; C3-Cs-cycloalkylcarbonyl; Cs-Cg- halogenocycloalkylcarbonyl; Ci-Cs-alkyicarbamoyl; di-Ci-Cs-alkyicarbamoyi; N-Ci-Cs- alkyloxycarbamoyl; Ci-Cs-alkoxycarbamoyl; N-Ci-Cs-alkyl-C 1 -Cs-alkoxy carbamoyl; aminothiocarbonyl; C2-C5-alkoxycarbonyl; Ci-Cs-halogenoalkoxycarbonyl; C3-C8- cycloalkoxycarbonyl;
Figure imgf000040_0001
C2-Cs-halogenoalkoxyalkylcarbonyl; C3-C10- cycloalkoxyalkylcarbonyl; Ci-Cs-alkylaminocarbonyl; di-Ci-Cs-alkylaminocarbonyl; C3-C8- cycloalkylaminocarbonyl; Ci-Cs-alkylcarbonyloxy; Ci-Cs-halogenoalkylcarbonyioxy; C3-C8- cycloalkylcarbonyloxy; Ci-Cs-alkylcarbonylamino; Ci-Cs-haiogenoalkyicarbonylamino; Ci-Cs- alkylaminocarbonyloxy; di-Ci-Cs-alkylaminocarbonyloxy; C 1 -CV alkyloxycarbonyloxy ; Ci-Cs- alkylsulfinyl; Ci-Cs-halogenoalkylsulfinyl; C 1 -Cs-alkylsulfonyl; Ci-Cg-halogenoalkylsulfonyl; Ci- C8-alkylsulfonyloxy; Ci-Cs-halogenoalkylsulfonyloxy; Ci-Cs-alkylaminosulfamoyl; di-G-Cs- alkylaminosulfamoyl; (C 1 -Cs-alkoxyimino)-C 1 -Cs-alkyl; (C3-C7-cycloalkoxyimino)-Ci-Cs-alkyl; hydroxyimino-C i -G-alkyl; (G-G-aUtoxyimino)-G-G-cycloalkyl; hydroxyimino-G-G- cycloalkyl; (G-Cr alkylimino)-oxy ; (G-G-alkylimino)-oxy-G-Cs-alkyl; (G-G-cycloalkylimino)- oxy-G -G-alkyl; (G-G-alkylimino)-oxy-G-G-cycloalkyl; (G-G-alkenyioxyimino)-G-G-alkyl; (G-G-alkynyloxyimino)-G-G-alkyl; (benzyloxyimino)-Ci-Cralkyl; Ci-Cs-a!koxya!kyl; G-G- alkyithioalkyl; C i -Cs-alkoxya!koxya!kyl; G-Cs-halogenoalkoxyalkyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; isocyano; amino; sulfanyl; pentafluoro- 6-sulfanyi; carboxaldehyde, hydroxycarbonyl, G-G-alkyl; G-G-haloalkyl; Ci-Cs-cyanoalkyl; G-G- alkyloxy; G-G-haiogenalkyloxy; tri(G-G-alkyl)silyi; tri(G-G-alkyi)siiyl-G-G-alkyl; C3-C7- cycloalkyl; G-G-halogencycloalkyl; G-G-cycloalkenyl; G-G-halogencycloalkenyl; G-Go- cycloalkylalkyl; C4-C 1 o-halocycloalkylalkyl; G-C 12-cycloalkylcycloalkyl; G-Cs-alkyl-G-G- cycioalkyi; Ci-Cs-alkoxy-C3-C7-cycloalkyl; tri(G-G-alkyl)silyl-G-G-cycloalkyl; G-G-alkenyi; G-G-alkynyl; C2-Cs-alkenyloxy; G-G-haiogenalkenyloxy; G-G-alkynyloxy; G-G- haiogenoalkynyloxy; Ci-Cs-alkylamino; G-G-halogenalkylamino; G - G- cy anoalkoxy ; G-G- cycioalkylalkoxy; G-G-cycloalkoxy; C 1 -Cg-alkylsulfanyl; G-G-halogenoalkylsulfanyl; G-G- alkylcarbonyl; G-G-halogenoalkylcarbonyl; arylcarbonyl; aryl-G-G-alkylcarbonyl; G-G- cycloalkylcarbonyl; C3-Cs-halogenocycloalkylcarbonyl; G-G-alkylcarbamoyl; di-G-G- alkylcarbamoyl; N-G-G-alkyloxycarbamoyl; C 1 -Cs-alkoxy carbamoyl; N-G-G-alkyl-G-G- alkoxycarbamoyl; aminothiocarbonyl; C 1 -G-alkoxycarbonyl; C 1 -G-halogenoalkoxycarbonyl; G- G-cycloalkoxycarbonyl; G-G-alkoxyalkylcarbonyi; G-G-halogenoalkoxyalkylcarbonyl; G-Go- cycloalkoxyalkylcarbonyl; G-G-alkylaminocarbonyl; di-G-G-alkylaminocarbonyl; G-G- cycloalkylaminocarbonyl; G-G-alkylcarbonyloxy; C 1 -G-halogenoalkylcarbonyloxy ; G-G- cycloalkylcarbonyloxy; G-G-alkylcarbonylamino; G-G-halogenoaU<ylearbonylamino; G-G- alkylaminocarbonyloxy; di-G-G-alkylaminocarbonyloxy; G-G-alkyloxycarbonyloxy; G-G- alkylsulfinyl; G-G-halogenoalkylsulfinyl; G-G-alkylsulfonyl; C 1 -G-halogenoalkylsulfonyl; G- G-alkylsulfonyloxy; G-G-halogenoalkyisulfonyloxy; G-G-alkylaminosulfamoyl; di-G-G- alkylaminosulfamoyl; (C 1 -G-alkoxyimino)-C 1 -G-alkyl; (C3-C7-cycloalkoxyimino)-G-Cs-alkyl; hydro xyimino-C 1 -G-alkyl; (G-G-alkoxyimino)-G-G-cycloalkyl; hydroxyimino-G-G- cycloalkyi; (G-Cs-alkylimino)-oxy ; (G-C8-alkylimino)-oxy-G-Cs-alkyl; (C3 -C7- cy cloalkylimino) - oxy-G-Cs-alkyl; (G-G-alkylimino)-oxy-C3-C7-cycloalkyl; (G-Cralkenyloxyimino)-G-G-alkyl; (G-G-alkynyloxyimino)-G-G-alkyi; (benzyloxyimino)-G-Cralkyl; G-G-alkoxyalkyl; G-G- alkylthioalkyi; G-G-alkoxyalkoxyalkyl; G-G-halogenoalkoxyalkyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino; salts or N- oxides. compounds of formula (XVII) the following preferred definitions apply: \V preferably represents in each case optionally branched Ci-Cs-alkyl, Ci-Cs-haloalkyl, C2-C?-alkenyl, CyC7-haloalkenyl, optionally halogen-, cyano-, Ci-C4-alkyl-, C i-Ct-haloalkyl- , Ci-C4-alkoxy-, C1-C4- haloalkoxy-, Ci-C4-alkylthio- or Ci-C4-haloalkyithio-substituted C3-C7-cycloaLkyl;
R1 more preferably represents in each case optionally branched Ci-C4-alkyl, Ci-C4-haloalkyl, C2-C5- alkenyi, C^-Cs-haloalkenyl, optionally halogen-, cyano-, Ci-Cvalkyl-, Ci-C4-haloaLkyl-, C i-C4-haloalkoxy-, Ci-C4-alkoxy-, Ci-C"4-alkylthio- or Ci-C4-haloalkylthio-substituted C3-C«-cycloaltyl.
R1 most preferably represents ieri-butyl, isopropyl, 1 -halocyclopropyl, l-(Ci-C4-alkyl)cyciopropyi, 1- (Ci-C4-alkoxy)cyclopropyl or l-(Ci-C4-alkyithio)cyclopropyi.
In preferred embodiments of the present invention R ' represents feri-butyi, isopropyl, 1 -chlorocyclopropyl, 1 -fluorocyclopropyl or 1 -methylcy clopropyl.
R ' preferably represents halogen; hydroxyl; cyano; isocyano; nitro; carboxaldehyde, Ci-Cs-alkyl; Ci- Cs-haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs-alkyloxy; C 1 -Cs-halogenalkyloxy ; C3-C7-cycloalkyl; C3-C7- halogencycloalkyl; C2-Cs-aUcenyl; C2-Cralkynyl; C2-Cs-alkenyloxy; C2-Cs-halogenauienyloxy; C3-C8- alkynyloxy; Cs-Cs-halogenoalkynyloxy; Ci-Cs-alkylsulfanyl; Ci-Cs-halogenoalkylsulfanyl; Ci-Cs- alkylcarbonyl; Ci-Cg-halogenoalkylcarbonyl; arylcarbonyl; aryl-Ci-Ce-alkylcarbonyl; C3-C8- cycloalkylcarbonyl; C3-Cs-halogenocycloalkylcarbonyl; aminothiocarbonyl; C2-Cs-alkoxycarbonyl; Ci-Cg- halogenoalkoxycarbonyl; C3 -C s- cy clo altoxy carbonyl; C 1 -Cs-alkylcarbonyloxy ; Ci-Cs- halogenoalkylcarbonyloxy;
Figure imgf000042_0001
benzyl; phenyl; 5-membered heteroaryl; 6- membered heteroaryl; benzyloxy; or phenyloxy; wherein the benzyl, phenyl, 5-membered heteroaryl, 6- membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; amino; sulfanyl; pentafluoro- 6-sulfanyl; Ci-Cs-alkyl; Ci-Cs- haloalkyl; Ci-Cs-alkyioxy; C 1 -Cs-halogenalkyloxy ; tri(Ci-Cs-alkyl)silyl; C3-C7-cycloalkyl; C2-Cs-alkenyl; C2-C8-aIkynyl.
R ' more preferably represents halogen; cyano; carboxaldehyde, Ci-Cs-alkyl; Ci-Cs-haloalkyl; Ci-Cs- cyanoaltyl; Ci-Cs-alkyloxy; Ci-Cs-halogenalkyloxy; C3-C7-cycloalkyl; C3 -C7-halogencycloalkyl; C2-C8- alkenyl; C2-Cs-alkynyl; Ci-Cs-alkylsulfanyl; Ci-Cs-halogenoalkylsulfanyi; Ci-Cg-alkylcarbonyl; Ci-Cs- halogenoalkylcarbonyl; C2-Cs-alkoxycarbonyl; C 1 -Cs-halogenoalkoxy carbonyl; benzyl; phenyl; 5- membered heteroaryl; 6-membered heteroaryl; benzyloxy; or phenyloxy; wherein the benzyl, phenyl, 5- membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; amino; sulfanyl; pentafluoro- 6-suifanyi; Ci-Cs- alkyl; Ci-Cs-haloalkyl; Ci-Cs-alkyloxy; Ci-Cs-haiogenalkyloxy; tri(C i-Cs-alkyl)silyl; C3-C7-cycloalkyl; C2- Cs-alkenyl; C2-Cs-alkynyl.
R ' most preferably represents represents halogen; cyano; carboxaldehyde, Ci-C4-alkyl; C1-C4- haloalkyl; Ci-C4-cyanoalkyl; Ci-C4-alkyloxy; C 1 -C4-halogenalky loxy ; C3-C7-cycloalkyl; C3-C7- halogencycloalkyl; C2-Cs-alkenyl; C2-C5-alkynyl; C 1 -C4-alk 'lsulfanyl; C 1 -Ct-halogenoalkylsulfanyl; C1-C4- alkylcarbonyl; C i -C4-halogenoalkylcarbonyl; C2-C4-alkoxycarbonyl; Ci-C4-halogenoalkoxycarbonyl; benzyl; phenyl; futyl; pyrrolyl; thienyl; pyridyl; benzyloxy; or phenyloxy; wherein the benzyl, phenyl, 5- membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; G-Cs-alkyl; Ci-Cg-haloalkyl; Ci-Cs-alkyloxy; G-Cs- halogenalkyloxy.
In preferred embodiments of the present invention R ' represents fluorine; chlorine; bromine; iodine; cyano; carboxaldehyde, Ci-C4-alkyl; G-G-haloalkyl; Ci-C4-cyanoalkyl; Ci-C4-alkyloxy; G-G-cycloalkyl; C2-C5- alkynyl; C 1 -C4-aLkylsulfanyl; G-G-alkyicarbonyl; C2-C4-alkoxycarbonyl; phenyl; or thienyl; wherein the phenyl, or thienyl may be optionally substituted by one or more group(s) selected from halogen; G-Cs-alkyl; Ci-CVhaloalkyl; G-Cs-alkyloxy; G-Cs-halogenalkyloxy.
In further preferred embodiments of the present invention R3 represents fluorine; chlorine; bromine; iodine; cyano; carboxaldehyde, methyl; trifluoromethyl; cyanomethyl; methoxy; methylsulfanyl; cyclopropyl; ethinyl; methylcarbonyl (acetyl); carboxyl; ethoxycarbonyl; phenyl; or 2-thienyl.
Preferred embodiments according to the present invention are compounds of formula (XVII), wherein R ' represents halogen or cyano; and
R1 has the same definition as given for formula (XVII).
In such preferred embodiments according to the present invention R' preferably represents fluorine; chlorine; bromine; iodine or cyano R1 has the same definition as given for formula (XVII).
Other preferred embodiments according to the present invention are compounds of formula (XVII), wherein R3 represents Ci-Cs-alkyl; G-Cs-haloalkyl; G-Cs-cyanoalkyl; Ci-Cs-alkyloxy; G-Cs- halogenalkyloxy; G-G-cycloalkyl; C3-C7-halogencycloalkyl; C3-C7-cycloalkenyl; C3-C7- halogencycloalkenyl; C4-C 10- cy cloalkylalkyl; C4-C 1 o-halocycloalkylalkyl; Ce- n- cycloalkylcycloalkyl; Ci-Cs-alkyl-C3-C7-cycloalkyl; Ci-Cs-alkoxy-C3-C7-cycloalkyl; G-G- alkenyl; C2-Cs-alkynyl; C2-Cs-alkenyloxy; C2-Cs-halogenalkenyloxy; C3-Cs-alkynyloxy; G-G- halogenoalkynyloxy; G-Cs-cycloalkylalkoxy; G-G-cycloalkoxy; benzyl; phenyl; 5 -membered heteroaryl; 6-membered heteroaryl; benzyloxy or phenyloxy; wherein the benzyl, phenyl, 5- membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydro xyl; cyano; amino; sulfanyl; pentafluoro-/v6-sulfanyi; Ci-Cs-alkyl; Ci-Cs-haloalkyl; Ci-Cs-alkyloxy; C 1 -Cs-halogenalkyloxy ; tri(Ci-C8-alkyl)silyl; C3-C7-cycloalkyl; C2-C8-alkenyl; C2-C8-alkynyl; and
R1 has the same definition as given for formula (XVII).
In such preferred embodiments according to the present invention R3 preferably represents G-Cs-alkyl; Ci-Cs-haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs-alkyloxy; Ci-Cs- halogenalkyloxy ; ; C3-C6-cycloalkyl; Cs-CT-halogencycloalkyl; C2-Cs-alkenyl; C2-Cs-alkynyl; Ci-Cs- alkylsulfanyl; Ci-Cs-halogenoalkylsulfanyl; benzyl; phenyl; 5-menibered heteroaryl; 6-membered heteroaryl; benzyloxy or phenyloxy wherein the benzyl, phenyl, 5-rnembered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; amino; sulfanyl; pentafluoro- 6-sulfanyl; G-Cs-alkyl; G-Cs-haloalkyl; G-Cs- alkyloxy; Ci-Cs-halogenalkyloxy; tri(Ci-Cs-alkyl)silyl; G-G-cycloalkyl; G-Cs-alkenyi; G-Cs-alkynyl; and R1 has the same definition as given for formula (XVII).
In such preferred embodiments according to the present invention
R3 most preferably represents represents Ci-C4-alkyl; G-G-haloalkyl; Ci-C4-cyanoalkyl; C1-C4- alkyloxy; G-C4-halogenalkyloxy; G-G-cycloalkyl; G-Crhalogencycloalkyl; G-G-alkenyl; C2-C5- alkynyl; Ci-C4-alkylsulfanyl; C1-C4-halogenoalkylsulfanyl; benzyl; phenyl; furyl; pyrrolyl; thienyl; pyridyl; benzyloxy or phenyloxy; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; G- Cs-aikyi; G-Cs-haloalkyi; Ci-Cs-aikyloxy; Ci -Cs-halogenalkyloxy; and R1 has the same definition as given for formula (XVII).
In such preferred embodiments according to the present invention
R ' even more preferably represents G-C4-alkyl; Ci-C4-haloalkyl; Ci-C4-cyanoalkyl; Ci-C4-alkyloxy; C3-C7-cycloalkyl; C2-C5-alkynyl; Ci-C4-alkylsulfanyl; phenyl; or thienyl; wherein the phenyl, or thienyl may be optionally substituted by one or more group(s) selected from halogen; G-Cs-alkyl; Ci-Cs-haloalkyl; Ci-
C8-alkyloxy; Ci-Cs-halogenalkyloxy; and R ' has the same definition as given for formula (XVII).
In such preferred embodiments according to the present invention
R3 even more preferably represents methyl; trifluoromethyl; cyanomethyl; methoxy; methylsulfanyl; cyclopropyl; ethinyl; phenyl; or 2-thienyl; and R1 has the same definition as given for formula (XVII).
Other preferred embodiments according to the present invention are compounds of formula (XVII), wherein
R ' represents carboxaldehyde, G-Cs-alkyicarbonyi; Ci-Cs-halogenoalkylcarbonyl; arylcarbonyl; C3- Cs-cycloalkylcarbonyl; Cs-Cs-halogenocycloalkylcarbonyl; Ci-Cs-alkylcarbamoyl; di-Ci-Cs- alkylcarbamoyl; N-Ci-Cs-alkyloxycarbamoyl; Ci-Cg-alkoxycarbamoyl; N-Ci-Cs-alkyl-Ci-Cg- alkoxycarbamoyl; C2-C5-alkoxycarbonyl; Ci-Cs-halogenoalkoxycarbonyl; Cs-Cs- cycloaLkoxycarbonyl; C2-Cs-alkoxyalkylcarbonyl; C2-C8-halogenoalkoxyalkylcarbonyl; C3-C10- cycloalkoxyalkylcarbonyl; Ci-Cs-alkylaminocarbonyl; di-Ci-Cs-altylaminocarbonyl; Cs-Cs- cycloalkylaminocarbonyl; Ci-Cs-alkylcarbonyloxy; C 1 -Cs-halogenoaLkylcarbonyloxy ; C3-C8- cycloalkylcarbonyloxy; Ci-Cs-alkylcarbonylamino; Ci-Cs-halogenoalkylcarbonylamino; Ci-Cs- alkylaminocarbonyloxy; di-Ci-Cs-alkylarninocarbonyloxy; C 1 -Cr a!kyloxycarbonyloxy ; Ci-Cs- alkylsulfinyl; C 1 -Cs-halogenoalkylsulfinyl; C 1 -Cs-alkylsulfonyl; C 1 -Cs-halogenoalkylsulfonyl; Ci- C8-aLkylsulfonyloxy; Ci-Cs-halogenoalkylsulfonyloxy; C 1 -C alkylaminosulfamoyl or di-Ci-Cs- alkylaminosulfamoyl; and and R1 has the same definition as given for formula (XVII). In such preferred embodiments according to the present invention
R ' preferably represents carboxaldehyde, C2-Cg-alk;ylcarbonyi; C 1 -Cs-halogenoalkylcarbonyl; arylcarbonyl; Ci-Cs-cycloalkylcarbonyl; C3 -Cs-halogenocycloalkylcarbonyl; C2-Cs-alkoxycarbonyl; Ci-Cs- halogenoalkoxycarbonyl; C3 -C 8- cy clo altoxy carbonyl; Ci-Cs-alkyicarbonyloxy; Ci-Cs- halogenoalkylcarbonyloxy; or C3-Cs-cycloalkylcarbonyloxy; and and R1 has the same definition as given for formula (XVII).
In such preferred embodiments according to the present invention
R3 more preferably represents carboxaldehyde, Ci-Cs-alkylcarbonyl; C 1 -Cs-halogenoalkylcarbonyl; C2-
C5-alkoxycarbonyl; or Ci-Cs-halogenoalkoxycarbonyi; and and R1 has the same definition as given for formula (XVII). In such preferred embodiments according to the present invention
R ' most preferably represents carboxaldehyde, C 1 -C4-alkylcarbonyl; Ci-C4-halogenoalkylcarbonyl; C2- C4-alkoxycarbonyi; or Ci-C4-haiogenoalkoxycarbonyi; and and R1 has the same definition as given for formula (XVII).
In such preferred embodiments according to the present invention R3 even more preferably represents carboxaldehyde, Ci-C4-alkylcarbonyl; or C2-C4-alkoxycarbonyl; and and R1 has the same definition as given for formula (XVII).
In such preferred embodiments according to the present invention R3 even more preferably represents carboxaldehyde, methylcarbonyl (acetyl); carboxyl; or ethoxycarbonyl; and and R1 has the same definition as given for formula (XVII).
The compounds of the formula (I) according to the invention can be converted into physiologically acceptable salts, e.g. as acid addition salts or metal salt complexes.
Depending on the nature of the substituents defined above, the compounds of the formula (I) have acidic or basic properties and can form salts, if appropriate also inner salts, or adducts with inorganic or organic acids or with bases or with metal ions. If the compounds of the formula (I) carry amino, alkylamino or other groups which induce basic properties, these compounds can be reacted with acids to give salts, or they are directly obtained as salts in the synthesis. If the compounds of the formula (I) carries hydroxyl, carboxyl or other groups which induce acidic properties, these compounds can be reacted with bases to give salts. Suitable bases are, for example, hydroxides, carbonates, bicarbonates of the alkali metals and alkaline earth metals, in particular those of sodium, potassium, magnesium and calcium, furthermore ammonia, primary, secondary and tertiary amines having (Ci-C4)-alkyl groups, mono-, di- and trialkanolamines of (C1-C4)- alkanols, choline and also chloro choline.
The salts obtainable in this manner also have fungicidal properties.
Examples of inorganic acids are hydrohalic acids, such as hydrogen fluoride, hydrogen chloride, hydrogen bromide and hydrogen iodide, sulphuric acid, phosphoric acid and nitric acid, and acidic salts, such as NaHS(>4 and KHSO4. Suitable organic acids are, for example, formic acid, carbonic acid and alkanoic acids, such as acetic acid, trifluoroacetic acid, trichloroacetic acid and propionic acid, and also glycolic acid, thio cyanic acid, lactic acid, succinic acid, citric acid, benzoic acid, cinnamic acid, maleic acid, fumaric acid, tartaric acid, sorbic acid oxalic acid, alky Isulphonic acids (sulphonic acids having straight- chain or branched alkyl radicals of 1 to 20 carbon atoms), ary Isulphonic acids or aryldisulphonic acids (aromatic radicals, such as phenyl and naphthyl, which carry one or two sulphonic acid groups), alkylphosphonic acids (phosphonic acids having straight- chain or branched alkyl radicals of 1 to 20 carbon atoms), arylphosphonic acids or aryldiphosphonic acids (aromatic radicals, such as phenyl and naphthyl, which carry one or two phosphonic acid radicals), where the alkyl and aryl radicals may carry further substituents, for example p- toluenesulphonic acid, 1 ,5-naphthalenedi sulphonic acid, salicylic acid, p-aminosalicylic acid, 2- phenoxybenzoic acid, 2-acetoxybenzoic acid, etc. Suitable metal ions are in particular the ions of the elements of the second main group, in particular calcium and magnesium, of the third and fourth main group, in particular aluminium, tin and lead, and also of the first to eighth transition group, in particular chromium, manganese, iron, cobalt, nickel, copper, zinc and others. Particular preference is given to the metal ions of the elements of the fourth period. Here, the metals can be present in various valencies that they can assume. The acid addition salts of the compounds of the formula (I) can be obtained in a simple manner by customary methods for forming salts, for example by dissolving a compound of the formula (I) in a suitable inert solvent and adding the acid, for example hydrochloric acid, and be isolated in a known manner, for example by filtration, and, if required, be purified by washing with an inert organic solvent. Suitable anions of the salts are those which are preferably derived from the following acids: hydrohalic acids, such as, for example, hydrochloric acid and hydrobromic acid, furthermore phosphoric acid, nitric acid and sulphuric acid.
The metal salt complexes of compounds of the formula (I) can be obtained in a simple manner by customary processes, for example by dissolving the metal salt in alcohol, for example ethanol, and adding the solution to the compound of the formula (I). Metal salt complexes can be isolated in a known manner, for example by filtration, and, if required, be purified by recrystallization.
Salts of the intermediates can also be prepared according to the processes mentioned above for the salts of compounds of formula (I).
N-oxides of compounds of the formula (I) or intermediates thereof can be obtained in a simple manner by customary processes, for example by N-oxidation with hydrogen peroxide (H2O2), peracids, for example peroxy sulfuric acid or peroxy carboxylic acids, such as meta-chloroperoxybenzoic acid or peroxymonosulfuric acid (Caro's acid).
Methods and uses
The invention also relates to a method for controlling unwanted microorganisms, characterized in that the compounds of the formula (I) are applied to the microorganisms and/or in their habitat.
The invention further relates to seed which has been treated with at least one compound of the formula (I).
The invention finally provides a method for protecting seed against unwanted microorganisms by using seed treated with at least one compound of the formula (I).
The compounds of the formula (I) have potent microbicidal activity and can be used for control of unwanted microorganisms, such as fungi and bacteria, in crop protection and in the protection of materials.
The compounds of the formula (I) have very good fungicidal properties and can be used in crop protection, for example for control of Plasmodiophoromycetes, Oomycetes, Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes and Deuteromycetes.
Bactericides can be used in crop protection, for example, for control of Pseudomonadaceae, Rhizobiaceae, Enterobacteriaceae, Corynebacteriaceae and Streptomycetaceae. The compounds of the formula (I) can be used for curative or protective control of phytopathogenic fungi. The invention therefore also relates to curative and protective methods for controlling phytopathogenic fungi by the use of the inventive active ingredients or compositions, which are applied to the seed, the plant or plant parts, the fruit or the soil in which the plants grow. Plants
All plants and plant parts can be treated in accordance with the invention. Plants are understood here to mean all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants may be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant cultivars which are protectable and non- pro tectable by plant breeders' rights. Plant parts are understood to mean all parts and organs of plants above and below the ground, such as shoot, leaf, flower and root, examples of which include leaves, needles, stalks, stems, flowers, fruit bodies, fruits and seeds, and also roots, tubers and rhizomes. The plant parts also include harvested material and vegetative and generative propagation material, for example cuttings, tubers, rhizomes, slips and seeds.
Plants which can be treated in accordance with the invention include the following: cotton, flax, grapevine, fruit, vegetables, such as Rosaceae sp. (for example pome fruits such as apples and pears, but also stone fruits such as apricots, cherries, almonds and peaches, and soft fruits such as strawberries), Ribesioidae sp., Juglandaceae sp. , Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp., Actinidaceae sp., Lauraceae sp., Musaceae sp. (for example banana trees and plantations), Rubiaceae sp. (for example coffee), Theaceae sp., Sterculiceae sp. , Rutaceae sp. (for example lemons, oranges and grapefruit); Solanaceae sp. (for example tomatoes), Liliaceae sp., Asteraceae sp. (for example lettuce), Umbelliferae sp., Cruciferae sp. , Chenopodiaceae sp. , Cucurbitaceae sp. (for example cucumber), Alliaceae sp. (for example leek, onion), Papilionaceae sp. (for example peas); major crop plants, such as Gramineae sp. (for example maize, turf, cereals such as wheat, rye, rice, barley, oats, millet and triticale), Asteraceae sp. (for example sunflower), Brassicaceae sp. (for example white cabbage, red cabbage, broccoli, cauliflower, Brussels sprouts, pak choi, kohlrabi, radishes, and oilseed rape, mustard, horseradish and cress), Fabacae sp. (for example bean, peanuts), Papilionaceae sp. (for example soya bean), Solanaceae sp. (for example potatoes), Chenopodiaceae sp. (for example sugar beet, fodder beet, swiss chard, beetroot); useful plants and ornamental plants for gardens and wooded areas; and genetically modified varieties of each of these plants.
Pathogens
Non-limiting examples of pathogens of fungal diseases which can be treated in accordance with the invention include: diseases caused by powdery mildew pathogens, for example Blumeria species, for example Blumeria graminis; Podosphaera species, for example Podosphaera leucotricha; Sphaerotheca species, for example Sphaerotheca fuliginea; Uncinula species, for example Uncinula necator; diseases caused by rust disease pathogens, for example Gymnosporangium species, for example Gymnosporangium sabinae; Hemileia species, for example Hemileia vastatrix; Phakopsora species, for example Phakopsora pachyrhizi or Phakopsora meibomiae; Puccinia species, for example Puccinia recondita, Puccinia graminis oder Puccinia striiformis; Uromyces species, for example Uromyces appendicular^; diseases caused by pathogens from the group of the Oomycetes, for example Albugo species, for example Albugo Candida; Bremia species, for example Bremia lactucae; Peronospora species, for example Peronospora pisi or P. brassicae; Phytophthora species, for example Phytophthora infestans; Plasmopara species, for example Plasmopara viticola; Pseudoperonospora species, for example Pseudoperono spora humuli or Pseudoperonospora cubensis; Pythium species, for example Pythium ultimum; leaf blotch diseases and leaf wilt diseases caused, for example, by Alternaria species, for example Alternaria solani; Cercospora species, for example Cercospora beticola; Cladiosporium species, for example Cladiosporium cucumerinum; Cochliobolus species, for example Cochliobolus sativus (conidial form: Drechslera, syn: Helminthosporium) or Cochliobolus miyabeanus; CoUetotrichum species, for example Colletotrichum lindemuthanium; Cycloconium species, for example Cycloconium oleaginum; Diaporthe species, for example Diaporthe citri; Elsinoe species, for example Elsinoe fawcettii; Gloeosporium species, for example Gloeosporium laeticolor; Glomerella species, for example Glomerella cingulata; Guignardia species, for example Guignardia bidwelli; Leptosphaeria species, for example Leptosphaeria maculans; Magnaporthe species, for example Magnaporthe grisea; Microdochium species, for example Microdochium nivale; Mycosphaerella species, for example Mycosphaerella graminicola, Mycosphaerella arachidicola or Mycosphaerella fijiensis; Phaeosphaeria species, for example Phaeosphaeria nodorum; Pyrenophora species, for example Pyrenophora teres or Pyrenophora tritici repentis; Ramularia species, for example Ramularia collo-cygni or Ramularia areola; Rhynchosporium species, for example Rhynchosporium secalis; Septoria species, for example Septoria apii or Septoria lycopersici; Stagonospora species, for example Stagonospora nodorum; Typhula species, for example Typhula incarnata; Venturia species, for example Venturia inaequalis; root and stem diseases caused, for example, by Corticium species, for example Corticium graminearum; Fusarium species, for example Fusarium oxysporum; Gaeumannomyces species, for example Gaeumannomyces graminis; Plasmodiophora species, for example Plasmodiophora brassicae; Rhizoctonia species, for example Rhizoctonia solani; Sarocladium species, for example Sarocladium oryzae; Sclerotium species, for example Sclerotium oryzae; Tapesia species, for example Tapesia acuformis; Thielaviopsis species, for example Thielaviopsis basicola; ear and panicle diseases (including corn cobs) caused, for example, by Alternaria species, for example Alternaria spp.; Aspergillus species, for example Aspergillus flaws; Cladosporium species, for example Cladosporium cladosporioides; Claviceps species, for example Claviceps purpurea; Fusarium species, for example Fusarium culmorum; Gibberella species, for example Gibberella zeae; Monographella species, for example Monographella nivalis; Stagnospora species, for example Stagnospora nodorum; diseases caused by smut fungi, for example Sphacelotheca species, for example Sphacelotheca reiliana; Tilletia species, for example Tilletia caries or Tilletia controversa; Urocystis species, for example Urocystis occulta; Ustilago species, for example Ustilago nuda; fruit rot caused, for example, by Aspergillus species, for example Aspergillus flavus; Botrytis species, for example Botrytis cinerea; Penicillium species, for example Penicillium expansum or Penicillium purpurogenum; Rhizopus species, for example Rhizopus stolonifer; Sclerotinia species, for example Sclerotinia sclerotiorum; Verticilium species, for example Verticilium alboatrum; seed- and soil-borne rot and wilt diseases, and also diseases of seedlings, caused, for example, by Alternaria species, for example Alternaria brassicicola; Aphanomyces species, for example Aphanomyces euteiches; Ascochyta species, for example Ascochyta lentis; Aspergillus species, for example Aspergillus flavus; Cladosporium species, for example Cladosporium herb arum; Cochliobolus species, for example Cochliobolus sativus (conidial form: Drechslera, Bipolaris Syn: Helminthosporium) ; Colletotrichum species, for example Colletotrichum coccodes; Fusarium species, for example Fusarium culmorum; Gibberella species, for example Gibberella zeae; Macrophomina species, for example Macrophomina phaseolina; Microdochium species, for example Microdochium nivale; Monographella species, for example Monographella nivalis; Penicillium species, for example Penicillium expansum; Phoma species, for example Phoma lingam; Phomopsis species, for example Phomopsis sojae; Phytophthora species, for example Phytophthora cactorum; Pyrenophora species, for example Pyrenophora graminea; Pyricularia species, for example Pyricularia oryzae; Pythium species, for example Pythium ultimum; Rhizoctonia species, for example Rhizoctonia solani; Rhizopus species, for example Rhizopus oryzae; Sclerotium species, for example Sclerotium rolfsii; Septoria species, for example Septoria nodorum; Typhula species, for example Typhula incarnata; Verticillium species, for example Verticillium dahliae; cancers, galls and witches' broom caused, for example, by Nectria species, for example Nectria galligena; wilt diseases caused, for example, by Monilinia species, for example Monilinia laxa; deformations of leaves, flowers and fruits caused, for example, by Exobasidium species, for example Exobasidium vexans; Taphrina species, for example Taphrina deformans; degenerative diseases in woody plants, caused, for example, by Esca species, for example Phaeomoniella chlamydospora, Phaeoacremonium aleophilum or Fomitiporia mediterranea; Ganoderma species, for example Ganoderma boninense; diseases of flowers and seeds caused, for example, by Botrytis species, for example Botrytis cinerea; diseases of plant tubers caused, for example, by Rhizoctonia species, for example Rhizoctonia solani; Helmintho sporium species, for example Helminthosporium solani; diseases caused by bacterial pathogens, for example Xanthomonas species, for example Xanthomonas campestris pv. oryzae; Pseudomonas species, for example Pseudomonas syringae pv. lachrymans; Erwinia species, for example Erwinia amylovora.
Preference is given to controlling the following diseases of soya beans:
Fungal diseases on leaves, stems, pods and seeds caused, for example, by Alternaria leaf spot (Alternaria spec, atrans tenuissima), Anthracnose (Colletotrichum gloeosporoides dematium var. truncatum), brown spot (Septoria glycines), cercospora leaf spot and blight (Cercospora kikuchii), choanephora leaf blight (Choanephora infundibulifera trispora (Syn.)), dactuliophora leaf spot (Dactuliophora glycines), downy mildew (Peronospora manshurica), drechslera blight (Drechslera glycini), frogeye leaf spot (Cercospora sojina), leptosphaerulina leaf spot (Leptosphaerulina trifolii), phyllostica leaf spot (Phyllosticta sojaecola), pod and stem blight (Phomopsis sojae), powdery mildew (Microsphaera diffusa), pyrenochaeta leaf spot (Pyrenochaeta glycines), rhizoctonia aerial, foliage, and web blight (Rhizoctonia solani), rust (Phakopsora pachyrhizi, Phakopsora meibomiae), scab (Sphaceloma glycines), stemphylium leaf blight (Stemphylium botryosum), target spot (Corynespora cassiicola).
Fungal diseases on roots and the stem base caused, for example, by black root rot (Calonectria crotalariae), charcoal rot (Macrophomina phaseolina), fusarium blight or wilt, root rot, and pod and collar rot (Fusarium oxysporum, Fusarium orthoceras, Fusarium semitectum, Fusarium equiseti), mycoleptodiscus root rot (Mycoleptodiscus terrestris), neocosmospora ( eo co smo spora vasinfecta), pod and stem blight (Diaporthe phaseolorum), stem canker (Diaporthe phaseolorum var. caulivora), phytophthora rot (Phytophthora megasperma), brown stem rot (Phialophora gregata), pythium rot (Pythium aphanidermatum, Pythium irregulare, Pythium debaryanum, Pythium myriotylum, Pythium ultimum), rhizoctonia root rot, stem decay, and damping-off (Rhizoctonia solani), sclerotinia stem decay (Sclerotinia sclerotiorum), sclerotinia southern blight (Sclerotinia rolfsii), thielaviopsis root rot (Thielaviopsis basicola).
Plant Growth Regulation
In some cases, the compounds of the formula (I) can, at particular concentrations or application rates, also be used as growth regulators or agents to improve plant properties, or as microbicides, for example as fungicides, antimycotics, bactericides, viricides (including compositions against viroids) or as compositions against MLO (Mycoplasma-like organisms) and RLO (Rickettsia-like organisms).
The compounds of the formula (I) intervene in physiological processes of plants and can therefore also be used as plant growth regulators. Plant growth regulators may exert various effects on plants. The effect of the substances depends essentially on the time of application in relation to the developmental stage of the plant, and also on the amounts of active ingredient applied to the plants or their environment and on the type of application. In each case, growth regulators should have a particular desired effect on the crop plants.
Growth regulating effects, comprise earlier germination, better emergence, more developed root system and/or improved root growth, increased ability of tillering, more productive tillers, earlier flowering, increased plant height and/or biomass, shorting of stems, improvements in shoot growth, number of kernels/ear, number of ears/m2, number of stolons and/or number of flowers, enhanced harvest index, bigger leaves, less dead basal leaves, improved phyllotaxy, earlier maturation /' earlier fruit finish, homogenous riping, increased duration of grain filling, better fruit finish, bigger fruit-Vegetable size, sprouting resistance and reduced lodging. Increased or improved yield is referring to total biomass per hectare, yield per hectare, kernel/'fruit weight, seed size and/or hectolitre weight as well as to improved product quality, comprising: improved processability relating to size distribution (kernel, fruit, etc.), homogenous riping, grain moisture, better milling, better vinification, better brewing, increased juice yield, harvestability, digestibility, sedimentation value, falling number, pod stability, storage stability, improved fiber length/'strength/uniformity, increase of milk and/or meet quality of silage fed animals, adaption to cooking and frying; further comprising improved marketability relating to improved fruit grain quality, size distribution (kernel, fruit, etc.), increased storage / shelf-life, firmness / softness, taste (aroma, texture, etc.), grade (size, shape, number of berries, etc.), number of berries/fruits per bunch, crispness, freshness, coverage with wax, frequency of physiological disorders, colour, etc.; further comprising increased desired ingredients such as e.g. protein content, fatty acids, oil content, oil quality, aminoacid composition, sugar content, acid content (pH), sugar/acid ratio (Brix), polyphenols, starch content, nutritional quality, gluten content index, energy content, taste, etc.; and further comprising decreased undesired ingredients such as e.g. less mycotoxines, less aflatoxines, geosmin level, phenolic aromas, lacchase, polyphenol oxidases and peroxidases, nitrate content etc.
Plant growth-regulating compounds can be used, for example, to slow down the vegetative growth of the plants. Such growth depression is of economic interest, for example, in the case of grasses, since it is thus possible to reduce the frequency of grass cutting in ornamental gardens, parks and sport facilities, on roadsides, at airports or in fruit crops. Also of significance is the inhibition of the growth of herbaceous and woody plants on roadsides and in the vicinity of pipelines or overhead cables, or quite generally in areas where vigorous plant growth is unwanted.
Also important is the use of growth regulators for inhibition of the longitudinal growth of cereal. This reduces or completely eliminates the risk of lodging of the plants prior to harvest. In addition, growth regulators in the case of cereals can strengthen the culm, which also counteracts lodging. The employment of growth regulators for shortening and strengthening culms allows the deployment of higher fertilizer volumes to increase the yield, without any risk of lodging of the cereal crop.
In many crop plants, vegetative growth depression allows denser planting, and it is thus possible to achieve higher yields based on the soil surface. Another advantage of the smaller plants obtained in this way is that the crop is easier to cultivate and harvest.
Reduction of the vegetative plant growth may also lead to increased or improved yields because the nutrients and assimilates are of more benefit to flower and fruit formation than to the vegetative parts of the plants.
Alternatively, growth regul ators can also be used to promote vegetative growth. This is of great benefit when harvesting the vegetative plant parts. However, promoting vegetative growth may also promote generative growth in that more assimilates are formed, resulting in more or larger fruits.
Furthermore, beneficial effects on growth or yield can be achieved through improved nutrient use efficiency, especially nitrogen (N)-use efficiency, phosphours (P)-use efficiency, water use efficiency, improved transpiration, respiration and/or C02 assimilation rate, better nodulation, improved Ca-metabolism etc.
Likewise, growth regulators can be used to alter the composition of the plants, which in turn may result in an improvement in quality of the harvested products. Under the influence of growth regulators, parthenocarpic fruits may be formed. In addition, it is possible to influence the sex of the flowers. It is also possible to produce sterile pollen, which is of great importance in the breeding and production of hybrid seed.
Use of growth regulators can control the branching of the plants. On the one hand, by breaking apical dominance, it is possible to promote the development of side shoots, which may be highly desirable particularly in the cultivation of ornamental plants, also in combination with an inhibition of growth. On the other hand, however, it is also possible to inhibit the growth of the side shoots. This effect is of particular interest, for example, in the cultivation of tobacco or in the cultivation of tomatoes.
Under the influence of growth regulators, the amount of leaves on the plants can be controlled such that defoliation of the plants is achieved at a desired time. Such defoliation plays a major role in the mechanical harvesting of cotton, but is also of interest for facilitating harvesting in other crops, for example in viticulture. Defoliation of the plants can also be undertaken to lower the transpiration of the plants before they are transplanted.
Furthermore, growth regulators can modulate plant senescence, which may result in prolonged green leaf area duration, a longer grain filling phase, improved yield quality, etc. Growth regulators can likewise be used to regulate fruit dehiscence. On the one hand, it is possible to prevent premature fruit dehiscence. On the other hand, it is also possible to promote fruit dehiscence or even flower abortion to achieve a desired mass ("thinning"). In addition it is possible to use growth regulators at the time of harvest to reduce the forces required to detach the fruits, in order to allow mechanical harvesting or to facilitate manual harvesting.
Growth regulators can also be used to achieve faster or else delayed ripening of the harvested material before or after harvest. This is particularly advantageous as it allows optimal adjustment to the requirements of the market. Moreover, growth regulators in some cases can improve the fruit colour. In addition, growth regulators can also be used to synchronize maturation within a certain period of time. This establishes the prerequisites for complete mechanical or manual harvesting in a single operation, for example in the case of tobacco, tomatoes or coffee.
By using growth regulators, it is additionally possible to influence the resting of seed or buds of the plants, such that plants such as pineapple or ornamental plants in nurseries, for example, germinate, sprout or flower at a time when they are normally not inclined to do so. In areas where there is a risk of frost, it may be desirable to delay budding or germination of seeds with the aid of growth regulators, in order to avoid damage resulting from late frosts.
Finally, growth regulators can induce resistance of the plants to frost, drought or high salinity of the soil. This allows the cultivation of plants in regions which are normally unsuitable for this purpose.
Resistance Induction / Plant Health and other effects
The compounds of the formula (I) also exhibit a potent strengthening effect in plants. Accordingly, they can be used for mobilizing the defences of the plant against attack by undesirable microorganisms.
Plant- strengthening (resistance-inducing) substances in the present context are substances capable of stimulating the defence system of plants in such a way that the treated plants, when subsequently inoculated with undesirable microorganisms, develop a high degree of resistance to these microorganisms.
Further, in context with the present invention plant physiology effects comprise the following:
Abiotic stress tolerance, comprising tolerance to high or low temperatures, drought tolerance and recovery after drought stress, water use efficiency (correlating to reduced water consumption), flood tolerance, ozone stress and UV tolerance, tolerance towards chemicals like heavy metals, salts, pesticides etc.
Biotic stress tolerance, comprising increased fungal resistance and increased resistance against nematodes, viruses and bacteria. In context with the present invention, biotic stress tolerance preferably comprises increased fungal resistance and increased resistance against nematodes.
Increased plant vigor, comprising plant health / plant quality and seed vigor, reduced stand failure, improved appearance, increased recovery after periods of stress, improved pigmentation (e.g. chlorophyll content, stay-green effects, etc.) and improved photosynthetic efficiency.
Mycotoxins In addition, the compounds of the formula (I) can reduce the mycotoxin content in the harvested material and the foods and feeds prepared therefrom. Mycotoxins include particularly, but not exclusively, the following: deoxynivalenol (DON), nivalenol, 15-Ac-DON, 3-Ac-DON, T2- and HT2-toxin, fumonisins, zearalenon, moniliformin, fusarin, diaceotoxyscirpenol (DAS), beauvericin, enniatin, fusaroproliferin, fusarenol, ochratoxins, patulin, ergot alkaloids and aflatoxins which can be produced, for example, by the following fungi: Fusarium spec, such as F. acuminatum, F. asiaticum, F. avenaceum, F. croohvellense, F. culmorum, F. graminearum (Gibberella zeae), F. equiseti, F. fujikoroi, F. musarum, F. oxysporum, F. proliferation, F. poae, F. pseudograminearum, F. sambucinum, F. scirpi, F. semitectum, F. solani, F. sporotrichoides, F. langsethiae, F. subglutinans, F. tricinctum, F. verticillioides etc., and also by Aspergillus spec, such as A. flavus, A. parasiticus, A. nomius, A. ochraceus, A. clavatus, A. terreus, A. versicolor, Penicillium spec, such as P. verrucosum, P. viridicatum, P. citrinum, P. expansum, P. claviforme, P. roqueforti, Claviceps spec, such as C. purpurea, C. fusiformis, C. paspali, C. africana, Stachybotrys spec, and others.
Material Protection The compounds of the formula (I) can also be used in the protection of materials, for protection of industrial materials against attack and destruction by phytopathogenic fungi.
In addition, the compounds of the formula (I) can be used as antifouling compositions, alone or in combinations with other active ingredients.
Industrial materials in the present context are understood to mean inanimate materials which have been prepared for use in industry. For example, industrial materials which are to be protected by inventive compositions from microbial alteration or destruction may be adhesives, glues, paper, wallpaper and board/cardboard, textiles, carpets, leather, wood, fibers and tissues, paints and plastic articles, cooling lubricants and other materials which can be infected with or destroyed by microorganisms. Parts of production plants and buildings, for example cooling-water circuits, cooling and heating systems and ventilation and air-conditioning units, which may be impaired by the proliferation of microorganisms may also be mentioned within the scope of the materials to be protected. Industrial materials within the scope of the present invention preferably include adhesives, sizes, paper and card, leather, wood, paints, cooling lubricants and heat transfer fluids, more preferably wood.
The compounds of the formula (I) may prevent adverse effects, such as rotting, decay, discoloration, decoloration or formation of mould.
In the case of treatment of wood the compounds of the formula (I) may also be used against fungal diseases liable to grow on or inside timber. The term "timber" means all types of species of wood, and all types of working of this wood intended for construction, for example solid wood, high-density wood, laminated wood, and plywood. The method for treating timber according to the invention mainly consists in contacting a composition according to the invention; this includes for example direct application, spraying, dipping, injection or any other suitable means.
In addition, the compounds of the formula (I) can be used to protect objects which come into contact with saltwater or brackish water, especially hulls, screens, nets, buildings, moorings and signalling systems, from fouling.
The compounds of the formula (I) can also be employed for protecting storage goods. Storage goods are understood to mean natural substances of vegetable or animal origin or processed products thereof which are of natural origin, and for which long-term protection is desired. Storage goods of vegetable origin, for example plants or plant parts, such as stems, leaves, tubers, seeds, fruits, grains, can be protected freshly harvested or after processing by (pre)drying, moistening, comminuting, grinding, pressing or roasting. Storage goods also include timber, both unprocessed, such as construction timber, electricity poles and barriers, or in the form of finished products, such as furniture. Storage goods of animal origin are, for example, hides, leather, furs and hairs. The inventive compositions may prevent adverse effects, such as rotting, decay, discoloration, decoloration or formation of mould. Microorganisms capable of degrading or altering the industrial materials include, for example, bacteria, fungi, yeasts, algae and slime organisms. The compounds of the formula (I) preferably act against fungi, especially moulds, wood-discoloring and wood-destroying fungi (Ascomycetes, Basidiomycetes, D enter omycetes and Zygomycetes), and against slime organisms and algae. Examples include microorganisms of the following genera: Alternaria, such as Alternaria tenuis; Aspergillus, such as Aspergillus niger; Chaetomium, such as Chaetomium glohosum; Coniophora, such as Coniophora puetana; Lentinus, such as Lentinus tigrinus; Penicillium, such as Penicillium glaucum; Polyporus, such as Polyporus versicolor; Aureobasidium, such as Aureobasidium pullulans; Sclerophoma, such as Sclerophoma pityophila; Trichoderma, such as Trichoderma viride; Ophiostoma spp., Ceratocystis spp., Humicola spp., Petriella spp., Trichurus spp., Coriolus spp., Gloeophyllum spp., Pleurotus spp., Poria spp., Serpula spp. and Tyromyces spp., Cladosporium spp., Paecilomyces spp. Mucor spp., Escherichia, such as Escherichia coli; Pseudomonas, such as Pseudomonas aeruginosa; Staphylococcus, such as Staphylococcus aureus, Candida spp. and Saccharomyces spp., such as Saccharomyces cerevisae.
Formulations
The present invention further relates to a composition for controlling unwanted microorganisms, comprising at least one of the compounds of the formula (I). These are preferably fungicidal compositions which comprise agriculturally suitable auxiliaries, solvents, carriers, surfactants or extenders.
According to the invention, a carrier is a natural or synthetic, organic or inorganic substance with which the active ingredients are mixed or combined for better applicability, in particular for application to plants or plant parts or seed. The carrier, which may be solid or liquid, is generally inert and should be suitable for use in agriculture. Useful solid carriers include: for example ammonium salts and natural rock flours, such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and synthetic rock flours, such as finely divided silica, alumina and silicates; useful solid carriers for granules include: for example, crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite and dolomite, and also synthetic granules of inorganic and organic flours, and granules of organic material such as paper, sawdust, coconut shells, maize cobs and tobacco stalks; useful emulsifiers and/or foam-formers include: for example nonionic and anionic emulsifiers, such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, for example alkylaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, arylsulphonates and also protein hydrolysates; suitable dispersants are nonionic and/or ionic substances, for example from the classes of the alcohol-POE and/or -POP ethers, acid and/or POP POE esters, alkylaryl and/or POP POE ethers, fat and/or POP POE adducts, POE- and/or POP-polyol derivatives, POE- and/or POP-sorbitan or -sugar adducts, alkyl or aryl sulphates, alkyl- or arylsulphonates and alkyl or aryl phosphates or the corresponding PO-ether adducts. Additionally suitable are oligo- or polymers, for example those derived from vinylic monomers, from acrylic acid, from EO and/or PO alone or in combination with, for example, (poly)alcohols or (poly)amines. It is also possible to use lignin and its sulphonic acid derivatives, unmodified and modified celluloses, aromatic and/or aliphatic sulphonic acids and also their adducts with formaldehyde.
The active ingredients can be converted to the customary formulations, such as solutions, emulsions, wettable powders, water- and oil-based suspensions, powders, dusts, pastes, soluble powders, soluble granules, granules for broadcasting, suspoemulsion concentrates, natural products impregnated with active ingredient, synthetic substances impregnated with active ingredient, fertilizers and also microencapsulations in polymeric substances.
The active ingredients can be applied as such, in the form of their formulations or the use forms prepared therefrom, such as ready-to-use solutions, emulsions, water- or oil-based suspensions, powders, wettable powders, pastes, soluble powders, dusts, soluble granules, granules for broadcasting, suspoemulsion concentrates, natural products impregnated with active ingredient, synthetic substances impregnated with active ingredient, fertilizers and also microencapsulations in polymeric substances. Application is accomplished in a customary manner, for example by watering, spraying, atomizing, broadcasting, dusting, foaming, spreading-on and the like. It is also possible to deploy the active ingredients by the ultra-low volume method or to inject the active ingredient preparation/the active ingredient itself into the soil. It is also possible to treat the seed of the plants.
The formulations mentioned can be prepared in a manner known per se, for example by mixing the active ingredients with at least one customary extender, solvent or diluent, emulsifier, dispersant and/or binder or fixing agent, wetting agent, a water repellent, if appropriate siccatives and UV stabilizers and if appropriate dyes and pigments, antifoams, preservatives, secondary thickeners, stickers, gibberellins and also other processing auxiliaries. The present invention includes not only formulations which are already ready for use and can be deployed with a suitable apparatus to the plant or the seed, but also commercial concentrates which have to be diluted with water prior to use.
The compounds of the formula (I) may be present as such or in their (commercial) formulations and in the use forms prepared from these formulations as a mixture with other (known) active ingredients, such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators, herbicides, fertilizers, safeners and/or semiochemicals.
The auxiliaries used may be those substances which are suitable for imparting particular properties to the composition itself or and/or to preparations derived therefrom (for example spray liquors, seed dressings), such as certain technical properties and/or also particular biological properties. Typical auxiliaries include: extenders, solvents and carriers.
Suitable extenders are, for example, water, polar and nonpolar organic chemical liquids, for example from the classes of the aromatic and nonaromatic hydrocarbons (such as paraffins, alkylbenzenes, alkylnaphthalenes, chlorobenzenes), the alcohols and polyols (which may optionally also be substituted, etherified and/or esterified), the ketones (such as acetone, cyclohexanone), esters (including fats and oils) and (poly)ethers, the unsubstituted and substituted amines, amides, lactams (such as N-alkylpyrrolidones) and lactones, the sulphones and sulphoxides (such as dimethyl sulphoxide).
Liquefied gaseous extenders or carriers are understood to mean liquids which are gaseous at standard temperature and under standard pressure, for example aerosol propellants such as halohydrocarbons, or else butane, propane, nitrogen and carbon dioxide.
In the formulations it is possible to use tackifiers such as carboxymethylcellulose, natural and synthetic polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or else natural phospholipids such as cephalitis and lecithins and synthetic phospholipids. Further additives may be mineral and vegetable oils. If the extender used is water, it is also possible to use, for example, organic solvents as auxiliary solvents. Useful liquid solvents are essentially: aromatics such as xylene, toluene or alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example petroleum fractions, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethylformamide and dimethyl sulphoxide, or else water.
Compositions comprising compounds of the formula (I) may additionally comprise further components, for example surfactants. Suitable surfactants are emulsifiers and/or foam formers, dispersants or wetting agents having ionic or nonionic properties, or mixtures of these surfactants. Examples thereof are salts of polyacrylic acid, salts of lignosulphonic acid, salts of phenolsulphonic acid or naphthalenesulphonic acid, polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines, substituted phenols (preferably alkylphenols or arylphenols), salts of sulphosuccinic esters, taurine derivatives (preferably alkyl taurates), phosphoric esters of polyethoxylated alcohols or phenols, fatty esters of polyoLs, and derivatives of the compounds containing sulphates, sulphonates and phosphates, for example alkyiaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, arylsulphonates, protein hydrolysates, lignosulphite waste liquors and methylcellulose. The presence of a surfactant is necessary if one of the active ingredients and/or one of the inert carriers is insoluble in water and when application is effected in water. The proportion of surfactants is between 5 and 40 per cent by weight of the inventive composition.
It is possible to use dyes such as inorganic pigments, for example iron oxide, titanium oxide and Prussian Blue, and organic dyes such as alizarin dyes, azo dyes and metal phthalocyanine dyes, and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.
Further additives may be perfumes, mineral or vegetable, optionally modified oils, waxes and nutrients (including trace nutrients), such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.
Additional components may be stabilizers, such as cold stabilizers, preservatives, antioxidants, light stabilizers, or other agents which improve chemical and/or physical stability.
If appropriate, other additional components may also be present, for example protective colloids, binders, adhesives, thickeners, thixotropic substances, penetrants, stabilizers, sequestering agents, complex formers. In general, the active ingredients can be combined with any solid or liquid additive commonly used for formulation purposes. The formulations contain generally between 0.05 and 99% by weight, 0.01 and 98% by weight, preferably between 0.1 and 95% by weight, more preferably between 0.5 and 90% of active ingredient, most preferably between 10 and 70 per cent by weight.
The formulations described above can be used for controlling unwanted microorganisms, in which the compositions comprising compounds of the formula (I) are applied to the microorganisms and/or in their habitat.
Mixtures
Compounds of the formula (I) can be used as such or in formulations thereof and can be mixed with known fungicides, bactericides, acaricides, nematicides or insecticides, in order thus to broaden, for example, the activity spectrum or to prevent development of resistance. Useful mixing partners include, for example, known fungicides, insecticides, acaricides, nematicides or else bactericides (see also Pesticide Manual, 14th ed.).
A mixture with other known active ingredients, such as herbicides, or with fertilizers and growth regulators, safeners and/or semiochemicals, is also possible. Seed Treatment
The invention furthermore includes a method for treating seed.
A further aspect of the present invention relates in particular to seeds (dormant, primed, pregerminated or even with emerged roots and leaves) treated with at least one of the compounds of the formula (I). The inventive seeds are used in methods for protection of seeds and emerged plants from the seeds from phytopathogenic harmful fungi. In these methods, seed treated with at least one inventive active ingredient is used.
The compounds of the formula (I) are also suitable for the treatment of seeds and young seedlings. A large part of the damage to crop plants caused by harmful organisms is triggered by the infection of the seeds before sowing or after germination of the plant. This phase is particularly critical since the roots and shoots of the growing plant are particularly sensitive, and even small damage may result in the death of the plant. Accordingly, there is great interest in protecting the seed and the germinating plant by using appropriate compositions.
It is also desirable to optimize the amount of the active ingredient used so as to provide the best possible protection for the seeds, the germinating plants and emerged seedlings from attack by phytopathogenic fungi, but without damaging the plants themselves by the active ingredient used. In particular, methods for the treatment of seed should also take into consideration the intrinsic phenotypes of transgenic plants in order to achieve optimum protection of the seed and the germinating plant with a minimum of crop protection compositions being employed. The present invention therefore also relates to a method for protecting seeds, germinating plants and emerged seedlings against attack by animal pests and/or phytopathogenic harmful microorganisms by treating the seeds with an inventive composition. The invention also relates to the use of the compositions according to the invention for treating seeds for protecting the seeds, the germinating plants and emerged seedlings against animal pests and/or phytopathogenic microorganisms. The invention further relates to seeds which has been treated with an inventive composition for protection from animal pests and/or phytopathogenic microorganisms.
One of the advantages of the present invention is that the treatment of the seeds with these compositions not only protects the seed itself, but also the resulting plants after emergence, from animal pests and/or phytopathogenic harmful microorganisms. In this way, the immediate treatment of the crop at the time of sowing or shortly thereafter protect plants as well as seed treatment in prior to sowing. It is likewise considered to be advantageous that the inventive active ingredients or compositions can be used especially also for transgenic seed, in which case the plant which grows from this seed is capable of expressing a protein which acts against pests, herbicidal damage or abiotic stress. The treatment of such seeds with the inventive active ingredients or compositions, for example an insecticidal protein, can result in control of certain pests. Surprisingly, a further synergistic effect can be observed in this case, which additionally increases the effectiveness for protection against attack by pests., microorganisms, weeds or abiotic stress.
The compounds of the formula (I) are suitable for protection of seed of any plant variety which is used in agriculture, in the greenhouse, in forests or in horticulture. More particularly, the seed is that of cereals (such as wheat, barley, rye, millet and oats), oilseed rape, maize, cotton, soybeen, rice, potatoes, sunflower, beans, coffee, beet (e.g. sugar beet and fodder beet), peanut, vegetables (such as tomato, cucumber, onions and lettuce), lawns and ornamental plants. Of particular significance is the treatment of the seed ofwheat, soybean, oilseed rape, maize and rice.
As also described below, the treatment of transgenic seed with the inventive active ingredients or compositions is of particular significance. This refers to the seed of plants containing at least one heterologous gene which allows the expression of a polypeptide or protein, e.g. having insecticidal properties. These heterologous genes in transgenic seeds may originate, for example, from microorganisms of the species Bacillus, Rhizobium, Pseudomonas, Serratia, Trichoderma, Clavibacter, Glomus or Gliocladium. These heterologous genes preferably originates from Bacillus sp., in which case the gene product is effective against the European corn borer and/or the Western corn rootworm. Particularly preferably, the heterologous genes originate from Bacillus thuringiensis.
In the context of the present invention, the inventive composition is applied to seeds either alone or in a suitable formulation. Preferably, the seed is treated in a state in which it is sufficiently stable for no damage to occur in the course of treatment. In general, seeds can be treated at any time between harvest and some time after sowing. It is customary to use seed which has been separated from the plant and freed from cobs, shells, stalks, coats, hairs or the flesh of the fruits. For example, it is possible to use seed which has been harvested, cleaned and dried down to a moisture content of less than 15% by weight. Alternatively, it is also possible to use seed which, after drying, for example, has been treated with water and then dried again, or seeds just after priming, or seeds stored in primed conditions or pre-germinated seeds, or seeds sown on nursery trays, tapes or paper.
When treating the seeds, it generally has to be ensured that the amount of the inventive composition applied to the seed and/or the amount of further additives is selected such that the germination of the seed is not impaired, or that the resulting plant is not damaged. This must be ensured particularly in the case of active ingredients which can exhibit phytotoxic effects at certain application rates. The compounds of the formula (I) can be applied directly, i.e. without containing any other components and without having been diluted. In general, it is preferable to apply the compositions to the seed in the form of a suitable formulation. Suitable formulations and methods for seed treatment are known to those skilled in the art. The compounds of the formula (I) can be converted to the customary formulations relevant to on- seed applications, such as solutions, emulsions, suspensions, powders, foams, slurries or combined with other coating compositions for seed, such as film forming materials, pelleting materials, fine iron or other metal powders, granules, coating material for inactivated seeds, and also ULV formulations. These formulations are prepared in a known manner, by mixing the active ingredients or active ingredient combinations with customary additives, for example customary extenders and solvents or diluents, dyes, wetting agents, dispersants, emulsifiers, antifoams, preservatives, secondary thickeners, adhesives, gibberellins, and also water. Useful dyes which may be present in the seed dressing formulations usable in accordance with the invention are all dyes which are customary for such purposes. It is possible to use either pigments, which are sparingly soluble in water, or dyes, which are soluble in water. Examples include the dyes known by the names Rhodamine B, C.I. Pigment Red 112 and C.I. Solvent Red 1.
Useful wetting agents which may be present in the seed dressing formulations usable in accordance with the invention are all substances which promote wetting and which are conventionally used for the formulation of active agrochemical ingredients. Usable with preference are alkylnaphthalenesulphonates, such as diisopropyl- or diisobutylnaphthalenesulphonates.
Useful dispersants and/or emulsifiers which may be present in the seed dressing formulations usable in accordance with the invention are all nonionic, anionic and cationic dispersants conventionally used for the formulation of active agrochemical ingredients. Usable with preference are nonionic or anionic dispersants or mixtures of nonionic or anionic dispersants. Useful nonionic dispersants include especially ethylene oxide/propylene oxide block polymers, alkylphenol polyglycol ethers and tristryrylphenol polyglycol ether, and the phosphated or sulphated derivatives thereof. Suitable anionic dispersants are especially lignosulphonates, polyacrylic acid salts and arylsulphonate/ formaldehyde condensates. Antifoams which may be present in the seed dressing formulations usable in accordance with the invention are all foam-inhibiting substances conventionally used for the formulation of active agrochemical ingredients. Silicone antifoams and magnesium stearate can be used with preference.
Preservatives which may be present in the seed dressing formulations usable in accordance with the invention are all substances usable for such purposes in agrochemical compositions. Examples include dichlorophene and benzyl alcohol hemiformal.
Secondary thickeners which may be present in the seed dressing formulations usable in accordance with the invention are all substances usable for such purposes in agrochemical compositions. Preferred examples include cellulose derivatives, acrylic acid derivatives, xanthan, modified clays and finely divided silica.
Adhesives which may be present in the seed dressing formulations usable in accordance with the invention are all customary binders usable in seed dressing products. Preferred examples include polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol and tylose.
The formulations for on- seed applications usable in accordance with the invention can be used to treat a wide variety of different kinds of seed either directly or after prior dilution with water. For instance, the concentrates or the preparations obtainable therefrom by dilution with water can be used to dress the seed of cereals, such as wheat, barley, rye, oats, and triticale, and also seeds of maize, soybean, rice, oilseed rape, peas, beans, cotton, sunflowers, and beets, or else a wide variety of different vegetable seeds. The formulations usable in accordance with the invention, or the dilute preparations thereof, can also be used for seeds of transgenic plants. In this case, additional synergistic effects may also occur in interaction with the substances formed by expression.
For treatment of seeds with the formulations usable in accordance with the invention, or the preparations prepared therefrom by adding water, all mixing units usable customarily for on- seed applications are useful. Specifically, the procedure in on- seed applications is to place the seeds into a mixer, to add the particular desired amount of the formulations, either as such or after prior dilution with water, and to mix everything until all applied formulations are distributed homogeneously on the seeds. If appropriate, this is followed by a drying operation.
The application rate of the formulations usable in accordance with the invention can be varied within a relatively wide range. It is guided by the particular content of the active ingredients in the formulations and by the seeds. The application rates of each single active ingredient is generally between 0.001 and 15 g per kilogram of seed, preferably between 0.01 and 5 g per kilogram of seed.
Antimycotic Effects
In addition, the compounds of the formula (I) also have very good antimycotic effects. They have a very broad antimycotic activity spectrum, especially against dermatophytes and yeasts, moulds and diphasic fungi (for example against Candida species, such as Candida albicans, Candida glabrata), and Epidermophyton fioccosum, Aspergillus species, such as Aspergillus niger and Aspergillus fumigatus, Trichophyton species, such as Trichophyton mentagrophytes, Microsporon species such as Microsporon canis and audouinii. The enumeration of these fungi by no means constitutes a restriction of the mycotic spectrum covered, and is merely of illustrative character.
The compounds can be used also to control important fungal pathogens in fish and Crustacea farming, e.g. saprolegnia diclina in trouts, saprolegnia parasitica in crayfish.
The compounds of the formula (I) can therefore be used both in medical and in non-medical applications.
The compounds of the formula (I) can be used as such, in the form of their formulations or the use forms prepared therefrom, such as ready-to-use solutions, suspensions, wettable powders, pastes, soluble powders, dusts and granules. Application is accomplished in a customary manner, for example by watering, spraying, atomizing, broadcasting, dusting, foaming, spreading-on and the like. It is also possible to deploy the active ingredients by the ultra-low volume method or to inject the active ingredient preparation/the active ingredient itself into the soil. It is also possible to treat the seed of the plants.
GMO As already mentioned above, it is possible to treat all plants and their parts in accordance with the invention. In a preferred embodiment, wild plant species and plant cultivars, or those obtained by conventional biological breeding methods, such as crossing or protoplast fusion, and also parts thereof, are treated. In a further preferred embodiment, transgenic plants and plant cultivars obtained by genetic engineering methods, if appropriate in combination with conventional methods (Genetically Modified Organisms), and parts thereof are treated. The terms "parts" or "parts of plants" or "plant parts" have been explained above. More preferably, plants of the plant cultivars which are commercially available or are in use are treated in accordance with the invention. Plant cultivars are understood to mean plants which have new properties ("traits") and have been obtained by conventional breeding, by mutagenesis or by recombinant DNA techniques. They can be cultivars, varieties, bio- or genotypes.
The method of treatment according to the invention can be used in the treatment of genetically modified organisms (GMOs), e.g. plants or seeds. Genetically modified plants (or transgenic plants) are plants of which a heterologous gene has been stably integrated into genome. The expression "heterologous gene" essentially means a gene which is provided or assembled outside the plant and when introduced in the nuclear, chloroplastic or mitochondrial genome gives the transformed plant new or improved agronomic or other properties by expressing a protein or polypeptide of interest or by downregulating or silencing other gene(s) which are present in the plant (using for example, antisense technology, cosuppression technology, RNA interference - RNAi - technology or microR A - miRNA - technology). A heterologous gene that is located in the genome is also called a transgene. A transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event.
Plants and plant cultivars which are preferably to be treated according to the invention include all plants which have genetic material which impart particularly advantageous, useful traits to these plants (whether obtained by breeding and/or biotechnological means).
Plants and plant cultivars which are also preferably to be treated according to the invention are resistant against one or more biotic stresses, i.e. said plants show a better defense against animal and microbial pests, such as against nematodes, insects, mites, phytopathogenic fungi, bacteria, viruses and/or viroids.
Plants and plant cultivars which may also be treated according to the invention are those plants which are resistant to one or more abiotic stresses. Abiotic stress conditions may include, for example, drought, cold temperature exposure, heat exposure, osmotic stress, flooding, increased soil salinity, increased mineral exposure, ozone exposure, high light exposure, limited availability of nitrogen nutrients, limited availability of phosphorus nutrients, shade avoidance.
Plants and plant cultivars which may also be treated according to the invention, are those plants characterized by enhanced yield characteristics. Increased yield in said plants can be the result of, for example, improved plant physiology, growth and development, such as water use efficiency, water retention efficiency, improved nitrogen use, enhanced carbon assimilation, improved photosynthesis, increased germination efficiency and accelerated maturation. Yield can furthermore be affected by improved plant architecture (under stress and non- stress conditions), including but not limited to, early flowering, flowering control for hybrid seed production, seedling vigor, plant size, internode number and distance, root growth, seed size, fruit size, pod size, pod or ear number, seed number per pod or ear, seed mass, enhanced seed filling, reduced seed dispersal, reduced pod dehiscence and lodging resistance. Further yield traits include seed composition, such as carbohydrate content and composition for example cotton or starch, protein content, oil content and composition, nutritional value, reduction in anti-nutritional compounds, improved processability and better storage stability.
Plants that may be treated according to the invention are hybrid plants that already express the characteristic of heterosis or hybrid vigor which results in generally higher yield, vigor, health and resistance towards biotic and abiotic stresses).
Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may be treated according to the invention are herbicide-tolerant plants, i.e. plants made tolerant to one or more given herbicides. Such plants can be obtained either by genetic transformation, or by selection of plants containing a mutation imparting such herbicide tolerance. Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are insect-resistant transgenic plants, i.e. plants made resistant to attack by certain target insects. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such insect resistance.
Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are tolerant to abiotic stresses. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such stress resistance.
Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention show altered quantity, quality and/or storage- stability of the harvested product and/or altered properties of specific ingredients of the harvested product. Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as cotton plants, with altered fiber characteristics. Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered fiber characteristics.
Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as oilseed rape or related Brassica plants, with altered oil profile characteristics. Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered oil profile characteristics.
Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as oilseed rape or related Brassica plants, with altered seed shattering characteristics. Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered seed shattering characteristics and include plants such as oilseed rape plants with delayed or reduced seed shattering.
Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as Tobacco plants, with altered post- translational protein modification patterns.
Application Rates
When using the compounds of the formula (I) as fungicides, the application rates can be varied within a relatively wide range, depending on the kind of application. The application rate of the inventive active ingredients is
• in the case of treatment of plant parts, for example leaves: from 0.1 to 10 000 g/ha, preferably from 10 to 1000 g/ha, more preferably from 50 to 300 g ha (in the case of application by watering or dripping, it is even possible to reduce the application rate, especially when inert substrates such as rockwool or perlite are used);
• in the case of seed treatment: from 0.1 to 200 g per 100 kg of seed, preferably from 1 to 150 g per 100 kg of seed, more preferably from 2.5 to 25 g per 100 kg of seed, even more preferably from 2.5 to 12.5 g per 100 kg of seed;
• in the case of soil treatment: from 0.1 to 10 000 g/ha, preferably from 1 to 5000 g/ha. These application rates are merely by way of example and are not limiting for the purposes of the invention. The invention is illustrated by the examples below. However, the invention is not limited to the examples.
Examples
Preparation examples
Preparation of compounds of the formula (1-27) according to process H:
Preparation of 2-(l-chlorocyclopropyl)-l-(4-chloro-2-fluor^^
l (1-27)
Figure imgf000067_0001
(1-27)
A solution of 4-chloro- IH- imidazole (1.10 g, 4eq, 10.7mmol) and 2-(l-chlorocyclopropyl)-2-(4-chloro-2- fluorobenzyl)oxirane (700 mg, 1 eq, 2.68 mmol) in 5mL acetonitrile was heated up to 150°C by microwave irradiation for 90min. Thereafter the reaction mixture was diluted with dichloromethane, the organic layer washed with sat. aq. NaHCCh and dried (MgSC ), then concentrated to dryness in vacuo. The residue was purified by chromatography over silica gel, eluted with a mixture of n-heptane/'ethyl acetate (100:0 to 50:50). After evaporation of the solvent 251 mg (24%) of 2-( 1 -chlorocyclopropyl)- 1 -(4-chloro-2-fluorophenyl)-3- (5-chloro- lH-imidazol- 1 -yl)propan-2-ol ( 1-27) were obtained as colourless solid. MS (ESI): 363.0 ([M+H]+)
Preparation of compounds of the formula (1-27) according to process M:
Preparation of 2-(l-chlorocvclopropvl)-l-(4-chloro-2-fluorophenvl)-3-(5-chloro-l/ -imidazol-l-yl)propan-2- ol 1-27)
Figure imgf000067_0002
(1-27)
At 0-5 °C (ice/NaCl bath) a solution of 4-chloro-2-fluorobenzyl bromide (5.97 g, 26.7 mmol, 1.3 eq) in Et20 (5 mL) was added dropwise to a suspension of magnesium turnings (1.50 g, 61.6 mmol, 3.0 equiv; activated by stirring lh at rt under Argon in the presence of a catalytic amount of iodine) in ΕΪΣΟ (15 mL). The mixture was stirred 45min at 5°C. Titration of the resulting solution using iV-phenylsalicylhydrazone as an indicator (Love & Jones, J. Org. Chem. 1999, 64, 3755) gave the concentration as 1.2 M.
To this solution at 5°C was added a solution of 1 -(1 -chlorocyclopropyl)-2-(5-chloro- l//-imidazol- 1 - yl)ethanone (5.00 g, 20.5 mmol, 1.0 eq) in Et20 (30 mL) dropwise over 5 min. The reaction mixture was further stirred while allowed to warm up to room temperature over lh. To the resulting solution, cooled down to 5°C, was added sat. aq. NH4CI. The resulting mixture was diluted with water, then extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with sat. aq. NaHCOj, dried (MgSC ), then concentrated to dryness in vacuo. The oily residue was purified by chromatography over silica gel, eluted with a mixture of «-heptane/ethyl acetate (100:0 to 60:40). After evaporation of the solvent, followed by trituration in «-heptane:Et20 (50:50), a colourless solid precipitated which was filtered off and washed with « -heptane to afford 2.27 g (30%) of 2-(l-chlorocyclopropyi)-l-(4-chloro-2-fluorophenyl)-3-(5-chloro- 1 H-imidazol- 1 -yl)propan-2-ol (1-27) as a colourless solid.
MS (ESI): 363.0 ([M+Hf)
Preparation of compounds of the formula (1-06) according to process H: Preparation of 1 -\2-( 1 -chlorocvclopropyl)-3-(2-chlorophenyl)-2-hydroxvpropyll - 177-imidazole-5- car nitrile (1-06)
Figure imgf000068_0001
(1-06)
A solution of 4-cyano- l//-imidazole (500 mg, 1.0 eq, 5.37mmol) and 2 -(2- chlorobenzyl)-2 -( 1 - chlorocyclopropyl)oxirane (1.96 g, 1.5 eq, 8.05 mmol) in a mixture of acetonitrile (3 mL) and DMF (1 mL) was heated up to 160°C by microwave irradiation for 90min. Thereafter the reaction mixture was diluted with dichloromethane, the organic layer washed with sat. aq. NaHCOs and dried (MgSC ), then concentrated to dryness in vacuo. Purification of the residue by flash chromatography [over silica gel, eluted with a mixture of n-heptane/ethyl acetate (100:0 to 50:50)] followed by preparative 1 1 PLC afforded, after evaporation of the solvents, afforded 1 12 mg (6%) l-[2-(l-chlorocyclopropyl)-3-(2-chlorophenyl)-2- hydroxypropyl]-lH-imidazole-5-carbonitrile ( 1-06) as a colourless oil.
MS (ESI): 336.1 ([M+H]+)
Preparation of compounds of the formula (1-34) according to process M:
Preparation of 1 -[2-( l-chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxypropyl] - l//-imidazole-5-carbonitrile
Figure imgf000068_0002
(1-34) At 0-5 °C (ice aCl bath) a solution o f 2 - fluorobenzyl bromide (1.30 g, 6.86 mmol, 1.2 eq) in ΕΪΣΟ (5 mL) was added dropwise to a suspension of magnesium turnings (417 mg, 17.1 mmol, 3.0 equiv; activated by stirring at rt under Argon in the presence of a catalytic amount of iodine) in ΕΪ2θ (15 mL). The mixture was stirred 45min at 5°C. To this solution at 0-5 °C was added a solution of 1 - [2-( 1 -chlorocyclopropyl)-2-oxoethyl] - lH-imidazole-5- carbonitrile (2.00 g, 60% purity, 5.72 mmol, 1.0 eq) in Et^O (30 mL) dropwise over 5 min. The reaction mixture was further stirred while allowed to warm up to room temperature over lh. To the resulting solution, cooled down to 5°C, was added sat. aq. NH4CI. The resulting mixture was diluted with water, then extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with sat. aq. NaHCC , dried (MgS04), then concentrated to dryness in vacuo. The oily residue was purified by chromatography over silica gel, eluted with a mixture of « -heptane/ethyl acetate (100:0 to 60:40). After evaporation of the solvent, 218 mg (12%) of 1 - [2- ( 1 - chloro cy clopropyl) - 3 -(2-fl.uorophenyl) - 2-hydroxypropyl] - 1 H -imidazole- 5 - carbonitrile (1-34) were obtained as a yellow oil.
MS (ESI): 320.1 ([M+H]+) Preparation of intermediates of the formula (Xll-l ) according to process D:
Pr aration of 2-( 1 -chlorocvclopropvl)-2-(4-chloro-2-fluorobenzyl)oxirane (XII-1)
Figure imgf000069_0001
(XII-1)
To a solution o f trimethy Isulfoxonium chloride (2.50 g, 1.2eq, 19.4mmol) in T! I F (80 mL) at 0°C and under Argon atmosphere was added sodium hydride (60% in mineral oil, 777 mg, 1.2 eq, 19.4 mmol). The resulting suspension was stirred at 0°C for 30min, then a solution of 1 - ( 1 - chlorocyclopropyl)-2-(4-chloro-2- fluorophenyl)ethanone (4.00 g, 1.0 eq, 16.1 mmol) in Ti ll-' (10 mL) was added. The mixture was stirred for 2h at 0°C, then for 20h at room temperature. After careful addition of water, the obtained solution extracted with ethyl acetate. The organic phase was dried (MgSC ), then concentrated to dryness in vacuo. Purification by column chromatography over silica gel (eluent » -heptane / ethyl acetate 95:5) afforded, after evaporation of the solvent, 3.69 g (81%) of 2-(l-chlorocyclopropyi)-2-(4-chloro-2-fluorobenzyl)oxirane (XII-1) as a colourless oil.
MS (EI): 260.0 ([M]+)
Preparation of intermediates of the formula (XV II) according to process K: Preparation of 1 -( 1 -ehlorocyclopropyl)-2-(5-chloro- lH-imidazol- 1 -yl)ethanone (XV'H-l )
Step 1: Preparation of l-allvl-4-chloro-lH-imidazole
Figure imgf000070_0001
To a solution of 4-chloro- lH-imidazole (180g, 1.76 mol, 1.00 eq) in dry dichloromethane (3.0 L) at 0°C was added aq. NaOI I (1 M, 2.11 L, 2.1 1 mmol, 1.20 eq) followed by tetra-»-butylammonium bromide (56.6 g, 0.176 mol, 0.10 eq). To this biphasic solution was added dropwise allyl bromide (167 mL, 1.93 mol, 1.10 eq) and the resulting mixture was stirred at room temperature for 20h. Thereafter the reaction mixture was diluted with water (1 L), extracted with dichloromethane (2 x 1 L), the combined organic layers were dried (MgS(>4) and concentrated in vacuo, to provide 290 g of a mixture of regioisomers (80% purity, 93% yield), which were separated by distillation at reduced pressure (0.1 mbar).
MS (EI): 142.1 ([M]+) Ste 2: Preparation of l-allyl-4-chloro-3-[2-(l-chlorocyclopropyl)-2-oxoethvll-lH-imidazol-3-ium iodide
Figure imgf000070_0002
A solution of 1 -allyl-4- chloro- 1 H-imidazole (15. Og, 105 mmol, 1 eq), 2-chloro-l-(l- chlorocyciopropyl)ethanone (19.3g, 126 mmol, 1.20 eq) and potassium iodide (21. lg, 127 mmol, 1.21 eq) in dry methanol (100 mL) was stirred at room temperature for lh, then at 70 °C for 21h. Thereafter, the reaction mixture was concentrated in vacuo, and diluted with cold ethyl acetate, whereupon a solid precipitated. The precipitate was filtered off to afford 34.6g (83%) of l-allyl-4-chloro-3-[2-(l-chlorocyclopropyl)-2- oxoethyl] - 1 H-imidazol-3 -ium iodide as an off-white solid.
MS (ESI): 259.1 ([M-I]+)
Step 3: Preparation of l-(l-chlorocvclopropvl)-2-(5-chloro-lH-imidazol-l-yl)ethanone (XVII-l )
Figure imgf000070_0003
(XV II-l )
To a solution of 1 -allyl-4-chloro-3 - [2-( 1 - chlorocy clopropyl)-2-oxoethyl] - 1 H-imidazol-3 -ium iodide (28.54g, 75.6 mmol, 1 eq) and morpholine (10. lg, 115 mmol, 1.52 eq) in dry dichloromethane (150 mL), previously degassed by bubbling a flow of Argon through it for 10 min, was added tetrakis(triphenylphosphine)palladium(0) (1.12g, 0.96 mmol, 0.013 eq). The resulting mixture was stirred at room temperature for 2h30, then diluted with water and extracted with ethyl acetate (3 x 50mL). The combined organic layers were washed with sat. aq. NH4CI, dried and concentrated to dryness in vacuo. Purification by column chromatography over silica gel (eluent DCM /MeOH 100:0 to 60:40) afforded, after evaporation of the solvent, 12.5 g (58%) of 1 -( 1 -chlorocyclopropyl)-2-(5-chloro- IH-imidazol- 1 -yl)ethanone (XV 11-1 ) as an orange-coloured oil.
MS (ESI): 219.1 ([M+H]+)
Preparation of l-(l-chlorocyciopropyl)-2-(5-cliloro-lH-imidazo!-l-yl)eihanone (XVII-2) tep 1: Preparation of 1 -ally!- 177- imidazole-4-carbonitrile
Figure imgf000071_0001
To a solution of l-H-imidazole-5-carbonitrile (lOOg, 1.02 mol, 1.00 eq) in dry dichloromethane (3.0 L) at 0°C was added aq. NaOI I (1 M, 1.23 L, 1.23 mmol, 1.20 eq) followed by tetra-«-butylammonium bromide (32.9 g, 0.102 mol, 0.10 eq). To this biphasic solution was added dropwise allyl bromide (92.7 mL, 1.07 mol, 1.05 eq) and the resulting mixture was stirred at room temperature for 20h. Thereafter the reaction mixture was diluted with water (1 L), extracted with dichloromethane (2 x 1 L), the combined organic layers were dried (MgS04) and concentrated in vacuo, to provide 163 g of a 75:25 mixture of regioisomers (80% purity, 96% yield), which were separated by distillation at reduced pressure (0.1-0.2 mbar).
MS (EI): 133.1 ([M]+) Step 2: Preparation of l-allyl-3-[2-(l-chlorocyclopropyl)-2-oxoethyl]-4-cyano-lff-imidazol-3-ium iodide
Figure imgf000071_0002
A solution of 1 -allyl-4- chloro- 1 H-imidazole (50. Og, 375 mmol, 1 eq), 2-chloro-l-(l- chloro cy clopropy l)ethanone (68.9g, 450 mmol, 1.20 eq) and potassium iodide (31.2g, 187 mmol, 0.50 eq) in dry methanol (150 mL) was stirred at 70°C for 46h. Thereafter, the reaction mixture was concentrated in vacuo, and diluted with toluene. The resulting solution was extracted with water, the aqueous phase washed with diisopropyl ether, then concentrated to dryness in vacuo. The residue was dissolved in acetonitrile, the insoluble were filtered off and the filtrate concentrated to dryness in vacuo to afford 98.6g (46%) of 1-allyl- 3-[2-(l-chlorocyclopropyl)-2-oxoethyl]-4-cyano-lH-imidazol-3-ium iodide (purity 66%) as a brown oil.
MS (ESI): 250.9 ([M-I]+)
Figure imgf000071_0003
(XVII-2) To a solution of l-allyl-3-[2-(l-chlorocyclopropyl)-2-oxoethyl]-4-cyano-lH-imidazol-3-ium iodide (13.49g, 67% purity, 23.9 mniol, 1 eq) and morpholine (2.51g, 28.7 mmol, 1.2 eq) in dry di chloromethane (150 mL), previously degassed by bubbling a flow of Argon through it for 10 min, was added tetrakis(triphenylphosphine)palladiirm(0) (553 mg, 0.47 mmol, 0.020 eq). The resulting mixture was stirred at room temperature for 24h, then diluted with water and extracted with dichloromethane. The combined organic layers were dried (MgSC ) and concentrated to dryness in vacuo. Purification by 2 column chromatographies over silica gel (first one: eluent DCM /MeOH 100:0 to 60:40 ; second one: eluent DCM /MeCN 100:0 to 95:5) afforded, after evaporation of the solvents, 5.12 g (55% purity, 56% yield) of l-[2-(l- chiorocyclopropyl)-2-oxoethyi]-lH-imidazole-5-carbonitrile (XVI 1-2) as an orange-coloured oil. MS (ESI): 210.0 ([M+Hf)
Preparation of compounds of the formula (XVII-2) according to process L:
Preparation of 3-[2-(l-chlorocvclopropvl)-2-oxo-ethvllimidazole-4-carbonitrile (XVII-2)
Figure imgf000072_0001
(XVII-2)
In a 500 mL teflon microwave reactor was placed 2-(5-bromoimidazol- 1 -yl)- 1 -( 1 - chlorocyclopropyl)ethanone (15.5 g, 1 eq, 58.8 mmol, 90% pure), Zn(CN)2 (7.60 g, 1.1 eq, 64.7 mmol), and Pd(PPl¾)4 (13.6 g, 0.2 eq, 11.7 mmol) in DM F (230 mL). The reactor was placed in the microwave and heated at 160 °C for 10 min. The mixture was then concentrated, and taken up in a mixture of water and ethyl acetate. To remove the palladium salts, the mixture was passed over a silica plug which was washed with ethyl acetate. To the filtrate was added water, the phases were separated, and the aqueous phase was extracted three times with ethyl acetate. The combined organic extracts were then washed with an aqueous solution of LiCl, dried, and concentrated. The crude product was purified by chromatography over silica (gradient 100% DCM to 100% of a mixture DC M MeOH = 9/1 as eluent). After evaporation of the solvent 14.2 g (61 ) yield, 53% pure) of the target compound (XVII-2) (contaminated with P1¾P) was obtained as a brown oil which was used without further purification.
MS (ESI): 210.0 ([M+H] ')
The following Table 1 illustrates in a non -limiting manner examples of compounds according to formula
(I).
Figure imgf000073_0001
Table 1
Fx \° Q 1 R2 R3 R4 R5 LogP
1-01 2-chlorophenyl 1 -chlorocyclopropyl H methoxycarbonyl H H 2,82W
2,32W;
1-02 2-chlorophenyl 1 -chlorocyclopropyl H chloro H H
2,00^
1-03 2-chlorophenyl 1 -chlorocyclopropyl H methyl H H L72W
1-04 2-chlorophenyl 1 -chlorocyclopropyl H bromo H H 2,27W
1-05 2-chlorophenyl 1 -chlorocyclopropyl H chloro fluoro H 2,17^
1-06 2-chlorophenyl 1 -chlorocyclopropyl H cyano H H 2,92W
1-07 2-chloropyridin-3 -yl 1 -chlorocyclopropyl H chloro H H 1,57W
1-08 2-chloro-4-fluorophenyl 1 -chlorocyclopropyl H chloro H H 2,47W
1-09 2-chlorophenyl 1 -chlorocyclopropyl H phenyl H H 2.30W
1-10 2-chloropyridin-3-yl 1 -chlorocyclopropyl H methyl H H L22W
1-11 2,4-dichloropyiidin-3-yl 1 -chlorocyclopropyl H chloro H H 2,02W
1-12 2-chlorophenyl 1 -chlorocyclopropyl H formyl H H 2,80W
1-13 2-chlorophenyl 1 -chlorocyclopropyl H methyl fluoro H 1,75W
1-14 2-chlorophenyl 1 -chlorocyclopropyl H iodo H H 2,14W
1-15 2-chlorophenyl 1 -chlorocyclopropyl H trifluoromethyl H H 3,63W
1-16 2-chlorophenyl 1 -chlorocyclopropyl H fluoro H H 1,94W
1-17 2,5-dichloropyridin-4-yl 1 -chlorocyclopropyl H chloro H H 2,18W
1-18 5 -chloro-2-fluoropyridin-4-yl 1 -chlorocyclopropyl H chloro H H 2,0lW
1-19 2-chlorophenyl 1 -chlorocyclopropyl H acetyl H H 2,90W
1-20 2-chlorophenyl 1 -chlorocyclopropyl H 2-thienyl H H 2,21 W
1-21 2-chlorophenyl 1 -chlorocyclopropyl H cyanomethyl H H 1,66W Ex N° Q 1 R2 R3 R4 R5 LogP
1-22 2-chlorophenyl 1 -chlorocyclopropyl H methylthio H H 2,08W
1-23 2-chlorophenyl 1 -chlorocyclopropyl H bromo fluoro H 2,32W
1-24 2-chlorophenyl 1 -chlorocyclopropyl H cyano fluoro H 2,82W
1-25 2-chloropyridin-3 -yl 1 -chlorocyclopropyl H bromo H H 1,56W
1-26 2-chloropyridin-3 -yl 1 -chlorocyclopropyl H cyano H H 2,0lW
I-27(*) 4-chloro-2-fluorophenyl 1 -chlorocyclopropyl H chloro H H 2,48W
1-28 2-fluorophenyl 1 -chlorocyclopropyl H chloro fluoro H 2,0lW
I-29(*) 4-chloro-2-fluorophenyl 1 -chlorocyclopropyl H cyano H H 3,02W
1-30 4-chloro-2-fluorophenyl 1 -chlorocyclopropyl H bromo H H 2,55M
1-31 2-fluorophenyl 1 -chlorocyclopropyl H cyano fluoro H 2,51^
1-32 2-fluorophenyl 1 -chlorocyclopropyl H chloro H H 2,07«
1-33 2-fluorophenyl 1 -chlorocyclopropyl H bromo H H 2,10«
I-34(*) 2-fluorophenyl 1 -chlorocyclopropyl H cyano H H 2,64^
1-35 2-fluorophenyl 1 -chlorocyclopropyl H methoxy H H 1,67^
1-36 2-fluorophenyl 1 -chlorocyclopropyl H ethynyl H H 1,89^
1-37 2-fluorophenyl 1 -chlorocyclopropyl H cyclopropyl H H 1,86^
1-38 2-chlorophenyl 1 -chlorocyclopropyl H ethynyl H H 2,09«
1-39 phenyl 1 -chlorocyclopropyl H chloro H H 2,04^
1-40 2-bromophenyl 1 -chlorocyclopropyl H cyano H H 3,06W
1-41 4-bromo-2-chlorophenyl 1 -chlorocyclopropyl H cyano H H 3,52
1-42 4-bromo-2-fluorophenyl 1 -chlorocyclopropyl H cyano H H 3,24W
1-43 4-bromo-2-chlorophenyl 1 -chlorocyclopropyl H chloro H H 3,02W
1-44 4-bromo-2-fluorophenyl 1 -chlorocyclopropyl H chloro H H 2,64W
1-45 3-bromophenyl 1 -chlorocyclopropyl H cyano H H 3,04W
1-46 3 -bromopyridin-4-yl 1 -chlorocyclopropyl H cyano H H L94W
1-47 2,5-dibromopyridin-4-yl 1 -chlorocyclopropyl H cyano H H 2,73 W
1-48 2,3-dibromopyridin-4-yl 1 -chlorocyclopropyl H cyano H H 2,60®
1-49 2,3-dichlorophenyl 1 -chlorocyclopropyl H cyano H H 3,25W Ex N° Q 1 R2 R3 R4 R5 LogP
1-50 2,3-dicMoropyridin-4-yl 1 -chlorocyclopropyl H cyano H H 2,47W
1-51 2,4-dimet ylphenyl 1 -chlorocyclopropyl H cyano H H 3,27W
1-52 2,4-dichlorophenyl 1 -chlorocyclopropyl H cyano H H 3,42W
2-chloro-4-(4-
1-53 1 -chlorocyclopropyl H cyano H H 4,54W chlorophenoxy)phenyi
1-54 2-methylphenyl 1 -chlorocyclopropyl H cyano H H 2,96W
1-55 2-methoxyphenyl 1 -chlorocyclopropyl H cyano H H 2,93 W
1-56 2,5-dichloropyridin-4-yl 1 -chlorocyclopropyl H cyano H H 2,62W
1-57 3 -chloropyridin-4-yl 1 -chlorocyclopropyl H cyano H H 1,88W
1-58 3,5-dichlorophenyl 1 -chlorocyclopropyl H cyano H H 3,55W
1-59 3-methyiphenyl 1 -chlorocyclopropyl H cyano H H 3,17W
1-60 2-cMoro-6-methyipyridin-4-yl 1 -chlorocyclopropyl H cyano H H
1-61 2,6-diciiloropyridin-4-yl 1 -chlorocyclopropyl H cyano H H 2,66«
1-62 2-chloropyridin-4-yl 1 -chlorocyclopropyl H cyano H H 2,04^
1-63 biphenyl-4-yl 1 -chlorocyclopropyl H cyano H H 3,68^
1-64 4-chlorophenyl 1 -chlorocyclopropyl H cyano H H 3,!0W
1-65 phenyl 1 -chlorocyclopropyl H cyano H H 2,64«
1-66 2,3-dichlorophenyl 1 -chlorocyclopropyl H chloro H H 2,69
1-67 2,3-dichloropyridin-4-yl 1 -chlorocyclopropyl H chloro H H 2,08w
1-68 2,4-dimethylphenyl 1 -chlorocyclopropyl H chloro H H 2,69™
1-69 2,4-dichlorophenyl 1 -chlorocyclopropyl H chloro H H 2,96™
2-chloro-4-(4-
1-70 1 -chlorocyclopropyl H chloro H H 4,06W chlorophenoxy)phenyl
1-71 2-methylphenyl 1 -chlorocyclopropyl H chloro H H 2,33™
1-72 3 -chloropyridin-4-yl 1 -chlorocyclopropyl H chloro H H 1,52™
1-73 3 -methylphenyl 1 -chlorocyclopropyl H chloro H H 2,30™
1-74 2,6-dichloropyridin-4-yl 1 -chlorocyclopropyl H chloro H H 2,23 W
1-75 2-chloropyridin-4-yl 1 -chlorocyclopropyl H chloro H H 1,62^
1-76 4-methylphenyl 1 -chlorocyclopropyl H chloro H H 2,30W Ex N° Q 1 R2 R3 R4 R5 LogP
1-77 4-chlorophenyl 1 -chlorocyclopropyl H chloro H H 2,45 W
1-78 2-chlorophenyl 1 -chlorocyclopropyl H amino H H 1,50W
1-79 2-chlorophenyl 1 -methylcyclopropyl H cyano H H 2,87W
1-80 2-chlorophenyl cyclopropyl H cyano H H 2,57!»!
1-81 2-chlorophenyl cyclobutyl H cyano H H 2,96!"!
1-82 2-chlorophenyl isopropyl H cyano H H 2,67!"!
1-83 2-chlorophenyl 2,2-dimethylpropyl H cyano H H 3,55!>!
1-84 2-chlorophenyl cyclopropylmethyl H cyano H H 2,84!»!
1-85 2,3-dichlorophenyl cyclobutyl H cyano H H 3,31W
1-86 4-chlorophenyl 2,2-dimethylpropyl H cyano H H 3,37!"!
2-[l-(trifluoromethyl)-
1-87 1 -chlorocyclopropyl H cyano H H 3,33!»! cyclopropyljphenyl
1-88 2-(trifluoromethyl)phenyl 1 -chlorocyclopropyl H cyano H H 3,15!"!
1-89 2-(trifluoromethyl)phenyl 1 -chlorocyclopropyl H chloro H H 2,62!"!
2-chloro-4-(trifluoromethyl) -
1-90 1 -chlorocyclopropyl H cyano H H 3,42!»! phenyl
2-chloro-4-(trifluoromethyl) -
1-91 1 -chlorocyclopropyl H chloro H H 3,04!"! phenyl
1-92 3 -(trifluoromethyl)pyridin-4-yl 1 -chlorocyclopropyl H cyano H H 2,18!"!
1-93 2,3,4-trifluorophenyl 1 -fluorocyclopropyl H cyano H H 2,52!"!
1-94 3 -chloro-2-fluorophenyl 1 -fluorocyclopropyl H cyano H H 2,68!"!
1-95 2,3-difluorophenyl 1 -fluorocyclopropyl H cyano H H 2,37!"!
1-96 4-chloro-2-fluorophenyl 1 -fluorocyclopropyl H cyano H H 2,78!"!
1-97 2,4-difluorophenyl 1 -fluorocyclopropyl H cyano H H 2,39!"!
1-98 2-chlorophenyl 1 -fluorocyclopropyl H cyano H H 2,53!"!
1-99 2-fluorophenyl 1 -fluorocyclopropyl H cyano H H 2,01!"!
1-100 4-fluorophenyl 1 -fluorocyclopropyl H cyano H H 2,35!"!
1-101 3-chloro-2,4-difluorophenyl 1 -chlorocyclopropyl H cyano H H 3,17!"!
1-102 2,3,4-trifluorophenyl 1 -methylcyclopropyl H cyano H H 2,82!"! Ex N° Q 1 R2 R3 R4 R5 LogP
1-103 2,3,4-trifluorophenyl 1 -chlorocyclopropyl H cyano H H 2,92W
1-104 2,3,4-trifluorophenyl cyclobutyl H cyano H H 2,78W
1-105 2,3,4-trifluorophenyl isopropyl H cyano H H 2,78W
1-106 2,3,4-trifluorophenyl cyclopropylmethyl H cyano H H 2,73 W
1-107 2-fluoro-4-methylphenyl 1 -chlorocyclopropyl H cyano H H 2,97W
1-108 2-fluoro-4-methylphenyl 1 -chlorocyclopropyl H chloro H H 2,34W
1-109 3 ,4-difluorophenyl 1 -chlorocyclopropyl H cyano H H 2,78^
1-110 3 ,4-difluorophenyl 1 -chlorocyclopropyl H chloro H H 2,23 W
I-l l l(*) 4-chloro-2-fluorophenyl 1 -chlorocyclopropyl H cyano H H 3,05W
I-112(*) 4-chloro-2-fluorophenyl 1 -chlorocyclopropyl H cyano H H 3,05^
I-113(*) 4-chloro-2-fluorophenyl 1 -chlorocyclopropyl H chloro H H 2,54*1
I-114(*) 4-chloro-2-fluorophenyl 1 -chlorocyclopropyl H chloro H H
1-115 4-chloro-2-fluorophenyl cyclopropyl H cyano H H 2,66
1-116 4-chloro-2-fluorophenyl cyclopropyl H carbamoyl H H i,49«
1-117 4-chloro-2-fluorophenyl cyclobutyl H cyano H H 3,13«
1-118 4-chloro-2-fluorophenyl isopropyl H cyano H H 2,9 lW
1-119 4-chloro-2-fluorophenyl 2,2-dimethylpropyl H cyano H H 3,71^
1-120 4-chloro-2-fluorophenyi cyclopropylmethyl H cyano H H 2,95 W
1-121 4-chloro-2-fluorophenyl cyclopropyl methyl cyano H H 3,31W
1-122 4-chloro-2-fluorophenyl 1 -chlorocyclopropyl ethyl chloro H H 3,10W
1-123 4-chloro-2-fluorophenyl 1 -chlorocyclopropyl ally! chloro H H 3,31W
1-124 2,4-difluorophenyl 1 -methylcyclopropyl H cyano H H 2,65W
1-125 2,4-difluorophenyl 1 -chlorocyclopropyl H cyano H H 2,78W
1-126 2,4-difluorophenyl 1 -chlorocyclopropyl H chloro H H 2,20W
1-127 2,4-difluorophenyl cyclobutyl H cyano H H 2,80W
1-128 2,4-difluorophenyl isopropyl H cyano H H 2,52W
1-129 2,4-difluorophenyl 2,2-dimethylpropyl H cyano H H 3,33W
1-130 2,4-difluorophenyl cyclopropylmethyl H cyano H H 2,69W Ex N° Q 1 R2 R3 R4 R5 LogP
1-131 2-fluorophenyl 1 -methylcyclopropyl H cyano H H 2,68!»!
I-132(*) 2-fluorophenyl 1 -chlorocyclopropyl H cyano H H 2,59W
I-133(*) 2-fluorophenyl 1 -chlorocyclopropyl H cyano H H 2,59!»!
(2-
1-134 2-fluorophenyl 1 -chlorocyclopropyl H H H 3,60W fluorophenyl)acetyl
1-135 2-fluorophenyl 1 -chlorocyclopropyl H ethoxycarbonyl H H 2,73 W
1-136 2-fluorophenyl cyclopropyl H cyano H H 2,28!»!
1-137 2-fluorophenyl cyclobutyl H cyano H H 2,46!»!
1-138 2-fluorophenyl tert-butyl H cyano H H 2,73 W
1-139 2-fluorophenyl isopropyl H cyano H H 2,40W
1-140 2-fluorophenyl 2,2-dimethyipropyl H cyano H H 3,23W
1-141 2-fluorophenyl cyclopropylmethyl H cyano H H 2,45!»!
1-142 2-fluoro-3 -methylphenyl 1 -chlorocyclopropyl H cyano H H 2,99!»!
1-143 2-fluoro-3 -methylphenyl 1 -chlorocyclopropyl H chloro H H 2,35!»!
1-144 2,3-difluorophenyl 1 -methylcyclopropyl H cyano H H 2,75!"!
1-145 3 -chloro-2-fluorophenyl 1 -chlorocyclopropyl H cyano H H 3,02!»!
1-146 2,3-difluorophenyl 1 -chlorocyclopropyl H cyano H H 2,75!»!
1-147 2,3-difluorophenyl 1 -chlorocyclopropyl H chloro H H 2,17!»!
1-148 2,3-difluorophenyl cyclobutyl H cyano H H 2,57ϊ»!
1-149 2,3-difluorophenyl isopropyl H cyano H H 2,47!»!
1-150 2,3-difluorophenyl 2,2-dimethyipropyl H cyano H H 3,27ϊ»!
1-151 2,3-difluorophenyl cyclopropylmethyl H cyano H H 2,66!»!
1-152 2-chloro-3 -fluoropyridin-4-yl 1 -chlorocyclopropyl H cyano H H 2,25!»!
1-153 4-fluoro-2-methyiphenyl 1 -chlorocyclopropyl H cyano H H 2,96!»!
1-154 2-chloro-4-fluorophenyl 1 -chlorocyclopropyl H cyano H H 3,00!»!
1-155 4-fluoro-2-methyiphenyl 1 -chlorocyclopropyl H chloro H H 2,46!»!
1-156 3,5-difluorophenyl 1 -chlorocyclopropyl H cyano H H 2,86!»!
1-157 4-fluorophenyl 1 -chlorocyclopropyl H cyano H H 2,75!»! Ex N° Q 1 R2 R3 R4 R5 LogP
1-158 4-fluorophenyl 1 -chlorocyclopropyl H chloro H H 2,13W
1-159 4-fluorophenyl 1 -chlorocyclobutyl H cyano H H 2,98W
1-160 4-fluorophenyl cyclobutyl H cyano H H 2,56W
1-161 4-fluorophenyl cyclopentyl H cyano H H 2,82W
1-162 4-fluorophenyl isopropyl H cyano H H 2,44W
1-163 3-fluoropyridin-4-yl 1 -chlorocyclopropyl H cyano H H L62W
1-164 3-fluoropyridin-4-yl 1 -chlorocyclopropyl H chloro H H 1,46W
1-165 5 -chloro-2-fluoropyridin-4-yi 1 -chlorocyclopropyl H cyano H H 2,38^
1-166 2-iodophenyl 1 -chlorocyclopropyl H cyano H H 3,13W
1-167 2-iodophenyl 1 -chlorocyclopropyl H chloro H H 2,58^
1-168 3 -chloropyridazin-4-yl 1 -chlorocyclopropyl H cyano H H 1,59
1-169 phenyl 1 -chlorocyclopropyl H phenylacetyl H H 3,56W
Optical rotation
Concentration c is expressed in g/100 mL (*) Ex 1-113 and 1-114 are the 2 cnantiomcrs of Ex 1-27 Ex 1-113: Optical rotation: -4 (c=1.00, MeOH, 20°C) Ex 1-114: Optical rotation: +4 (c=l,00, MeOH, 20°C) (*) Ex 1-1 11 and 1-112 are the 2 cnantiomcrs of Ex 1-29 Ex 1-11 1: Optical rotation: -12 (c=1.00, MeOH, 25°C) Ex 1-112: Optical rotation: +12 (c=1.00, MeOH, 25°C) (*) Ex 1-132 and 1-133 are the 2 cnantiomcrs of Ex 1-34 Ex 1-132: Optical rotation: -16.2 (c=0.99, MeOH; 20°C) Ex 1-133: Optical rotation: +14.2 (c=1.13, MeOH, 20°C)
Measurement of LogP values was performed according to EEC directive 79/831 Annex V.A8 by 11 PLC (High Performance Liquid Chromatography) on reversed phase columns with the following methods: M LogP value is determined by measurement of LC-UV, in an acidic range, with 0.1% formic acid in water and acetonitrile as eluent (linear gradient from 10% acetonitrile to 95% acetonitrile).
Μ LogP value is determined by measurement of LC-UV, in a neutral range, with 0.001 molar ammonium acetate solution in water and acetonitrile as eluent (linear gradient from 10% acetonitrile to 95% acetonitrile).
[ i LogP value is determined by measurement of LC-UV, in an acidic range, with 0.1% phosphoric acid and acetonitrile as eluent (linear gradient from 10% acetonitrile to 95% acetonitrile).
If more than one LogP value is available within the same method, all the values are given and separated by
"+".
Calibration was done with straight- chain alkan2-ones (with 3 to 16 carbon atoms) with known LogP values (measurement of LogP values using retention times with linear interpolation between successive alkanones). Lambda-max- values were determined using UV- spectra from 200 nm to 400 nm and the peak values of the chromatographic signals.
The following Table 2 illustrates in a non -limiting manner examples of compounds according to formula (XVII).
Table 2
Figure imgf000080_0001
Fx N° RL T R33 I LLooggPP
XVil- l 1 -chlorocyclopropyl chloro 0,75^
XVII-2 1 -chlorocyclopropyl cyano 1,35^
XVI!-3 cyclopropyl cyano 0,74^
XVI I -4 1 -fluorocyclopropyl cyano 1,05^
XVI 1-5 1 -chlorocyclopropyl fluoro 0,32[al
XVII-6 1 -chlorocyclopropyl methoxycarbonyl 1,20^
ΧΥΊΙ-7 tert-butyl cyano l,47[a!
XVII-8 2-chloropropan-2-yl cyano l,65[a!
XVII-9 1 -cyanocyclopropyl cyano 0,90^
XVII- 10 1 -chlorocyclopropyl iodo 0,70^
XVII- 11 2-fluoropropan-2-yl cyano l,31[a! Fx N° 1 R3 LogP
XVII- 12 cyclopropylmethyl cyano l,27[a!
XVII- 13 2,2-dimethylpropyl cyano 1,88^
XVII- 14 isopropyl cyano 1,14^
XVII- 15 cyclopentyl cyano l,57w
XVII- 16 1 -fluorocyclopentyl cyano 1,8
XVII- 17 cyclobutyl cyano 1,26^
XVII- 18 1 -chlorocyclobutyl cyano l,86[ai
XVII- 19 butyl cyano 1,60^
Measurement of LogP values was performed as outlined above.
NMR- Peak lists
IH-NMR data of selected examples are written in form of lH-NMR-peak lists. To each signal peak are listed the δ-value in ppm and the signal intensity in round brackets. Between the δ-value - signal intensity pairs are semicolons as delimiters.
The peak list of an example has therefore the form: δι (intensity i); 62 (intensitV2); ; δ; (intensit i); ; δη (intensityn)
Intensity of sharp signals correlates with the height of the signals in a printed example of a NMR spectrum in cm and shows the real relations of signal intensities. From broad signals several peaks or the middle of the signal and their relative intensity in comparison to the most intensive signal in the spectrum can be shown.
For calibrating chemical shift for 1 1 1 spectra, we use tetramethylsilane and/or the chemical shift of the solvent used, especially in the case of spectra measured in DM SO. Therefore in NMR peak lists, tetramethylsilane peak can occur but not necessarily. The IH-NMR peak lists are similar to classical IH-NMR prints and contains therefore usually all peaks, which are listed at classical NMR-interpretation.
Additionally they can show like classical IH-NMR prints signals of solvents, stereoisomers of the target compounds, which are also object of the invention, and/or peaks of impurities.
To show compound signals in the delta-range of solvents and/or water the usual peaks of solvents, for example peaks of DMSO in DMSO-De and the peak of water are shown in our I H-NMR peak lists and have usually on average a high intensity . The peaks of stereoisomers of the target compounds and/or peaks of impurities have usually on average a lower intensity than the peaks of target compounds (for example with a purity >90%).
Such stereoisomers and/or impurities can be typical for the specific preparation process. Therefore their peaks can help to recognize the reproduction of our preparation process via "side-products-fing^rints".
An expert, who calculates the peaks of the target compounds with known methods (MestreC, ACD- simulation, but also with empirically evaluated expectation values) can isolate the peaks of the target compounds as needed optionally using additional intensity filters. This isolation would be similar to relevant peak picking at classical 1H-NMR interpretation.
Further details of NMR-data description with peak lists you find in the publication "Citation of NMR Peaklist Data within Patent Applications" of the Research Disclosure Database Number 564025.
jExample 1-01 : 1 H-NMR (499.9 Mi l/, CDC13):
5= 7.934 (2.9); 7.744 (2.8); 7.511 (1.1); 7.508 (1.2); 7.496 (1.2); 7.493 (1.3); 7.411 (1.1); 7.408 (1.1); 7.395 (1.5):
7.392 (1.4); 7.293 (0.5); 7.290 (0.6); 7.278 (1.4); 7.275 (1.3); 7.263 (1.2); 7.260 (1.1); 7.255 (1.1): 7.251 (1.2): 7.240 (1.2); 7.236 (1.2); 7.225 (0.5); 7.221 (0.4); 4.780 (1.7); 4.750 (2.2); 4.541 (2.2); 4.511 (1.8): 4.118 (4.3): 3.765 (16.0); 3.663 (2.0); 3.635 (2.2); 3.162 (1.9); 3.135 (1.8); 2.002 (1.6); 0.858 (0.4); 0.846 (0.6) 0.843 (0.6): 0.836 (0.6); 0.831 (0.8); 0.825 (0.8); 0.821 (0.7); 0.810 (0.7); 0.788 (0.5); 0.776 (0.5); 0.773 (0.7) 0.766 (0.8): 0.762 (0.5); 0.755 (0.7); 0.752 (0.9); 0.741 (0.6); 0.675 (0.7); 0.664 (0.8); 0.661 (0.7); 0.654 (0.6) 0.649 (0.8): 0.643 (0.7); 0.640 (0.5); 0.628 (0.5); 0.509 (0.6); 0.498 (0.7); 0.495 (0.7); 0.488 (0.7); 0.484 (0.7) 0.477 (0.6): 0.474 (0.7); 0.462 (0.5); 0.000 (2.8)
jExample 1-02: ¾-NMR (499.9 MHz, CDCI3):
5= 7.710 (12.0); 7.529 (0.4); 7.519 (5.2); 7.514 (5.4); 7.504 (4.7); 7.500 (6.2); 7.394 (5.2); 7.391 (4.1); 7.380
(6.1) ; 7.376 (6.7); 7.365 (0.8); 7.357 (0.5); 7.291 (0.3); 7.284 (1.5); 7.280 (2.3); 7.269 (6.7); 7.263 (11.5); 7.261 (8.8); 7.255 (12.3); 7.251 (6.4); 7.246 (6.7); 7.242 (5.7); 7.231 (2.3); 7.227 (1.8); 7.206 (0.5); 6.942 (12.3); 4.441
(9.2) ; 4.411 (12.5); 4.388 (0.3); 4.249 (12.1); 4.219 (9.2); 3.384 (5.3); 3.355 (13.7); 3.321 (14.9); 3.292 (6.1): 2.432 (5.3); 2.037 (1.1); 1.847 (0.9); 1.269 (0.4); 1.255 (0.7); 1.241 (0.3); 0.818 (0.6); 0.811 (1.3); 0.797 (3.1): 0.791 (6.5); 0.781 (12.8); 0.779 (13.4); 0.774 (16.0); 0.767 (5.5); 0.764 (6.8); 0.757 (5.5); 0.754 (5.7); 0.748 (2.2); 0.743 (1.8); 0.731 (1.0); 0.720 (1.5); 0.711 (0.9); 0.696 (2.6); 0.689 (5.0); 0.682 (3.8); 0.679 (4.7); 0.673 (2.4); 0.665 (3.5); 0.660 (2.5); 0.644 (0.7); 0.636 (0.3); 0.000 (5.1); -0.007 (0.3)
Example 1-03: ' H-N R (499.9 MHz, CDCI3):
5= 7.628 (1.1); 7.468 (1.7); 7.463 (1.7); 7.450 (1.9); 7.320 (1.9); 7.316 (1.6); 7.306 (2.0); 7.302 (2.3); 7.198 (0.9): 7.190 (5.6); 7.182 (3.2); 7.175 (4.1); 7.167 (2.6); 7.162 (2.0); 7.151 (0.6); 6.692 (1.4); 4.350 (2.3); 4.320 (2.6): 3.978 (2.5); 3.949 (2.2); 3.394 (0.3); 3.365 (0.3); 3.314 (0.7); 3.285 (6.2); 3.280 (6.4); 3.251 (0.6); 2.145 (0.4): 2.108 (16.0); 1.214 (0.9); 1.185 (7.0); 1.162 (0.8); 1.140 (0.4); 0.823 (0.6); 0.809 (1.1); 0.795 (0.7); 0.784 (0.4): 0.777 (0.4); 0.768 (0.4); 0.689 (5.2); 0.680 (2.0); 0.670 (1.1); 0.656 (0.4); 0.646 (1.0); 0.635 (2.0); 0.626 (4.6): 0.611 (1.1); 0.017 (0.4); 0.000 (17.0); -0.071 (3.6)
jExample 1-04: 1 H-NMR (499.9 MHz, CDCI3): δ= 7.817 (6.8); 7.516 (5.8); 7.512 (5.8); 7.502 (5.9); 7.498 (6.6); 7.408 (0.5); 7.397 (6.9); 7.393 (5.9); 7.383 (7.9): 7.379 (8.8); 7.367 (0.7); 7.361 (0.4); 7.346 (0.4); 7.284 (2.5); 7.273 (7.1); 7.270 (7.5); 7.264 (8.6); 7.259 (16.9): 7.249 (7.4); 7.245 (6.2); 7.234 (2.3); 7.231 (1.7); 7.219 (0.5); 7.211 (0.6); 7.161 (0.4); 7.025 (12.3); 4.4 1 (8.8):
4.422 (12.8); 4.305 (12.6); 4.275 (8.9); 3.726 (0.4); 3.388 (8.3); 3.360 (15.4); 3.300 (16.0); 3.272 (8.7): 2.256
(3.1) 2.039 (1.5); 1.676 (0.6); 1.333 (0.4); 1.307 (0.5); 1.300 (0.4); 1.284 (0.6); 1.271 (1.0); 1.256 (2.8) 1.242 (0.7) 1.230 (1.3); 0.961 (0.4); 0.894 (0.3); 0.880 (0.6); 0.867 (0.4); 0.836 (1.0); 0.828 (2.0); 0.815 (3.2) 0.806 (6.3): 0.801 (6.0); 0.793 (10.5); 0.784 (15.4); 0.774 (7.1); 0.772 (6.9); 0.763 (4.7); 0.751 (1.7); 0.741 (0.5) 0.715 (0.7) 0.692 (2.3); 0.681 (4.3); 0.671 (6.4); 0.657 (3.5); 0.650 (2.1); 0.633 (0.4); 0.554 (0.4); 0.070 (2.8) 0.006 (1.2): 0.000 (34.5); -0.007 (1.8)
Example 1-05: 1 H-NMR (499.9 MHz, de-DMSO)
5= 7.934 (3.4); 7.920 (3.6); 7.845 (10.1); 7.844 (9.5); 7.518 (3.1); 7.502 (5.2); 7.463 (2.0); 7.460 (1.3) ; 7.448
(3.7) 7.435 (1.6); 7.433 (2.2); 7.429 (1.4); 7.418 (2.8); 7.416 (2.8); 7.403 (3.8); 7.388 (1.5); 6.966 (9.9). ; 6.965 (9.1) 6.396 (6.3); 6.306 (6.4); 6.290 (11.7); 4.734 (4.8); 4.704 (6.0); 4.474 (3.7); 4.471 (3.9); 4.444 (3.2) ; 4.441 (3.0) 3.286 (20.7); 2.507 (2.3); 2.503 (4.9); 2.500 (6.7); 2.496 (4.9); 2.493 (2.5); 1.986 (0.4); 0.494 (0.7) ; 0.483 (1.6) 0.471 (7.7); 0.461 (16.0); 0.450 (2.3); 0.440 (0.7); 0.428 (0.5); 0.319 (0.5); 0.292 (3.2); 0.273 (1.8) ; 0.267 (1.6) 0.261 (1.2); 0.000 (3.7) |Example 1-06: 'H-NMR (499.9 MHz, de-DMSO)
5= 7.916 (15.7); 7.786 (15.0); 7.659 (4.8); 7.655 (5.2); 7.644 (4.5); 7.641 (5.6); 7.630 (0.4); 7.465 (5.0); 7.4621
(4.1) 7.451 (6.2); 7.447 (6.4); 7.434 (0.4); 7.340 (1.4); 7.337 (2.0); 7.326 (5.6); 7.322 (5.8); 7.315 (6.2) 7.312 (8.5) 7.310 (8.4); 7.308 (5.7); 7.300 (5.5); 7.296 (5.0); 7.286 (1.8); 7.282 (1.3); 5.404 (16.0); 4.652 (7.3): 4.623 (7.9) 3.919 (8.8); 3.890 (8.4); 3.578 (7.8); 3.549 (8.7); 3.299 (11.7); 3.102 (8.1); 3.074 (7.3); 2.506 (2.2): 2.503 (3.0) 2.499 (2.2); 2.496 (1.1); 1.036 (1.8); 1.023 (2.9); 1.021 (2.9); 1.014 (2.8); 1.009 (2.8); 1.002 (3.2) 1.000 (3.2) 0.987 (2.3); 0.763 (1.8); 0.748 (2.8); 0.742 (2.9); 0.736 (2.6); 0.729 (3.2); 0.727 (3.4); 0.715 (2.4) 0.576 (2.2) 0.565 (3.2); 0.562 (2.9); 0.555 (2.5); 0.550 (3.2); 0.543 (2.8); 0.540 (2.3); 0.529 (2.0); 0.487 (2.4) 0.476
(2.6); 0.473 (3.0); 0.466 (3.1); 0.462 (2.6); 0.455 (2.5); 0.451 (2.7); 0.440 (1.7); 0.000 (1.9)
|Example 1-07: 1 H-NMR (499.9 MHz, de-DMSO) δ= 12.333 (1.1); 8.324 (0.5); 8.320 (0.6); 8.315 (0.6); 8.311 (0.6); 7.962 (0.5); 7.958 (0.6); 7.947 (0.6); 7.943 (0.6); 7.598 (13.0); 7.597 (13.1); 7.547 (1.2); 7.545 (1.3); 7.412 (0.6); 7.403 (0.6); 7.397 (0.6); 7.387 (0.6); 7.176 (16.0); 7.174 (15.9); 7.164 (1.8); 7.161 (1.5); 4.505 (0.8); 4.476 (0.9); 3.955 (0.8); 3.926 (0.8); 3.324 (0.8); 3.296 (1.1); 3.185 (1.0); 3.157 (0.7); 2.508 (1.7); 2.504 (2.4); 2.501 (1.8); 0.664 (0.3); 0.550 (0.4); 0.539 (0.4); 0.535 (0.4); 0.529 (0.5); 0.523 (0.5); 0.517 (0.4); 0.000 (1.2)
jExample 1-08: 1 H-NMR (300.2 MHz, CDCb):
5= 7.759 (9.6); 7.576 (3.6); 7.556 (3.8); 7.548 (4.2); 7.527 (3.9); 7.300 (20.4); 7.204 (3.8); 7.195 (4.2): 7.176
(3.8) 7.167 (4.1); 7.081 (2.5); 7.072 (2.3); 7.054 (3.6); 7.045 (3.2); 7.026 (2.6); 7.012 (10.2); 7.009 (9.9): 4.471 (5.4): 4.422 (10.1); 4.314 (9.6); 4.265 (5.2); 3.412 (4.0); 3.364 (8.3); 3.283 (9.2); 3.234 (4.4); 2.194 (14.0) 2.083 (1.0) 1.653 (16.0); 1.321 (0.5); 1.291 (3.1); 1.273 (0.6); 0.919 (0.3); 0.894 (0.6); 0.884 (1.0); 0.862 (2.1): 0.852 (2.7) 0.844 (3.1); 0.833 (6.9); 0.825 (8.4); 0.817 (9.3); 0.809 (2.9); 0.800 (4.0); 0.789 (3.6); 0.785 (3.5): 0.775 (1.3) 0.768 (1.0); 0.760 (1.1); 0.744 (0.7); 0.723 (1.1); 0.716 (1.3); 0.707 (4.4); 0.690 (3.4); 0.680 (1.4); 0.665
(1.8); 0.658 (1.2); 0.048 (0.6); 0.037 (14.4); 0.027 (0.6)
|Example 1-09: 1 H-NMR (499.9 MHz, CDCI3):
5= 7.813 (12.6); 7.343 (6.3); 7.327 (9.5); 7.314 (9.9); 7.301 (21.2); 7.278 (9.4); 7.265 (18.3); 7.208 (3.1); 7.194 (6.1); 7.179 (4.2); 7.155 (5.3); 7.140 (6.6); 7.126 (2.9); 7.066 (12.8); 4.571 (6.5); 4.541 (8.3); 4.310 (8.1); 4.281 (6.7); 3.268 (6.4); 3.239 (8.1); 3.007 (7.7); 2.978 (6.4); 1.775 (4.0); 1.257 (2.0); 1.237 (0.7); 0.882 (0.6); 0.868 (0.4); 0.842 (0.4); 0.765 (1.8); 0.760 (1.9); 0.741 (6.9); 0.718 (10.6); 0.695 (3.8); 0.669 (3.8); 0.648 (16.0); 0.000 (10.1)
jExample 1-10: * H-NMR (499.9 MHz, de-DMSO):
5= 8.363 (1.1); 8.308 (2.0); 8.304 (2.2); 8.299 (2.3); 8.295 (2.2); 8.157 (1.4); 8.154 (1.3); 8.142 (1.4); 7.586 (4.2):
7.445 (0.4); 7.399 (1.9): 7.390 (2.0); 7.384 (2.1); 7.374 (1.9); 6.847 (0.4); 6.572 (3.9); 4.382 (2.6); 4.352 (2.9): 3.835 (2.7); 3.806 (2.5): 3.317 (1.9); 3.289 (3.7); 3.257 (0.4); 3.233 (2.9); 3.205 (1.6); 2.893 (1.0); 2.733 (0.8): |2.507 (3.0); 2.504 (4.2) 2.500 (3.4); 2.279 (0.4); 2.1 11 (16.0); 2.087 (0.4); 2.073 (3.0); 2.063 (1.6); 1.987 (0.6): 1.234 (0.6); 1.176 (0.3): 1.036 (0.7); 1.032 (0.8); 1.021 (1.1); 1.008 (0.8); 0.679 (0.5); 0.664 (2.0); 0.660 (1.8):
0.650 (3.6); 0.630 (1.6); 0.610 (1.5); 0.594 (1.6); 0.582 (1.0); 0.000 (1.7)
jExample 1-11 : 1 H-NMR (499.9 MHz, CDCI3):
5= 8.238 (6.2); 8.227 (6.2); 8.142 (0.5); 8.131 (0.5); 7.673 (9.6); 7.620 (0.9); 7.359 (6.4); 7.349 (6.1); 7.272 (3.6): 6.901 (9.9); 6.889 (0.5); 6.657 (0.5); 6.646 (0.5); 4.694 (5.7); 4.664 (6.2); 4.596 (0.4); 4.566 (0.7); 4.448 (0.6): 4.418 (0.4); 4.125 (4.9); 4.095 (4.4); 3.691 (0.5); 3.661 (16.0); 3.641 (0.7); 3.631 (0.4); 3.237 (0.6); 3.203 (0.5): 2.651 (8.1); 1.878 (2.3); 1.359 (0.4); 1.346 (0.4); 1.114 (0.4); 1.096 (0.4); 0.996 (0.5); 0.984 (2.1); 0.975 (2.7): 0.968 (2.7); 0.962 (5.6); 0.954 (3.1); 0.947 (3.7); 0.941 (3.6); 0.928 (1.3); 0.879 (2.2); 0.866 (3.2); 0.857 (1.7): 0.853 (2.3); 0.845 (2.2); 0.831 (1.5); 0.745 (2.0); 0.733 (2.0); 0.729 (2.2); 0.725 (2.2); 0.718 (1.8); 0.713 (1.9): 0.709 (1.9); 0.697 (1.2); 0.000 (2.4)
Example 1-12: 1 H-NMR (499.9 MHz, CDCI3):
5= 9.532 (13.6); 8.008 (1 1.8); 7.826 (13.8); 7.506 (4.9); 7.503 (5.0); 7.491 (5.5); 7.488 (5.5); 7.416 (5.1): 7.401
(6.1) 7.400 (6.1); 7.313 (2.5); 7.300 (5.8); 7.299 (5.6); 7.286 (4.1); 7.273 (4.4); 7.269 (4.6); 7.261 (8.9) 7.255 (5.0) 7.242 (2.0); 7.239 (1.8); 4.806 (7.1); 4.776 (8.5); 4.480 (8.6); 4.450 (7.2); 4.041 (0.8); 3.904 (0.5): 3.897 (1.0) 3.827 (16.0); 3.702 (7.7); 3.674 (8.5); 3.132 (7.8); 3.104 (7.1); 2.837 (0.4); 1.663 (5.9); 0.908 (1.7): 0.897 (2.9) 0.894 (2.8); 0.887 (2.6); 0.882 (3.1); 0.875 (3.2); 0.873 (3.0); 0.861 (2.7); 0.817 (2.1); 0.803 (3.0) 0.796 (3.2) 0.791 (2.4); 0.782 (3.7); 0.770 (2.4); 0.682 (2.7); 0.671 (3.5); 0.668 (3.2); 0.661 (2.5); 0.657 (3.1) 0.650 (2.7) 0.635 (1.9); 0.530 (2.6); 0.518 (3.1); 0.516 (3.3); 0.508 (3.0); 0.505 (2.9); 0.497 (2.8); 0.494 (2.8); 0.483] (1.8): 0.000 (4.5) |Example 1-13: 'H-NMR (499.9 MHz, de-DMSO) δ= 7.944 (1.9); 7.929 (2.0); 7.817 (0.4); 7.814 (0.3); 7.665 (4.2); 7.519 (2.4); 7.503 (2.8); 7.462 (1.2); 7.447 (2.3):
7.432 (1.4) 7.420 (1.9) 7.418 (1.9); 7.404 (2.2); 7.390 (0.9); 6.928 (0.7); 6.620 (3.6); 6.379 (3.0) 6.360 (0.5): 6.290 (3.2) 6.284 (1.1) 6.271 (0.5); 6.179 (4.8); 4.712 (0.4); 4.682 (0.5); 4.650 (2.4); 4.620 (2.9) 4.399 (0.3): 4.365 (0.4) 4.356 (1.9) 4.354 (1.9); 4.339 (0.4); 4.335 (0.4); 4.326 (1.7); 3.299 (0.7); 2.890 (1.0) 2.732 (0.9): 2.503 (2.7) 2.500 (3.4) 2.496 (2.5); 2.278 (16.0); 2.163 (0.9); 2.092 (2.7); 1.236 (1.0); 0.877 (0.4) 0.436 (0.5): 0.426 (0.8) 0.414 (4.5): 0.410 (3.5); 0.396 (3.9); 0.384 (1.4); 0.373 (0.9); 0.268 (1.1); 0.260 (2.3): 0.246 (1.7):
0.236 (0.9); 0.229 (0.5); 0.164 (0.3); 0.000 (1.2)
jExample 1-14: 1 H-NMR (499.9 MHz, CDCb):
5= 7.901 (15.1); 7.518 (6.0); 7.514 (6.5); 7.503 (5.7); 7.499 (7.0); 7.417 (0.3); 7.402 (6.2); 7.399 (5.1); 7.387] (7.9); 7.383 (7.7); 7.370 (0.4); 7.291 (2.1); 7.288 (2.7); 7.277 (7.3); 7.273 (7.5); 7.265 (8.8); 7.263 (10.2); 7.260| (1 1.4); 7.258 (1 1.7); 7.250 (6.7); 7.246 (5.9); 7.235 (2.2); 7.231 (1.7); 7.137 (0.4); 7.120 (16.0); 7.01 1 (0.4) 7.008 (0.3); 6.944 (0.5); 5.201 (0.9); 4.464 (10.8); 4.434 (14.7); 4.280 (13.8); 4.250 (10.2); 3.387 (7.8); 3.358| (14.4); 3.295 (16.0); 3.267 (8.8); 2.368 (0.7); 2.199 (12.4); 2.178 (1.7); 1.615 (1.6); 1.257 (0.6); 0.854 (0.4): 0.842 (1.4); 0.836 (2.2); 0.825 (5.2); 0.819 (3.6); 0.810 (7.2); 0.800 (6.9); 0.793 (6.9); 0.790 (11.7); 0.784 (15.1): 0.775 (6.5); 0.768 (9.6); 0.758 (3.3); 0.755 (1.8); 0.724 (0.5); 0.700 (1.4); 0.688 (4.0); 0.684 (4.6); 0.674 (7.3): 0.667 (2.6); 0.659 (3.1); 0.655 (2.6); 0.648 (0.4); 0.639 (0.7); 0.069 (2.1); 0.006 (1.2); 0.000 (31.8); -0.007 (1.3)
[Example 1-15: 1 H-NMR (499.9 MHz, CDCI3):
5= 7.925 (14.4); 7.616 (0.4); 7.517 (0.4); 7.508 (5.2); 7.502 (5.1); 7.493 (4.3); 7.489 (6.2); 7.458 (0.4) 7.442 (11.1); 7.421 (0.4); 7.393 (5.5); 7.389 (4.0); 7.387 (3.3); 7.379 (5.6); 7.374 (6.8) , 7.365 (0.8); 7.301 (0.5): 7.299 (0.5); 7.293 (1.5); 7.289 (2.3); 7.278 (6.9); 7.274 (7.8); 7.272 (8.1); 7.266 (14.1) , 7.260 (7.2); 7.257 (6.9): 7.253 (5.6); 7.242 (1.8); 7.238 (1.2); 4.593 (0.3); 4.500 (7.2); 4.470 (14.3); 4.414 (1 1.4): ; 4.384 (5.7); 3.999 (0.4) 3.971 (0.3); 3.433 (0.5); 3.394 (7.6); 3.382 (0.7); 3.365 (9.8); 3.354 (0.6); 3.174 (11.5): 3.145 (9.0); 2.451 (0.6) 2.322 (16.0); 1.643 (1.4); 1.255 (1.0); 0.903 (1.3); 0.892 (3.1); 0.887 (2.7); 0.877 (5.2) 0.872 (5.3); 0.866 (3.7) 0.858 (8.2); 0.853 (5.8); 0.840 (8.5); 0.832 (1 1.9); 0.824 (6.0); 0.818 (3.1); 0.814 (1.5) 0.809 (3.9); 0.804 (2.8) 0.800 (1.2); 0.789 (1.8); 0.684 (0.4); 0.665 (3.2); 0.657 (4.3); 0.655 (4.4); 0.646 (5.0); 0.637 (3.3); 0.633 (3.3) 0.622 (2.6); 0.071 (1.9); 0.006 (0.7); 0.000 (15.4); -0.007 (1.0)
jExample 1-16: 1 H-NMR (499.9 MHz, CDCI3):
5= 7.51 1 (0.5); 7.503 (4.7); 7.497 (4.1); 7.491 (2.8); 7.488 (3.4); 7.484 (5.4); 7.476 (0.4); 7.422 (0.4); 7.414 (4.8): 7.410 (3.1); 7.407 (2.6); 7.400 (4.5); 7.395 (6.0); 7.386 (0.5); 7.298 (12.3); 7.283 (6.5); 7.279 (7.8); 7.278 (8.0): 7.271 (13.5); 7.263 (21.7); 7.259 (5.2); 7.248 (1.5); 7.244 (1.0); 6.532 (6.0); 6.531 (5.9); 6.517 (6.1); 6.515 (5.9): 4.444 (9.5); 4.415 (10.7); 3.999 (9.5); 3.969 (8.4); 3.422 (4.3); 3.394 (14.0); 3.371 (13.3); 3.342 (4.0); 2.396 (1 1.9); 1.722 (2.1); 1.255 (0.5); 0.784 (0.8); 0.776 (0.9); 0.774 (0.8); 0.766 (5.4); 0.756 (16.0); 0.747 (5.4); 0.741 (2.3); 0.738 (5.4); 0.730 (2.4); 0.726 (0.8); 0.717 (1.8); 0.712 (1.9); 0.704 (4.9); 0.696 (4.8); 0.694 (6.1); 0.689 (4.1); 0.675 (5.7); 0.666 (4.9); 0.654 (2.6); 0.650 (1.8); 0.632 (0.4); 0.070 (1.1); 0.006 (0.5); 0.000 (12.1); -0.007 (0.4)
|Example Ϊ-17: 1 H-NMR (499.9 MHz, CDCI3):
5= 8.368 (16.0); 7.711 (7.4); 7.561 (15.6); 7.262 (2.8); 6.973 (8.5); 4.459 (6.8); 4.429 (9.3); 4.278 (9.2); 4.248 (6.9); 3.386 (6.1); 3.358 (8.7); 3.236 (9.4); 3.208 (6.7); 2.537 (0.8); 2.043 (0.7); 1.258 (0.7); 1.255 (0.6); 0.895 (0.9); 0.889 (0.8); 0.884 (1.0); 0.882 (1.6); 0.869 (3.8); 0.863 (9.1); 0.859 (1 1.2); 0.844 (2.8); 0.839 (0.9); 0.836 (1.2); 0.830 (2.1); 0.824 (0.7); 0.794 (2.0); 0.788 (1.3); 0.776 (2.8); 0.764 (8.3); 0.756 (8.2); 0.751 (4.0); 0.742 (2.1); 0.735 (1.1); 0.730 (1.0); 0.724 (1.1); 0.070 (1.6); 0.006 (0.8); 0.000 (23.9); -0.007 (1.3)
jExample 1-18: ' H-NMR (499.9 MHz, CDCI3):
5= 8.198 (16.0); 7.687 (12.8); 7.266 (1.4); 7.215 (10.7); 7.210 (11.0); 6.921 (13.5); 4.451 (9.2); 4.421 (12.8): 4.278 (12.7); 4.249 (9.4); 3.423 (8.3); 3.395 (11.7); 3.266 (10.7); 3.238 (7.8); 3.221 (0.4); 3.183 (2.1); 2.006 (0.4); 0.879 (0.8); 0.876 (1.2); 0.873 (1.2); 0.865 (3.7); 0.861 (2.6); 0.857 (4.5); 0.852 (6.5); 0.847 (9.1); 0.843 (10.2); 0.831 (2.8); 0.828 (3.0); 0.825 (1.9); 0.821 (1.3); 0.813 (3.4); 0.807 (6.3); 0.796 (13.9); 0.792 (7.0); 0.783 (2.7); 0.779 (2.3); 0.773 (1.2); 0.763 (0.3); 0.071 (0.5); 0.006 (0.3); 0.000 (11.2); -0.007 (0.6)
jExample 1-19: H-NMR (499.9 MHz, CDCb): 5= 7.975 (3.0); 7.827 (3.0); 7.528 (1.0); 7.525 (1 1); 7.513 (1.2); 7.509 (1.3): 7.408 (1.1) 7.406 (1.2); 7.392 (1.4):
7.390 (1.5) 7.315 (0.6): 7.312 (0.6); 7.300 (1.4); 7.297 (1.3); 7.285 (0.9); 7.282 (0.8) 7.262 (1.0): 7.258 (1.0): 7.246 (1.2) 7.243 (1.2): 7.231 (0.5); 7.228 (0.5) ;; 4.761 (1.7); 4.732 (2.1); 4.478 (2.2) 4.468 (4.1): 4.449 (1.8): 3.729 (2.0) 3.702 (2.2): 3.090 (1.9); 3.062 (1.7); 2: .420 (16.0); 0.930 (0.5); 0.919 (0.6): 0.915 (0.7) 0.908 (0.7): 0.904 (0.8) 0.897 (0.8): 0.894 (0.8); 0.882 (0.7); 0.81 1 (0.5); 0.799 (0.5); 0.796 (0.7) 0.789 (0.8): 0.785 (0.6): 0.778 (0.7) 0.775 (0.9): 0.764 (0.7); 0.687 (0.7) ;; 0.676 (0.8); 0.672 (0.7); 0.666 (0.6) 0.661 (0.8): 0.655 (0.7): 0.651 (0.5) 0.640 (0.5); 0.521 (0.6); 0.510 (0.7); 0.506 (0.7); 0.499 (0.7); 0.495 (0.7); 0.488 (0.6); 0.485 (0.7):
0.474 (0.5); 0.000 (1.4) |Example 1-20: 'H-NMR (400.1 MHz, CDC13): δ= 7.822 (15.7); 7.820 (16.0); 7.585 (0.9); 7.582 (0.9); 7.545 (0.5); 7.542 (0.6); 7.537 (0.5); 7.534 (0.5); 7.498 (0.3); 7.475 (0.4); 7.426 (0.4); 7.409 (0.4); 7.403 (0.6); 7.380 (6.2); 7.375 (7.1); 7.365 (6.5); 7.361 (12.5); 7.357 (10.3); 7.348 (7.7); 7.342 (7.6); 7.327 (0.5); 7.313 (0.9); 7.305 (0.8); 7.300 (0.7); 7.293 (0.6); 7.287 (0.8); 7.282
(1.4) ; 7.277 (9.6); 7.274 (10.4); 7.264 (12.4); 7.260 (40.3); 7.248 (2.4); 7.242 (3.0); 7.229 (7.7); 7.224 (7.1): 7.214 (8.3); 7.212 (9.8); 7.209 (9.6); 7.205 (6.2); 7.196 (8.0); 7.192 (6.2); 7.178 (2.3); 7.174 (1.8); 7.164 (0.4): 7.146 (16.5); 7.143 (16.7); 7.131 (0.3); 6.970 (8.0); 6.961 (12.0); 6.957 (7.4); 6.948 (11.5); 6.926 (1 1.6); 6.923| |(12.3); 6.917 (8.0); 6.914 (7.4); 4.600 (10.7); 4.563 (14.8); 4.386 (14.5); 4.349 (10.5); 4.003 (0.7); 3.967 (0.6): 3.494 (0.5); 3.458 (0.8); 3.366 (10.9); 3.330 (14.4); 3.138 (12.2); 3.102 (9.1); 2.000 (1.6); 1.954 (9.0); 1.690
(4.5) ; 1.257 (0.4); 0.834 (3.3); 0.827 (2.2); 0.821 (1.4); 0.818 (2.4); 0.814 (3.4); 0.801 (9.6); 0.793 (2.8); 0.779 (9.7); 0.776 (8.3); 0.771 (5.1); 0.764 (0.7); 0.751 (6.4); 0.747 (3.4); 0.739 (7.6); 0.731 (1.1); 0.727 (0.7); 0.719 (5.0); 0.713 (12.1); 0.710 (14.7); 0.706 (13.8); 0.694 (3.8); 0.689 (2.5); 0.681 (1.4); 0.674 (2.4); 0.664 (0.5) 0.655 (0.5); 0.651 (0.5); 0.645 (0.5); 0.640 (0.5); 0.635 (0.4); 0.070 (1.0); 0.008 (0.5); 0.000 (17.4); -0.009 (0.6) jExample 1-21 : 1 H-NMR (499.9 MHz, de-DMSO): δ= 7.658 (5.5); 7.654 (6.4); 7.649 (16.0); 7.647 (15.7); 7.643 (7.4); 7.639 (6.6); 7.471 (5.7); 7.468 (5.5); 7.456
(7.3) ; 7.453 (7.0); 7.367 (0.4); 7.357 (2.3); 7.354 (2.5); 7.342 (6.4); 7.339 (6.1); 7.328 (5.5); 7.324 (6.3); 7.322
(6.4) ; 7.318 (5.7); 7.307 (5.5); 7.303 (5.6); 7.292 (2.2); 7.288 (1.8); 6.836 (12.6); 6.835 (12.3); 5.283 (13.0): 4.524 (5.7); 4.494 (6.1); 3.972 (3.5); 3.971 (3.4); 3.935 (12.7); 3.910 (12.1); 3.909 (11.7); 3.873 (3.2); 3.871 (3.1); 3.819 (0.8); 3.818 (0.8); 3.712 (8.4); 3.682 (8.1); 3.625 (7.7); 3.597 (8.4); 3.324 (29.6); 3.043 (7.7); 3.014
(7.1) ; 2.505 (3.4); 2.502 (4.6); 2.498 (3.4); 2.072 (15.1); 1.067 (1.7); 1.053 (3.1); 1.046 (2.8); 1.041 (2.7); 1.033 (3.3); 1.032 (3.2); 1.019 (2.1); 0.755 (1.7); 0.740 (2.8); 0.734 (3.0); 0.728 (2.6); 0.721 (3.3); 0.719 (3.4); 0.707 (2.3); 0.586 (2.2); 0.575 (3.3); 0.572 (3.1); 0.565 (2.6); 0.561 (3.2); 0.553 (2.7); 0.551 (2.4); 0.539 (1.9); 0.441
(2.2) ; 0.429 (2.7); 0.426 (3.0); 0.420 (3.0); 0.415 (2.7); 0.408 (2.6); 0.405 (2.7); 0.393 (1.7); 0.000 (2.6)
(Example 1-22: 'H-NMR (400.1 MHz, de-DMSO): δ= 7.81 1 (2.3); 7.808 (2.4); 7.616 (0.8); 7.609 (0.8); 7.600 (0.5); 7.597 (0.7); 7.592 (1.0); 7.430 (0.9); 7.426 (0.6):
7.423 (0.5); 7.413 (0.9); 7.407 (1.2); 7.307 (0.4); 7.293 (1.2); 7.288 (1.2); 7.285 (1.3) 7.277 (2.4) 7.270 (1.1): 7.267 (1.1); 7.261 (1.0); 7.248 (0.4); 7.071 (2.5); 7.069 (2.6); 5.108 (2.7); 4.471 (1.0) 4.435 (1.3) 4.176 (1.6): 4.140 (1.3); 3.266 (1.1); 3.230 (1.7); 3.130 (1.5); 3.095 (1.0); 2.511 (0.4); 2.506 (0.8) 2.502 (1.1) 2.497 (0.8): 2.493 (0.4); 2.210 (16.0); 0.956 (0.3); 0.951 (0.4); 0.938 (0.6); 0.931 (0.5); 0.925 (0.5), 0.918 (0.5) 0.81 1 (0.3): 0.805 (0.5); 0.801 (0.6); 0.795 (0.5); 0.790 (0.3); 0.774 (0.4); 0.765 (0.5); 0.743 (0.4); 0.718 (0.8); 0.706 (0.8): 0.703 (0.8); 0.695 (1.3); 0.689 (0.8); 0.681 (0.6); 0.672 (0.6); 0.000 (1.0)
|Example 1-23: 1 H-NMR (499.9 MHz, de-DMSO): δ= 7.932 (4.1); 7.918 (16.0); 7.674 (0.4); 7.521 (3.8); 7.505 (6.3); 7.464 (2.3); 7.450 (4.4); 7.434 (2.6); 7.4191
(3.3): 7.417 (3.4) 7.402 (4.5); 7.389 (1.8); 7.004 (1 1.4); 6.932 (0.4); 6.399 (7.4); 6.310 (7.4); 6.300 (14.0); 4.712 (5.2) 4.682 (7.0): 4.510 (4.7); 4.482 (3.5); 4.481 (3.4); 3.317 (0.8); 2.506 (3.3); 2.502 (4.6); 2.499 (3.5); 2.073 (0.4) 0.858 (0.3): 0.542 (0.5); 0.532 (1.5); 0.520 (2.2); 0.510 (5.1); 0.505 (3.0); 0.493 (5.7); 0.484 (6.7); 0.478 (5.3) 0.470 (2.1): 0.468 (2.1); 0.462 (1.6); 0.449 (0.7); 0.308 (1.3); 0.296 (2.2); 0.290 (3.6); 0.286 (3.6); 0.272 (2.5): 0.263 (1.3); 0.000 (4.9)
jExample 1-24: 1 H-NMR (499.9 MHz, de-DMSO): δ= 8.428 (3.7); 8.097 (15.3); 7.882 (5.3); 7.880 (5.5); 7.872 (16.0); 7.867 (6.3); 7.864 (5.5); 7.523 (4.5); 7.508 (7.2); 7.467 (2.7); 7.452 (5.1); 7.437 (3.0); 7.422 (4.0); 7.421 (4.0); 7.407 (5.4); 7.392 (2.1); 6.735 (0.7); 6.446 (8.2); 6.357 (8.3); 4.861 (6.4); 4.831 (8.5); 4.665 (5.5); 4.637 (4.2); 3.172 (0.9); 2.507 (4.0); 2.503 (5.3); 2.500 (4.0); 0.427 (0.4); 0.417 (1.6); 0.399 (4.2); 0.390 (4.9); 0.383 (6.5); 0.372 (5.7); 0.367 (6.9); 0.361 (4.7); 0.346 (6.0); 0.340 (4.5); 0.329 (5.3); 0.321 (1.8); 0.311 (1.7); 0.301 (0.5); 0.000 (3.4)
jExample 1-25: 'H-NMR (499.9 MHz, CDCb): δ= 8.330 (10.3); 8.327 (10.9); 8.321 (10.8); 8.318 (10.1); 8.174 (1.1); 7.982 (1.4); 7.929 (9.4); 7.927 (9.4); 7.914
(9.8) ; 7.842 (8.2); 7.276 (1.4); 7.260 (8.2); 7.250 (8.9); 7.245 (8.7); 7.235 (7.6); 7.001 (13.5); 6.939 (0.3); 4.465 (9.6); 4.436 (14.8); 4.340 (14.8); 4.311 (9.7); 4.294 (0.5); 4.276 (0.3); 4.249 (0.4); 4.220 (0.4); 4.079 (0.3); 4.066 (0.6); 4.052 (0.4); 4.037 (0.5); 3.417 (11.7); 3.389 (16.0); 3.270 (0.3); 3.247 (15.4); 3.218 (1 1.3); 2.957 (6.9): 2.870 (6.6); 2.670 (0.3); 1.459 (0.3); 1.441 (0.6); 1.427 (0.7); 1.256 (0.4); 0.856 (1.3); 0.845 (3.4); 0.839 (2.9): 0.830 (7.5); 0.823 (8.2); 0.818 (10.2); 0.809 (11.2); 0.797 (7.6); 0.787 (12.1); 0.778 (7.8); 0.765 (6.4); 0.757 (4.5); 0.744 (3.4); 0.733 (4.7); 0.723 (5.1); 0.718 (5.5); 0.715 (5.4); 0.709 (4.0); 0.705 (3.8); 0.699 (3.4); 0.688
(1.9) ; 0.000 (7.7) |Example 1-26: 'H-NMR (499.9 MHz, de-DMSO)
5= 8.340 (5.3); 8.337 (6.0); 8.331 (5.9); 8.327 (6.0); 8.040 (5.1); 8.037 (5.5); 8.025 (5.7); 8.022 (5.7); 7.943) (16.0); 7.812 (15.5); 7.434 (5.5); 7.425 (5.6); 7.419 (5.6); 7.409 (5.3); 5.753 (13.1); 5.512 (15.2); 4.652 (6.4): 4.622 (7.0); 4.029 (8.2); 4.000 (7.7); 3.436 (6.8); 3.407 (8.4); 3.315 (34.7); 3.196 (8.1); 3.167 (6.6); 2.506 (5.5): 2.502 (7.6); 2.499 (6.0); 0.954 (1.6); 0.940 (2.9); 0.933 (2.6); 0.928 (2.7); 0.919 (3.2); 0.906 (2.2); 0.753 (1.7): 0.739 (2.8); 0.732 (2.9); 0.727 (2.5); 0.717 (3.5); 0.705 (2.3); 0.598 (2.1); 0.587 (3.0); 0.584 (3.0); 0.577 (2.4): 0.572 (3.1); 0.566 (2.7); 0.563 (2.3); 0.551 (1.9); 0.498 (2.2); 0.487 (2.5); 0.484 (2.9); 0.477 (2.9); 0.473 (2.6): 0.466 (2.4); 0.462 (2.7); 0.451 (1.6); 0.000 (2.9)
jExample 1-27: 1 H-NMR (499.9 MHz, de-DMSO)
5= 7.741 (13.6); 7.528 (3.8); 7.512 (7.5); 7.496 (4.0); 7.364 (5.1); 7.361 (5.1); 7.345 (5.1); 7.341 (4.9); 7.245 (5.6); 7.241 (5.2); 7.228 (5.0); 7.225 (4.5); 6.952 (13.8); 5.750 (6.9); 5.274 (16.0); 4.375 (6.2); 4.346 (7.8); 4.138 (7.8); 4.109 (6.3); 3.303 (14.3); 3.152 (5.2); 3.124 (6.3); 2.901 (6.2); 2.873 (5.1); 2.501 (10.0); 1.236 (0.5); 0.726 (0.5); 0.710 (2.6); 0.705 (2.5); 0.701 (2.3); 0.696 (3.3); 0.684 (3.7); 0.679 (2.9); 0.648 (2.4); 0.639 (3.5); 0.636 (3.4); 0.626 (4.2); 0.616 (4.0); 0.596 (7.1); 0.583 (13.0); 0.571 (3.4); 0.550 (0.9); 0.000 (2.7)
|Example 1-28: 1 H-NMR (499.9 MHz, de-DMSO):
5= 7.628 (7.7); 7.543 (1.3); 7.529 (2.7); 7.515 (1.5); 7.290 (0.7); 7.276 (1.7); 7.262 (1.8); 7.248 (0.9); 7.061 (2.7): 7.047 (4.0); 7.034 (2.8); 7.019 (1.6); 6.756 (7.1); 6.124 (4.2); 6.048 (9.0); 6.034 (4.4); 4.543 (3.7); 4.513 (4.6): 4.248 (3.0); 4.220 (2.5); 3.108 (16.0); 2.295 (2.7); 2.292 (3.6); 2.289 (2.7); 1.778 (0.4); 0.233 (0.6); 0.222 (1.2): 0.219 (1.1); 0.21 1 (1.2); 0.207 (1.5); 0.200 (1.5); 0.197 (1.4); 0.185 (1.6); 0.182 (1.3); 0.166 (1.5); 0.160 (1.7): 0.155 (1.1); 0.146 (2.0); 0.135 (1.3); 0.080 (1.1); 0.069 (1.6); 0.059 (1.0); 0.054 (1.4); 0.049 (1.3); 0.033 (0.8): 0.014 (1.4); 0.003 (1.4); 0.000 (1.6); -0.007 (1.6); -0.011 (1.3); -0.018 (1.2); -0.022 (1.3); -0.033 (0.7); -0.210| (1.4)
|Example 1-29: 1 H-NMR (499.9 MHz, CDC13):
5= 7.855 (6.9); 7.651 (7.3); 7.375 (1.8); 7.359 (3.8); 7.342 (2.2); 7.262 (5.2); 7.189 (2.3); 7.185 (3.0); 7.173 (1.8):
7.169 (3.2) 7.165 (3.5) 7.145 (2.5); 7.141 (2.3); 5.297 (16.0); 4.680 (3.8); 4.650 (4.3); 4.206 (4.2); 4.177 (3.7): 3.319 (2.2) 3.290 (3.2): 3.154 (3.3); 3.126 (2.3); 2.227 (2.1); 2.213 (2.1); 2.002 (0.9); 1.256 (1.4); 1.242 (0.5): 0.720 (0.6) 0.708 (0.9): 0.698 (1.6); 0.690 (1.9); 0.686 (2.1); 0.678 (2.3); 0.672 (2.1); 0.663 (2.5); 0.654 (1.7): 0.641 (1.0) 0.631 (1.1); 0.583 (1.1); 0.573 (1.0); 0.561 (1.7); 0.550 (2.5); 0.542 (1.7); 0.526 (1.8); 0.518 (1.9):
0.515 (2.0); 0.506 (1.8); 0.497 (0.9); 0.494 (0.9); 0.484 (0.7); 0.070 (1.6); 0.000 (5.4)
jExample 1-30: 1 H-NMR (499.9 MHz, de-DMSO)
5= 7.828 (13.6); 7.513 (3.6); 7.496 (7.4); 7.480 (4.1); 7.357 (4.4); 7.353 (4.7); 7.338 (4.4); 7.334 (4.7); 7.237 (5.0); 7.233 (4.9); 7.220 (4.5); 7.216 (4.5); 6.993 (13.1); 5.272 (16.0); 4.352 (5.6); 4.323 (8.3); 4.217 (8.4); 4.188 (5.8); 3.328 (12.3); 3.163 (5.1); 3.134 (5.9); 2.821 (5.8); 2.793 (5.0); 2.509 (2.5); 2.506 (3.4); 2.502 (2.6); 0.741 (0.7); 0.734 (0.7); 0.731 (0.7); 0.709 (13.7); 0.688 (1.6); 0.681 (1.7); 0.675 (1.0); 0.645 (2.2); 0.623 (8.5); 0.601 (6.0); 0.596 (5.1); 0.581 (1.4); 0.576 (1.4); 0.571 (1.2); 0.000 (1.5)
Example 1- 1 : 1 H-NMR (499.9 MHz, de-DMSO):
5= 7.827 (10.4); 7.662 (0.6); 7.639 (10.3); 7.563 (0.4); 7.486 (1.7); 7.471 (3.3); 7.458 (1.7); 7.272 (0.9) 7.258
(2.0) 7.244 (2.1); 7.230 (1.1); 7.043 (3.6); 7.029 (5.0); 7.020 (3.3); 7.015 (3.1); 7.002 (2.0); 6.153 (16.0): 6.063 (5.5) 4.640 (4.8); 4.610 (6.1); 4.401 (3.8); 4.373 (3.0); 4.371 (3.0); 3.805 (0.5); 3.791 (0.5); 3.089 (4.1): 2.274 (1.9) 2.271 (2.7); 2.267 (2.0); 1.756 (2.0); 1.001 (0.4); 0.957 (0.6); 0.943 (1.1); 0.928 (0.6); 0.147 (0.7) 0.136 (1.1) 0.126 (1.5); 0.121 (1.7); 0.116 (1.8); 0.1 10 (1.8); 0.102 (1.7); 0.085 (1.0); 0.072 (1.7); 0.063 (2.1); 0.0501 (2.6): 0.042 (5.5); 0.033 (2.6); 0.020 (2.1); 0.013 (2.3); 0.000 (2.5); -0.008 (1.8); -0.013 (2.1); -0.019 (1.7); -0.023) (1.5): -0.034 (1.2); -0.045 (0.6); -0.234 (1.8)
jExample 1-32: 'H-NMR (499.9 MHz, de-DMSO):
5= 7.741 (11.9); 7.594 (0.3); 7.592 (0.4); 7.523 (2.4); 7.511 (4.3); 7.508 (4.6); 7.495 (2.5); 7.493 (2.4); 7.317 (1.1); 7.314 (1.2); 7.302 (2.8); 7.287 (3.1); 7.276 (1.6); 7.273 (1.5); 7.232 (0.4); 7.230 (0.4); 7.160 (3.6); 7.149 (4.3); 7.142 (4.9); 7.135 (7.3); 7.121 (4.6); 6.948 (1 1.7); 5.754 (0.4); 5.226 (16.0); 4.397 (6.1); 4.368 (7.4); 4.088
(7.6) ; 4.058 (6.5); 3.331 (1.1); 3.128 (4.2); 3.100 (6.4); 3.007 (6.5); 2.979 (4.2); 2.507 (2.6); 2.504 (3.5); 2.500
(2.7) ; 0.755 (0.5); 0.737 (2.6); 0.727 (3.1); 0.716 (3.1); 0.710 (2.3); 0.631 (1.1); 0.622 (2.3); 0.617 (2.4); 0.608
(3.8) ; 0.604 (2.5); 0.597 (3.1); 0.584 (5.3); 0.580 (4.8); 0.572 (13.9); 0.559 (3.1); 0.553 (1.0); 0.539 (0.7); 0.000 (1.9)
jExample Ϊ-33: 1 H-NMR (499.9 MHz, de-DMSO)
5= 7.824 (13.1); 7.510 (2.3); 7.507 (2.4); 7.495 (4.4); 7.492 (4.6); 7.479 (2.5); 7.477 (2.4); 7.311 (1.1): 7.308
(1 .2) 7.296 (2.8); 7.281 (3.3); 7.269 (1.6); 7.267 (1.5); 7.153 (3.6); 7.140 (4.7); 7.134 (5.0); 7.127 (7.2) 7.1131 (4.1): 6.984 (12.7); 5.205 (16.0); 4.373 (6.0); 4.344 (7.8); 4.164 (8.1); 4.135 (6.4); 3.323 (1.9); 3.139 (4.8) 3.111 (6.1) 2.927 (6.2); 2.899 (4.8); 2.507 (3.1); 2.503 (4.1); 2.500 (3.1); 0.755 (0.6); 0.746 (1.4); 0.742 (1.5) 0.734 (2.6) 0.726 (2.8); 0.721 (3.7); 0.717 (3.5); 0.707 (3.9); 0.701 (3.9); 0.700 (3.9); 0.689 (3.3); 0.678 (2.0) 0.668 (0.9) 0.661 (0.3); 0.648 (0.4); 0.641 (0.4); 0.631 (1.3); 0.626 (1.3); 0.623 (1.2); 0.615 (3.3); 0.602 (5.3) 0.597 (3.5) 0.591 (3.2); 0.587 (4.6); 0.583 (3.4); 0.575 (2.7); 0.567 (1.3); 0.562 (1.2); 0.559 (1.0); 0.549 (0.3): 0.000 (1.8) |Example 1-34: 'H-NMR (499.9 MHz, de-DMSO) 5= 7.951 (16.0); 7.815 (15.2); 7.552 (2.6); 7.539 (4.8); 7.536 (5.1); 7.523 (2.7); 7.521 (2.7); 7.339 (1.2) 7.336
(1.3) 7.324 (3.1): 7.313 (3.0); 7.309 (3.5): 7.298 (1.9); 7.295 (1.7); 7.188 (3.8); 7.173 (7.7); 7.159 (7.5) 7.153 (3.7) 7.145 (3.5): 7.110 (0.3); 5.430 (15.9) ; 4.585 (6.5): , 4.555 (7.2): 4.069 (8.0): 4.040 (7.3); 3.320 (5.6): 3.222 (4.9) 3.194 (7.2): 3.085 (6.7); 3.057 (4.5); 2.507 (2.9); 2.503 (4.0); 2.500 (3.1); 2.074 (3.3); 0.885 (0.5) 0.818 (1.6) 0.804 (2.8): 0.796 (2.6); 0.791 (2.7); 0.782 (3.1); 0.770 (2.3); 0.631 (1.6); 0.617 (2.7); 0.610 (2.9) 0.605 (2.3) 0.596 (3.4): 0.584 (2.4); 0.501 (2.2); 0.490 (3.1); 0.487 (2.9); 0.480 (2.2); 0.475 (3.1); 0.469 (2.6) 0.466 (2.1) 0.454 (1.9): 0.426 (2.4); 0.415 (2.5); 0.412 (2.9); 0.405 (3.0); 0.401 (2.5); 0.394 (2.4); 0.390 (2.6) 0.379
(1.5); 0.000 (1.8)
|Example 1-35: 1 H-NMR (499.9 MHz, de-DMSO): δ= 7.488 (0.7); 7.475 (1.3); 7.473 (1.4); 7.460 (0.7); 7.458 (0.7); 7.293 (0.3); 7.281 (0.8); 7.266 (1.0); 7.255 (0.5): 7.252 (0.5); 7.234 (3.7); 7.136 (1.1); 7.126 (1.3); 7.118 (1.5); 7.112 (2.3); 7.098 (1.6); 6.228 (3.7); 5.036 (3.7): 4.181 (1.8); 4.152 (2.3); 3.944 (2.3); 3.915 (1.9); 3.784 (16.0); 3.324 (0.6); 3.094 (1.4); 3.066 (1.9); 2.917 (1.9): 2.889 (1.4); 2.502 (1.4); 2.499 (1.1); 0.650 (3.8); 0.634 (0.4); 0.630 (0.4); 0.626 (0.4); 0.561 (0.6); 0.536 (2.0): 0.515 (1.9); 0.499 (0.5); 0.495 (0.4); 0.492 (0.4); 0.000 (0.6)
|Example 1-36: 'H-NMR (499.9 MHz, de-DMSO)
8= 7.797 (11.6); 7.662 (0.5); 7.629 (1.2); 7.542 (2.3); 7.529 (4.0); 7.526 (4.5): 7.513 (2.3); 7.511 (2.4) 7.494
(0.7) 7.468 (1.2); 7.384 (0.3); 7.381 (0.3); 7.370 (0.5); 7.367 (0.5) 7.358 (1.3); 7.354 (1.5); 7.343 (2.6) 7.327 (3.4) 7.321 (12.2); 7.263 (0.5); 7.248 (0.4); 7.230 (0.6); 7.222 (0.6): 7.209 (1.1); 7.195 (3.6); 7.185 (4.0) 7.177 (4.4): 7.171 (6.6); 7.157 (4.3); 5.332 (1.5); 5.242 (13.2); 4.886 (0.4); 4.677 (16.0): , 4.531 (0.6); 4.502 (0.7) 4.453 (4.7) 4.424 (7.1); 4.332 (0.6); 4.322 (7.2); 4.293 (4.9); 4.262 (0.4); 4.040 (0.8); 4.004 (0.7); 3.992 (1.8) 3.975
(0.6) 3.373 (12.7); 3.218 (4.3); 3.190 (5.1); 3.167 (0.3); 3.139 (0.8): , 3.114 (0.8); 2.924 (5.3); 2.896 (4.3) 2.562 (5.6) 2.559 (7.7); 2.556 (5.9); 1.057 (0.4); 0.804 (0.8); 0.796 (0.8); 0.791 (1.3); 0.776 (3.1); 0.766 (5.4) 0.762 (4.6) 0.743 (1.5); 0.738 (1.3); 0.730 (1.6); 0.711 (0.4); 0.688 (0.4); 0.676 (1.7); 0.669 (1.2); 0.655 (2.3) 0.644 (4.3) 0.628 (4.0); 0.624 (3.6); 0.616 (2.0); 0.607 (1.4); 0.603 (1.4); 0.595 (1.2); 0.588 (0.5); 0.458 (0.4); 0.450
(0.4); 0.443 (0.4); 0.439 (0.5); 0.435 (0.5); 0.429 (0.4); 0.423 (0.3)
[Example 1-37: 'H-NMR (499.9 MHz, de-DMSO):
5= 7.539 (10.7); 7.523 (4.1); 7.508 (2.1); 7.315 (0.9); 7.303 (2.3) 7.288 (2.6); 7.277 (1.4); 7.274 (1.3) 7.170
(2.8) 7.152 (6.6); 7.138 (5.9); 7.123 (2.6); 6.509 (8.4); 5.099 (11.1); 4.409 (4.5): , 4.380 (5.5) 4.111 (5.6) 4.082 (4.8) 3.323 (1.4); 3.081 (16.0); 2.502 (4.1); 2.073 (2.8); 1.820 (0.6); 1.809 (1.4): , 1.803 (1.6) 1.793 (2.8) 1.783 (1.8) 1.777 (1.6); 1.767 (0.8); 1.337 (0.4); 0.818 (0.8); 0.805 (2.9); 0.800 (3.6); 0.792 (4.7) 0.781 (4.4) 0.772 (3.1) 0.764 (1.3); 0.711 (1.0); 0.703 (1.2); 0.700 (1.4); 0.693 (2.2); 0.683 (2.1); 0.675 (2.2) 0.670 (1.0) 0.665 (1.1) 0.657 (1.5); 0.647 (1.8); 0.642 (1.9); 0.633 (4.4); 0.614 (4.6); 0.598 (9.0); 0.582 (2.1) 0.570 (0.5) 0.563 (0.8) 0.537 (0.8); 0.526 (1.6); 0.518 (2.5); 0.508 (2.8); 0.500 (2.1); 0.489 (1.0); 0.434 (1.1); 0.424 (2.1); 0.416
(2.7); 0.405 (2.5); 0.397 (1.5); 0.387 (0.8); 0.000 (1.0)
Example 1-38: 'H-NMR (499.9 MHz, de-DMSO):
5= 7.712 (13.6); 7.604 (4.0); 7.600 (4.3); 7.590 (3.9); 7.586 (4.8); 7.418 (4.0); 7.415 (3.6); 7.404 (4.8) 7.400
(5.4) 7.389 (0.4): 7.296 (1.7); 7.284 (4.7); 7.281 (5.0); 7.275 (5.0); 7.270 (8.5); 7.260 (4.9); 7.252 (13.7): 7.242 (1.6): 5.753 (2.3) 5.143 (13.6); 4.583 (16.0); 4.453 (5.9); 4.424 (7.0); 4.137 (7.4); 4.108 (6.4); 3.322 (7.1) 3.235 (3.3) 3.206 (9.8): 3.182 (9.5); 3.154 (3.2); 2.503 (4.2); 2.074 (0.5); 0.927 (1.4); 0.914 (2.1); 0.904 (3.4) 0.897 (2.4) 0.893 (2.6) 0.884 (2.1); 0.782 (1.6); 0.772 (2.8); 0.764 (3.4); 0.751 (2.1); 0.742 (2.4); 0.719 (2.0): 0.710 (1.5) 0.699 (3.2): 0.687 (3.8); 0.677 (3.7); 0.674 (4.0); 0.666 (3.1); 0.661 (2.9); 0.652 (2.8); 0.645 (1.3) 0.641 (1.3): 0.632 (1.0); 0.000 (1.1)
|Example 1-39: 'H-NMR (300.2 MHz, de-DMSO):
5= 8.157 (0.4); 7.760 (12.3); 7.395 (8.1); 7.373 (12.7); 7.319 (6.1); 7.297 (12.0); 7.272 (11.5); 7.243 (4.4); 7.220] (1.3); 6.981 (12.1); 5.798 (0.6); 5.779 (1.4); 5.257 (16.0); 4.516 (0.8); 4.395 (5.4); 4.372 (0.7); 4.347 (8.3); 4.181 (8.2); 4.132 (5.4); 3.346 (23.0); 3.193 (5.8); 3.147 (7.2); 2.816 (6.9); 2.770 (5.6); 2.525 (15.7); 1.317 (0.5); 1.2931 (0.4); 1.258 (0.4); 0.617 (1.7); 0.582 (4.7); 0.571 (7.1); 0.554 (8.0); 0.536 (13.1); 0.513 (3.7); 0.499 (2.7); 0.4781 (1.5); 0.456 (2.3); 0.438 (3.7); 0.421 (3.5); 0.396 (2.2); 0.379 (1.2); 0.023 (12.2) Example 1-40: 'H-NMR (300.2 MHz, CDCls):
5= 7.892 (14.7); 7.731 (0.3); 7.682 (15.1); 7.662 (0.5); 7.648 (6.0); 7.644 (6.2); 7.621 (7.2); 7.617 (7.2) 7.600 (2.3); 7.552 (4.9); 7.547 (5.3); 7.527 (6.9); 7.521 (7.0); 7.409 (3.4); 7.405 (3.5); 7.384 (6.7); 7.380 (6.6): 7.359 (3.8); 7.355 (3.5); 7.298 (16.2); 7.265 (4.1); 7.259 (4.4); 7.239 (5.5); 7.234 (5.8); 7.214 (2.7); 7.208 (2.8) 7.146 (0.7); 7.116 (0.5); 5.486 (0.8); 4.760 (9.4); 4.711 (1 1.3); 4.696 (1.1); 4.651 (1.2); 4.377 (0.8); 4.332 (0.6) 4.263
(1 1.0); 4.215 (9.2); 4.190 (0.4); 4.166 (1.0); 4.142 (1.0); 4.119 (0.3); 3.825 (0.4); 3.538 (2.4); 3.490 (15.1); 3.473
(16.0); 3.425 (2.6); 3.395 (1.2); 3.346 (1.1); 2.488 (12.9); 2.078 (4.3); 2.041 (12.4); 1.696 (12.8): 1.603 (0.3):
1.316 (1.1) 1.292 (2.3) 1.269 (1.2); 1.166 (0.4); 1.149 (0.5); 1.128 (0.9) 1.106 (0.4); 1.058 (0.3) 1.031 (0.6): 1.024 (0.4) 1.016 (0.4) 1.006 (0.4); 0.990 (0.4); 0.879 (0.7); 0.850 (2.2) 0.840 (2.8); 0.832 (3.3) 0.827 (2.4): 0.808 (3.9) 0.804 (3.1) 0.796 (4.0); 0.762 (0.8); 0.752 (3.0); 0.740 (2.5) 0.732 (4.6); 0.718 (5.6) 0.713 (4.9): 0.705 (4.4) 0.700 (5.1) 0.693 (5.0); 0.687 (5.1); 0.673 (4.9); 0.666 (2.6) 0.653 (3.9); 0.620 (4.2) 0.612 (3.5):
0.609 (4.2); 0.589 (2.7); 0.586 (3.3); 0.576 (2.7); 0.571 (1.6); 0.566 (2.2); 0.537 (0.7); 0.044 (0.5); 0.033 (15.3) 0.022 (0.6)
|Example 1-41 : 1 H-NMR (300.2 MHz, CDCI3): δ= 7.868 (6.3); 7.659 (5.2); 7.605 (5.1); 7.468 (0.8); 7.465 (0.8); 7.430 (9.9); 7.403 (1.4); 7.300 (2.1); 4.731 (3.9): 4.682 (4.7); 4.232 (3.1); 4.183 (2.6); 3.389 (16.0); 2.987 (1.3); 2.891 (0.8); 2.677 (1.1); 2.661 (1.5); 2.033 (3.1): 0.853 (0.3); 0.823 (1.2); 0.814 (1.3); 0.805 (1.9); 0.800 (1.5); 0.782 (2.0); 0.778 (1.8); 0.770 (2.1); 0.733 (1.3): 0.713 (1.8); 0.695 (3.2); 0.688 (2.6); 0.680 (2.4); 0.670 (3.4); 0.655 (2.0); 0.649 (1.5); 0.635 (1.3); 0.588 (1.4): 0.577 (1.9); 0.552 (1.8); 0.544 (1.6); 0.534 (1.1); 0.024 (1.0)
|Example 1-42: 1 H-NMR (300.2 MHz, CDCI3):
8= 7.977 (0.5); 7.886 (8.8); 7.690 (4.6); 7.677 (5.5); 7.597 (0.4); 7.588 (0.4); 7.381 (0.8); 7.373 (0.9); 7.352]
(16.0); 7.333 (8.0); 7.321 (3.3); 7.314 (3.4); 7.306 (3.0): 7.300 (10.2); 7.099 (0.4); 7.072 (0.4); 4.930 (1.2) 4.873
(0.4) 4.823 (0.5): 4.724 (5.7) 4.675 (7.0) 4.560 (0.5) 4.511 (0.4) 4.247 (5.3) 4.198 (4.4) 3.353 (2.8): 3.3051 (4.9) 3.188 (7.1): 3.140 (4.0) 2.458 (0.7) 2.437 (0.7) 2.268 (0.9) 2.244 (0.7) 2.042 (1.6) 1.673 (0.5) 1.021 (0.3) 0.921 (0.4): 0.754 (0.9) 0.747 (1.7) 0.726 (4.3) 0.711 (4.4) 0.702 (5.5) 0.698 (5.2) 0.675 (1.7) 0.6631 (1.1) 0.653 (1.8): 0.646 (1.9) 0.626 (2.5) 0.623 (2.5) 0.613 (1.1) 0.605 (0.5) 0.595 (2.2) 0.592 (2.4) 0.577
(4.6); 0.573 (4.7); 0.553 (4.2); 0.539 (2.6); 0.526 (2.2); 0.512 (1.1); 0.505 (1.0); 0.495 (1.2); 0.104 (0.3); 0.034) (4.9)
[Example 1-43: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.765 (6.1); 7.601 (6.7); 7.448 (16.0); 7.444 (15.3); 7.300 (50.8); 7.021 (6.9) 5.339 (3.6); 4.471 (3.9); 4.422 (7.1); 4.317 (7.0); 4.267 (3.8); 3.402 (3.4); 3.354 (7.2); 3.274 (7.5); 3.226 (3.6) 2.358 (0.5); 2.154 (3.2); 2.128 (0.6); 2.085 (0.4); 1.633 (3.1); 1.322 (0.4); 1.292 (4.0); 1.261 (0.4); 0.888 (0.7) 0.865 (1.6); 0.842 (5.5); 0.838 (5.0); 0.831 (3.3); 0.820 (5.9); 0.811 (1.6); 0.802 (2.0); 0.786 (2.7); 0.779 (2.0) 0.776 (1.9); 0.755 (0.5); 0.738
(0.5); 0.718 (3.2); 0.703 (1.4); 0.698 (2.0); 0.687 (1.0); 0.675 (1.1); 0.049 (1.7); 0.038 (49.4); 0.028 (1.7)
|Example 1-44: H-NMR (300.2 MHz, CDCb): δ= 7.722 (14.8); 7.719 (16.0); 7.391 (3.6); 7.377 (1.1); 7.362 (8.5); 7.338 (8.5); 7.318 (8.5); 7.312 (13.6); 7.305) (9.2); 7.300 (12.0); 7.289 (4.7); 7.285 (4.1); 7.272 (7.3); 7.267 (5.5); 6.940 (12.8); 6.937 (14.2); 4.446 (7.8): 4.397 (15.7); 4.312 (15.1); 4.263 (7.6); 3.322 (5.4); 3.318 (5.6); 3.274 (7.3); 3.271 (7.8); 3.040 (8.0); 3.037 (8.1): 2.993 (6.1); 2.990 (6.2); 2.075 (0.6); 2.037 (1.8); 0.826 (2.5); 0.812 (3.5); 0.794 (6.5); 0.789 (6.9); 0.778 (8.1): 0.761 (1 1.4); 0.750 (9.6); 0.736 (7.4); 0.715 (5.6); 0.704 (7.0); 0.693 (2.8); 0.688 (3.8); 0.682 (3.7); 0.676 (4.2): 0.659 (2.4); 0.657 (2.3); 0.644 (2.1); 0.626 (0.9); 0.032 (5.8)
[Example 1-45: 'H-NMR (300.2 MHz, de-DMSO): δ= 7.977 (4.5); 7.975 (4.5); 7.862 (4.6); 7.860 (4.3); 7.631 (2.9); 7.483 (1.3): 7.457 (1.7); 7.434 (1.4); 7.408 (2.0):
7.312 (2.5): 7.286 (3.3) 7.260 (1.2); 5.776 (16.0); 5.557 (5.7); 5.451 (0.5); 4.594 (2.0); 4.545 (2.4); 4.184 (2.4): 4.135 (2.0) 4.061 (0.6) 4.037 (0.6); 3.343 (87.6); 3.194 (1.6); 3.148 (2.4); 2.994 (2.3): 2.948 (1.5); 2.653 (0.4): 2.620 (0.4) 2.533 (2.8): 2.527 (5.8); 2.521 (7.9); 2.515 (5.8); 2.510 (2.8); 2.094 (0.5): 2.008 (2.7); 1.218 (0.7): 1.194 (1.5) 1.171 (0.7): 0.572 (0.5); 0.566 (0.5); 0.557 (0.7); 0.541 (0.7); 0.529 (1.5): 0.505 (0.8); 0.496 (0.9): 0.479 (2.0) 0.474 (2.4): 0.468 (2.5); 0.460 (2.4); 0.446 (1.0); 0.435 (0.9); 0.414 (1.4): 0.402 (0.8); 0.385 (0.8): 0.370 (0.5): 0.020 (5.3)
|Example 1-46: 1 H-NMR (300.2 MHz, CDCI3):
8= 8.765 (15.1); 8.753 (4.7); 8.545 (8.1); 8.529 (9.9); 8.515 (2.6); 7.887 (16.0); 7.699 (13.4); 7.691 (4.9); 7.646)
(0.4); 7.551 (12.1); 7.535 (1 1.8); 7.300 (19.5); 5 334 (2.7); 4.751 (10.8); 4.702 (13.2); 4.307 (8.7): 4.297 (3.1):
4.258 (7.2) 4.249 (2.5) 3.555 (5.0); 3.546 (1.9); 3.508 (9.5); 3.499 (3.9); 3.41 1 (10.1); 3.364 (5.3) 2.993 (0.5): 2.791 (0.5) 2.716 (0.5) 2.600 (5.1) 2.042 (5.0): 1.887 (0.9) 1.771 (6.2); 1.284 (0.6); 0.875 (1.9) 0.863 (2.2): 0.856 (2.4) 0.843 (4.4) 0.832 (3.5) 0.821 (4.7): 0.809 (5.5) 0.783 (4.4); 0.772 (4.6); 0.767 (5.9) 0.753 (4.6): 0.741 (1.2) 0.732 (2.8) 0.720 (4.9) 0.710 (1.6) 0.698 (3.2) 0.685 (2.2); 0.680 (1.8); 0.663 (3.9) 0.649 (4.7): 0.646 (4.3) 0.634 (3.6) 0.623 (5.9) 0.612 (5.1): 0.601 (3.7) 0.592 (5.0); 0.577 (2.6); 0.569 (2.3) 0.557 (1.8):
0.102 (1.0); 0.042 (0.5); 0.031 (14.8): 0.020 (0.7) |Example 1-47: 'H-NMR (300.2 MHz, CDC13): δ= 8.513 (15.9); 7.869 (12.0); 7.738 (16.0); 7.683 (12.1); 7.681 (1 1.8); 7.653 (0.4); 7.300 (4.6); 4.750 (6.4); 4.701 (7.8); 4.582 (0.4); 4.448 (0.4); 4.292 (7.9); 4.243 (6.6); 4.153 (0.5); 4.129 (0.5); 3.510 (4.5); 3.463 (8.6); 3.427 (0.4); 3.375 (9.7); 3.328 (5.0); 2.921 (15.9); 2.072 (2.0); 1.941 (5.3); 1.310 (0.6); 1.286 (1.2); 1.262 (0.6); 1.139 (0.3); 0.947 (0.5); 0.915 (2.4); 0.908 (1.9); 0.899 (2.8); 0.892 (2.0); 0.875 (2.6); 0.868 (1.9); 0.859 (2.8); 0.804
(2.0) ; 0.788 (2.0); 0.782 (3.0); 0.766 (3.4); 0.758 (0.9); 0.749 (5.4); 0.741 (5.5); 0.724 (3.7); 0.707 (2.9); 0.701
(2.1) ; 0.685 (1.9); 0.623 (2.7); 0.614 (1.8); 0.608 (2.5); 0.589 (2.0); 0.583 (2.9); 0.573 (1.8); 0.566 (2.3); 0.534
(0.5); 0.097 (1.5); 0.025 (3.1)
|Example 1-48: 1 H-NMR (300.2 MHz, CDCI3): δ= 8.282 (1.7); 8.267 (6.1); 8.251 (5.0); 7.847 (9.1); 7.635 (2.5); 7.618 (7.4); 7.600 (0.4); 7.512 (10.3) 7.496
(10.0); 7.300 (2.6); 5.483 (0.6); 4.724 (4.9); 4.675 (5.9); 4.252 (4.2); 4.203 (3.5); 4.148 (0.7) 4.132 (0.9): 4.124
(1.9) 4.108 (0.9); 4.100 (1.9); 4.076 (0.7); 3.606 (0.6); 3.596 (0.5); 3.544 (16.0); 3.496 (1.2) 3.393 (3.6): 3.328 (0.5) 2.373 (0.4); 2.053 (4.1); 2.047 (8.5); 1.503 (1.3); 1.287 (3.9); 1.270 (6.4); 1.264 (7.4) 1.246 (1.7) 1.240 (2.6) 0.908 (1.6); 0.899 (2.2); 0.887 (3.9); 0.864 (3.8); 0.857 (2.8); 0.845 (3.1); 0.840 (3.4) 0.813 (2.8) 0.794 (1.9) 0.781 (2.5); 0.775 (2.8); 0.754 (8.3); 0.731 (2.6); 0.714 (1.8); 0.692 (0.9); 0.630 (1.4); 0.604 (2.6); 0.599
(2.7): 0.586 (2.5); 0.580 (2.1); 0.562 (1.8); 0.544 (0.8); 0.013 (0.6); 0.007 (0.8)
[Example 1-49: s H-NMR (300.2 MHz, CDCI3): δ= 7.861 (15.8); 7.631 (13.3); 7.478 (7.3); 7.470 (8.6); 7.452 (10.1); 7.444 (12.2); 7.301 (2.8); 7.276 (6.5); 7.250] |(9.8); 7.224 (4.1); 4.750 (8.5); 4.702 (10.1); 4.206 (9.2); 4.157 (7.8); 3.562 (4.9); 3.514 (15.1); 3.474 (11.9): 3.426 (3.8); 2.836 (1.4); 2.806 (2.9); 2.791 (2.9); 2.043 (0.4); 2.027 (16.0); 0.851 (1.4); 0.836 (2.6); 0.819 (3.2): 0.812 (4.0); 0.804 (3.8); 0.794 (4.9); 0.778 (0.8); 0.767 (3.1); 0.744 (1.7); 0.722 (4.2); 0.707 (10.5); 0.689 (8.1): 0.685 (9.6); 0.671 (3.6); 0.663 (2.6); 0.649 (1.5); 0.599 (2.2); 0.573 (4.1); 0.563 (3.7); 0.555 (4.4); 0.550 (3.7): 0.530 (2.8); 0.517 (1.4); 0.020 (1.9)
Example 1-50: 1 H-NMR (300.2 MHz, CDCI3):
5= 8.313 (5.9); 8.297 (6.2); 7.877 (10.0); 7.680 (9.7); 7.616 (0.4); 7.509 (6.2); 7.493 (5.9); 7.302 (3.8) 7.300
(3.2) ; 4.756 (4.8): 4.707 (5.8); 4.286 (5.8); 4.237 (4.8); 4.155 (0.4); 4.131 (0.4); 3.559 (2.0); 3.513 (8.3) 3.488
(8.3) ; 3.442 (1.9): 2.776 (3.0); 2.072 (1.6); 2.042 (16.0); 1.843 (0.8); 1.312 (0.4); 1.288 (0.9); 1.264 (0.4) 0.865
(1.5) ; 0.857 (1.3): 0.843 (2.6); 0.822 (2.0); 0.809 (2.8); 0.784 (1.9); 0.765 (2.8); 0.749 (2.7); 0.729 (3.6) 0.718
(3.6) ; 0.697 (2.4): 0.679 (2.4); 0.663 (1.6); 0.609 (2.3); 0.597 (2.0); 0.574 (2.9); 0.562 (1.4); 0.553 (1.7) 0.029 (3.5)
|Example 1-51 : H-NMR (300.2 MHz, CDCI3): δ= 7.891 (5.0); 7.677 (4.7); 7.675 (4.8); 7.300 (3.9); 7.201 (2.0); 7.176 (2.9); 7.152 (0.5); 7.144 (0.6); 7.078 (4.7): 7.049 (1.4); 4.698 (2.8); 4.650 (3.5); 4.279 (3.4); 4.259 (0.3); 4.231 (2.7); 3.454 (2.4); 3.407 (2.9); 3.051 (3.0): 3.004 (2.4); 2.397 (0.4); 2.376 (0.4); 2.347 (15.1); 2.295 (16.0); 2.082 (0.4); 2.072 (0.4); 2.016 (0.5); 1.939 (0.3): 1.91 1 (0.3); 0.925 (0.6); 0.917 (0.8); 0.911 (0.8); 0.897 (1.3); 0.893 (1.5); 0.876 (1.1); 0.862 (1.3); 0.756 (1.1): 0.744 (1.0); 0.738 (1.3); 0.725 (1.5); 0.703 (1.2); 0.698 (1.7); 0.690 (1.7); 0.683 (1.0); 0.665 (1.5); 0.647 (1.7): 0.629 (1.4); 0.615 (2.0); 0.603 (1.3); 0.580 (1.4); 0.569 (0.6); 0.560 (0.7); 0.555 (0.5); 0.037 (3.5)
Example 1-52: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.884 (11.5); 7.683 (1 1.5); 7.666 (0.6); 7.617 (1.3); 7.505 (7.3); 7.477 (16.0); 7.469 (8.5); 7.375 (0.6): 7.335 (5.3); 7.328 (4.7); 7.307 (4.0); 7.300 (1 1.4); 7.210 (0.6); 7.203 (0.6); 7.182 (0.4); 7.175 (0.4); 7.138 (0.4) 5.333 (2.5); 4.740 (7.0); 4.691 (8.4); 4.571 (0.4); 4.398 (0.5); 4.252 (7.2); 4.204 (6.0); 3.464 (1.8); 3.416 (10.9) 3.400 (12.7); 3.352 (2.9); 3.304 (0.8); 2.502 (3.2); 2.498 (3.2); 2.473 (1.8); 1.765 (0.8); 1.742 (0.5); 1.119 (0.6) 1.100 (0.5); 1.022 (0.5); 1.006 (0.4); 0.832 (1.2); 0.828 (1.6); 0.820 (1.7); 0.810 (2.7); 0.805 (2.2); 0.786 (3.1) 0.773
(4.5) ; 0.745 (2.7); 0.733 (2.7); 0.727 (3.3); 0.711 (3.1); 0.692 (2.6); 0.689 (4.1); 0.679 (4.1); 0.674 (2.5) 0.662
(1.6) ; 0.653 (3.1); 0.640 (3.6); 0.635 (3.3); 0.622 (3.1); 0.600 (4.5); 0.588 (3.0); 0.568 (3.8); 0.558 (1.0) 0.554 (1.6); 0.545 (1.5); 0.541 (1.4); 0.032 (7.1)
Example 1-53: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.885 (13.4); 7.662 (10.7); 7.599 (0.8); 7.486 (8.0); 7.458 (8.9); 7.389 (1.4); 7.378 (13.0); 7.371 (4.4): 7.355
(5.7): 7.349 (15.0); 7.337 (2.2); 7.300 (3.2); 7.060 (8.7); 7.051 (9.9); 7.028 (1.9); 7.017 (16.0); 7.009 (4.8) 6.994 (5.2) 6.987 (13.5); 6.975 (6.7); 6.966 (4.6); 6.947 (5.2); 6.938 (4.3); 4.755 (7.1); 4.706 (8.4); 4.562 (0.4): 4.455 (0.6): 4.410 (0.3); 4.221 (7.1); 4.172 (6.0); 3.457 (1.7); 3.409 (10.9); 3.393 (10.9); 3.344 (1.8); 3.307 (0.4) 3.258 (0.3) 2.579 (2.7); 2.528 (0.9); 2.033 (2.9); 1.913 (0.4); 0.864 (0.9); 0.849 (1.8); 0.831 (2.7); 0.825 (2.9): 0.817 (2.8) 0.807 (3.5); 0.792 (0.7); 0.780 (2.3); 0.766 (1.2); 0.752 (2.3); 0.744 (2.8); 0.729 (8.1); 0.712 (5.6) 0.707 (6.6) 0.694 (2.8); 0.686 (1.5); 0.672 (1.1); 0.622 (1.7); 0.612 (0.7); 0.596 (3.3); 0.585 (2.7); 0.578 (3.2) 0.573 (2.6): 0.553 (2.2); 0.540 (1.0); 0.029 (2.7) |Example 1-54: 'H-NMR (300.2 MHz, de-DMSO) δ= 8.042 (0.3); 8.039 (0.3); 7.958 (4.6); 7.893 (0.4); 7.837 (4.5); 7.479 (1.1); 7.465 (1.3) , 7.463 (1.4); 7.451 (1.3): 7.208 (0.4); 7.191 (1.0); 7.169 (6.6); 7.159 (3.3); 7.150 (2.4); 7.138 (1.8); 5.677 (0.8); 5.570 (0.4); 5.237 (4.5): 5.204 (0.4); 4.567 (1.7); 4.553 (0.4); 4.519 (2.1); 4.060 (2.7); 4.011 (2.2); 3.359 (6.0); 3.214 (1.6); 3.166 (2.9): 3.139 (0.3); 3.076 (2.7); 3.028 (1.4); 2.533 (3.9); 2.527 (8.2); 2.521 (11.1); 2.515 (8.0); 2.509 (3.8); 2.340 (1.3): 2.318 (16.0); 2.249 (0.6); 2.009 (0.8); 1.195 (0.4); 0.959 (0.4); 0.938 (0.8); 0.934 (0.8); 0.923 (0.8); 0.914 (0.8): 0.903 (0.9); 0.899 (0.9); 0.879 (0.7); 0.761 (0.5); 0.736 (0.8); 0.726 (0.9); 0.716 (0.7); 0.707 (0.8); 0.701 (1.1): 0.682 (0.8); 0.604 (0.6); 0.587 (1.0); 0.570 (0.5); 0.562 (1.1); 0.550 (1.4); 0.525 (1.2); 0.514 (1.0); 0.506 (0.7): 0.495 (0.7); 0.489 (0.8); 0.471 (0.4); 0.031 (0.5); 0.020 (13.0); 0.009 (0.5)
[Example 1-55: 1 H-NMR (300.2 MHz, de-DMSO): δ= 7.916 (3.6); 7.914 (3.6); 7.802 (3.8); 7.799 (3.6); 7.440 (1.2); 7.435 (1.3); 7.416 (1.4) ; 7.410 (1.4); 7.315 (0.6):
7.310 (0.6) 7.288 (1.2): 7.263 (0.9); 7.258 (0.8); 7.049 (1.8); 7.024 (1.4); 6.975 (1.0); 6.972 (0.9): 6.951 (1.7): 6.947 (1.6) 6.926 (0.8): 6.922 (0.7); 5.138 (3.0); 5.136 (3.0); 4.640 (1.2); 4.591 (1.4); 4.084 (1.0): 4.061 (3.1): 4.037 (3.1) 4.013 (1.0) 3.896 (2.0); 3.847 (2.6); 3.838 (16.0); 3.528 (1.6); 3.481 (1.8): 3.340 (8.9) 2.866 (1.7): 2.820 (1.5) 2.533 (1.5) 2.527 (3.2); 2.521 (4.3); 2.515 (3.1); 2.509 (1.5); 2.009 (13.8): 1.218 (3.8) 1.194 (7.5): 1.171 (3.7) 1.004 (0.4) 0.980 (0.6); 0.968 (0.6); 0.960 (0.6); 0.948 (0.7); 0.925 (0.5); 0.727 (0.4) 0.702 (0.6): 0.692 (0.7) 0.683 (0.5) 0.672 (0.7); 0.667 (0.8); 0.648 (0.6); 0.541 (0.5); 0.523 (0.7); 0.518 (0.6) 0.506 (0.5): 0.499 (0.8) 0.488 (0.6) 0.482 (0.4); 0.464 (0.4); 0.428 (0.6); 0.410 (0.6); 0.403 (0.7); 0.392 (0.7) 0.386 (0.6):
0.374 (0.5); 0.368 (0.5); 0.350 (0.3); 0.020 (5.8)
jExample 1-56: 'H-NMR (300.2 MHz, CDC13): 5= 8.420 (11.8); 7.879 (11.9); 7.686 (9.7); 7.580 (16.0); 7.300 (6.9); 4.763 (6.7) 4.714 (8.0) 4.282 (5.7): 4.233 (4.7); 4.156 (0.3); 4.132 (0.3): 3.487 (3.0); 3.440 (7.7); 3.387 (9.0); 3.340 (3.6) 2.844 (1.3) 2.074 (1.7) 2.043 (8.1); 1.892 (1.3); 1.311 (0.4): 1.288 (0.9); 1.264 (0.4); 0.886 (1.7); 0.879 (1.7) 0.868 (2.7) 0.862 (2.9) 0.844 (2.7); 0.829 (3.3); 0.788 (2.0): 0.767 (2.8); 0.751 (2.8); 0.732 (2.3); 0.726 (3.9) 0.719 (3.9) 0.693 (2.4) 0.675 (2.4); 0.656 (1.5); 0.602 (3.2): 0.587 (2.5); 0.568 (2.8); 0.563 (2.7); 0.552 (1.7) 0.545 (1.7); 0.538 (1.1); 0.027 (5.5)
Example 1-57: 1 H-NMR (300.2 MHz, CDCI3): δ= 8.646 (16.0); 8.525 (7.0); 8.509 (7.2); 8.484 (0.6); 7.892 (9.9); 7.698 (14.7); 7.658 (0.4); 7.646 (0.4): 7.534
(7.0) 7.518 (6.7): 7.479 (0.4); 7.462 (0.4); 7.300 (15.2); 6.882 (0.4); 4.762 (7.0); 4.713 (8.5); 4.291 (8.1): 4.242 (6.7): 4.187 (0.6) 4.163 (1.9); 4.139 (1.9); 4.126 (0.3); 4.116 (0.7); 3.511 (3.7); 3.465 (10.4); 3.420 (10.9): 3.373 (3.9) 2.996 (0.4): 2.650 (1.9); 2.619 (4.5) 2.077 (8.6); 2.043 (3.7); 1.814 (0.7); 1.315 (2.4); 1.291 (4.6) 1.267 (2.3) 0.852 (1.2): 0.838 (1.3); 0.832 (1.5) 0.821 (2.2); 0.807 (3.3); 0.797 (3.2); 0.786 (3.3); 0.768 (3.0) 0.758 (3.9) 0.754 (3.9): 0.737 (2.8); 0.726 (0.8) 0.719 (1.6); 0.706 (2.5); 0.677 (2.3); 0.663 (1.5); 0.651 (1.7): 0.638 (2.1) 0.628 (4.0); 0.613 (3.3); 0.602 (3.5) 0.592 (3.1); 0.582 (2.7); 0.575 (2.3); 0.562 (1.2); 0.557 (1.4); 0.549
(1.2); 0.537 (1.1); 0.042 (0.4); 0.031 (10.0); 0.020 (0.4)
jExample 1-58: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.884 (15.4); 7.703 (16.0); 7.668 (0.4); 7.654 (0.7); 7.380 (5.6); 7.374 (10.5); 7.368 (6.7); 7.336 (0.3); 7.298j |(11.8); 7.286 (22.8); 7.280 (20.5); 7.145 (0.4); 7.139 (0.3); 4.666 (6.8); 4.617 (9.2); 4.362 (9.6); 4.313 (7.0): 3.537 (7.6); 3.491 (8.4); 3.100 (0.5); 2.765 (8.2); 2.719 (7.3); 2.343 (15.8); 2.044 (3.7); 1.728 (7.6); 0.807 (1.2): 0.785 (1.6); 0.772 (3.2); 0.749 (4.8); 0.738 (9.4); 0.725 (5.8); 0.705 (3.7); 0.690 (1.6); 0.670 (1.9); 0.602 (0.6): 0.567 (1.9); 0.554 (2.3); 0.537 (4.2); 0.518 (3.8); 0.497 (2.8); 0.434 (3.3); 0.416 (4.2); 0.395 (3.6); 0.380 (2.7): 0.366 (1.5); 0.044 (0.6); 0.033 (11.3)
|Example 1-59: 1 H-NMR (300.2 MHz, ck-DMSO): δ= 8.025 (0.3); 8.021 (0.3); 7.957 (4.9); 7.955 (4.9); 7.848 (5.1); 7.845 (4.7); 7.800 (0.5); 7.223 (3.0); 7.207 (4.5): 7.190 (4.3); 7.165 (0.6); 7.089 (1.2); 7.073 (1.4); 7.061 (0.9); 5.570 (0.6); 5.396 (5.9); 5.329 (0.4); 4.567 (2.1): |4.518 (2.6); 4.480 (0.3); 4.137 (2.8); 4.088 (2.4); 4.061 (1.6); 4.037 (1.6); 4.014 (0.5); 3.341 (42.9); 3.135 (1.7): 3.089 (2.8); 2.980 (2.8); 2.934 (1.6); 2.533 (4.3); 2.527 (9.2); 2.521 (12.8); 2.515 (9.2); 2.509 (4.3); 2.307 (16.0): 2.009 (7.0); 1.218 (1.8); 1.195 (3.7); 1.171 (1.8); 0.674 (0.4); 0.657 (0.7); 0.651 (0.7); 0.634 (1.0); 0.621 (1.0): 0.616 (1.0); 0.608 (0.8); 0.579 (0.4); 0.546 (0.4); 0.523 (0.6); 0.513 (1.0); 0.497 (0.9); 0.482 (2.7); 0.454 (1.6): 0.444 (0.8); 0.423 (1.2); 0.406 (0.8); 0.397 (1.1); 0.381 (0.7); 0.372 (0.7); 0.031 (0.5); 0.020 (13.7); 0.009 (0.5)
|Example 1-60: 'H-NMR (300.2 MHz, de-DMSO) δ= 7.988 (4.9); 7.877 (4.9); 7.344 (3.9); 7.310 (3.8); 5.786 (16.0); 5.699 (5.9); 4.603 (1.9); 4.554 (2.4); 4.222 (2.4); 4.173 (2.0); 4.067 (0.9); 4.043 (0.9); 3.354 (56.6); 3.333 (0.6); 3.194 (1.6); 3.149 (2.4); 3.002 (2.3); 2.956 (1.6); 2.534 (15.6); 2.528 (21.2); 2.522 (15.4); 2.489 (0.4); 2.459 (15.3); 2.420 (0.8); 2.309 (1.0); 2.015 (3.9): 1.355 (1.8); 1.261 (0.7); 1.224 (1.2); 1.200 (2.2); 1.177 (1.0); 1.081 (0.4); 0.640 (0.6); 0.620 (0.7); 0.606 (1.0): 0.598 (1.3); 0.583 (0.5); 0.562 (1.0); 0.550 (1.1); 0.529 (4.4); 0.508 (1.1); 0.497 (0.7); 0.475 (0.8); 0.441 (1.2): 0.435 (1.2); 0.420 (0.7); 0.400 (0.7); 0.387 (0.4); 0.037 (0.7); 0.026 (25.7); 0.015 (1.1) |Example 1-61 : 'H-NMR (300.2 MHz, CDC13):
5= 7.886 (5.9); 7.713 (6.2); 7.378 (16.0); 7.351 (0.4); 7.320 (0.4); 7.300 (5.1); 7.236 (0.7); 7.226 (1.1); 4.678 (2.5); 4.630 (3.5); 4.611 (0.4); 4.401 (3.5); 4.383 (0.3); 4.352 (2.6); 3.530 (2.7); 3.485 (3.1); 3.312 (3.6); 3.020
(1.1) ; 2.919 (1.0); 2.843 (2.9); 2.798 (2.6); 2.050 (5.3); 1.841 (0.5); 0.757 (0.8); 0.732 (4.6); 0.724 (3.0); 0.712
(1.2) ; 0.692 (0.4); 0.569 (0.6); 0.540 (2.9); 0.531 (2.6); 0.521 (2.0); 0.509 (2.5); 0.484 (0.4); 0.478 (0.4); 0.033 (4.2)
[Example 1-62: 'H-NMR (300.2 MHz, CDCb):
5= 8.425 (1.9); 8.408 (1.9); 7.889 (3.1); 7.730 (3.1); 7.728 (2.8); 7.390 (2.3); 7.300 (16.2); 7.286 (1.6); 7.281| (1.3); 4.689 (1.6); 4.641 (2.2); 4.401 (2.2); 4.352 (1.6); 3.580 (1.8); 3.535 (2.0); 2.795 (1.9); 2.750 (1.7); 2.111 (4.1); 1.625 (16.0); 0.760 (1.6); 0.749 (2.8); 0.740 (2.1); 0.704 (0.6); 0.560 (0.5); 0.554 (0.6); 0.549 (0.5); 0.544 (0.4); 0.528 (0.7); 0.518 (0.9); 0.513 (0.9); 0.504 (0.6); 0.417 (0.7); 0.409 (1.0); 0.406 (0.9); 0.397 (0.6); 0.382 (0.4); 0.373 (0.6); 0.370 (0.6); 0.361 (0.4); 0.048 (0.6); 0.037 (14.4); 0.026 (0.6)
[Example 1-63: ! H-NMR (400.1 MHz, de-DMSO):
5= 8.032 (0.9); 7.972 (14.7); 7.844 (15.4); 7.813 (1.0); 7.698 (1 1.1); 7.679 (13.2); 7.634 (12.3); 7.614 (16.0): 7.500 (15.0); 7.480 (15.2); 7.464 (14.0); 7.444 (8.2); 7.372 (4.8); 7.354 (6.7); 7.336 (2.5); 5.758 (1.1); 5.492] [(14.2); 5.416 (0.9); 4.592 (6.0); 4.555 (7.0); 4.181 (7.1); 4.145 (6.1); 4.071 (0.4); 4.036 (0.4); 3.325 (141.0): 3.209 (5.0); 3.174 (7.1); 3.149 (0.4); 3.1 14 (0.5); 3.045 (7.0); 3.025 (0.9); 3.011 (4.8); 2.991 (0.4); 2.676 (0.6): 2.511 (71.8); 2.507 (87.8); 2.334 (0.5); 0.681 (1.3); 0.666 (2.5); 0.652 (3.4); 0.640 (3.1); 0.626 (2.2); 0.547 (1.2): 0.529 (2.2); 0.522 (3.0); 0.504 (4.0); 0.491 (4.5); 0.476 (3.9); 0.459 (3.3); 0.451 (2.3); 0.432 (3.7); 0.421 (2.8): 0.415 (2.8); 0.407 (3.4); 0.394 (2.1); 0.389 (2.1); 0.376 (1.1)
Example 1-64: 1 H-NMR (300.2 MHz, CDCI3):
5= 7.860 (16.0); 7.659 (13.3); 7.657 (12.8); 7.368 (7.5); 7.340 (20.5): 7.308 (26.9); 7.300 (9.4); 7.286 (4.3); 7.280
(9.4) 5.325 (0.9); 4.646 (7.4); 4.597 (9.9); 4.332 (9.3); 4.284 (7.0) 3.531 (6.4); 3.485 (7.2); 2.800 (8.4); 2.754 (7.5) 2.648 (1.3); 2.567 (1.7); 2.544 (1.7); 2.067 (0.6); 2.050 (0.5) 2.032 (0.6); 0.740 (1.0); 0.719 (1.2); 0.705 (2.7) 0.677 (9.5); 0.649 (3.4); 0.634 (1.2); 0.631 (1.2); 0.614 (1.6) 0.571 (0.9); 0.536 (2.0); 0.529 (2.5); 0.523 (2.2) 0.510 (4.0); 0.493 (3.9); 0.488 (3.8); 0.472 (2.9); 0.408 (3.4); 0.392 (4.1); 0.372 (2.9); 0.364 (2.0); 0.356
(2.8); 0.346 (1.6); 0.311 (0.4); 0.026 (2.5)
Example 1-65: H-NMR (300.2 MHz, CDCb):
5= 7.879 (11.1); 7.671 (12.0); 7.440 (1.0); 7.430 (1.5); 7.424 (1.0); 7.418 (1.4); 7.411 (6.1); 7.400 (2.9) 7.393
(6.5): 7.387 (16.0); 7.380 (6.9); 7.367 (4.0); 7.346 (10.0); 7.338 (7.5); 7.320 (5.1); 7.314 (3.8); 7.300 (4.1) 4.675 (5.7) 4.626 (7.5); 4.326 (7.6); 4.278 (5.9); 3.556 (6.3); 3.510 (7.1); 2.845 (6.9); 2.799 (6.1); 2.198 (10.1): 1.866 (0.5) 0.770 (1.1); 0.752 (1.1); 0.748 (1.4); 0.735 (2.7); 0.717 (3.1); 0.712 (3.6); 0.697 (4.8); 0.694 (4.4) 0.679 (3.7) 0.675 (3.6); 0.657 (3.3); 0.644 (1.3); 0.640 (1.3); 0.622 (1.8); 0.583 (0.3); 0.544 (1.8); 0.529 (1.8): 0.524 (1.7) 0.51 1 (3.7); 0.494 (2.7); 0.488 (2.8); 0.471 (2.2); 0.391 (2.9); 0.373 (3.0); 0.369 (2.9); 0.352 (3.6); 0.337
(2.0); 0.334 (2.0); 0.319 (1.3); 0.033 (3.3)
|Example 1-66: 1 H-NMR (300.2 MHz, CDCI3):
5= 7.757 (12.4); 7.494 (5.9); 7.484 (5.8); 7.479 (5.2); 7.469 (7.8); 7.457 (7.7); 7.301 (14.4); 7.276 (5.8); 7.249j |(8.1); 7.223 (3.7); 7.004 (12.6); 5.320 (0.4); 4.496 (6.5); 4.447 (10.5); 4.298 (10.2); 4.249 (6.3); 3.491 (3.2): 3.443 (12.3); 3.412 (12.9); 3.365 (3.4); 2.280 (11.4); 2.083 (0.6); 1.690 (5.5); 1.321 (0.6); 1.293 (1.9); 1.274 (0.4); 0.941 (0.4); 0.919 (1.1); 0.908 (0.5); 0.894 (0.7); 0.886 (1.0); 0.860 (2.7); 0.838 (16.0); 0.824 (6.5); 0.817 (6.4); 0.810 (3.4); 0.807 (3.3); 0.794 (3.6); 0.784 (6.2); 0.757 (0.6); 0.735 (5.4); 0.725 (2.3); 0.712 (2.3); 0.704 (1.8); 0.693 (1.9); 0.666 (0.3); 0.038 (12.5)
[Example 1-67: 'H-NMR (300.2 MHz, CDCb):
5= 8.306 (8.6); 8.290 (8.9); 7.752 (10.9); 7.718 (0.5); 7.695 (0.5); 7.690 (0.5); 7.678 (0.4); 7.655 (0.5); 7.649j (0.4); 7.594 (0.3); 7.575 (0.4); 7.570 (0.3); 7.515 (9.0); 7.499 (8.9); 7.300 (30.1); 7.021 (11.1); 7.019 (11.0): 4.51 1 (6.1); 4.462 (10.0); 4.321 (9.9); 4.272 (6.1); 3.509 (4.8); 3.463 (10.2); 3.387 (10.5); 3.341 (5.0); 2.381 (14.8); 2.083 (0.4); 1.641 (16.0); 1.291 (3.1); 0.928 (1.6); 0.920 (2.0); 0.913 (2.8); 0.901 (1.5); 0.887 (7.2); 0.874 (8.6); 0.854 (3.5); 0.839 (3.8); 0.821 (3.8); 0.810 (3.4); 0.786 (1 1.1); 0.778 (8.2); 0.759 (1.1); 0.748 (2.0); 0.736 (1.3); 0.702 (0.3); 0.048 (1.2); 0.037 (27.6); 0.026 (1.7)
|Example 1-68: 'H-NMR (300.2 MHz, CDCI3):
5= 7.769 (4.2); 7.300 (5.9); 7.224 (2.0); 7.198 (2.5); 7.125 (0.4); 7.1 14 (0.5); 7.048 (6.2); 7.023 (1.7); 6.996 (4.5): 6.994 (4.5); 5.337 (2.3); 4.413 (0.8); 4.364 (5.6); 4.350 (5.4); 4.301 (0.8); 3.416 (2.4); 3.368 (2.9); 2.916 (3.0): 2.869 (2.5); 2.340 (15.4); 2.282 (0.4); 2.215 (16.0); 1.722 (1.0); 1.323 (0.6); 1.293 (3.2); 1.248 (0.3); 0.953 (0.6): 0.938 (0.7); 0.929 (1.0); 0.920 (1.4); 0.909 (1.0); 0.896 (2.1); 0.884 (3.4); 0.870 (2.4); 0.855 (2.1); 0.848 (2.7): 0.824 (2.3); 0.817 (1.7); 0.807 (1.3); 0.800 (1.5); 0.783 (0.7); 0.724 (1.4); 0.710 (1.2); 0.695 (1.5); 0.688 (1.1): 0.676 (0.9); 0.669 (0.8); 0.658 (0.6); 0.109 (0.5); 0.039 (5.1) |Example 1-69: 'H-NMR (300.2 MHz, CDC13): δ= 7.722 (10.8); 7.719 (10.5); 7.526 (7.5); 7.498 (9.4); 7.432 (8.6); 7.425 (9.1); 7.300 (3.6); 7.287 (5.8); 7.280] |(5.3); 7.259 (4.6); 7.252 (4.2); 6.951 (10.9); 6.948 (10.3); 4.465 (6.2); 4.416 (10.0); 4.275 (9.5); 4.226 (5.9): 3.389 (3.5); 3.341 (10.1); 3.296 (1 1.1); 3.248 (4.0); 2.807 (5.2); 2.063 (0.8); 2.034 (2.8); 0.865 (0.5); 0.856 (0.6): 0.833 (3.6); 0.815 (16.0); 0.810 (10.4); 0.800 (4.9); 0.793 (7.3); 0.784 (6.0); 0.778 (4.6); 0.771 (2.3); 0.756 (5.2): 0.750 (2.9); 0.737 (2.0); 0.735 (2.0); 0.729 (1.2); 0.718 (0.7); 0.710 (1.2); 0.702 (0.7); 0.029 (2.4)
jExample 1-70: 1 H-NMR (300.2 MHz, de-DMSO): δ= 7.732 (11.0); 7.729 (10.3); 7.655 (6.6); 7.627 (7.3); 7.509 (1.3); 7.497 (13.3); 7.489 (4.3); 7.475 (4.7); 7.467] |(15.2); 7.456 (1.6); 7.136 (8.6); 7.128 (10.4); 7.1 18 (16.0); 7.111 (4.8); 7.096 (4.5); 7.088 (13.0); 7.077 (1.3): 7.045 (4.9); 7.037 (4.1); 7.017 (4.5); 7.008 (4.0); 6.965 (11.3); 6.961 (10.5); 5.779 (1.9); 5.253 (3.9); 4.467 (4.9): |4.418 (5.9); 4.012 (5.7); 3.964 (4.9); 3.351 (20.3); 3.302 (6.0); 3.153 (5.6); 3.106 (3.7); 2.537 (3.1); 2.531 (6.5): 2.525 (8.7); 2.519 (6.4); 2.513 (3.0); 1.027 (0.8); 1.01 1 (1.5); 0.992 (1.7); 0.985 (2.1); 0.970 (1.8); 0.961 (1.2): 0.947 (0.7); 0.793 (0.7); 0.772 (1.2); 0.756 (2.2); 0.725 (5.2); 0.702 (4.0); 0.688 (4.2); 0.667 (2.5); 0.646 (1.4): 0.629 (0.4); 0.032 (0.4); 0.021 (9.6); 0.010 (0.4)
|Example 1-71 : 1 H-NMR (300.2 MHz, CDCb): δ= 7.761 (3.9); 7.365 (0.8); 7.359 (1.0); 7.352 (1.1); 7.343 (1.5); 7.333 (1.4); 7.321 (0.4); 7.300 (3.8); 7.239 (8.2):
7.230 (5.4); 7.190 (0.5): 6.991 (3.8); 6.989 (3.9); 4.423 (0.7); 4.374 (5.2); 4.360 (5.1); 4.31 1 (0.7); 3.453 (2.4): 3.406 (2.9); 2.968 (3.1): 2.921 (2.6); 2.370 (0.6); 2.261 (16.0); 2.196 (0.6); 1.781 (0.8); 1.293 (0.5); 0.959 (0.4): 0.943 (0.5); 0.934 (0.7): 0.926 (1.0); 0.920 (1.1); 0.901 (1.6); 0.891 (2.9); 0.885 (1.5); 0.880 (2.0); 0.858 (2.3): 0.850 (0.8); 0.832 (2.0): 0.826 (1.4); 0.815 (1.0); 0.808 (1.2); 0.791 (0.5); 0.711 (1.1); 0.696 (1.0); 0.681 (1.4):
0.675 (1.0); 0.662 (0.8); 0.656 (0.7); 0.645 (0.6); 0.038 (3.0)
|Example 1-72: 1 H-NMR (300.2 MHz, CDCb): δ= 8.630 (16.0); 8.509 (10.1); 8.492 (10.4); 7.760 (11.4); 7.757 (11.1); 7.545 (8.5); 7.528 (8.2); 7.300 (39.8): 7.021 (12.0); 7.018 (1 1.5); 5.338 (4.2); 4.498 (6.9); 4.449 (12.1); 4.331 (11.9); 4.282 (6.8); 3.453 (5.6); 3.407] (10.6); 3.313 (1 1.4); 3.266 (6.0); 2.341 (10.1); 1.666 (7.6); 1.291 (3.9); 1.258 (0.5); 0.939 (0.5); 0.913 (1.8): 0.900 (1.5); 0.891 (3.1); 0.866 (7.2); 0.858 (5.6); 0.852 (4.3); 0.846 (5.2); 0.835 (7.1); 0.824 (3.9); 0.815 (3.4): 0.805 (4.3); 0.798 (3.9); 0.792 (4.2); 0.784 (3.3); 0.780 (3.6); 0.770 (0.9); 0.742 (5.3); 0.736 (4.1); 0.716 (3.4): 0.709 (1.8); 0.704 (1.9); 0.693 (2.0); 0.665 (0.5); 0.106 (0.6); 0.047 (1.3); 0.036 (33.4); 0.025 (1.3)
|Example 1-73: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.750 (4.6); 7.301 (7.1); 7.276 (2.7); 7.251 (2.1); 7.171 (2.1); 7.134 (2.3); 7.100 (3.5); 6.992 (4.7); 4.426 (0.8): (4.377 (4.7); 4.359 (5.4); 4.310 (0.9); 3.504 (2.9); 3.459 (3.0); 2.626 (3.0); 2.580 (2.7); 2.382 (16.0); 1.945 (4.4): 1.708 (2.4); 1.294 (0.5); 1.247 (0.4); 0.921 (0.6); 0.835 (0.7); 0.814 (1.4); 0.797 (2.9); 0.794 (3.1); 0.775 (4.1): 0.767 (3.9); 0.746 (1.3); 0.736 (0.4); 0.729 (0.7); 0.709 (0.4); 0.459 (0.7); 0.445 (1.1); 0.436 (1.3); 0.430 (1.9): 0.406 (1.3); 0.390 (0.8); 0.038 (5.3)
Example 1-74: 1 H-NMR (300.2 MHz, CDCI3) δ= 7.645 (4.5); 7.403 (16.0); 7.300 (34.9); 6.949 (0.3); 6.929 (4.8); 6.926 (4.7); 5.339 (0.7); 4.519 (2.5) 4.469
(4.2); 4.338 (3.9) 4.288 (2.4); 3.668 (1.1); 3.484 (2.8); 3.438 (3.2); 2.738 (2.8); 2.693 (2.5); 1.617 (8.1) 1.292 (2.1); 0.918 (1.1) 0.911 (0.6); 0.892 (1.5); 0.882 (1.7); 0.873 (2.1); 0.861 (1.7); 0.856 (1.9); 0.838 (1.7) 0.820 (0.9); 0.784 (1.3) 0.765 (1.6); 0.748 (0.8); 0.742 (1.3); 0.730 (1.0); 0.706 (0.7); 0.673 (1.1); 0.654 (1.0): 0.647 (1.1); 0.639 (1.2): 0.628 (0.9); 0.619 (0.9); 0.613 (0.9); 0.593 (0.5); 0.107 (0.5); 0.049 (1.0); 0.038 (30.0): 0.027 (1.2)
(Example 1-75: 1 H-NMR (300.2 MHz, CDCb): δ= 8.360 (9.8); 8.343 (10.1); 7.648 (13.7); 7.646 (13.8); 7.457 (12.2); 7.362 (6.9); 7.357 (6.5); 7.345 (6.7); 7.340] ](6.3); 7.300 (37.5); 6.906 (14.4); 6.903 (14.1); 5.322 (0.6); 4.539 (8.2); 4.490 (12.4); 4.314 (11.7); 4.265 (7.9): 3.870 (7.2); 3.506 (8.5); 3.460 (9.5); 2.743 (8.5); 2.698 (7.7); 1.666 (16.0); 1.291 (9.9); 0.927 (0.9); 0.917 (0.8): 0.908 (3.5); 0.896 (3.9); 0.881 (4.8); 0.870 (6.8); 0.863 (6.8); 0.844 (7.2); 0.839 (6.4); 0.820 (1.7); 0.740 (3.2): 0.720 (4.0); 0.710 (3.6); 0.693 (3.4); 0.688 (3.6); 0.681 (1.8); 0.661 (2.2); 0.627 (3.4); 0.607 (3.3); 0.603 (4.0): 0.591 (3.1); 0.581 (2.8); 0.573 (2.4); 0.567 (2.8); 0.547 (1.6); 0.106 (0.7); 0.048 (0.9); 0.037 (28.3); 0.026 (1.2)
[Example 1-76: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.746 (3.5); 7.301 (7.4); 7.189 (23.7); 6.991 (3.6); 4.419 (0.5); 4.370 (3.8); 4.356 (4.4); 4.307 (0.6); 3.503 (2.3); 3.457 (2.5); 2.622 (2.5); 2.576 (2.3); 2.385 (16.0); 2.360 (0.3); 1.875 (2.8); 1.673 (2.6); 1.293 (0.6); 0.921 (0.6); 0.832 (0.5); 0.809 (0.6); 0.803 (1.1); 0.795 (1.7); 0.784 (2.4); 0.781 (2.4); 0.771 (3.9); 0.769 (4.0); 0.756 (1.5); 0.749 (1.6); 0.741 (0.6); 0.732 (0.6); 0.457 (0.5); 0.445 (0.8); 0.433 (1.3); 0.430 (1.2); 0.406 (1.1); 0.394 (0.6); 0.039 (6.2)
[Example 1-77: 1 H-NMR (300.2 MHz, de-DMSO): δ= 7.759 (7.9); 7.411 (3.1); 7.403 (1.8); 7.381 (14.9); 7.366 (16.0); 7.345 (1.8); 7.337 (3.1); 6.988 (7.9); 6.985
(7.5) ; 5.334 (11.6); 4.388 (3.4); 4.339 (5.5); 4.203 (5.5); 4.154 (3.5); 3.346 (31.1); 3.202 (3.8); 3.156 (4.6); 2.775 (4.3); 2.729 (3.6); 2.530 (10.1); 2.524 (13.3); 2.518 (9.8); 2.097 (0.7); 2.012 (1.1); 1.197 (0.5); 0.624 (1.0); 0.605
(1.6) ; 0.597 (2.1); 0.590 (2.7); 0.583 (3.0); 0.571 (2.8); 0.563 (3.1); 0.551 (2.8); 0.535 (3.5); 0.519 (2.5); 0.497 (2.2); 0.484 (1.7); 0.473 (2.3); 0.459 (2.0); 0.444 (2.3); 0.432 (1.2); 0.415 (1.1); 0.397 (0.5); 0.023 (8.8) |Example 1-78: 'H-NMR (499.9 MHz, CDC13): δ= 7.681 (0.4); 7.672 (3.4); 7.667 (3.3); 7.657 (3.0); 7.653 (4.3); 7.646 (8.7); 7.645 (8.5); 7.554 (0.7); 7.551 (0.8):
7.540 (0.7); 7.536 (0.7): 7.390 (3.5); 7.386 (2.6); 7.376 (3.8); 7.372 (4.3); 7.362 (0.7) 7.354 (0.5): 7.343 (1.0): 7.340 (0.9); 7.328 (1.1) 7.325 (1.0); 7.301 (1.3); 7.278 (11.1); 7.251 (0.9); 7.247 (1.4): 7.236 (4.0) 7.232 (4.4): 7.230 (4.5); 7.224 (7.9): 7.218 (4.1) 7.215 (4.2) 7.210 (3.5) 7.200 (1.7) 7.196 (1.4) 7.191 (1.0) 7.177 (1.3): 7.174 (1.3); 7.162 (1.1): 7.159 (1.4) 7.155 (1.2) 7.144 (0.8) 7.140 (0.8) 7.130 (0.4) 7.126 (0.3) 6.538 (8.6): 6.537 (8.3); 6.208 (1.2): 6.206 (1.2) 5.301 (2.1) 4.609 (5.9) 4.579 (6.4) 4.463 (0.3) 4.189 (0.4) 4.178 (0.4): 4.140 (0.4); 4.126 (0.5): 4.112 (0.5) 4.097 (0.4) 4.075 (0.3) 4.061 (0.4) 4.046 (0.4) 4.035 (0.4) 4.027 (0.4): 4.017 (0.4); 4.007 (0.4): 3.996 (0.4) 3.987 (0.4) 3.975 (0.4) 3.964 (0.4) 3.958 (0.4) 3.946 (0.4) 3.935 (0.4): 3.925 (0.4); 3.915 (0.4): 3.906 (0.4) 3.877 (6.3) 3.847 (6.0) 3.825 (0.6) 3.807 (0.5) 3.793 (0.6) 3.780 (0.5): 3.764 (0.5); 3.754 (0.4): 3.725 (1.6) 3.720 (6.2) 3.704 (0.8) 3.698 (1.8) 3.691 (7.2) 3.679 (4.0) 3.666 (8.9):
3.653 (1 1.9); 3.639 (9.2); 3.626 (4.0); 3.613 (1.1); 3.598 (0.4); 3.587 (0.5); 3.580 (0.3); 3.567 (1.1) 3.553 (0.4): 3.539 (1.2); 3.525 (0.4); 3.204 (5.7); 3.176 (5.1); 3.1 17 (5.6); 3.102 (15.1); 3.087 (16.0); 3.072 (5.5) 3.056 (1.1):
3.045 (0.4); 2.347 (0.5); 2.041 (0.9); 1.600 (0.3); 1.557 (15.8); 1.542 (31.8); 1 527 (16.3); 1.486 (37.3): 1.474 1(38.6); 1.41 1 (0.8); 1.396 (0.5); 1.358 (0.4); 1.344 (0.4); 1.257 (0.6); 1.243 (0.4) 1.236 (0.4) 1.228 (0.4): 1.225
(0.4) 1.217 (0.4): 1.215 (0.4) 1.207 (0.4) 1.204 (0.4) 1.194 (0.4) 1.088 (1.3) 1.074 (2.0): 1.067 (2.0) 1.061 (1.9) 1.052 (2.3): 1.040 (1.7) 0.972 (0.4) 0.961 (0.5) 0.958 (0.5) 0.948 (0.6) 0.941 (0.4) 0.937 (0.5) 0.927 (0.6) 0.887 (0.4): 0.876 (0.4) 0.873 (0.3) 0.866 (0.6) 0.855 (0.6) 0.852 (0.6) 0.842 (0.5) 0.809 (0.7) 0.804 (1.5) 0.799 (0.8): 0.789 (2.3) 0.783 (2.3) 0.777 (2.3) 0.768 (2.7) 0.756 (2.1) 0.645 (1.5) 0.633 (2.5) 0.624 (1.5) 0.619 (2.5): 0.612 (2.3) 0.600 (2.6) 0.589 (2.1) 0.586 (2.5) 0.579 (2.4) 0.574 (1.7) 0.567 (1.8) 0.564 (2.2): 0.553 (1.2); 0.006 (0.5); 0.000 (1 1.6) -0.006 (0.8)
jExample 1-79: 1 H-NMR (300.2 MHz, CDCI3):
8= 7.730 (4.5); 7.656 (4.9); 7.654 (4.6); 7.469 (1.3); 7.462 (0.8); 7.453 (1.7); 7.450 (1.3): , 7.440 (1.9); 7.429 (0.4):
7.425 (0.4) 7.358 (0.4): 7.347 (0.7); 7.344 (1.0); 7.335 (1.5); 7.326 (3.4); 7.316 (5.2); 7.307 (3.0); 7.298 (5.2): 7.293 (2.2) 7.284 (1.8): 7.270 (0.4); 4.494 (2.5); 4.445 (3.2); 4.108 (3.4); 4.060 (2.7); 3.320 (1.4); 3.272 (4.9): 3.237 (4.7) 3.189 (1.4): 1.920 (5.7); 1.721 (1.9); 1.399 (16.0); 1.340 (0.5); 0.447 (0.4); 0.432 (0.7); 0.417 (1.2): 0.405 (0.8) 0.400 (0.9): 0.386 (0.8); 0.263 (0.6); 0.247 (1.0); 0.234 (1.1); 0.221 (0.4); 0.214 (0.7); 0.203 (0.9): 0.181 (1.1) 0.169 (0.8): 0.163 (0.4); 0.153 (1.6); 0.139 (1.4); 0.135 (1.3); 0.122 (1.2); 0.095 (1.4); 0.084 (1.2): 0.076 (1.2): 0.065 (1.6); 0.054 (0.7); 0.047 (0.7); 0.033 (3.4)
jExample 1-80: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.714 (15.7); 7.684 (2.1); 7.668 (16.0); 7.648 (0.3); 7.501 (0.4); 7.498 (0.3); 7.478 (0.7); 7.467 (4.7); 7.455 (5.2); 7.449 (3.8); 7.446 (3.2); 7.436 (6.4); 7.423 (1.5); 7.368 (0.8); 7.357 (3.5); 7.345 (4.6); 7.338 (4.9); 7.326 (9.1); 7.309 (4.1); 7.299 (16.1); 7.297 (16.8); 7.285 (1 1.5); 7.277 (9.4); 7.265 (8.1); 7.253 (1.1); 7.236 (0.4): 7.188 (0.7); 7.175 (0.4); 7.170 (0.4); 7.157 (0.5); 4.588 (0.6); 4.454 (0.4); 4.445 (0.4); 4.369 (0.4); 4.321 (0.4): |4.301 (4.4); 4.253 (12.9); 4.208 (15.0); 4.189 (0.5); 4.160 (5.3); 4.142 (1.0); 4.119 (0.7); 4.087 (0.4); 3.287 (8.3): 3.241 (13.0); 3.136 (0.6); 3.089 (13.4); 3.043 (8.5); 2.078 (3.9); 1.901 (3.0); 1.879 (2.0); 1.842 (2.0); 1.781 (1.0): 1.766 (0.9); 1.742 (0.9); 1.341 (0.6); 1.316 (1.9); 1.300 (3.7); 1.293 (4.8); 1.269 (1.3); 1.056 (1.1); 1.038 (2.5): 1.029 (2.6); 1.021 (1.7); 1.011 (5.0); 1.001 (1.8); 0.993 (2.8); 0.983 (2.9); 0.965 (1.5); 0.937 (1.3); 0.916 (4.0): 0.892 (1.6); 0.395 (1.1); 0.380 (1.5); 0.377 (1.4); 0.364 (2.9); 0.349 (3.8); 0.335 (3.4); 0.321 (2.4); 0.318 (2.3): 0.304 (2.0); 0.287 (1.9); 0.274 (2.5); 0.270 (2.3); 0.257 (3.3); 0.246 (2.9); 0.243 (3.5); 0.229 (3.0); 0.216 (1.3): 0.212 (1.3); 0.198 (1.4); 0.165 (0.5); 0.105 (0.6); 0.045 (0.4); 0.034 (7.7); 0.026 (1.3); 0.010 (2.2); -0.007 (3.5);■ 0.024 (4.5); -0.039 (4.1); -0.056 (2.0); -0.065 (2.4); -0.078 (2.7); -0.082 (4.4); -0.095 (4.8); -0.114 (3.6); -0.1281 (2.1); -0.146 (1.0)
jExample 1-81 : 1 H-NMR (300.2 MHz, CDCI3): δ= 7.772 (14.8); 7.655 (16.0); 7.653 (15.7); 7.457 (1.0); 7.448 (4.3); 7.440 (2.7); 7.433 (4.7); 7.430 (4.8); 7.418 (6.0); 7.408 (1.3); 7.404 (0.9); 7.331 (1.8); 7.320 (2.6); 7.316 (4.0); 7.308 (4.8); 7.298 (43.1); 7.285 (17.8); 7.276 (9.2); 7.270 (5.8); 7.268 (5.9); 7.263 (6.9); 7.253 (8.1); 7.240 (1.2); 7.230 (0.5); 4.241 (0.4); 4.177 (6.3); 4.128 (10.6); 3.995 (11.8); 3.947 (7.1); 3.132 (9.2); 3.085 (12.5); 2.844 (12.4); 2.797 (9.2); 2.751 (0.7); 2.723 (2.7): 2.711 (1.1); 2.692 (2.9); 2.675 (1.6); 2.665 (1.9); 2.653 (0.7); 2.637 (0.8); 2.183 (11.7); 2.044 (13.5); 1.924 (0.6): 1.891 (1.9); 1.873 (8.0); 1.868 (10.1); 1.860 (11.8); 1.852 (9.2); 1.847 (9.2); 1.840 (7.9); 1.834 (7.6); 1.814 (3.1): 1.804 (3.6); 1.774 (1.6); 1.754 (0.4); 1.743 (0.4); 1.721 (1.1); 1.709 (1.3); 1.696 (1.7); 1.688 (2.1); 1.677 (2.9): 1.661 (1.9); 1.653 (1.7); 1.630 (14.7); 1.610 (1.5); 1.603 (1.8); 1.590 (2.3); 1.582 (2.2); 1.559 (2.1); 1.535 (0.6): 1.531 (0.5); 0.106 (1.4); 0.047 (1.2); 0.036 (32.4); 0.025 (1.1)
jExample 1-82: 1 H-NMR (300.2 MHz, CDCI3):
§= 7.764 (4.5); 7.624 (4.7); 7.622 (4.1); 7.461 (1.3); 7.454 (0.8); 7.447 (0.8); 7.442 (1.2); 7.439 (1.1); 7.430 (1.9): 7.362 (0.8); 7.352 (0.8); 7.349 (0.9); 7.345 (0.9); 7.338 (1.3); 7.330 (2.6); 7.317 (1.0); 7.301 (3.5); 7.298 (4.4): 7.294 (2.6); 7.283 (3.0); 7.274 (1.8); 7.270 (1.5); 7.265 (1.4); 7.250 (0.4); 4.380 (2.2); 4.332 (2.8); 3.961 (3.0): 3.913 (2.4); 3.148 (1.9); 3.101 (3.6); 3.008 (4.1); 2.961 (2.1); 2.381 (1.7); 2.374 (1.9); 1.802 (0.6); 1.797 (0.7): 1.782 (0.5); 1.759 (1.0); 1.736 (1.5); 1.713 (1.2); 1.690 (0.5); 1.153 (16.0); 1.130 (14.0); 0.031 (1.7) |Example 1-83: 'H-NMR (300.2 MHz, de-DMSO) δ= 8.029 (1.8); 7.855 (1.9); 7.852 (1.7); 7.581 (0.5); 7.572 (0.5); 7.556 (0.4); 7.549 (0.6); 7.471 (0.6); 7.465 (0.4): 7.449 (0.6); 7.440 (0.8); 7.312 (0.7); 7.305 (0.9); 7.292 (1.4); 7.281 (0.7); 7.271 (0.5); 4.761 (2.5); 4.317 (0.7): |4.269 (0.9); 4.047 (0.9); 4.040 (0.4); 4.000 (0.7); 3.349 (6.5); 3.221 (0.7); 3.175 (0.9); 2.828 (0.8); 2.781 (0.7): 2.536 (0.7); 2.531 (1.5); 2.525 (2.0); 2.519 (1.4); 2.513 (0.7); 2.012 (1.3); 1.521 (0.5); 1.471 (1.1); 1.407 (1.1): 1.357 (0.5); 1.221 (0.4); 1.197 (0.7); 1.173 (0.4); 0.973 (16.0); 0.022 (1.6)
[Example 1-84: 1 H-NMR (300.2 MHz, CDC13): δ= 7.806 (14.6); 7.695 (0.4); 7.658 (16.0); 7.656 (13.1); 7.501 (0.6); 7.462 (0.5): 7.452 (4.6); 7.444 (2.9): 7.438
(3.2) ; 7.433 (3.8); 7.430 (3.6); 7.421 (6.4); 7.409 (1.0); 7.400 (0.5); 7.389 (0.4); 7.377 (3.5); 7.368 (3.0) 7.365
(3.3) ; 7.360 (2.8); 7.353 (3.8); 7.346 (7.5); 7.335 (1.5); 7.313 (1.1); 7.305 (2.8); 7.300 (7.9); 7.289 (8.9) 7.284 (9.7); 7.281 (7.9); 7.271 (11.6); 7.261 (6.4); 7.258 (5.7); 7.253 (5.1); 7.237 (1.4) ; 7.229 (0.8); 5.094 (0.3) 4.885 (0.3); 4.458 (0.6); 4.410 (0.7); 4.359 (6.4); 4.311 (9.2); 4.109 (10.5); 4.061 (7.4); 3.291 (8.0); 3.245 (1 1.0) 3.010 (11.0); 2.963 (8.1); 2.555 (5.8); 2.076 (0.6); 2.039 (3.8); 1.787 (4.3); 1.759 (0.4) ; 1.673 (3.5); 1.653 (3.7): 1.625
(4.5) ; 1.605 (4.7); 1.341 (0.9); 1.314 (4.7); 1.289 (5.3); 1.266 (3.7); 1.241 (4.1); 0.875 (0.6); 0.867 (0.7) 0.849 (1.7); 0.839 (1.4); 0.830 (2.0); 0.824 (2.2); 0.815 (1.5); 0.804 (2.0); 0.786 (1.0); 0.779 (0.9); 0.762 (0.4) 0.652 (2.2); 0.637 (8.0); 0.626 (4.2); 0.615 (6.9); 0.599 (2.1); 0.183 (0.4); 0.168 (0.5); 0.147 (3.1); 0.133 (7.2); 0.128
(6.6) ; 0.117 (7.9); 0.102 (2.6); 0.086 (0.5); 0.080 (0.5); 0.032 (5.4)
jExample 1-85: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.761 (15.4); 7.636 (16.0); 7.442 (5.2); 7.436 (5.6); 7.416 (6.4); 7.410 (6.7): 7.298 (6.3); 7.273 (3.5); 7.2661 (4.4); 7.247 (10.1); 7.241 (8.4); 7.218 (10.0); 7.206 (0.4); 7.193 (11.0); 7.167 (3.6); 4.163 (6.1); 4.135 (0.4)
4.1 14 (10.2); 3.984 (1 1.3); 3.936 (6.8); 3.179 (8.2); 3.133 (11.1); 2.890 (11.5); 2.843 (8.6); 2.749 (0.7) 2.722
(2.5) 2.713 (1.0): 2.694 (3.0) 2.675 (1.5) 2.668 (1.7) 2.663 (1.9) 2.642 (0.5) 2.635 (0.6); 2.486 (2.7); 2.473 (2.3) 2.461 (2.5): 2.447 (2.7) 2.073 (1.4) 1.927 (0.6) 1.897 (1.3) 1.885 (1.3) 1.860 (8.6); 1.854 (9.0); 1.845 (8.8) 1.836 (7.4): 1.828 (7.5) 1.823 (7.2) 1.816 (5.7) 1.799 (4.0) 1.771 (1.6) 1.755 (0.4); 1.717 (1.1); 1.705 (1.1) 1.687 (1.9): 1.680 (2.0) 1.671 (2.4) 1.659 (2.1) 1.649 (2.0) 1.632 (1.5) 1.627 (1.4); 1.609 (2.6); 1.601 (2.1) 1.582 (2.2): 1.576 (1.9) 1.547 (0.5) 1.334 (0.6) 1.311 (1.2) 1.294 (3.4) 1.287 (3.5); 1.263 (0.6); 0.931 (1.3): 0.909 (4.0); 0.886 (1.5); 0.100 (0.3); 0.028 (5.9)
jExample 1-86: ! H-NMR (300.2 MHz, CDCI3): δ= 7.836 (1.2); 7.705 (1.2); 7.363 (1.2); 7.357 (0.4); 7.342 (0.5); 7.335 (1.6); 7.302 (2.8); 7.152 (1.5); 7.130 (0.4): 7.125 (1.1); 4.394 (0.7); 4.346 (0.9); 4.006 (0.6); 3.958 (0.5); 2.980 (0.6); 2.935 (0.8); 2.561 (0.8); 2.515 (0.6): 1.741 (1.1); 1.626 (2.4); 1.613 (0.6); 1.563 (1.1); 1.460 (1.0); 1.410 (0.5); 1.084 (16.0); 0.039 (2.2)
jExample 1-87: 1 H-NMR (499.9 MHz, CDCI3): δ= 7.806 (2.0); 7.741 (0.7); 7.725 (0.7); 7.657 (1.7); 7.493 (0.5); 7.478 (0.6); 7.386 (0.4); 7.383 (0.4); 7.371 (0.9): 7.369 (0.8); 7.356 (0.6); 7.353 (0.5); 7.315 (0.6); 7.312 (0.6); 7.300 (0.9); 7.297 (0.8); 7.285 (0.4); 7.282 (0.4): 7.259 (5.0); 4.554 (0.5); 4.525 (0.8); 4.415 (0.6); 4.386 (0.4); 3.537 (0.8); 1.558 (2.2); 1.422 (1.4); 1.370 (0.6): 1.336 (1.4); 1.332 (0.9); 1.284 (2.0); 1.256 (16.0); 1.177 (0.7); 1.162 (0.6); 1.157 (0.6); 1.142 (0.5); 1.107 (1.1): 1.087 (0.9); 1.074 (0.8); 1.048 (0.7); 1.041 (0.8); 1.036 (0.7); 1.029 (0.6); 1.021 (0.6); 1.006 (0.4); 0.902 (0.6): 0.894 (1.3); 0.889 (1.2); 0.881 (2.1); 0.869 (1.7); 0.856 (1.5); 0.848 (1.7); 0.842 (1.5); 0.834 (1.5); 0.818 (0.7): 0.754 (0.3); 0.731 (0.4); 0.716 (0.5); 0.683 (0.5); 0.673 (0.4); 0.669 (0.4); 0.659 (0.4); 0.000 (5.0)
jExample 1-88: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.887 (16.0); 7.686 (10.0); 7.663 (12.5); 7.626 (4.0); 7.599 (9.3); 7.572 (7.1); 7.523 (5.5); 7.497 (5.9); 7.472 (2.0); 7.301 (2.9); 4.683 (7.1); 4.635 (9.3); 4.372 (8.8); 4.323 (6.6); 3.634 (5.7); 3.588 (6.4); 3.071 (0.9); 3.023 (1.3); 2.996 (0.8); 2.957 (0.6); 2.910 (6.1); 2.864 (5.0); 2.034 (0.9); 0.695 (0.8); 0.648 (1 1.4); 0.603 (1.9); 0.570 (0.9); 0.530 (2.9); 0.525 (3.0); 0.519 (2.3); 0.512 (1.9); 0.496 (2.7); 0.489 (3.7); 0.484 (3.7); 0.477 (2.7); 0.442 (0.5); 0.374 (0.6); 0.330 (4.0); 0.326 (4.0); 0.305 (1.5); 0.294 (2.3); 0.290 (2.3); 0.028 (2.1)
|Example 1-89: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.707 (16.0); 7.646 (0.4); 7.614 (3.2); 7.587 (6.6); 7.558 (5.1); 7.503 (4.2): 7.478 (4.7); 7.452 (1.8); 7.300 (10.5); 6.952 (10.0); 5.320 (0.4); 4.500 (4.3); 4.451 (8.4); 4.359 (8.5); 4.310 (4.4) 3.609 (5.6); 3.563 (6.2); 3.529 (0.4); 3.505 (0.4); 2.950 (4.7); 2.768 (5.9); 2.722 (5.3); 1.727 (2.8); 1.292 (0.6); 1.269 (0.4); 1.246 (0.6); 1.223 (0.3); 0.920 (0.5); 0.851 (3.4); 0.848 (3.4); 0.820 (8.7); 0.790 (7.1); 0.710 (2.6); 0.690 (3.2); 0.675 (1.7); 0.662 (2.8); 0.651 (1.5); 0.631 (1.4); 0.442 (2.1); 0.421 (2.4); 0.414 (2.9); 0.391 (2.7); 0.382 (2.0); 0.361 (1.4); 0.037 (9.6)
jExample 1-90: 'H-NMR (300.2 MHz, CDCI3): δ= 7.891 (8.6); 7.869 (5.7); 7.687 (8.8); 7.576 (16.0); 7.572 (14.3); 7.300 (4.7); 4.765 (5.1); 4.716 (6.3); 4.31 1 (6.0); 4.263 (5.0); 3.578 (2.9); 3.530 (7.1); 3.471 (8.1); 3.423 (3.3); 2.543 (5.3); 1.759 (0.4); 1.291 (0.5); 0.914 (0.5); 0.808 (1.3); 0.802 (1.0); 0.780 (2.3); 0.774 (2.5); 0.766 (4.4); 0.743 (2.9); 0.739 (3.3); 0.735 (3.0); 0.724 (2.7); 0.704 (0.8); 0.699 (1.6); 0.688 (0.4); 0.659 (0.6); 0.596 (1.1); 0.580 (1.0); 0.569 (3.0); 0.557 (9.5); 0.542 (2.7); 0.529 (0.6); 0.514 (0.6); 0.105 (0.7); 0.033 (3.8) |Example 1- 1 : 'H-NMR (300.2 MHz, CDC13):
5= 7.908 (6.6); 7.734 (8.1); 7.527 (16.0); 7.494 (0.7); 7.301 (2.0); 6.953 (8.2); 4.483 (3.8); 4.434 (6.8); 4.322 (6.7); 4.273 (3.8); 4.160 (0.7); 4.136 (0.7); 3.488 (3.0); 3.440 (7.0); 3.379 (7.3); 3.331 (3.1); 3.015 (0.9); 2.087 (0.6); 2.073 (3.1); 1.364 (0.3); 1.312 (1.8); 1.288 (4.5); 1.265 (1.4); 0.973 (0.6); 0.963 (0.4); 0.951 (0.7); 0.912 (1.3); 0.889 (1.1); 0.876 (1.4); 0.854 (2.0); 0.841 (4.4); 0.824 (6.8); 0.814 (9.1); 0.796 (4.8); 0.781 (2.5); 0.776 (2.3); 0.756 (1.8); 0.720 (2.0); 0.707 (2.4); 0.690 (3.3); 0.666 (1.5); 0.653 (1.0); 0.031 (1.4)
(Example 1-92: 1 H-NMR (300.2 MHz, CDCI3): δ= 8.908 (10.2); 8.773 (6.5); 8.756 (6.8); 7.851 (12.2); 7.784 (5.7); 7.767 (5.5); 7.640 (12.8); 7.638 (12.0); 7.300 (5.7); 4.703 (5.9); 4.654 (6.9); 4.136 (7.6); 4.087 (6.6); 3.493 (16.0); 2.978 (5.6); 2.974 (5.6); 2.037 (7.0); 2.009 (0.6); 1.283 (0.6); 1.022 (1.1); 1.003 (1.8); 0.986 (2.4); 0.978 (2.3); 0.967 (2.8); 0.961 (3.0); 0.933 (1.7); 0.902 (1.5); 0.879 (2.7); 0.867 (2.2); 0.860 (2.8); 0.839 (8.8); 0.819 (2.7); 0.813 (2.2); 0.801 (2.3); 0.777 (1.2); 0.651 (1.3); 0.624 (2.8); 0.617 (2.4); 0.607 (2.6); 0.599 (2.3); 0.582 (2.1); 0.564 (1.2); 0.099 (0.6); 0.026 (4.7)
[Example 1-93: 1 H-NMR (400.1 MHz, de-DMSO): δ= 7.920 (0.9); 7.881 (15.0); 7.844 (0.8); 7.812 (16.0); 7.810 (15.3); 7.776 (0.8); 7.733 (0.7); 7.304 (0.8); 7.301 (0.8); 7.281 (6.7); 7.268 (8.6); 7.254 (5.2); 7.245 (4.0); 7.221 (0.7); 5.505 (12.5); 4.716 (0.8); 4.557 (1.5); 4.480 (4.2); 4.477 (4.1); 4.443 (5.3); 4.441 (5.2); 4.210 (6.2); 4.173 (4.9); 3.305 (189.7); 3.195 (0.5); 3.182 (0.6); 3.161 (3.6); 3.126 (5.5); 3.011 (5.3); 2.976 (3.4); 2.664 (0.5); 2.659 (0.7); 2.655 (0.5); 2.494 (85.6); 2.490 (110.7): 2.486 (80.5); 2.321 (0.5); 2.317 (0.6); 2.313 (0.5); 0.818 (0.3); 0.808 (0.4); 0.785 (0.4); 0.780 (0.4); 0.759 (0.4): 0.613 (0.6); 0.594 (1.0); 0.583 (1.4); 0.564 (1.8); 0.549 (1.9); 0.532 (1.5); 0.517 (1.5); 0.513 (1.6); 0.497 (1.6): 0.479 (1.5); 0.475 (1.6); 0.460 (1.7); 0.445 (2.0); 0.430 (2.2); 0.411 (1.6); 0.396 (1.1); 0.382 (1.0); 0.353 (1.1): 0.333 (1.4); 0.325 (2.3); 0.319 (1.5); 0.310 (2.4); 0.299 (1.9); 0.292 (1.7); 0.284 (1.6); 0.266 (0.8); 0.045 (1.1): 0.030 (1.4); 0.025 (1.6); 0.018 (2.1); 0.011 (1.7); 0.000 (2.4); -0.008 (1.6); -0.015 (1.8); -0.023 (1.3); -0.027 (1.2): -0.042 (0.8)
Example 1-94: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.757 (15.2); 7.693 (16.0); 7.690 (14.9); 7.663 (1.6); 7.646 (0.4); 7.460 (3.0); 7.454 (3.2) 7.434 (5.0): 7.429
(5.1) 7.410 (3.6): 7.404 (3.7): 7.363 (0.3); 7.300 (48.5); 7.263 (2.3); 7.258 (2.4); 7.237 (5.3) 7.217 (4.0) 7.211 (3.4) 7.174 (6.2): 7.171 (5.9); 7.148 (7.7); 7.145 (7.6); 7.122 (2.8); 7.119 (2.9); 5.426 (1.8) 5.418 (1.8) 4.617 (4.7) 4.611 (4.7): 4.569 (6.0); 4.562 (5.9); 4.392 (0.3); 4.233 (6.4); 4.230 (6.4); 4.185 (5.0) 4.181 (5.0) 3.333 (3.2) 3.286 (7.1): 3.216 (7.3); 3.168 (3.2); 2.997 (1.2); 2.919 (1.0); 2.211 (0.5); 2.129 (4.2) 2.116 (4.3) 1.683 (0.4) 1.672 (0.6): 1.660 (0.8); 1.627 (5.8); 1.610 (2.0); 1.604 (1.4); 1.589 (0.8); 1.582 (1.0) 1.569 (0.6): 0.857 (1.0) 0.838 (0.9): 0.833 (1.1); 0.813 (1.7); 0.798 (2.5); 0.793 (2.8); 0.779 (2.8); 0.770 (3.3) 0.756 (2.9) 0.753 (3.0) 0.747 (2.2): 0.738 (2.3); 0.731 (2.6); 0.726 (2.7); 0.713 (3.6); 0.703 (2.8); 0.690 (2.9) 0.687 (2.9) 0.671 (2.0) 0.650 (1.0): 0.646 (1.1); 0.628 (1.2); 0.423 (1.2); 0.401 (1.2); 0.389 (1.5); 0.384 (2.3) 0.366 (3.7) 0.349 (4.1) 0.332 (3.1); 0.322 (2.7) ; 0.315 (2.6); 0.309 (2.6); 0.304 (2.9); 0.287 (4.0); 0.274 (2.7); 0.269 (3.4); 0.252 1(2.3); 0.236 (1.2); 0.231 (1.1); 0.212 (0.9); 0.107 (0.8); 0.048 (1.9); 0.037 (47.9); 0.027 (2.1)
[Example 1-95: 1 H-NMR (300.2 MHz, CDCb): δ= 7.756 (15.5); 7.729 (0.4); 7.688 (16.0); 7.661 (0.5); 7.300 (36.2); 7.249 (1.0); 7.242 (1.1); 7.222 (2.4): 7.216
(3.1) ; 7.209 (1.3); 7.198 (2.7); 7.191 (4.2); 7.182 (3.8); 7.167 (3.0); 7.162 (4.7); 7.159 (4.5); 7.156 (4.5) 7.138
(5.2) ; 7.126 (2.5); 7.112 (6.1); 7.106 (4.0); 7.085 (3.8); 7.072 (1.5); 7.066 (1.8); 7.045 (0.5); 4.620 (4.8): 4.614 (4.8); 4.572 (6.1); 4.565 (6.1); 4.230 (6.6); 4.227 (6.6); 4.194 (0.7); 4.182 (5.2); 4.178 (5.3); 4.170 (2.2) 4.146 (1.6); 4.123 (0.6); 3.347 (3.3); 3.299 (7.1); 3.222 (7.5); 3.174 (3.5); 2.161 (3.5); 2.118 (0.4); 2.083 (7.3) 1.640 (14.9); 1.321 (2.0); 1.297 (4.0); 1.273 (1.9); 0.865 (0.8); 0.842 (1.0); 0.823 (2.1): 0.805 (2.5); 0.801 (2.8): 0.786 (2.6); 0.774 (3.3); 0.756 (4.5); 0.738 (4.1); 0.719 (3.5); 0.707 (2.6); 0.693 (2.9); 0.672 (2.0); 0.649 (1.2) 0.630 (1.1); 0.437 (1.2); 0.417 (1.3); 0.415 (1.3); 0.403 (1.5); 0.397 (2.6); 0.380 (3.6); 0.363 (3.7); 0.343 (2.9) 0.327 (3.8); 0.312 (2.5); 0.307 (2.3); 0.291 (3.7); 0.277 (2.8); 0.272 (3.1); 0.255 (2.4); 0.239 (1.3); 0.234 (1.3); 0.215 (1.0); 0.107 (4.3); 0.048 (1.0); 0.037 (33.4); 0.026 (1.4)
[Example 1-96: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.730 (15.9); 7.677 (0.4); 7.654 (16.0); 7.640 (0.8); 7.504 (0.4); 7.500 (0.4); 7.312 (2.8); 7.300 (7.8) 7.284
(7.5) 7.258 (6.1): 7.190 (18.8); 7.159 (9.5); 7.153 (3.9): , 4.640 (0.5) , 4.635 (0.4): 4.626 (0.5); 4.621 (0.5) 4.584 (4.7) 4.578 (4.7): 4.535 (6.0); 4.529 (6.1); 4.218 (6.7) 4.215 (6.5) 4.170 (5.2) 4.166 (5.1) 3.270 (3.3) 3.222 (7.4) 3.150 (7.7): 3.103 (3.5); 2.682 (2.7); 2.039 (7.0) 1.926 (3.0) 1.917 (2.8) 0.829 (0.8) 0.809 (0.9) 0.804 (0.9) 0.788 (2.1): 0.769 (2.4); 0.764 (2.7); 0.748 (2.6) 0.738 (3.1) 0.721 (4.4) 0.700 (3.9) 0.682 (3.3) 0.671 (2.4) 0.656 (2.8): 0.653 (2.5); 0.634 (2.0); 0.616 (0.9) 0.612 (0.9) 0.593 (1.0) 0.436 (1.1) 0.416 (1.2): 0.413 (1.4) 0.402 (1.4): 0.395 (2.5); 0.378 (3.3); 0.360 (3.6) 0.344 (2.3) 0.341 (2.4) 0.325 (1.7) 0.301 (1.8) 0.285 (2.0) 0.280 (2.0): 0.265 (3.6); 0.250 (2.5); 0.246 (2.8) 0.230 (2.3) 0.223 (1.2) 0.213 (1.3) 0.208 (1.1) 0.188 (0.9): 0.029 (4.4) |Example 1-97: 'H-NMR (300.2 MHz, CDCls): δ= 7.744 (14.8); 7.669 (16.0); 7.352 (1.6); 7.344 (0.7); 7.330 (2.3); 7.322 (4.2); 7.300 (1 1.4); 7.273 (2.5): 6.969 (1.9); 6.960 (2.9); 6.942 (5.0); 6.935 (8.5); 6.914 (3.7); 6.908 (9.9); 6.900 (2.7) 6.879 (3.1); 6.871 (2.2) 5.424 (0.4); 5.417 (0.4); 4.589 (4.5); 4.583 (4.4); 4.540 (5.8); 4.534 (5.7); 4.221 (6.4) 4.217 (6.2); 4.172 (4.9) 4.169 (4.9); 3.272 (3.0); 3.224 (6.8); 3.150 (7.0); 3.102 (3.1); 2.482 (3.7); 2.477 (4.1) 2.465 (4.3); 2.460 (4.4) 2.041 (12.2); 1.822 (4.9); 1.803 (0.6); 1.290 (0.3); 0.830 (0.7); 0.810 (0.8); 0.806 (0.8) 0.788 (1.7); 0.770 (2.3) 0.765 (2.5); 0.752 (2.8); 0.744 (3.1); 0.731 (2.8); 0.728 (2.7); 0.721 (2.1); 0.710 (2.3) 0.703 (2.4); 0.699 (2.5) 0.685
(3.1) ; 0.678 (2.8); 0.665 (2.8); 0.661 (2.7); 0.644 (2.0); 0.624 (0.8); 0.621 (0.9) 0.602 (1.0); 0.423 (1.2): 0.404
(1.2) ; 0.401 (1.2); 0.389 (1.4); 0.382 (2.2); 0.366 (3.3); 0.348 (3.7); 0.332 (2.5) 0.329 (2.4); 0.315 (2.0) 0.308 (2.1); 0.294 (2.1); 0.289 (2.1); 0.273 (3.9); 0.259 (2.5); 0.255 (2.7); 0.239 (2.3) 0.233 (1.2); 0.222 (1.2); 0.216 (1.0); 0.198 (0.9); 0.103 (1.1); 0.031 (6.5)
|Example 1-98: 1 H-NMR (300.2 MHz, CDCI3):
8= 7.748 (10.0); 7.666 (10.6); 7.587 (0.4); 7.561 (0.4); 7.488 (0.4); 7.477 (3.0); 7.464 (2.8); 7.458 (3.6) 7.446 (4.6); 7.433 (1.4); 7.427 (2.6); 7.415 (3.1); 7.410 (2.7); 7.406 (2.4); 7.396 (4.8); 7.384 (0.9); 7.345 (1.7) 7.332 (10.5); 7.321 (6.5); 7.313 (5.9); 7.300 (12.2); 7.288 (0.8); 5.028 (0.3): ; 4.632 (3.4) ; 4.625 (3.4); 4.583 (4.3): 4.577
(4.3): 4.232 (4.5); 4.228 (4.3); 4.183 (3.6); 4.179 (3.4); 3.382 (16.0); 3.379 (15.8): , 2.566 (2.9); 2.040 (8.5) 0.879 (0.6) 0.858 (0.8): 0.854 (0.8) 0.838 (1.3) 0.818 (1.5) 0.813 (1.9); 0.795 (1.8) 0.787 (0.9); 0.771 (1.5) 0.768 (1.2) 0.763 (1.5): 0.752 (1.7) 0.746 (2.6) 0.741 (1.7) 0.728 (1.7); 0.722 (1.7) 0.705 (0.9); 0.697 (1.6): 0.679 (2.0) 0.675 (1.6): 0.656 (1.5) 0.639 (0.7) 0.634 (0.8) 0.615 (0.8); 0.473 (0.9) 0.452 (0.9); 0.449 (0.9) 0.439 (1.1) 0.434 (1.6): 0.414 (2.3) 0.411 (1.9) 0.400 (1.7) 0.392 (1.5); 0.380 (1.6) 0.377 (1.6); 0.358 (1.2) 0.335 (1.3) 0.317 (1.4); 0.311 (1.4); 0.300 (1.8); 0.293 (1.4); 0.282 (1.7); 0.277 (1.9); 0.263 (1.0); 0.258 (1.4); 0.244
(0.9); 0.239 (0.8); 0.219 (0.7); 0.033 (5.9)
[Example 1-99: 1 H-NMR (499.9 MHz, CDCI3): 5= 7.709 (15.3); 7.626 (16.0); 7.350 (1.3); 7.347 (1.6); 7.339 (1.7); 7.335 (3.4); 7.332 (3.2); 7.319 (4.0) 7.315
(2.6) 7.305 (4.4): 7.291 (5.7); 7.288 (5.2); 7.276 (3.5); 7.273 (3.1); 7.265 (7.5) ; 7.179 (4.3); 7.177 (4.8) 7.164 (6.8) 7.162 (7.5): 7.149 (3.0); 7.147 (3.3); 7.136 (3.8); 7.117 (5.0); 7.099 (3.1) ; 7.098 (3.1); 4.554 (5.1) 4.551 (5.0) 4.525 (5.8): 4.521 (5.8); 4.160 (6.6); 4.131 (5.8); 3.499 (0.4); 3.485 (1.3) ; 3.471 (1.3); 3.457 (0.4) 3.252 (3.5) 3.223 (7.9); 3.181 (8.0); 3.153 (3.5); 2.416 (5.5); 2.413 (5.8); 2.403 (5.5); 2.400 (5.5); 1.722 (10.7): 1.311 (0.4) 1.297 (0.5): 1.284 (0.3); 1.220 (1.4); 1.206 (2.7); 1.192 (1.3); 0.896 (0.9) ; 0.882 (2.0); 0.867 (1.0) 0.766 (0.9) 0.753 (1.2): 0.751 (1.3); 0.742 (1.7); 0.739 (1.2); 0.727 (2.9); 0.714 (2.6) 0.701 (1.8); 0.699 (1.3) 0.686 (3.9) 0.674 (3.9): 0.660 (2.1); 0.647 (2.6); 0.635 (3.0); 0.633 (2.6); 0.620 (2.0) 0.610 (1.1); 0.608 (1.3) 0.596 (1.1) 0.387 (1.2): 0.372 (1.7); 0.366 (1.7); 0.363 (2.2); 0.359 (1.4); 0.351 (3.5) 0.343 (2.1); 0.337 (2.1): 0.330 (2.3) 0.329 (2.3): 0.316 (1.5); 0.269 (1.6); 0.257 (1.9); 0.254 (2.1); 0.247 (2.5) 0.242 (1.9); 0.234 (3.2) 0.226 (1.5): 0.222 (2.0); 0.213 (1.4); 0.211 (1.4); 0.198 (1.0); 0.006 (0.4); 0.000 (7.0)
|Example 1-100: 1 H-NMR (400.1 MHz, de-DMSO) δ= 7.859 (1.6); 7.845 (15.2); 7.797 (16.0); 7.796 (15.4); 7.743 (0.9); 7.741 (0.9); 7.357 (6.5); 7.343 (8.2); 7.336 (8.9); 7.321 (7.4); 7.277 (0.4); 7.263 (0.5); 7.256 (0.6); 7.242 (0.5); 7.138 (0.9); 7.119 (8.6); 7.097 (14.1); 7.075 (6.9); 5.738 (1.3); 5.393 (9.9); 5.388 (9.8); 4.475 (1.1); 4.465 (1.3); 4.453 (4.4); 4.416 (5.3); 4.095 (6.3); 4.058 (5.3); 3.306 (97.7); 3.1 11 (0.7); 3.088 (0.8); 3.057 (3.2); 3.022 (6.1); 2.955 (6.2); 2.920 (3.2); 2.656 (0.4); 2.496 (23.8); 2.492 (44.4); 2.487 (57.6); 2.483 (41.8); 2.314 (0.4); 0.765 (0.3); 0.759 (0.6); 0.547 (0.3); 0.532 (0.7): 0.519 (0.9); 0.515 (0.9); 0.503 (1.7); 0.489 (1.9); 0.485 (2.1); 0.473 (2.4); 0.468 (2.7); 0.452 (3.2); 0.438 (3.2): 0.433 (2.4); 0.423 (2.9); 0.418 (2.5); 0.408 (2.3); 0.404 (2.2); 0.390 (1.6); 0.374 (0.8); 0.360 (0.8); 0.312 (1.1): 0.298 (1.3); 0.295 (1.4); 0.282 (2.2); 0.271 (2.5); 0.256 (2.7); 0.245 (1.6); 0.231 (0.9); 0.025 (1.1); 0.014 (1.4): 0.010 (1.6); 0.000 (2.8); -0.013 (2.3); -0.016 (2.3); -0.025 (2.2); -0.038 (1.3); -0.043 (1.1); -0.057 (0.8)
Example 1-101 : 1 H-NMR (300.2 MHz, CDCI3) δ= 7.897 (16.0); 7.686 (16.0); 7.405 (2.4); 7.385 (2.7); 7.377 (4.3); 7.357 (4.4); 7.350 (3.2); 7.330 (2.8) 7.300 (10.0); 7.081 (3.5); 7.075 (3.6); 7.053 (5.3); 7.048 (5.5); 7.025 (3.0); 7.019 (3.0); 4.744 (9.1); 4.695 (1 1.0) 4.258 (11.0); 4.209 (9.2); 4.163 (0.4); 4.139 (0.3); 3.402 (3.7); 3.397 (3.7); 3.354 (6.1); 3.349 (6.3); 3.215 (6.3) 3.212
(6.3) 3.167 (3.8); 3.164 (3.8); 2.395 (6.3); 2.379 (6.0); 2.078 (1.5); 1.790 (9.0) 1.338 (0.6); 1.315 (1.3) 1.298 (3.8) 1.292 (3.9); 1.268 (0.7); 0.935 (1.4); 0.914 (4.5); 0.890 (1.7); 0.778 (1.4) 0.766 (1.4); 0.759 (1.8) 0.756
(1.6) 0.735 (4.0); 0.724 (5.0); 0.717 (5.9); 0.710 (5.8); 0.702 (5.6); 0.699 (5.7) 0.692 (3.0); 0.675 (2.5): 0.663 (2.0) 0.652 (3.3); 0.642 (0.5); 0.621 (3.5); 0.609 (1.9); 0.603 (0.8); 0.590 (3.8) 0.573 (6.0); 0.563 (4.7) 0.548 (5.1): 0.541 (4.8); 0.530 (4.7); 0.518 (2.8); 0.505 (1.8); 0.498 (1.6); 0.486 (1.6); 0.032 (10.1); 0.021 (0.4) jExample 1-102: 1 H-NMR (400.1 MHz, de-DMSO): δ= 8.172 (1.8); 8.038 (1.9); 7.549 (0.4); 7.530 (0.4); 7.477 (0.4); 7.456 (0.4); 5.982 (0.4); 4.872 (2.2); 4.636 (0.8): 4.599 (1.0); 4.337 (0.9); 4.301 (0.8); 3.547 (16.0); 3.306 (0.5); 3.271 (0.7); 3.101 (0.7); 3.065 (0.5); 2.736 (8.0): 2.732 (9.9); 2.728 (7.4); 1.443 (5.2); 0.437 (0.4); 0.213 (0.4); 0.017 (0.5); 0.000 (1.1); -0.017 (0.4) |Example 1-103: 'H-NMR (300.2 MHz, CDC13) δ= 7.900 (15.1); 7.692 (16.0); 7.300 (13.8); 7.224 (1.1); 7.216 (1.1); 7.206 (1.3); 7.196 (2.6); 7.187 (2.0): 7.170 (3.1); 7.163 (1.9); 7.152 (1.5); 7.144 (1.6); 7.090 (1.8); 7.084 (1.8); 7.067 (1.9); 7.060 (4.1); 7.053 (2.8) 7.036 (2.6); 7.030 (3.5); 7.023 (1.4); 7.006 (1.1); 7.000 (1.2); 4.751 (9.0); 4.702 (10.9); 4.249 (10.3); 4.200 (8.6) 3.402 (3.4); 3.398 (3.6); 3.354 (5.7); 3.349 (6.0); 3.208 (6.2); 3.164 (3.6); 3.160 (3.8); 2.245 (2.7); 2.080 (0.5) 2.045 (14.9); 1.729 (1.7); 0.789 (1.3); 0.777 (1.2); 0.769 (2.0); 0.751 (2.7); 0.745 (3.6); 0.734 (4.6); 0.727 (5.7): 0.721
(5.8) ; 0.713 (5.3); 0.710 (5.6); 0.701 (3.3); 0.682 (2.1); 0.675 (1.9); 0.663 (3.1); 0.648 (0.4); 0.631 (3.6) 0.619
(1.9) ; 0.613 (0.9); 0.598 (3.6); 0.583 (5.2); 0.580 (5.4); 0.572 (4.2); 0.553 (4.4); 0.546 (4.5); 0.536 (4.0) 0.525 (2.8); 0.511 (1.7); 0.503 (1.6); 0.491 (1.6); 0.046 (0.3); 0.035 (11.5); 0.024 (0.5)
jExample 1-104: 1 H-NMR. (300.2 MHz, CDCI3) δ= 7.792 (15.1); 7.664 (15.8); 7.661 (16.0); 7.644 (0.4); 7.298 (18.4); 7.029 (0.9); 7.009 (0.6); 6.996 (4.1): 6.984 (6.2); 6.980 (4.2); 6.968 (9.8); 6.955 (4.1); 6.951 (6.1); 6.938 (1.0); 6.926 (0.5); 6.918 (0.6); 4.112 (5.2): 4.063 (11.4); 3.988 (11.5); 3.940 (5.3); 2.946 (4.2); 2.941 (4.2); 2.899 (5.7); 2.893 (5.6); 2.688 (0.6); 2.651 (6.6) 2.645 (6.1); 2.632 (3.4); 2.616 (2.0); 2.603 (6.0); 2.598 (5.6); 2.580 (0.7); 2.573 (0.8); 2.133 (10.6); 2.044 (4.6): 1.948 (0.7); 1.920 (1.6); 1.884 (7.3); 1.875 (9.8); 1.868 (8.2); 1.853 (8.6); 1.841 (6.6); 1.833 (4.1); 1.826 (3.6) 1.812 (2.5); 1.798 (3.3); 1.772 (1.3); 1.748 (0.8); 1.740 (1.1); 1.728 (1.7); 1.716 (1.8); 1.704 (2.5); 1.695 (2.9): 1.675
(11.6) ; 1.660 (2.5); 1.652 (3.0); 1.641 (2.3); 1.624 (1.9); 1.618 (2.1); 1.607 (1.3); 1.587 (0.6); 0.044 (0.6): 0.034
(16.7) ; 0.023 (0.6)
jExample 1-105: 1 H-NMR (300.2 Mi l/, CDCI3): δ= 7.805 (6.7); 7.732 (0.6); 7.728 (0.9); 7.723 (0.5); 7.712 (0.3); 7.705 (1.2); 7.700 (1.1); 7.692 (0.8); 7.688 (1.1):
7.683 (0.7) 7.672 (7.9); 7.670 (7.5); 7.660 (1.2); 7.593 (0.6); 7.587 (0.6); 7.573 (0.4); 7.568 (0.8); 7.563 (0.7): 7.529 (0.9) 7.519 (0.9); 7.515 (0.5); 7.509 (0.7); 7.504 (1.1); 7.499 (0.9); 7.494 (1.1); 7.481 (0.5); 7.476 (0.5): 7.471 (0.4) 7.298 (12.5); 7.034 (0.4); 7.003 (3.1); 6.991 (1.9); 6.986 (2.7); 6.977 (4.6); 6.961 (4.8); 6.932 (0.4): 4.306 (3.1) 4.257 (4.4); 4.024 (4.4); 3.975 (3.1); 3.074 (2.0); 3.068 (2.0); 3.026 (2.5); 3.021 (2.5); 2.670 (2.5): 2.665 (2.5) 2.622 (2.0); 2.617 (2.0); 2.080 (1.1); 2.028 (4.9); 2.026 (4.9); 2.024 (5.0); 1.744 (0.6); 1.721 (1.5): 1.699 (2.2) 1.675 (1.8); 1.653 (8.3); 1.318 (0.5); 1.294 (1.3); 1.288 (1.9); 1.271 (0.6); 1.139 (14.8); 1.131 (16.0):
1.116 (14.0); 1.108 (14.7); 0.046 (0.5); 0.035 (12.5); 0.024 (0.5)
jExample 1-106: 1 H-NMR (400.1 MHz, CDCI3) δ= 7.788 (15.0); 7.677 (0.5); 7.653 (16.0); 7.261 (27.0); 6.996 (0.7); 6.991 (0.5); 6.972 (6.2); 6.959 (9.2): 6.946
(5.8) 6.937 (3.9); 6.914 (0.9); 5.298 (1.5); 4.257 (5.7) 4.221 (8.9); 4.147 (0.4); 4.129 (1.1); 4.112 (1.3) 4.099 (9.8) 4.063 (6.3); 3.074 (4.2); 3.071 (4.4); 3.039 (5.1) 3.036 (5.3); 2.726 (4.9); 2.722 (5.1); 2.690 (4.0) 2.686 (4.2): 2.223 (14.5); 2.042 (4.5); 2.004 (1.5); 1.801 (0.3): 1.576 (29.5); 1.546 (3.2); 1.530 (3.3); 1.509 (4.1) 1.494 (4.2) 1.303 (0.7); 1.275 (5.0); 1.258 (6.4); 1.239 (3.9) 1.221 (3.4); 0.776 (0.7); 0.763 (1.7); 0.756 (1.5) 0.745 (2.4) 0.728 (2.1); 0.714 (1.1); 0.710 (1.0); 0.697 (0.4); 0.633 (3.2); 0.621 (7.8); 0.611 (4.8); 0.603 (6.3); 0.591!
(2.6); 0.108 (3.0); 0.096 (8.4); 0.085 (9.0); 0.008 (1.2); 0.000 (25.3)
|Example 1-107: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.893 (4.9); 7.674 (4.9); 7.300 (5.1); 7.269 (2.8); 7.242 (1.6); 7.030 (2.0); 7.004 (1.8); 6.992 (1.9); 6.953 (1.7):
4.730 (3.0); 4.682 (3.6) 4.201 (3.3); 4.152 (2.7); 3.311 (0.7); 3.263 (3.3); 3.240 (3.4); 3.191 (0.7); 2.401 (16.0): 2.357 (0.7); 2.349 (0.8) 2.334 (0.4); 2.317 (0.4); 0.767 (0.8); 0.755 (0.6); 0.749 (1.4); 0.724 (1.6); 0.722 (1.5): 0.716 (1.5); 0.701 (1.4) 0.691 (1.3); 0.684 (2.0); 0.671 (2.9); 0.663 (1.6); 0.653 (1.4); 0.644 (1.6); 0.641 (1.7): 0.631 (1.5); 0.623 (1.0) 0.613 (1.0); 0.559 (1.3); 0.554 (1.1); 0.550 (1.3); 0.528 (1.4); 0.518 (0.8); 0.507 (0.9): 0.036 (3.0)
|Example 1-108: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.755 (4.5); 7.467 (0.4); 7.311 (1.4); 7.301 (7.1); 7.285 (2.8); 7.259 (1.6); 7.032 (0.5); 7.001 (2.1); 6.984 (5.1): 6.957 (1.8); 6.918 (1.7); 5.338 (1.9); 5.321 (1.2); 4.454 (2.4); 4.405 (4.3); 4.291 (4.0); 4.242 (2.2); 4.171 (0.9):
[4.147 (0.9); 3.295 (1.6); 3.247 (2.5); 3.075 (2.5); 3.028 (1.6); 2.393 (16.0); 2.231 (1.2); 2.207 (1.2); 2.083 (4.1): 1.827 (0.4); 1.815 (0.5); 1.711 (1.7); 1.561 (0.4); 1.549 (0.4); 1.321 (1.1); 1.297 (2.5); 1.273 (1.2); 0.827 (0.7): 0.804 (1.4); 0.792 (1.8); 0.782 (2.5); 0.768 (1.8); 0.763 (2.9); 0.748 (4.6); 0.733 (0.5); 0.725 (1.5); 0.710 (1.0): 0.688 (1.5); 0.669 (1.3); 0.658 (1.1); 0.654 (1.2); 0.645 (1.0); 0.627 (0.8); 0.610 (0.4); 0.038 (6.1)
|Example 1-109: 1 H-NMR (300.2 MHz, CDCI3) δ= 7.875 (16.0); 7.682 (11.3); 7.300 (5.9); 7.274 (2.8); 7.268 (2.9); 7.249 (3.0); 7.242 (3.8); 7.238 (3.6) 7.230
(3.6) 7.212 (3.0); 7.205 (3.6); 7.199 (4.1); 7.193 (3.8); 7.165 (4.8); 7.138 (2.6); 7.100 (3.5); 7.091 (3.8) 7.066 (2.1) 4.651 (7.1); 4.603 (9.5); 4.353 (9.0); 4.305 (6.6); 3.530 (5.3); 3.484 (5.9); 2.781 (5.5); 2.735 (5.0) 2.655 (0.7) 2.633 (0.7); 2.565 (0.8); 2.532 (0.9); 2.481 (0.9); 2.075 (0.9); 2.042 (13.0); 1.862 (0.4); 1.290 (0.5): 0.765 (0.7) 0.743 (0.9); 0.731 (2.1); 0.706 (10.6); 0.701 (10.2); 0.684 (3.0); 0.677 (2.1); 0.648 (1.3); 0.588 (1.0) 0.575 (0.4) 0.548 (3.2); 0.542 (3.0); 0.528 (3.5); 0.512 (3.7); 0.508 (4.1); 0.492 (2.7); 0.463 (0.4); 0.414 (2.5); 0.399
(3.7); 0.387 (1.7); 0.380 (2.0); 0.365 (3.3); 0.030 (4.7) |Example 1-110: 'H-NMR (300.2 MHz, CDC13) δ= 7.832 (0.4); 7.793 (0.4); 7.674 (15.3); 7.624 (0.3); 7.612 (0.4); 7.321 (4.0); 7.300 (11.0); 7.257 (4.1); 7.185|
(1.7) ; 7.157 (4.9); 7.126 (11.5); 7.106 (12.2); 7.017 (0.4); 6.994 (0.3); 6.908 (16.0); 5.321 (0.4); 4.494 (7.0) 4.445 (11.6); 4.306 (11.4); 4.257 (7.0); 3.526 (0.6); 3.484 (9.1); 3.438 (14.4); 2.677 (9.0); 2.630 (8.1); 1.823 (1.1); 1.813 (1.1); 1.351 (0.4); 1.327 (0.7); 1.294 (1.4); 1.268 (0.7); 1.244 (0.9); 1.221 (0.5); 0.940 (0.9); 0.918
(1.8) ; 0.901 (1.6); 0.883 (3.7); 0.858 (7.4); 0.848 (5.8); 0.824 (8.7); 0.803 (6.0); 0.783 (3.0); 0.736 (4.0); 0.716 (5.1); 0.690 (4.4); 0.683 (3.9); 0.657 (2.2); 0.551 (3.3); 0.530 (5.1); 0.515 (4.1); 0.507 (3.7); 0.496 (4.2); 0.472 (2.1); 0.035 (7.2)
|Example 1-111 : 'H-NMR (499.9 MHz, de-DMSO)
5= 7.955 (12.1); 7.821 (1 1.6); 7.560 (3.0); 7.544 (6.3); 7.527 (3.5); 7.397 (3.6); 7.393 (3.8); 7.377 (3.8) 7.373
(3.9): 7.272 (4.0); 7.268 (3.9); 7.255 (3.7); 7.251 (3.5); 5.749 (12.8); 5.463 (12.7); 4.567 (5.0); 4.538 (5.7) 4.120
(6.1) : 4.091 (5.6); 3.301 (29.2); 3.106 (16.0); 2.504 (4.5); 2.501 (5.9); 2.498 (4.3); 0.778 (1.2); 0.766 (2.0) 0.764 (2.0) 0.757 (2.0); 0.752 (2.1); 0.745 (2.4); 0.743 (2.3); 0.731 (1.8); 0.633 (1.2); 0.618 (2.0); 0.612 (2.2) 0.606 (1.8) 0.597 (2.6); 0.585 (1.9); 0.512 (1.7); 0.501 (2.5); 0.498 (2.1); 0.491 (1.7); 0.486 (2.4); 0.480 (2.0) 0.477 (1.6) 0.465 (1.4); 0.439 (1.9); 0.427 (2.0); 0.424 (2.2); 0.417 (2.3); 0.413 (2.0); 0.406 (1.9); 0.403 (2.0); 0.392]
(1.2) : 0.000 (3.1)
Example 1-112: ! H-NMR (499.9 Mi l/, de-DMSO)
5= 7.955 (12.0); 7.821 (1 1.5); 7.561 (3.0); 7.544 (6.2); 7.527 (3.4); 7.396 (3.6); 7.392 (3.9); 7.377 (3.8) 7.373
(3.9) 7.272 (4.0) 7.268 (3.9); 7.255 (3.7); 7.251 (3.5); 5.749 (15.4); 5.464 (12.8); 4.567 (5.0); 4.538 (5.7) 4.120 (6.0): 4.091 (5.5) 3.303 (25.0); 3.106 (16.0); 2.505 (3.7); 2.501 (4.9); 2.498 (3.6); 0.779 (1.2); 0.766 (2.0) 0.765 (2.0) 0.757 (2.0): 0.753 (2.1); 0.745 (2.4); 0.743 (2.3); 0.731 (1.8); 0.633 (1.2); 0.618 (2.0); 0.612 (2.2) 0.606 (1.8) 0.597 (2.6): 0.585 (1.9); 0.512 (1.7); 0.501 (2.5); 0.498 (2.2); 0.491 (1.7); 0.487 (2.4); 0.480 (2.0) 0.465 (1.4) 0.439 (1.8): 0.428 (2.0); 0.425 (2.2); 0.418 (2.3); 0.414 (1.9); 0.407 (1.8); 0.403 (2.0); 0.392 (1.1) 0.000 (2.2)
|Example 1-113: 1 H-NMR (499.9 MHz, de-DMSO)
5= 7.742 (12.1); 7.529 (3.4); 7.512 (7.0); 7.496 (3.9); 7.363 (4.0); 7.359 (4.3); 7.344 (4.2); 7.339 (4.4); 7.244)
(4.4): 7.240 (4.3); 7.228 (4.1); 7.224 (3.9); 6.952 (11.3); 5.275 (16.0); 4.375 (5.8); 4.346 (7.4); 4.139 (7.4); 4.109 (6.1) 3.307 (7.5); 3.152 (4.5); 3.124 (5.5); 2.902 (5.4); 2.874 (4.4); 2.506 (2.4); 2.503 (3.3); 2.499 (2.4); 0.728 (0.4) 0.71 1 (2.1); 0.706 (1.9); 0.703 (1.6); 0.697 (2.6); 0.686 (3.1); 0.680 (2.6); 0.671 (0.7); 0.649 (1.9); 0.640 (2.7) 0.637 (2.7); 0.627 (3.5); 0.616 (3.5); 0.597 (6.0); 0.583 (11.8); 0.570 (3.0); 0.563 (1.2); 0.557 (0.7); 0.550 (0.8): 0.000 (3.1)
jExample I- 1 14: 'H-NMR (499.9 MHz, de-DMSO)
5= 7.742 (12.7); 7.529 (3.5); 7.512 (7.2); 7.496 (4.0); 7.363 (4.1); 7.359 (4.3); 7.344 (4.2); 7.340 (4.4); 7.244)
(4.6): 7.241 (4.4); 7.228 (4.2); 7.224 (4.0); 6.952 (1 1.8); 5.275 (16.0); 4.375 (6.0); 4.346 (7.6); 4.139 (7.6); 4.109 (6.2) 3.307 (8.6); 3.153 (4.7); 3.124 (5.8); 2.902 (5.7); 2.874 (4.6); 2.506 (2.7); 2.502 (3.6); 2.499 (2.7); 0.728 (0.4) 0.71 1 (2.2); 0.706 (2.0); 0.703 (1.7); 0.697 (2.7); 0.686 (3.3); 0.680 (2.7); 0.671 (0.7); 0.649 (2.0); 0.640 (2.8) 0.637 (2.8); 0.627 (3.7); 0.616 (3.6); 0.597 (6.2); 0.583 (12.2); 0.571 (3.2); 0.563 (1.2); 0.557 (0.7); 0.550 (0.8): 0.000 (2.8)
|Example 1-115: 'H-NMR (499.9 MHz, CDCb):
5= 7.656 (4.8); 7.627 (5.2); 7.626 (4.9); 7.263 (4.6); 7.187 (1.1); 7.172 (2.4); 7.160 (0.6); 7.155 (2.1); 7.143 (1.4): 7.139 (2.6); 7.135 (2.8); 7.133 (2.6); 7.124 (1.9); 7.1 19 (3.8); 7.115 (1.2); 5.297 (16.0); 4.196 (1.7); 4.167 (4.4): 4.133 (4.3); 4.104 (1.8); 3.053 (1.6); 3.051 (1.6); 3.025 (2.0); 3.023 (2.1); 2.826 (1.9); 2.824 (2.0); 2.799 (1.5): 2.796 (1.6); 1.602 (0.9); 0.933 (0.3); 0.922 (0.7); 0.916 (0.8); 0.911 (0.6); 0.905 (1.5); 0.900 (0.6); 0.895 (0.9): 0.889 (0.9); 0.878 (0.5); 0.340 (0.3); 0.330 (0.5); 0.329 (0.5); 0.321 (0.7); 0.312 (1.2); 0.304 (0.8); 0.301 (0.9): 0.294 (0.8); 0.293 (0.8); 0.283 (0.6); 0.259 (0.6); 0.250 (0.8); 0.248 (0.8); 0.242 (0.8); 0.239 (0.9); 0.232 (1.2): 0.223 (0.9); 0.220 (0.7); 0.215 (0.6); 0.213 (0.6); 0.204 (0.5); 0.000 (4.8); -0.028 (0.4); -0.038 (0.9); -0.048 (1.2): -0.058 (1.5); -0.068 (1.4); -0.078 (0.6); -0.110 (0.6); -0.121 (1.2); -0.130 (1.3); -0.141 (1.1); -0.150 (0.8); -0.161| |(0.4)
|Example 1-116: 'H-NMR (499.9 MHz, de-DMSO)
5= 8.144 (5.6); 7.865 (1.9); 7.737 (15.8); 7.575 (16.0); 7.354 (4.6); 7.338 (10.3): 7.332 (7.8); 7.328 (8.1); 7.321 (7.9); 7.313 (8.0); 7.309 (8.0); 7.191 (6.3); 7.187 (6.3); 7.174 (5.4); 7.170 (5.4) 5.153 (3.4); 4.658 (7.0); 4.630 (8.2); 4.327 (8.0); 4.299 (7.1); 3.311 (0.5); 2.910 (5.3); 2.883 (6.6); 2.687 (5.9) 2.660 (4.7); 2.509 (3.2); 2.505 (6.5); 2.502 (9.0); 2.498 (6.8); 2.495 (3.6); 0.810 (0.9); 0.799 (2.0); 0.793 (2.4) 0.789 (2.1); 0.782 (4.1); 0.772
(2.7); 0.766 (2.4); 0.755 (1.2); 0.000 (4.5); -0.01 1 (0.9); -0.017 (1.1); -0.021 (1.2); -0.028 (3.0); -0.034 (2.7) 0.039 (2.9); -0.045 (3.8); -0.056 (2.1); -0.062 (1.8); -0.071 (1.6); -0.078 (1.9); -0.082 (2.2); -0.089 (3.4); -0.095) (2.5); -0.099 (3.2); -0.106 (3.5); -0.116 (1.7); -0.123 (2.7); -0.130 (2.0); -0.135 (2.6); -0.141 (3.7); -0.152 (3.9); 0.159 (2.8); -0.170 (1.3); -0.303 (1.2); -0.314 (2.5); -0.321 (3.7); -0.332 (3.6); -0.339 (2.3); -0.349 (1.2) |Example 1-117: 'H-NMR (300.2 MHz, CDCls): δ= 7.784 (7.2); 7.628 (7.6); 7.298 (2.3); 7.216 (1 1); 7.189 (3.0); 7.164 (2.8); 7.140 (8.0); 7.1 11 (4.6); 4.091 (2.4):
4.043 (4.9) 3.963 (4.9): 3.914 (2.4); 2.912 (2.1); 2.908 (2.0); 2.866 (2.9); 2.862 (2.9); 2.646 (3.0); 2.642 (3.0): 2.626 (0.9) 2.600 (3.2) 2.595 (3.1); 2.562 (2.0); 2.556 (2.1); 2.539 (1.2); 2.517 (0.7); 2.067 (0.9); 2.032 (16.0): 1.925 (0.6) 1.916 (0.6) 1.892 (1.3); 1.887 (1.5); 1.867 (3.1); 1.853 (4.4); 1.846 (3.7); 1.835 (2.7); 1.827 (2.5): 1.799 (0.8) 1.790 (1.1) 1.762 (0.6); 1.712 (0.6); 1.696 (0.6); 1.671 (1.5); 1.661 (0.9); 1.652 (0.9); 1.646 (0.8): 1.618 (0.6) 1.608 (0.8) 1.599 (1.0); 1.592 (1.0); 1.587 (1.0); 1.576 (0.8); 1.567 (1.1); 1.539 (0.3); 1.282 (0.5): 10.023 (1.8)
(Example 1-118: 'H-NMR (300.2 MHz, CDCI3)
5= 7.81 1 (6.8); 7.676 (7.6); 7.673 (7.2); 7.298 (14.6); 7.222 (1.0); 7.195 (3.1); 7.171 (11.6); 7.166 (5.3); 7.148
(3.1) ; 7.142 (3.9); 4.306 (3.2); 4.257 (4.4); 4.012 (4.4); 3.964 (3.2); 3.044 (2.2); 3.040 (2.3); 2.997 (2.8); 2.993 (3.0); 2.668 (2.8); 2.664 (3.1); 2.621 (2.2); 2.617 (2.5); 1.960 (4.5); 1.952 (4.5); 1.735 (0.6); 1.712 (1.6); 1.689
(2.2) ; 1.666 (1.8); 1.643 (0.9); 1.627 (1 1.5); 1.130 (14.8); 1.120 (16.0); 1.107 (14.0); 1.097 (14.5); 0.047 (0.5) 0.036 (15.0); 0.025 (0.6)
|Example 1-119: ! H-NMR (300.2 MHz, de-DMSO): δ= 8.022 (1.8); 7.854 (1.9); 7.852 (1.7); 7.493 (0.4); 7.466 (1.0); 7.438 (0.6); 7.423 (0.6); 7.416 (0.7); 7.390 (0.6): 7.383 (0.7); 7.273 (0.7); 7.266 (0.6); 7.246 (0.5); 7.238 (0.5); 4.756 (2.5); 4.277 (0.6); 4.229 (0.9); 4.076 (0.9): 4.029 (0.6); 3.348 (6.6); 3.036 (0.5); 2.990 (0.6); 2.638 (0.6); 2.592 (0.5); 2.537 (0.7); 2.531 (1.5); 2.525 (2.1): 2.519 (1.5); 2.513 (0.7); 2.098 (0.5); 1.451 (0.4); 1.402 (1.0); 1.358 (1.0); 1.308 (0.4); 0.965 (16.0); 0.022 (1.6) jExample 1-120: 1 H-NMR (300.2 MHz, CDCI3) δ= 7.828 (11.7); 7.713 (0.4); 7.688 (12.3); 7.320 (0.3); 7.300 (15.9); 7.248 (2.1): 7.222 (5.2); 7.197 (4.4): 7.172 (12.6); 7.143 (8.3); 5.338 (2.5); 4.300 (4.3); 4.251 (7.5); 4.193 (0.5); 4.169 (1.3) 4.146 (1.5); 4.129 (8.0) 4.081 (4.5); 3.101 (4.3); 3.055 (5.5); 2.760 (5.4); 2.714 (4.1); 2.283 (11.7); 2.082 (5.6); 2.045 (1.8); 1.638 (16.0) 1.594 (2.4); 1.573 (2.6); 1.546 (3.3); 1.525 (3.5); 1.320 (2.2); 1.296 (5.2); 1.272 (3.4): 1.267 (3.9); 1.243 (2.5) 1.219 (2.7); 0.918 (0.6); 0.835 (0.7); 0.817 (1.5); 0.794 (2.1); 0.773 (1.9); 0.753 (1.0): 0.729 (0.4); 0.664 (2.5); 0.648
(7.1); 0.632 (3.9); 0.624 (6.0); 0.607 (1.9); 0.141 (2.4); 0.126 (8.0); 0.1 10 (8.9); 0.095 (2.0); 0.036 (15.2)
|Example 1-121 : 1 H-NMR (300.2 MHz, CDCI3): δ= 7.678 (2.9); 7.638 (2.9); 7.300 (2.1); 7.264 (0.7); 7.235 (1.5); 7.210 (1.4); 7.184 (1.5); 7.177 (2.3); 7.169 (1.5):
7.162 (1.2); 7.154 (0.9): 7.150 (0.8); 7.136 (1.3); 7.129 (0.9); 5.334 (2.3); 4.046 (1.0); 4.044 (1.0); 3.998 (2.0): 3.904 (2.1); 3.856 (1.1) 3.471 (16.0); 2.907 (0.9); 2.902 (0.9); 2.860 (1.1); 2.854 (1.1); 2.418 (1.3); 2.415 (1.3): 12.371 (1.1); 2.368 (1.1): 1.712 (0.5); 0.652 (0.4); 0.638 (0.4); 0.628 (0.6); 0.621 (0.7); 0.615 (0.5); 0.605 (1.5): 0.599 (0.9); 0.587 (1.0); 0.581 (1.5); 0.560 (1.9); 0.547 (0.4); 0.537 (0.9); 0.476 (1.4); 0.465 (0.7); 0.453 (2.0): 0.431 (1.1); 0.409 (0.4); 0.034 (2.2)
Example 1-122: 1 H-NMR (300.2 MHz, CDCI3)
8= 7.746 (8.2); 7.443 (2.2); 7.415 (4.8); 7.389 (2.9); 7.300 (30.4); 7.164 (4.8); 7.142 (6.7); 7.113 (4.3): 6.996
(9.0); 4.459 (4.2): 4.409 (5.7): 4.129 (5.6); 4.078 (4.2); 3.915 (0.5); 3.893 (2.2); 3.868 (3.6); 3.845 (2.8) 3.821 (1.0); 3.797 (0.9): 3.774 (2.8): 3.750 (3.7); 3.726 (2.2); 3.700 (0.7); 3.178 (3.3); 3.128 (5.8); 3.008 (5.9) 2.958 (3.4); 2.179 (0.5) 2.061 (1.1) 1.989 (1.0); 1.295 (6.4); 1.259 (8.9); 1.236 (16.0); 1.214 (8.3); 1.142 (0.6): 1.061 (0.4); 1.007 (2.3): 0.995 (2.3): 0.972 (3.0); 0.920 (1.2); 0.868 (4.1); 0.827 (13.3); 0.798 (2.0); 0.704 (0.3): 0.038
(24.4)
jExample 1-123: H-NMR (300.2 MHz, CDCI3) δ= 7.679 (10.8): 7.452 (3.5) 7.440 (1.0); 7.423 (7.2); 7.396 (4.4); 7.300 (36.5); 7.155 (3.9); 7.147 (7.3): 7.142
(6.9): 7.135 (5.3); 7.124 (5.0); 7.122 (4.8); 7.108 (6.2); 7.101 (4.0); 6.972 (11.6); 6.969 (11.5); 6.949 (0.4) 5.957 (1.0) 5.941 (1.9); 5.923 (1.5); 5.906 (2.2); 5.900 (1.5); 5.890 (1.4); 5.884 (2.4); 5.866 (1.8); 5.849 (2.5) 5.833 (1.3) 5.287 (1.7); 5.281 (4.6); 5.276 (5.1); 5.271 (2.2); 5.240 (2.2); 5.235 (5.4); 5.230 (6.2); 5.224 (5.4) 5.219 (4.5) 5.213 (2.1); 5.205 (2.0); 5.200 (4.8); 5.195 (4.4); 4.490 (7.4); 4.439 (10.1): , 4.417 (1.3); 4.412 (2.0) 4.406 (1.4) 4.402 (1.4); 4.396 (2.0); 4.391 (1.2); 4.377 (1.9); 4.371 (3.3); 4.366 (2.3); 4.362 (2.3); 4.356 (3.2) 4.351 (1.9) 4.271 (3.2); 4.259 (2.1); 4.254 (3.3); 4.231 (2.0); 4.219 (1.2); 4.214 (1.8); 4.167 (9.7); 4.117 (7.3) 3.987 (0.5) 3.224 (3.7); 3.174 (6.5); 3.050 (7.5); 2.999 (4.4); 1.741 (1.6); 1.667 (0.6); 1.292 (1.4); 1.034 (0.4) 1.009 (1.6) 1.001 (2.6); 0.984 (4.1); 0.967 (3.8); 0.960 (3.8); 0.946 (1.1); 0.924 (2.6); 0.91 1 (4.0); 0.906 (3.8): 0.891 (4.4) 0.871 (4.9); 0.855 (1.1); 0.848 (3.5); 0.840 (8.6); 0.823 (16.0); 0.802 (4.8) ; 0.789 (1.1); 0.771 (1.0) 0.048 (0.6): 0.037 (26.6); 0.026 (1.3)
|Example 1-124: 1 H-NMR (300.2 MHz, CDCb): δ= 7.750 (4.7); 7.646 (5.0); 7.298 (1.7); 7.265 (0.6); 7.244 (0.8); 7.235 (1.4); 7.214 (1.5); 7.208 (1.0); 7.186 (0.8):
6.929 (0.6); 6.919 (1.2): 6.913 (1.1); 6.903 (1.3); 6.893 (1.9); 6.884 (1.2); 6.877 (1.9); 6.869 (1.6); 6.849 (1.1): 6.841 (0.7); 4.417 (2.3): 4.368 (3.3); 4.143 (3.2); 4.095 (2.3); 3.159 (1.4); 3.156 (1.3); 3.112 (2.0); 3.108 (2.0):
[2.924 (2.0); 2.877 (1.4) 2.874 (1.4); 2.031 (5.8); 1.899 (2.4); 1.346 (16.0); 0.259 (0.6); 0.234 (4.2); 0.213 (0.8): 0.189 (0.5); 0.098 (0.7); 0.090 (0.5); 0.072 (1.2); 0.056 (3.4); 0.046 (3.5); 0.039 (1.7); 0.027 (1.0); 0.023 (1.7): 0.015 (0.4); 0.009 (0.4); 0.001 (0.4) |Example 1-125: 'H-NMR (300.2 MHz, CDC13) δ= 7.887 (15.3); 7.886 (15.3); 7.672 (16.0); 7.670 (15.5); 7.646 (0.4); 7.465 (2.2); 7.444 (2.7); 7.437 (5.0); 7.4161
(5.1) 7.409 (3.1); 7.387 (2.7); 7.300 (6.4); 6.984 (2.0); 6.982 (2.0); 6.976 (2.6); 6.973 (2.7); 6.955 (3.7) 6.946 (5.7) 6.938 (4.1); 6.930 (3.5); 6.919 (3.3); 6.910 (4.1); 6.904 (4.4); 6.896 (2.9); 6.876 (3.2); 6.867 (2.5) 4.727 (9.5) 4.678 (1 1.4); 4.235 (11.2); 4.186 (9.3); 4.160 (0.3); 3.350 (3.7); 3.348 (3.7); 3.302 (7.2); 3.299 (7.3) 3.205 (7.6) 3.157 (3.9); 2.446 (7.7); 2.424 (7.6); 2.073 (1.3); 2.038 (5.2); 1.855 (2.6); 1.312 (0.4); 1.288 (0.8) 1.264 (0.3) 0.759 (1.6); 0.750 (1.6); 0.743 (2.1); 0.724 (4.2); 0.708 (5.4); 0.700 (6.7); 0.695 (6.7); 0.687 (7.0) 0.684 (6.6) 0.675 (3.9); 0.656 (2.2); 0.649 (2.6); 0.641 (4.5); 0.624 (4.5); 0.615 (2.5); 0.605 (0.6); 0.593 (4.5) 0.580 (5.7) 0.576 (5.5); 0.569 (4.8); 0.564 (2.0); 0.549 (5.1); 0.542 (5.1); 0.535 (2.0); 0.528 (3.3); 0.521 (3.4) 0.507 (2.0): 0.499 (1.8); 0.491 (1.7); 0.101 (0.4); 0.029 (4.2)
[Example 1-126: 1 H-NMR (300.2 Mi l/, de-DMSO) δ= 10.098 (0.4); 7.969 (0.4); 7.946 (0.5); 7.863 (0.3); 7.838 (0.4); 7.765 (12.2); 7.675 (0.4); 7.638 (0.4); 7.587]
(1.9) 7.559 (4.4); 7.535 (4.5); 7.506 (2.0); 7.421 (0.4); 7.228 (2.5); 7.221 (2.6); 7.196 (4.5); 7.188 (4.5); 7.163 (2.5) 7.155 (2.5); 7.090 (2.7); 7.061 (4.7); 7.034 (2.4); 6.978 (12.1); 6.934 (0.5); 5.781 (1.5); 5.430 (0.3); 5.328 (0.5) 5.283 (14.6); 4.654 (0.4); 4.641 (0.4); 4.411 (5.2); 4.362 (7.5); 4.151 (7.6); 4.102 (5.2); 4.039 (0.3); 4.028 (0.4) 3.429 (0.4); 3.345 (58.4); 3.168 (4.4); 3.120 (6.3); 3.078 (0.4); 2.935 (6.3); 2.887 (4.3); 2.751 (0.6); 2.662 (0.4) 2.525 (49.8); 2.385 (0.4); 2.297 (0.4); 0.720 (2.5); 0.704 (3.1); 0.688 (5.3); 0.639 (6.9); 0.613 (8.0); 0.598
(16.0); 0.503 (0.5); 0.377 (0.3); 0.219 (0.3); 0.023 (37.8); -0.078 (0.6); -0.221 (0.4); -0.271 (0.4); -3.211 (0.3) jExample 1-127: 1 H-NMR (300.2 MHz, CDCI3) δ= 7.796 (15.7); 7.646 (16.0); 7.298 (8.7); 7.249 (1.8); 7.240 (0.6); 7.228 (2.4); 7.220 (4.7); 7.198 (4.3); 7.192)
(3.2) 7.170 (2.7); 6.922 (1.9); 6.913 (2.9); 6.896 (4.5); 6.888 (7.3); 6.862 (8.6); 6.834 (3.1); 6.826 (2.1); 4.101 (5.2): 4.053 (10.9); 3.970 (1 1.1); 3.922 (5.4); 2.916 (4.4); 2.912 (4.3); 2.869 (6.1); 2.865 (6.1); 2.665 (0.7); 2.646 (6.5) 2.641 (7.5); 2.624 (1.4); 2.610 (2.9); 2.599 (5.9); 2.580 (2.0); 2.567 (0.7); 2.550 (0.8); 2.292 (2.7); 2.244 (1.2) 2.039 (6.4); 1.923 (0.7); 1.914 (0.8); 1.893 (2.5); 1.873 (8.6); 1.861 (9.7); 1.852 (10.0); 1.845 (8.6); 1.831 (4.5) 1.828 (4.5); 1.825 (4.5); 1.813 (2.8); 1.796 (3.0); 1.782 (1.6); 1.768 (2.3); 1.750 (0.9); 1.733 (0.6); 1.721! (1.3) 1.714 (1.0); 1.708 (1.1); 1.695 (1.7); 1.681 (3.1); 1.668 (2.0); 1.655 (1.9); 1.644 (0.9); 1.622 (1.6); 1.610j (2.0): 1.600 (2.5); 1.586 (1.8); 1.578 (2.1); 1.564 (1.0); 1.549 (0.6); 0.030 (7.2)
|Example 1-128: ! H-NMR (300.2 MHz, CDCI3): δ= 7.792 (7.2); 7.636 (7.8); 7.634 (7.5); 7.298 (3.4); 7.271 (0.9); 7.250 (1.0); 7.241 (2.1); 7.231 (0.4); 7.220 (2.1): 7.214 (1.5); 7.192 (1.2); 6.929 (0.9); 6.919 (1.6); 6.910 (1.5); 6.902 (2.7); 6.893 (2.7); 6.880 (1.6); 6.874 (3.1): 6.869 (2.4); 6.867 (2.4); 6.846 (1.6); 6.838 (1.0); 4.301 (3.5); 4.253 (4.6); 3.996 (4.4); 3.947 (3.3); 3.027 (2.1): 3.024 (2.1); 2.980 (2.7); 2.976 (2.7); 2.671 (2.9); 2.624 (2.2); 2.252 (4.2); 2.245 (4.7); 1.786 (3.4); 1.735 (0.6): 1.712 (1.6); 1.689 (2.3); 1.666 (1.9); 1.644 (0.8); 1.328 (0.3); 1.306 (0.4); 1.128 (15.0); 1.118 (16.0); 1.105| 1(14.3); 1.095 (14.4); 0.030 (2.9)
jExample 1-129: H-NMR (300.2 MHz, de-DMSO):
8= 8.024 (1.7); 8.022 (1.7); 7.853 (1.8); 7.850 (1.7); 7.491 (0.5); 7.468 (0.5); 7.462 (0.3); 7.211 (0.4); 7.205 (0.4): 7.056 (0.5); 7.049 (0.4); 4.734 (2.6); 4.266 (0.6); 4.219 (0.9); 4.069 (0.9); 4.022 (0.6); 3.349 (4.6); 3.022 (0.5):
[2.976 (0.6); 2.640 (0.6); 2.594 (0.5); 2.537 (0.5); 2.531 (1.0); 2.525 (1.4); 2.519 (1.0); 2.513 (0.5); 1.453 (0.4): 1.403 (1.0); 1.349 (1.0); 1.300 (0.4); 0.961 (16.0); 0.873 (0.4); 0.784 (0.5); 0.022 (0.9)
|Example 1-130: 1 H-NMR (300.2 MHz, CDCI3) δ= 7.821 (14.5); 7.688 (0.5); 7.666 (15.4); 7.664 (14.7); 7.520 (0.4); 7.475 (0.4); 7.300 (8.5); 7.291 (1.9): 7.279
(0.6) 7.270 (2.1); 7.261 (4.4); 7.248 (0.9); 7.239 (4.1); 7.233 (3.0); 7.212 (2.5); 7.017 (0.3); 6.932 (1.7) 6.922 (2.9) 6.910 (2.9); 6.903 (5.2); 6.898 (5.7); 6.873 (6.2); 6.847 (3.2); 6.839 (2.1); 4.444 (0.4); 4.392 (0.4) 4.295 (5.4) 4.247 (9.3); 4.121 (10.1); 4.072 (6.0); 3.098 (4.2); 3.094 (4.3); 3.051 (5.5); 3.047 (5.6); 2.763 (5.3) 2.760 (5.4): 2.716 (4.1); 2.713 (4.2); 2.473 (12.1); 2.041 (1.5); 1.814 (0.5); 1.764 (16.0); 1.586 (3.1); 1.565 (3.3) 1.538 (4.3) 1.527 (1.8); 1.517 (4.5); 1.312 (0.7); 1.292 (4.3); 1.268 (4.7); 1.244 (3.2); 1.220 (3.5); 0.853 (0.6) 0.845 (0.7) 0.827 (1.6); 0.817 (1.4); 0.803 (2.2); 0.793 (1.5); 0.780 (1.9); 0.763 (1.0); 0.756 (0.9); 0.740 (0.4): 0.658 (3.1) 0.641 (7.5); 0.627 (4.4); 0.617 (6.3); 0.600 (2.7); 0.139 (3.0); 0.124 (8.0); 0.108 (8.7); 0.093 (2.2) 0.042 (0.4): 0.031 (5.9)
jExample 1-131 : 1 H-NMR (300.2 MHz, CDCI3): δ= 7.763 (4.7); 7.666 (5.0); 7.380 (0.4); 7.373 (0.4); 7.362 (0.5); 7.355 (1.1); 7.348 (0.9); 7.329 (1.2); 7.322 (0.7)
7.31 1 (0.6); 7.300 (4.2); 7.270 (0.6); 7.264 (0.7); 7.246 (1.5); 7.239 (1.5); 7.221 (1.4) 7.214 (1.1) 7.199 (1.8): 7.197 (1.8); 7.172 (2.3); 7.150 (0.8); 7.147 (0.8); 7.140 (1.1); 7.134 (1.5); 7.105 (1.0) 4.446 (2.4) 4.397 (3.3):
[4.150 (3.1); 4.102 (2.2); 3.194 (1.3); 3.147 (2.2); 3.007 (2.3); 2.959 (1.4); 1.819 (1.6) 1.803 (1.6) 1.696 (1.5): 1.690 (2.2); 1.679 (0.9); 1.370 (16.0); 1.343 (0.7); 0.310 (0.3); 0.297 (0.4); 0.281 (0.7): 0.262 (2.4) 0.251 (2.7) 0.234 (0.9); 0.215 (0.4); 0.205 (0.5); 0.104 (0.7); 0.093 (0.4); 0.080 (0.9); 0.062 (2.7); 0.059 (2.8); 0.050 (3.0): 0.043 (2.1); 0.036 (4.1); 0.027 (0.7); 0.018 (0.4); 0.012 (0.4); 0.004 (0.4) |Example 1-132: 'H-NMR (499.9 MHz, CDCb) δ= 7.857 (10.6): , 7.638 (10.7); 7.404 (1.8); 7.401 (2.0); 7.389 (3.8); 7.385 (4.2); 7.373 (2.2); 7.370 (2.4) 7.356
(1.2) 7.352 (1.1); 7.345 (1.3); 7.341 (2.7); 7.337 (2.1); 7.329 (2.3); 7.325 (2.9); 7.321 (1.6); 7.313 (1.6) 7.310
(1.4) 7.262 (9.3); 7.196 (3.1); 7.195 (3.2); 7.181 (5.2); 7.180 (5.2); 7.166 (2.4); 7.165 (2.4); 7.136 (2.8) 7.116 (3.4) 7.098 (2.5); 5.297 (16.0); 4.697 (6.9); 4.668 (7.8); 4.183 (7.4); 4.154 (6.8): 3.317 (2.8); 3.289 (6.0): 3.242 (6.3) 3.213 (3.0); 2.340 (6.6); 2.324 (6.7); 1.637 (4.8); 1.255 (0.3); 1.241 (0.3); 0.719 (1.3); 0.710 (1.5) 0.706 (1.5) 0.699 (2.7); 0.690 (2.9); 0.685 (3.2); 0.676 (3.7); 0.664 (3.2); 0.655 (3.4); 0.653 (3.7); 0.643 (3.8) 0.636 (1.0) 0.632 (2.0); 0.623 (2.9); 0.616 (0.5); 0.604 (2.9); 0.595 (2.1); 0.591 (1.2); 0.583 (3.9); 0.573 (3.6) 0.571 (3.3) 0.562 (2.8); 0.550 (0.4); 0.532 (3.3); 0.523 (3.0); 0.518 (2.9); 0.510 (3.2); 0.502 (2.0); 0.498 (1.9) 0.489 (1.6): 0.006 (0.3); 0.000 (9.1); -0.007 (0.5)
[Example 1-133: 'H-NMR (499.9 MHz, CDCb) 5= 7.858 (11.5); 7.639 (11.6); 7.403 (1.9); 7.400 (2.2); 7.388 (4.0); 7.385 (4.5); 7.373 (2.3) 7.370 (2.5) 7.356
(1.1) 7.353 (1.1); 7.345 (1.3); 7.341 (2.8); 7.338 (2.2); 7.329 (2.3); 7.325 (3.1); 7.321 (1.7) 7.314 (1.6) 7.310
(1.4) 7.262 (10.6); 7.197 (3.2); 7.195 (3.5); 7.182 (5.4): , 7.180 (5.7): 7.167 (2.4); 7.165 (2.5) 7.136 (2.9) 7.116 (3.6) 7.099 (2.5): 5.297 (16.0); 4.697 (7.4) ;; 4.668 (8.3): 4.183 (7.9); 4.154 (7.1); 3.317 (3.0) 3.289 (6.5) 3.242 (6.8) 3.213 (3.1) 2.330 (7.0); 2.314 (7.1); 1.626 (5.0); 1.255 (0.4); 1.241 (0.4); 0.719 (1.3) 0.710 (1.5) 0.706 (1.6) 0.699 (2.9) 0.690 (3.1); 0.685 (3.4); 0.676 (3.9); 0.665 (3.4); 0.656 (3.6); 0.653 (3.9) 0.644 (3.8) 0.636 (1.0) 0.632 (1.9) 0.623 (2.8); 0.615 (0.4); 0.604 (2.8); 0.594 (2.1); 0.591 (1.2); 0.583 (4.0) 0.573 (3.6) 0.571 (3.5) 0.562 (2.8); 0.532 (3.3); 0.524 (3.1); 0.518 (3.0); 0.511 (3.4); 0.502 (1.9); 0.498 (1.9); 0.489 (1.5); 0.006
(0.4); 0.000 (10.3); -0.007 (0.7)
|Example 1-134: 1 H-NMR (300.2 MHz, CDCb) 5= 8.441 (0.5); 8.030 (16.0); 7.698 (1.0); 7.695 (1.0); 7.663 (1.1); 7.466 (0.8); 7.460 (0.9); 7.441 (1.9) 7.435
(2.1) 7.416 (1.3): 7.410 (1.4) 7.390 (0.4) 7.385 (0.4): , 7.330 (0.4): 7.323 (0.7): 7.315 (0.6) 7.313 (0.6): 7.300 (4.4) 7.289 (1.5): 7.279 (2.2) 7.272 (2.0) 7.263 (1.2): , 7.261 (1.2): 7.253 (1.9): 7.247 (1.0) 7.232 (1.9) 7.226 (1.7) 7.215 (0.5): 7.207 (1.5) 7.201 (1.2) 7.190 (0.6): , 7.187 (0.7): 7.164 (2.1) 7.160 (2.1): 7.147 (1.9) 7.143 (2.9) 7.139 (3.1): 7.135 (3.1) 7.122 (2.2) 7.118 (3.6): , 7.111 (2.2): 7.105 (1.9) 7.101 (1.5) 7.097 (1.4) 7.093 (1.6) 7.088 (1.5): 7.083 (2.1) 7.078 (2.3) 7.072 (2.3): , 7.067 (2.0): 7.055 (1.2) 7.052 (1.1) 7.044 (1.3) 7.041 (1.2) 7.033 (0.5): 4.758 (0.5) 4.749 (1.2) 4.700 (4.7): , 4.670 (4.6): 4.621 (1.2) 4.570 (0.6) 4.521 (0.4) 4.192 (0.5) 4.169 (1.7): 4.150 (9.5) 4.141 (5.4) 4.121 (0.7): , 4.006 (0.5): 3.950 (0.5) 3.396 (0.4) 3.351 (0.5) 3.327 (1.5) 3.280 (2.6): 3.166 (2.2) 3.162 (2.2) 3.120 (1.3): , 3.115 (1.3): 3.064 (0.4) 3.059 (0.4) 2.080 (7.3): 2.033 (8.3) 1.806 (1.6): 1.318 (1.9) 1.294 (3.8) 1.271 (1.9): , 0.807 (0.4): 0.771 (0.4) 0.753 (1.0) 0.746 (0.8) 0.735 (0.6) 0.728 (2.2): 0.719 (1.7) 0.716 (1.8) 0.709 (1.5): , 0.705 (1.7): 0.696 (2.3) 0.693 (2.6) 0.679 (1.2) 0.674 (2.0) 0.658 (1.4): 0.646 (1.9) 0.631 (1.7) 0.620 (0.9): , 0.616 (0.8): 0.605 (1.3) 0.598 (1.1) 0.589 (0.4) 0.572 (0.6) 0.519 (1.2): 0.503 (1.1) 0.498 (1.3) 0.484 (1.2): 0.480 (1.2): 0.469 (0.8) 0.461 (0.9) 0.444 (0.6) 0.037 (2.9)
(Example 1-135: ! H-NMR (499.9 MHz, CDCb): 5= 8.328 (1.3); 8.065 (0.9); 7.919 (5.3); 7.746 (5.4); 7.425 (1.2); 7.423 (1.2); 7.410 (2.3); 7.407 (2.3); 7.395 (1.4):
7.392 (1.4); 7.292 (0.5) 7.289 (0.6); 7.282 (0.6) 7.278 (1.4) 7.274 (1.3): 7.260 (10.2): 7.251 (0.9); 7.247 (0.9): 7.144 (1.5); 7.143 (1.6) 7.129 (2.8); 7.128 (2.9) 7.115 (1.6) 7.113 (1.6) , 7.081 (1.5); 7.074 (0.6); 7.072 (0.6): 7.063 (2.2); 7.046 (1.3) 7.044 (1.3); 7.016 (0.3) 5.296 (1.3) 4.886 (0.8) , 4.716 (2.5); 4.687 (4.0); 4.601 (3.9): 4.571 (2.4); 4.462 (0.5) 4.427 (0.6); 4.267 (1.0) 4.256 (2.1) 4.249 (0.7) , 4.241 (6.5); 4.234 (1.6); 4.227 (6.8): 4.219 (1.0); 4.213 (2.5) 4.205 (0.8); 4.201 (0.8) 4.197 (0.7) 4.161 (0.4) , 4.119 (4.7); 4.093 (0.6); 3.965 (0.8): 3.936 (0.4); 3.931 (0.7) 3.906 (0.4); 3.487 (0.5) 3.457 (0.4) 3.359 (2.8) , 3.330 (3.0); 3.292 (0.9); 3.284 (0.6): 3.263 (0.4); 3.238 (0.3) 3.209 (0.6); 3.135 (0.5) ; 3.114 (2.2) ; 3.111 (2.3) ; 3.086 (1.8); 3.083 (1.8); 2.954 (0.3):
1.612 (10.0); 1.319 (7.9); 1.305 (16.0); 1.291 (8.3); 1.278 (2.9); 1.264 (1.6); 1.256 (0.4): 1.228 (0.4); 0.909 (0.5):
0.894 (0.4); 0.891 (0.4) 0.879 (0.3); 0.775 (0.8); 0.764 (1.3); 0.760 (1.2); 0.753 (1.6) 0.749 (1.9); 0.742 (1.5): 0.739 (1.5); 0.734 (1.2) 0.732 (1.2); 0.728 (1.6); 0.719 (1.1); 0.715 (0.7); 0.708 (0.7) 0.705 (1.2); 0.698 (1.5): 0.694 (0.7); 0.687 (1.3) 0.684 (1.8); 0.673 (1.3); 0.647 (1.5); 0.636 (1.6); 0.633 (1.3) 0.626 (0.9); 0.622 (1.4): 0.616 (1.1); 0.612 (0.7); 0.601 (0.8); 0.504 (1.2); 0.494 (1.3); 0.491 (1.3); 0.483 (1.3); 0.480 (1.3); 0.472 (1.1): 0.469 (1.1); 0.458 (0.8); 0.000 (7.3); -0.007 (0.4)
Example 1-136: 1 H-NMR (300.2 MHz, CDCb)
5= 7.708 (15.0); 7.660 (0.6); 7.656 (0.6); 7.641 (15.5); 7.357 (1.3); 7.351 (1.5); 7.339 (1.5); 7.332 (3.3); 7.325
(2.7) ; 7.306 (3.8); 7.300 (6.2); 7.287 (3.5); 7.282 (4.1); 7.263 (4.8); 7.258 (4.9); 7.238 (3.9); 7.232 (3.0); 7.174
(4.8) ; 7.170 (5.2); 7.146 (11.4); 7.120 (6.3); 7.114 (4.8); 7.086 (3.0); 4.448 (0.3); 4.438 (0.4); 4.250 (3.1); 4.202 (12.3); 4.173 (12.9); 4.125 (3.3); 3.137 (4.4); 3.134 (4.2); 3.091 (6.6); 3.088 (6.4); 2.927 (6.3); 2.923 (6.3); 2.882
(4.1) ; 2.877 (4.2); 2.113 (3.7); 2.069 (1.1); 2.047 (0.4); 2.031 (16.0); 1.987 (1.2); 1.966 (0.6); 1.284 (0.3); 0.981 (0.9); 0.963 (2.0); 0.953 (2.2); 0.945 (1.5); 0.936 (4.1); 0.926 (1.6); 0.918 (2.4); 0.908 (2.4); 0.890 (1.2); 0.368 (1.0); 0.353 (1.4); 0.349 (1.3); 0.337 (2.5); 0.322 (3.3); 0.308 (2.6); 0.305 (2.8); 0.294 (2.1); 0.290 (2.0); 0.275 (1.8); 0.259 (1.7); 0.245 (2.2); 0.241 (2.1); 0.231 (2.5); 0.227 (2.8); 0.214 (3.1); 0.200 (2.7); 0.187 (1.2); 0.183
(1.2) ; 0.169 (1.2); 0.054 (1.3); 0.037 (2.6); 0.027 (3.9); 0.022 (3.9); 0.004 (4.6); -0.011 (3.6); -0.028 (1.6); -0.083 (1.6); -0.101 (3.2); -0.115 (3.9); -0.133 (3.2); -0.147 (2.0); -0.165 (0.9) |Example 1-137: 'H-NMR (300.2 MHz, CDCls) δ= 7.796 (14.3); 7.644 (0.5); 7.632 (16.0); 7.629 (15.4); 7.446 (0.4); 7.443 (0.5) 7.397 (0.4) 7.341 (1.2): 7.334
(1.5); 7.323 (1.5); 7.316 (3.2); 7.309 (2.8) 7.298 (8.0); 7.290 (3.9); 7.283 (2.6) 7.272 (2.2) 7.265 (2.4) 7.254 (2.0); 7.248 (2.2); 7.229 (5.0); 7.222 (4.7) 7.204 (4.0); 7.197 (3.1); 7.169 (5.0) 7.165 (5.9) 7.144 (5.6) 7.140 (6.9); 7.131 (4.4); 7.119 (2.5); 7.115 (2.7) 7.104 (3.4); 7.098 (4.7); 7.094 (3.6) 7.070 (2.9) 7.066 (2.6): 4.291 (0.4); 4.234 (0.4); 4.112 (5.2); 4.064 (10.5) ; 3.976 (10.1); 3.928 (5.1); 2.960 (4.3) , 2.956 (4.3): 2.913 (6.0) 2.909
(6.2) ; 2.698 (6.1); 2.694 (6.2); 2.667 (0.8): 2.652 (4.8); 2.647 (5.1); 2.634 (1.6): 2.617 (2.1) 2.61 1 (2.2) 2.602
(1.8) ; 2.583 (2.1); 2.563 (0.5); 2.553 (0.9): 2.412 (8.9); 2.403 (9.1); 2.035 (0.5): 1.953 (0.4) 1.943 (1.1) 1.913
(1.9) ; 1.898 (2.4); 1.882 (5.1); 1.874 (6.7); 1.864 (7.1); 1.857 (8.5); 1.850 (13.3): 1.837 (6.0): 1.827 (4.1) 1.812 (2.7); 1.801 (2.5); 1.791 (1.0); 1.777 (1.2) 1.744 (0.5); 1.730 (0.5); 1.713 (0.9): 1.699 (0.9) 1.683 (1.7) 1.672
(3.3) ; 1.661 (2.1); 1.652 (1.7); 1.633 (0.9) 1.623 (0.7); 1.618 (0.7); 1.610 (0.6): 1.594 (1.1) 1.590 (1.0) 1.580
(1.4) ; 1.570 (1.9); 1.564 (1.9); 1.557 (2.2) 1.544 (1.8); 1.537 (2.3); 1.523 (0.7); 1.513 (1.1); 0.102 (0.7); 0.029 (5.6)
|Example 1-138: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.694 (1.1); 7.583 (1.3); 7.580 (1.2); 7.300 (0.9); 7.239 (0.3); 7.082 (0.4); 7.057 (0.7); 7.053 (0.9); 7.034 (0.6): 7.031 (0.6); 7.028 (0.7); 7.011 (0.3); 7.005 (0.3); 4.358 (0.5); 4.310 (0.8); 4.144 (0.6); 4.142 (0.6); 4.096 (0.4): |4.093 (0.4); 3.253 (0.4); 3.249 (0.4); 3.204 (0.4); 3.200 (0.4); 2.786 (0.5); 2.738 (0.4); 2.403 (0.5); 2.381 (0.5): 1.094 (16.0); 0.035 (0.9)
jExample 1-139: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.801 (4.4); 7.631 (4.7); 7.351 (0.3); 7.344 (0.4); 7.333 (0.4); 7.326 (0.9); 7.319 (0.9); 7.308 (0.7); 7.298 (2.5):
7.293 (0.8); 7.282 (0.6) 7.275 (0.7); 7.270 (0.6); 7.264 (0.7); 7.245 (1.5); 7.239 (1.4); 7.220 (1.2); 7.214 (0.9): 7.180 (1.4); 7.176 (1.7) 7.155 (1.7); 7.151 (2.3); 7.130 (0.7); 7.126 (0.8); 7.120 (1.0); 7.114 (1.4); 7.086 (0.9): 7.083 (0.8); 4.320 (2.1) 4.271 (2.9); 4.001 (2.7); 3.953 (2.0); 3.063 (1.3); 3.059 (1.3); 3.016 (1.8); 3.012 (1.8): |2.729 (1.9); 2.682 (1.5) 2.299 (1.3); 2.289 (1.8); 1.844 (0.6); 1.746 (0.4); 1.723 (1.0); 1.700 (1.4); 1.677 (1.2): 1.654 (0.5); 1.342 (0.5); 1.320 (0.5); 1.134 (9.0); 1.112 (16.0); 1.089 (8.6); 0.030 (1.4)
|Example 1-140: 1 H-NMR (300.2 MHz, de-DMSO): δ= 8.035 (1.8); 8.033 (1.8); 7.853 (1.8); 7.851 (1.7); 7.446 (0.5); 7.440 (0.7); 7.415 (0.4); 7.324 (0.4); 7.320 (0.4): 7.304 (0.4); 7.296 (0.5); 7.212 (0.5); 7.183 (1.0); 7.161 (0.8); 7.157 (0.8); 7.136 (0.4); 4.743 (2.4); 4.248 (0.6): 4.201 (1.0); 4.078 (0.9); 4.030 (0.6); 3.351 (11.6); 3.054 (0.5); 3.008 (0.7); 2.697 (0.6); 2.650 (0.5); 2.537 (0.7): 2.531 (1.3); 2.525 (1.8); 2.519 (1.3); 2.513 (0.6); 1.478 (0.5); 1.429 (0.9); 1.333 (0.9); 1.283 (0.5); 0.961 (16.0): 0.889 (1.3); 0.763 (0.7); 0.022 (0.8)
|Example 1-141 : 1 H-NMR (300.2 MHz, CDCI3) δ= 7.834 (14.4); 7.701 (0.5); 7.699 (0.4); 7.670 (16.0); 7.668 (13.6); 7.507 (0.6); 7.446 (0.7): 7.443 (0.6): 7.355
(1.2) 7.349 (1.6): 7.337 (2.0); 7.330 (3.2); 7.323 (2.9); 7.310 (2.7); 7.300 (13.2); 7.286 (3.8) 7.280 (3.9) 7.263 (5.1) 7.256 (4.5): 7.237 (3.8); 7.231 (2.9); 7.185 (4.7) ; 7.182 (5.4); 7.161 (5.7); 7.157 (7.2) 7.151 (4.7) 7.136 (2.5) 7.132 (2.8): 7.124 (3.7); 7.118 (5.0); 7.090 (3.0) ; 7.087 (2.6); 5.096 (0.4); 4.889 (0.4): 4.461 (0.7) 4.413 (0.7) 4.314 (5.5): 4.266 (9.3); 4.134 (9.8); 4.086 (5.9) ; 3.154 (4.6); 3.150 (4.5); 3.107 (5.9) 3.104 (5.9) 2.823 (5.8): 2.819 (5.8) 2.776 (4.4); 2.773 (4.4); 2.392 (8.0); 2.079 (0.4); 2.042 (13.0); 1.724 (11.6) 1.622 (3.2) 1.601 (3.4) 1.574 (4.2): 1.553 (4.4); 1.326 (0.8); 1.293 (0.3) 1.275 (4.3); 1.251 (4.8); 1.227 (3.3) 1.203 (3.7) 0.881 (0.6) 0.873 (0.8): 0.855 (1.8); 0.845 (1.4); 0.835 (2.1) ; 0.830 (2.2); 0.820 (1.4); 0.81 1 (2.0) 0.792 (1.0) 0.785 (0.9) 0.768 (0.4) 0.670 (0.4); 0.653 (2.7); 0.636 (7.8) 0.625 (4.4); 0.614 (6.8); 0.597 (2.5) 0.161 (0.3): 0.140 (3.1) 0.126 (7.7): 0.122 (6.7); 0.110 (8.3); 0.095 (2.4) 0.079 (0.4); 0.074 (0.5); 0.044 (0.5) 0.034 (8.8) 0.023 (0.4)
|Example 1-142: "H-NMR (300.2 MHz, CDCI3): δ= 7.885 (8.5); 7.658 (7.7); 7.300 (2.6); 7.238 (1.5); 7.214 (3.7); 7.197 (3.8); 7.175 (2.2); 7.109 (3.7); 7.084 (4.4):
7.059 (1.7) 4.737 (4.8); 4.689 (5.7); 4.195 (5.3); 4.146 (4.5); 3.329 (0.4); 3.281 (11.9); 3.233 (0.3); 2.539 (1.1):
2.528 (1.4) 2.514 (2.5); 2.502 (1.2); 2.488 (1.7); 2.325 (16.0); 2.319 (16.0); 2.036 (2.7); 0.766 (1.1); 0.753 (1.1): 0.747 (2.3) 0.724 (2.5); 0.720 (2.4); 0.716 (2.6); 0.694 (2.3); 0.688 (2.6); 0.676 (2.6); 0.665 (4.4); 0.660 (3.5): 0.646 (2.8) 0.638 (4.7); 0.629 (2.7); 0.619 (1.4); 0.61 1 (1.8); 0.585 (0.5); 0.559 (2.1); 0.556 (2.2); 0.550 (2.2):
0.528 (3.0); 0.519 (1.3); 0.507 (1.4); 0.478 (0.3); 0.030 (2.3)
jExample 1-143: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.732 (7.7); 7.729 (8.0); 7.300 (1.2); 7.265 (1.4); 7.240 (2.8); 7.221 (1.6); 7.216 (1.6); 7.175 (1.2); 7.153 (2.7):
7.128 (1.8) 7.063 (3.8); 7.038 (5.2); 7.013 (2.0); 6.933 (7.9); 6.930 (8.1); 5.318 (0.9); 4.460 (4.2); 4.41 1 (6.7): 4.262 (6.4) 4.213 (4.0); 3.300 (2.2); 3.296 (2.3); 3.253 (3.9); 3.249 (4.0); 3.136 (4.2); 3.091 (2.3); 3.088 (2.3): 2.887 (2.6) 2.865 (2.6); 2.301 (15.6); 2.294 (16.0); 2.066 (1.3); 1.307 (0.7); 1.292 (1.2); 1.283 (1.6); 1.259 (0.4): 0.930 (0.4) 0.909 (1.3); 0.885 (0.5); 0.807 (0.9); 0.792 (1.5); 0.780 (2.3); 0.767 (3.1); 0.760 (3.4); 0.745 (12.9): 0.735 (5.4) 0.713 (3.0); 0.707 (4.7); 0.697 (2.7); 0.689 (2.4); 0.682 (1.5); 0.668 (1.6); 0.651 (0.9); 0.634 (0.4): 0.028 (1.0) |Example 1-144: 'H-NMR (300.2 MHz, CDCls): δ= 7.759 (4.9); 7.655 (4.5); 7.300 (2.1); 7.199 (0.3); 7.176 (0.8); 7.172 (1.0); 7.153 (0.8); 7.146 (1.2); 7.139 (0.8):
7.131 (0.9); 7.122 (0.8) 7.114 (1.6); 7.106 (1.1); 7.103 (1.1); 7.089 (1.2); 7.079 (0.6); 7.076 (0.6); 7.060 (0.6): 7.030 (0.8); 7.025 (1.2) 7.010 (0.9); 7.005 (1.4); 7.000 (1.4); 6.987 (0.5); 6.980 (0.7); 6.975 (0.4); 4.441 (2.4): 4.393 (3.3); 4.167 (3.2) 4.119 (2.3); 3.246 (1.4); 3.241 (1.4); 3.199 (2.0); 3.194 (2.0); 2.983 (2.1); 2.978 (2.1): 2.936 (1.5); 2.931 (1.5); 1.853 (1.1); 1.846 (1.1); 1.369 (16.0); 0.270 (0.4); 0.243 (5.9); 0.220 (0.6); 0.203 (0.4):
0.124 (0.8); 0.089 (3.1); 0.061 (2.6); 0.030 (2.2)
(Example 1-145: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.897 (8.2); 7.683 (8.5); 7.453 (1.4); 7.448 (1.5); 7.426 (2.6); 7.423 (2.7); 7.402 (1.7); 7.397 (1.9); 7.376 (1.4):
7.371 (1.4); 7.350 (3.0); 7.329 (2.0); 7.323 (1.6); 7.300 (7.0); 7.180 (2.7); 7.177 (2.4) 7.154 (4.0) 7.128 (1.7): 7.125 (1.5); 4.753 (4.7); 4.704 (5.6); 4.241 (5.5); 4.192 (4.7); 4.165 (0.7); 4.141 (0.7) 3.406 (1.7) 3.401 (1.7): 3.359 (3.7); 3.354 (3.7); 3.280 (3.8); 3.275 (3.8); 3.232 (1.8); 3.227 (1.8); 2.353 (2.4) 2.333 (2.8) 2.078 (3.2): 2.043 (16.0); 1.739 (0.7); 1.316 (0.9); 1.292 (1.7); 1.269 (0.8); 0.782 (0.7); 0.773 (0.8) 0.765 (1.0) 0.762 (0.8): 0.747 (2.0); 0.731 (2.3); 0.721 (2.7); 0.711 (2.8); 0.702 (2.6); 0.698 (2.6); 0.689 (1.4) 0.675 (1.2): 0.663 (1.1): 0.654 (2.1); 0.648 (0.5); 0.638 (2.3); 0.628 (1.2); 0.609 (2.2); 0.601 (0.6); 0.593 (2.8); 0.589 (2.6); 0.580 (2.5):
0.563 (2.6); 0.554 (2.3); 0.541 (1.9); 0.530 (1.5); 0.519 (0.9); 0.511 (0.9); 0.502 (0.8); 0.033 (6.5)
jExample 1-146: 1 H-NMR (300.2 MHz, CDCI3) δ= 7.894 (13.3); 7.668 (16.0); 7.298 (7.4); 7.237 (1.0); 7.230 (1.3); 7.225 (1.3); 7.214 (2.6) 7.205 (4.7) 7.194
(6.9) 7.177 (9.3); 7.170 (9.4); 7.153 (8.2); 7.145 (3.5); 7.131 (2.6); 7.125 (1.5); 7.118 (0.9). 7.102 (0.7) 4.755 (8.5) 4.706 (10.1); 4.231 (9.6); 4.182 (8.1); 3.409 (3.0); 3.404 (3.0); 3.361 (6.6); 3.357 (6.7) 3.289 (7.2): 3.285 (7.3) 3.242 (3.2); 3.237 (3.3); 2.424 (3.7); 2.038 (9.5); 0.778 (2.3); 0.769 (1.7); 0.757 (5.0) 0.735 (3.9) 0.725 (6.1) 0.712 (4.2); 0.700 (4.0); 0.695 (4.6); 0.682 (4.3); 0.669 (1.2); 0.660 (6.1); 0.648 (5.4) 0.625 (4.3) 0.612 (4.3) 0.607 (4.0); 0.595 (3.2); 0.563 (5.1); 0.552 (4.1); 0.530 (5.5); 0.518 (2.0); 0.508 (2.5) 0.476 (0.4) 0.029 (7.2)
|Example 1-147: H-NMR (300.2 MHz, CDCb) δ= 7.752 (15.2); 7.461 (0.7); 7.367 (1.0); 7.348 (0.5); 7.339 (0.4); 7.321 (0.5); 7.300 (14.9); 7.234 (3.0): 7.209
(7.0) 7.184 (5.1): 7.181 (5.2); 7.157 (4.7); 7.148 (6.2); 7.141 (8.2); 7.127 (6.1); 7.122 (9.1); 7.118 (6.8): 7.099 (3.8) 7.097 (3.8): 7.086 (1.8); 7.069 (1.5); 7.036 (0.6); 7.020 (1.0); 6.979 (15.9); 6.935 (0.6); 6.910 (0.4) 6.782 (0.6) 5.319 (2.3): 5.058 (0.4); 4.828 (0.4); 4.761 (0.3); 4.712 (0.7); 4.645 (0.7); 4.488 (9.2); 4.439 (15.7) 4.393 (0.4) 4.355 (0.4): 4.312 (15.1); 4.263 (8.8); 3.526 (0.6); 3.503 (0.4); 3.480 (0.4); 3.402 (5.7); 3.398 (5.7) 3.355 (8.0) 3.350 (8.0): 3.132 (8.5); 3.127 (8.4); 3.084 (6.0) 3.080 (6.0) 2.419 (3.4); 1.842 (0.6); 1.824 (1.3) 1.812 (1.7) 1.796 (1.8): 1.785 (1.8); 1.575 (0.4); 1.560 (0.9) 1.548 (0.8) 1.331 (0.4); 1.290 (1.4); 1.267 (0.7) 1.244 (1.0) 1.220 (0.5): 1.133 (2.6); 0.940 (0.5); 0.917 (1.2) 0.894 (0.6) 0.863 (1.0); 0.846 (2.7); 0.826 (3.2) 0.823 (3.3): 0.811 (8.1); 0.801 (6.0); 0.793 (7.0); 0.782 (12.0) 0.778 (9.6): 0.761 (16.0); 0.742 (7.3); 0.727 (4.3) 0.706 (3.2) 0.698 (4.9); 0.679 (4.9); 0.674 (3.5); 0.669 (5.1) 0.662 (4.9) 0.656 (3.7); 0.637 (3.2); 0.620 (1.7) 0.035 (12.0)
|Example 1-148: 1 H-NMR (300.2 MHz, CDCI3) δ= 7.801 (15.8); 7.659 (16.0); 7.657 (15.8); 7.298 (18.4); 7.186 (1.0); 7.180 (1.1); 7.159 (2.6); 7.153 (3.1) 7.148
(1.5) 7.135 (2.8); 7.127 (4.3); 7.120 (5.1); 7.103 (5.7); 7.097 (6.1); 7.078 (4.2); 7.070 (1.7); 7.066 (1.9) 7.050 (1.8) 7.016 (2.4); 7.011 (3.5); 6.991 (3.7); 6.986 (4.4); 6.974 (1.5); 6.966 (2.0); 4.168 (0.5); 4.144 (0.6) 4.125 (5.4): 4.077 (11.5); 3.997 (11.5); 3.949 (5.5); 2.995 (4.7); 2.990 (4.8); 2.949 (6.3); 2.943 (6.5); 2.702 (6.4) 2.697 (7.0) 2.667 (2.8); 2.656 (5.7); 2.650 (5.8); 2.641 (3.1); 2.619 (1.4); 2.610 (2.3); 2.581 (0.8); 2.147 (3.6): 2.138 (3.8): 2.080 (2.3); 1.935 (0.6); 1.907 (1.9); 1.884 (9.6); 1.874 (10.0); 1.869 (9.1); 1.859 (12.9); 1.834 (4.5) 1.804 (3.3) 1.776 (1.5); 1.731 (1.2); 1.721 (1.6); 1.709 (1.8); 1.689 (3.1); 1.673 (5.9); 1.665 (5.6); 1.660 (3.8) 1.645 (1.7) 1.633 (2.1); 1.618 (2.7); 1.612 (2.8); 1.593 (2.4); 1.587 (2.4); 1.555 (1.0); 1.538 (0.5); 1.452 (0.6) 1.439 (1.2) 1.327 (2.3); 1.318 (2.8); 1.294 (8.1); 1.270 (2.4); 1.208 (0.7); 1.097 (0.7); 1.068 (0.7); 1.012 (0.4) 0.937 (1.8) 0.916 (5.1); 0.889 (5.5); 0.863 (5.1); 0.299 (0.3); 0.121 (1.4); 0.117 (3.3); 0.105 (85.0); 0.092 (3.4); 0.080
(0.9); 0.045 (0.7); 0.034 (17.3); 0.024 (0.8); -0.094 (0.3)
jExample 1-149: 1 H-NMR (300.2 MHz, CDCI3) δ= 7.821 (5.2); 7.685 (5.6); 7.682 (5.7); 7.298 (22.5); 7.203 (0.3); 7.197 (0.4); 7.175 (0.9); 7.169 (1.1): 7.164
(0.5) 7.152 (1.0): 7.144 (1.5) 7.137 (1.8); 7.121 (1.3); 7.118 (1.9); 7.113 (2.2); 7.109 (1.5); 7.095 (1.3) 7.092
(1.4) 7.085 (0.6): 7.081 (0.6) 7.065 (0.6); 7.016 (1.2); 6.997 (1.3); 6.991 (1.5); 6.979 (0.5); 6.972 (0.7) 4.327 (2.5) 4.279 (3.4): 4.035 (3.3) 3.987 (2.4); 3.120 (1.6); 3.115 (1.7); 3.073 (2.0); 3.068 (2.1); 2.727 (2.0) 2.722 (2.1) 2.680 (1.6); 2.675 (1.7); 1.897 (3.4); 1.890 (3.5); 1.757 (0.4); 1.735 (1.2); 1.712 (1.7); 1.689 (1.4); 1.666
(0.6); 1.602 (16.0); 1.147 (11.2); 1.132 (12.6); 1.125 (11.4); 1.109 (10.9); 0.048 (0.8); 0.037 (23.6); 0.026 (0.9) |Example 1-150: 'H-NMR (300.2 MHz, de-DMSO): δ= 8.024 (1.7); 8.022 (1.6); 7.853 (1.8); 7.850 (1.7); 7.708 (0.5); 7.327 (0.4); 7.300 (0.3); 7.292 (0.4); 7.265 (0.4): 7.258 (0.5); 7.254 (0.5); 7.234 (0.4); 7.171 (0.4); 7.166 (0.4); 7.162 (0.4); 7.145 (0.4); 4.783 (2.5); 4.288 (0.6): 4.240 (0.9); 4.092 (0.9); 4.044 (0.6); 3.349 (4.5); 3.103 (0.5); 3.058 (0.6); 2.728 (0.6); 2.683 (0.4); 2.537 (0.4): 2.531 (0.8); 2.525 (1.1); 2.519 (0.8); 2.513 (0.4); 2.098 (0.4); 1.482 (0.4); 1.432 (1.0); 1.374 (1.0); 1.325 (0.4): 0.973 (16.0); 0.787 (1.4); 0.021 (0.6)
|Example 1-151 : 'H-NMR (300.2 MHz, CDCb) δ= 7.837 (3.9); 7.691 (4.3); 7.688 (4.1); 7.300 (8.6); 7.169 (0.6); 7.163 (0.8); 7.157 (0.4); 7.146 (0.7); 7.138 (1.1):
7.130 (1.3); 7.114 (1.4); 7.107 (1.6); 7.090 (1.2); 7.081 (0.5); 7.078 (0.6); 7.062 (0.6) 7.050 (0.7) 7.045 (0.9): 7.026 (0.9); 7.020 (1.0); 7.008 (0.4); 7.001 (0.4); 4.317 (1.4); 4.269 (2.5); 4.151 (2.8) 4.103 (1.6) 3.181 (1.2): 3.175 (1.2); 3.134 (1.6); 3.129 (1.6); 2.825 (1.5); 2.820 (1.5); 2.779 (1.2); 2.773 (1.2), 2.284 (3.5) 2.047 (1.0): 1.641 (16.0); 1.632 (1.1); 1.61 1 (1.0); 1.583 (1.2); 1.563 (1.2); 1.292 (1.2); 1.268 (1.3): 1.244 (0.9) 1.220 (1.0): 10.837 (0.5); 0.828 (0.4); 0.812 (0.6); 0.803 (0.4); 0.792 (0.5); 0.671 (0.9); 0.654 (2.2); 0.645 (1.0); 0.640 (1.2):
0.631 (1.9); 0.626 (1.5); 0.614 (0.7); 0.152 (0.8); 0.136 (2.2); 0.121 (2.4); 0.106 (0.6); 0.036 (6.3)
Example 1-152: 1 H-NMR (300.2 MHz, CDCb) δ= 8.204 (8.7); 8.188 (9.1); 7.886 (16.0); 7.689 (0.6); 7.668 (14.8); 7.464 (5.4); 7.448 (10.4); 7.431 (5.2): 7.300 (5.1); 4.745 (7.6); 4.696 (9.4); 4.324 (9.6); 4.275 (7.9); 3.477 (4.9); 3.430 (7.2); 3.409 (0.3); 3.283 (1.9): 3.249 (7.9); 3.202 (4.9); 2.136 (0.7); 2.039 (15.8); 1.017 (0.4); 0.767 (1.1); 0.763 (1.2); 0.754 (1.2); 0.741 (3.5) 0.719 (4.8); 0.712 (7.5); 0.704 (6.5); 0.686 (3.6); 0.659 (3.9); 0.646 (4.4); 0.613 (3.0); 0.605 (3.9); 0.601 (3.8) 0.595 (3.1); 0.585 (1.1); 0.557 (1.5); 0.549 (3.4); 0.542 (3.4); 0.525 (3.9); 0.507 (1.8); 0.499 (1.8); 0.493 (1.6) 0.021 (4.0)
[Example 1-153: 1 H-NMR (300.2 MHz, CDCI3): δ= 7.878 (4.4); 7.677 (4.3); 7.345 (0.8); 7.326 (1.0); 7.317 (1.3); 7.300 (3.4); 6.983 (2.8): 6.954 (3.1); 6.931 (0.8):
6.922 (0.4); 4.680 (2.4): 4.631 (3.0); 4.310 (2.9); 4.262 (2.2); 4.164 (0.5); 4.140 (0.6); 3.480 (2.2); 3.433 (2.6): 3.012 (2.8); 2.964 (2.4): 2.313 (16.0); 2.077 (2.5); 1.849 (0.8); 1.835 (1.0); 1.813 (0.4); 1.719 (0.4); 1.316 (0.7): 1.292 (1.4); 1.268 (0.7): 0.927 (0.7); 0.918 (0.8); 0.914 (0.8); 0.905 (0.6); 0.889 (0.9); 0.884 (1.2); 0.878 (1.3): 0.873 (1.1); 0.772 (0.7): 0.763 (1.1); 0.759 (1.2); 0.750 (1.0); 0.734 (0.5); 0.729 (0.6); 0.723 (0.8); 0.717 (0.8): 0.647 (1.0); 0.611 (3.3); 0.603 (3.8); 0.596 (2.3); 0.591 (2.8); 0.556 (0.4); 0.033 (2.8)
jExample 1-154: 1 H-NMR (300.2 MHz, CDCb)
5= 7.881 (12.7); 7.671 (13.0); 7.553 (4.4); 7.533 (4.6); 7.524 (5.2); 7.504 (4.8); 7.300 (4.6); 7.224 (4.6) 7.215 (5.2); 7.196 (4.6); 7.188 (5.1); 7.097 (3.0); 7.089 (2.7); 7.071 (3.9); 7.069 (4.0); 7.062 (3.6); 7.061 (3.5) 7.043 (2.7); 7.034 (2.3); 4.741 (7.7); 4.692 (9.3); 4.242 (9.1); 4.193 (7.6); 3.456 (1.2); 3.408 (14.2); 3.401 (15.3) 3.352 (1.2); 2.504 (16.0); 2.037 (1.5); 1.835 (0.9); 0.859 (0.4); 0.829 (1.5); 0.824 (1.9); 0.816 (2.0); 0.806 (3.2): 0.803 (3.1); 0.793 (1.1); 0.782 (3.5); 0.770 (4.7); 0.739 (3.1); 0.727 (3.2); 0.721 (4.0); 0.706 (4.1); 0.683 (4.8) 0.674 (4.7); 0.670 (3.2); 0.659 (1.6); 0.649 (3.9); 0.635 (4.2); 0.630 (3.7); 0.617 (3.5); 0.595 (4.9); 0.583 (3.5) 0.563 (4.5); 0.549 (1.9); 0.540 (1.9); 0.537 (1.7); 0.506 (0.3); 0.029 (3.8)
Example 1-155: 1 H-NMR (300.2 MHz, CDCb)
5= 7.759 (4.0); 7.757 (3.9); 7.362 (1.0); 7.354 (0.5); 7.342 (1.4); 7.331 (1.5); 7.312 (1.4); 7.300 (10.8): 7.007
(4.4); 7.004 (4.2); 6.960 (2.8); 6.930 (2.5); 6.921 (1.3); 6.910 (1.0); 6.900 (0.4); 5.338 (6.6); 4.363 (11.2): 3.427 (2.4); 3.380 (2.8); 2.896 (3.1); 2.848 (2.6); 2.238 (16.0); 2.083 (0.8); 1.653 (0.6); 1.592 (2.3); 1.297 (0.9) 1.292 (0.8); 0.960 (0.4); 0.937 (0.5); 0.927 (1.1); 0.920 (0.8); 0.900 (4.1); 0.894 (2.7); 0.884 (1.7); 0.875 (2.4) 0.868 (0.9); 0.858 (1.1); 0.852 (0.9); 0.842 (1.3); 0.834 (1.9); 0.817 (1.1); 0.810 (1.3); 0.794 (0.7); 0.686 (1.2) 0.673 (1.3); 0.660 (0.9); 0.653 (1.1); 0.649 (0.8); 0.638 (1.0); 0.632 (1.0); 0.629 (0.7); 0.049 (0.4); 0.038 (10.2); 0.027] (0.5)
|Example 1-156: 1 H-NMR (300.2 MHz, CDCb)
6= 7.880 (16.0); 7.701 (0.4); 7.677 (14.3); 7.300 (5.3); 6.980 (0.6): 6.973 (1.3); 6.957 (6.1) 6.950 (8.5): 6.930
(8.1) 6.923 (6.8); 6.908 (1.4) 6.900 (0.7) 6.848 (1.7) 6.841 (2.5) 6.833 (1.3) 6.818 (3.4) 6.81 1 (4.9) 6.803 (2.3) 6.789 (1.8); 6.781 (2.5) 6.774 (1.2) 4.656 (7.2) 4.607 (9.8) 4.355 (9.7) 4.306 (7.2) 3.533 (6.4) 3.487 (7.3) 2.828 (8.1); 2.782 (7.1) 2.733 (0.7) 2.041 (3.0) 1.990 (0.4) 1.961 (0.4) 0.777 (0.9) 0.762 (1.0) 0.757 (1.1) 0.743 (2.4); 0.727 (4.1) 0.714 (7.5) 0.704 (5.4) 0.684 (3.2) 0.669 (1.4) 0.650 (1.6) 0.604 (0.8) 0.570 (1.9) 0.560 (2.1); 0.554 (1.9) 0.541 (4.0) 0.524 (4.2) 0.519 (4.1) 0.504 (3.3) 0.464 (3.2) 0.449 (3.7) 0.429 (2.6): 0.422 (1.8); 0.413 (2.2); 0.400 (1.3); 0.029 (4.8)
jExample 1-157: 1 H-NMR (300.2 MHz, CDCb) δ= 7.878 (15.2); 7.681 (16.0); 7.345 (6.9); 7.338 (3.3); 7.327 (7.9); 7.316 (9.4); 7.299 (13.4); 7.129 (1.3): 7.120 (9.2); 7.1 13 (3.0); 7.091 (16.0); 7.069 (2.8); 7.062 (7.1); 7.052 (0.9); 4.659 (7.9) 4.645 (0.5); 4.61 1 (10.6) 4.343 (10.7); 4.295 (8.1); 3.557 (7.9); 3.510 (8.8); 2.788 (8.7); 2.741 (7.8); 2.209 (9.6) ; 2.039 (2.8); 1.285 (1.0) 0.763
(1.4) ; 0.746 (1.1); 0.740 (1.5); 0.727 (3.6); 0.71 1 (4.8); 0.705 (5.9); 0.697 (1 1.9) 0.689 (6.5); 0.668 (4.5) 0.654
(1.5) ; 0.650 (1.4); 0.633 (2.2); 0.578 (0.9); 0.543 (2.2); 0.535 (2.7); 0.529 (2.5); 0.516 (4.1); 0.499 (3.8) 0.494 (3.8); 0.477 (2.9); 0.378 (3.5); 0.361 (4.1); 0.357 (3.9); 0.340 (3.2); 0.334 (2.3); 0.325 (3.1); 0.322 (2.9) 0.313 (1.8); 0.279 (0.4); 0.031 (5.4) |Example 1-158: 'H-NMR (300.2 MHz, de-DMSO)
5= 7.757 (12.7); 7.421 (6.1); 7.402 (8.3); 7.393 (8.9); 7.374 (7.3); 7.312 (0.6); 7.296 (0.6); 7.286 (0.6); 7.274] (0.7); 7.245 (0.7); 7.148 (7.6); 7.118 (12.4); 7.089 (6.0); 6.986 (11.9); 5.298 (16.0); 5.254 (0.6); 5.215 (0.4): 4.388 (5.2); 4.339 (8.3); 4.194 (8.2); 4.145 (5.3); 3.930 (0.4); 3.346 (27.3); 3.196 (5.6); 3.150 (6.8); 2.913 (1.9): 2.882 (0.6); 2.868 (0.6); 2.853 (0.3); 2.781 (6.5); 2.754 (2.4); 2.734 (5.3); 2.525 (20.5); 0.617 (2.1); 0.575 (5.7): 0.564 (5.3); 0.556 (5.8); 0.543 (5.2); 0.522 (4.6); 0.505 (4.2); 0.484 (3.7); 0.472 (3.1); 0.459 (4.1); 0.444 (3.5): 0.431 (4.0); 0.417 (2.3); 0.401 (1.9); 0.382 (1.0); 0.062 (0.3); 0.023 (20.6)
Example 1-159: ! H-NMR (499.9 MHz, CDC13)
5= 7.838 (1.2); 7.799 (5.3); 7.655 (1.5); 7.635 (5.8); 7.622 (2.8); 7.606 (2.6); 7.467 (0.3); 7.260 (52.3): 7.215
(3.2); 7.204 (3.9); 7.198 (4.3); 7.187 (3.8); 7.143 (0.8); 7.132 (1.0); 7.126 (1.2); 7.114 (1.7); 7.102 (1.6) 7.096 (1.9); 7.085 (1.7); 7.070 (3.9); 7.053 (6.7); 7.036 (3.5); 7.015 (3.3); 6.998 (3.5); 6.980 (1.3); 5.299 (0.7) 4.742 (5.7); 4.478 (4.5); 4.460 (3.7); 4.431 (4.3); 4.180 (0.7); 4.173 (0.4); 4.152 (1.1); 4.141 (4.0); 4.112 (3.4) 4.022 (1.0); 3.994 (0.7); 3.656 (0.7); 3.164 (3.4); 3.135 (3.9); 2.963 (0.9); 2.945 (2.1); 2.928 (2.1); 2.91 1 (1.2) 2.875 (0.8); 2.847 (0.9); 2.745 (3.8); 2.717 (3.4); 2.555 (1.4); 2.538 (1.7); 2.530 (1.1); 2.526 (1.1); 2.513 (1.8): 2.494 (1.0); 2.392 (0.7); 2.374 (1.6); 2.367 (1.0); 2.354 (1.2); 2.348 (1.9); 2.330 (1.3); 2.300 (0.6); 2.279 (4.6) 2.264 (2.0); 2.242 (1.9); 2.224 (1.2); 2.205 (0.5); 2.106 (0.6); 2.089 (1.5); 2.074 (2.2); 2.058 (1.5); 2.042 (0.6) 2.006 (0.3); 1.975 (0.5); 1.958 (1.2); 1.950 (1.1); 1.941 (1.6); 1.932 (1.4); 1.925 (1.5); 1.916 (1.1); 1.908 (0.8) 1.811 (0.9); 1.801 (1.0); 1.794 (1.3); 1.786 (1.4); 1.776 (1.2); 1.769 (1.1); 1.759 (1.0); 1.751 (0.7); 1.742 (0.7): 1.733 (0.6); 1.717 (0.5); 1.703 (0.9); 1.697 (0.7); 1.685 (1.9); 1.681 (1.6); 1.663 (2.3): 1.657 (2.0); 1.645 (1.6) 1.626 (1.0); 1.569 (6.6); 1.493 (1.0); 1.481 (0.9); 1.474 (0.9); 1.333 (0.5); 1.255 (16.0) 1.158 (0.7); 1.146 (0.7) 1.103
(0.6); 0.894 (1.1); 0.880 (1.6); 0.867 (0.9); 0.859 (0.5); 0.841 (0.6); 0.831 (0.6); 0.730 (0.3); 0.715 (0.5); 0.000| (51.3)
[Example 1-160: 1 H-NMR (400.1 MHz, de-DMSO)
5= 7.920 (13.7); 7.771 (14.5); 7.311 (5.8); 7.297 (7.3); 7.290 (8.0); 7.275 (6.6); 7.122 (7.4); 7.100 (12.3); 7.078) (5.8); 5.006 (16.0); 3.978 (3.5); 3.942 (9.0); 3.905 (9.5); 3.869 (3.7); 3.323 (1 18.5); 2.712 (3.9); 2.677 (8.0): 2.618 (7.7); 2.584 (4.2); 2.512 (52.4); 2.507 (66.9); 2.503 (47.9); 2.436 (0.6); 2.414 (1.7); 2.395 (2.4); 2.372 (1.8); 2.350 (0.7); 2.334 (0.5); 2.006 (1.6); 1.984 (2.6); 1.961 (1.2); 1.949 (0.9); 1.748 (0.5); 1.726 (1.7); 1.703 (3.0); 1.687 (3.6); 1.680 (3.9); 1.671 (4.6); 1.654 (4.6); 1.639 (3.8); 1.619 (1.6); 1.558 (0.5); 1.536 (1.4); 1.515 (2.4); 1.497 (1.8); 1.475 (0.6); 1.350 (0.7); 1.336 (1.3); 1.324 (2.1); 1.311 (1.9); 1.298 (1.8); 1.280 (0.5)
|Example 1-161 : 'H-NMR (499.9 MHz, CDCI3)
5= 7.829 (12.7); 7.647 (12.8); 7.261 (15.7); 7.223 (0.7); 7.144 (7.9); 7.128 (11.0); 7.1 17 (8.6); 7.030 (8.6): 7.013 (12.8); 6.996 (5.9); 6.969 (0.8); 4.178 (6.1); 4.149 (8.3); 4.129 (0.8); 4.114 (0.6); 4.100 (0.4); 4.020 (7.9): 3.992 (5.5); 2.976 (0.7); 2.963 (0.7); 2.875 (6.4); 2.847 (7.2); 2.554 (7.4); 2.526 (6.1); 2.043 (1.4); 1.992 (1.8) 1.975 (3.8); 1.958 (5.5); 1.940 (4.2); 1.923 (1.7); 1.878 (0.7); 1.756 (7.7); 1.742 (8.2); 1.704 (16.0); 1.671 (6.6): 1.657 (7.1); 1.647 (6.9); 1.633 (5.6); 1.615 (5.6); 1.581 (27.9); 1.480 (6.4); 1.474 (6.5); 1.272 (1.0); 1.258 (2.0): 0.882 (0.4); 0.000 (14.9)
jExample 1-162: 'H-NMR (400.1 MHz, de-DMSO):
5= 7.948 (6.6); 7.809 (6.9); 7.808 (6.9); 7.335 (2.9); 7.330 (1.5); 7.321 (3.6); 7.314 (3.9); 7.305 (1.7); 7.299 (3.3): 7.101 (3.7); 7.079 (6.2); 7.062 (1.3); 7.057 (3.0); 4.806 (9.3); 4.222 (2.8); 4.186 (3.6); 3.941 (3.7); 3.905 (3.0): 3.323 (54.8); 2.843 (2.5); 2.809 (3.1); 2.554 (3.3); 2.516 (13.3); 2.512 (23.1); 2.507 (29.9); 2.503 (21.7); 2.499) (10.8); 2.079 (0.5); 1.994 (0.4); 1.525 (0.5); 1.508 (1.3); 1.491 (1.9); 1.473 (1.5); 1.456 (0.6); 0.946 (16.0); 0.929| (14.8)
jExample 1-163: 'H-NMR (300.2 MHz, de-DMSO): 5= 8.552 (2.6); 8.546 (2.6); 8.400 (1.7); 8.384 (1.7); 8.005 (3.5); 8.003 (3.4) 7.871 (3.6); 7.868 (3.3); 7.610 (1.0):
7.593 (1.2) 7.589 (1.2) 7.572 (1.0); 5.786 (16.0); 5.693 (3.7); 4.630 (1.4): 4.581 (1.8); 4.226 (1.8); 4.177 (1.5): 3.355 (7.3) 3.265 (0.8) 3.218 (1.9); 3.162 (1.8); 3.116 (0.9); 2.540 (1.7); 2.534 (3.6); 2.528 (4.9); 2.522 (3.6): 2.516 (1.7) 2.015 (0.4) 1.081 (0.4); 0.750 (0.5); 0.745 (0.5); 0.731 (0.6); 0.726 (0.6); 0.714 (0.6); 0.709 (0.6): 0.692 (0.6) 0.655 (0.4) 0.630 (0.6); 0.620 (0.7); 0.613 (0.4); 0.596 (0.9); 0.579 (0.8); 0.560 (0.7); 0.544 (0.8): 0.538 (0.7) 0.520 (0.8); 0.510 (0.6); 0.486 (0.4); 0.477 (0.7); 0.460 (0.6); 0.454 (0.7); 0.442 (0.7); 0.425 (0.5):
0.418 (0.5); 0.026 (5.8)
jExample 1-164: 'H-NMR (300.2 MHz, CDCI3)
5= 8.203 (8.1); 8.186 (8.3); 7.680 (10.6); 7.646 (0.5); 7.300 (62.7); 7.284 (3.8); 7.280 (4.9); 7.056 (9.5); 6.949j (0.8); 6.929 (11.4); 4.527 (7.3); 4.478 (11.9); 4.340 (11.3); 4.290 (7.0); 3.548 (7.9); 3.503 (1 1.0); 2.784 (8.0): 2.739 (7.2); 1.638 (15.4); 1.592 (1.6); 1.291 (16.0); 1.186 (0.4); 1.166 (0.4); 1.139 (0.5); 0.918 (1.1); 0.894 (4.5): 0.889 (4.5); 0.862 (10.9); 0.832 (8.8); 0.775 (0.4); 0.742 (3.2); 0.722 (4.1); 0.718 (3.3); 0.707 (1.9); 0.693 (4.2): 0.683 (1.7); 0.663 (2.0); 0.608 (3.2); 0.588 (2.9); 0.580 (3.6); 0.575 (2.8); 0.557 (3.9); 0.547 (2.4); 0.527 (1.6): 0.048 (1.5); 0.037 (42.1); 0.026 (1.6) |Example 1-165: 'H-NMR (300.2 MHz, CDCls): δ= 8.268 (8.9); 7.884 (9.2); 7.691 (8.7); 7.300 (5.0); 7.226 (6.2); 7.218 (6.2); 4.766 (5.1); , 4.717 (6.2); 4.291 (5.2):
4.243 (4.3); 4.158 (0.4): 4.134 (0.4); 3.526 (2.8); 3.479 (6.8); 3.421 (6.0); 3.374 (2.4); 2.773 (1.1); 2.762 (1.6): 2.722 (1.9); 2.074 (1.8): 2.042 (16.0); 1.313 (0.5); 1.289 (0.9); 1.265 (0.5); 0.892 (0.9); 0.882 (1.3); 0.875 (1.4): 0.863 (2.2); 0.858 (2.1): 0.840 (2.3); 0.825 (2.9); 0.795 (2.0); 0.779 (2.3); 0.775 (2.7); 0.759 (2.7); 0.740 (1.8): 0.731 (2.9); 0.721 (2.4); 0.714 (1.4); 0.710 (1.3); 0.691 (2.0); 0.674 (2.5); 0.658 (1.3); 0.655 (1.3); 0.612 (2.7): 0.597 (2.2); 0.582 (1.7); 0.574 (2.2); 0.562 (1.4); 0.555 (1.4); 0.545 (0.9); 0.029 (4.8)
[Example 1-166: 1 H-NMR (300.2 MHz, CDCI3) δ= 7.916 (6.8); 7.894 (16.0); 7.683 (12.5); 7.558 (4.8); 7.553 (5.2); 7.533 (7.2); 7.528 (7.4); 7.438 (3.9): 7.413 (6.7); 7.388 (3.2); 7.300 (9.4); 7.081 (3.4); 7.076 (3.0) 7.055 (5.6); 7.030 (2.9); 7.025 (2.4); 4.742 (8.3) 4.694 (10.2); 4.295 (8.2); 4.247 (6.7); 3.634 (5.6); 3.586 (8.4): 3.408 (12.1); 3.360 (8.1); 2.289 (7.1); 2.260 (1.5) 2.219 (0.8); 2.041 (2.7); 1.736 (0.5); 1.289 (0.8); 0.924 (0.7) 0.894 (2.9); 0.883 (2.4); 0.875 (4.3); 0.870 (3.0) 0.852 (3.7); 0.847 (2.9); 0.840 (3.9); 0.812 (0.8); 0.777 (2.4) 0.767 (2.5); 0.757 (3.7); 0.746 (8.5); 0.738 (5.1) 0.726 (5.2); 0.720 (9.7); 0.707 (4.7); 0.699 (3.2); 0.686 (4.0) 0.654 (3.6); 0.647 (4.1); 0.620 (4.7); 0.613 (2.4) 0.600 (2.4); 0.584 (0.3); 0.572 (0.6); 0.106 (1.4); 0.034 (6.8)
[Example 1-167: 'H-NMR (300.2 MHz, CDCI3): δ= 7.892 (3.7); 7.889 (3.6); 7.866 (3.9); 7.862 (3.8); 7.778 (5.3); 7.631 (0.5): ; 7.593 (3.1) 7.588 (3.3); 7.568 (4.0):
7.563 (3.8) 7.51 1 (0.4): 7.484 (0.4); 7.413 (2.2); 7.410 (2.2); 7.388 (4.0); 7.385 (3.9) 7.363 (2.1): 7.359 (2.0): 7.329 (1.2) 7.315 (1.9) 7.300 (19.1); 7.290 (1.9); 7.265 (0.4); 7.253 (0.5); 7.241 (0.4): 7.229 (0.7) 7.211 (0.4): 7.204 (0.5) 7.185 (0.8) 7.175 (0.5) 7.162 (0.5) 7.054 (2.2) 7.048 (2.2) 7.021 (8.0) 7.003 (2.3) 6.997 (2.0): 6.973 (0.4) 6.947 (0.3) 6.910 (0.5) 6.890 (0.7) 5.338 (3.0) 4.558 (0.5) 4.521 (0.6) 4.472 (0.4) 4.459 (3.0): 4.410 (7.9) 4.356 (7.7) 4.307 (2.9) 3.615 (4.4) 3.567 (5.8) 3.346 (0.4) 3.271 (6.1) 3.223 (4.6) 3.012 (0.3): 2.994 (0.4) 2.074 (1.7) 1.825 (0.4) 1.806 (0.5) 1.763 (0.8) 1.755 (0.8) 1.744 (0.8) 1.733 (0.8) 1.520 (0.9): 1.498 (0.8) 1.471 (0.5) 1.464 (0.5) 1.293 (2.4) 1.262 (0.5) 1.215 (0.5) 1.191 (0.8) 1.172 (0.5) 1.006 (0.8): 10.918 (0.7) 0.890 (1.5); 0.867 (16.0); 0.854 (4.6); 0.837 (3.6); 0.826 (3.5); 0.813 (2.2); 0.803 (1.3); 0.755 (3.0)
0.739 (1.8); 0.721 (2.0); 0.712 (1.2); 0.038 (14.1)
[Example 1-168: 1 H-NMR (300.2 MHz, de-DMSO)
5= 9.221 (3.3); 9.204 (3.4); 8.065 (0.3); 7.997 (4.5); 7.937 (2.9); 7.920 (2.8); 7.870 (4.7); 7.845 (0.3); 5.786] (16.0); 5.762 (4.8); 4.668 (1.7); 4.619 (2.1); 4.213 (2.3); 4.164 (1.9); 3.354 (41.8); 3.333 (7.9); 3.290 (0.5); 2.534] (12.3); 2.528 (16.7); 2.522 (12.1); 1.355 (1.0); 1.262 (0.6); 1.081 (0.5); 0.929 (0.4); 0.907 (0.7); 0.886 (0.8): 0.872 (0.9); 0.850 (0.7); 0.790 (0.4); 0.765 (0.7); 0.755 (0.8); 0.731 (1.0); 0.712 (0.8); 0.658 (0.7); 0.640 (0.9): 0.616 (0.9); 0.606 (0.8); 0.581 (0.5); 0.564 (0.8); 0.540 (0.8); 0.528 (0.8); 0.522 (0.7); 0.505 (0.7); 0.485 (0.4): 0.037 (0.8); 0.026 (22.4); 0.015 (1.0)
[Example 1-169: 1 H-NMR (300.2 MHz, CDCI3) δ= 8.012 (9.3); 7.997 (8.8); 7.387 (2.5); 7.382 (3.5); 7.360 (16.0); 7.354 (7.3); 7.345 (9.8); 7.342 (10.7); 7.335] (10.0); 7.326 (7.1); 7.319 (8.7); 7.306 (2.3); 7.300 (13.9); 7.281 (7.3); 7.275 (7.1); 7.254 (4.1); 4.718 (0.9); 4.669, (10.3); 4.661 (10.1); 4.612 (0.9); 4.200 (13.8); 4.175 (0.9); 4.126 (9.8); 4.1 17 (9.8); 4.068 (0.8); 3.310 (5.0): 3.265 (6.4); 2.969 (6.0); 2.924 (4.7); 1.671 (4.9); 0.623 (0.4); 0.618 (0.4); 0.608 (0.6); 0.595 (2.5); 0.580 (9.2): 0.575 (5.3); 0.567 (3.2); 0.562 (2.0); 0.557 (1.7); 0.552 (1.6); 0.547 (2.1); 0.533 (2.8); 0.524 (3.4); 0.518 (2.8): 0.512 (1.8); 0.491 (1.3); 0.485 (3.4); 0.475 (1.9); 0.453 (2.0); 0.442 (0.8); 0.042 (8.0)
[Example XVII- 1 : 1 H-NMR (499.9 MHz, CDCI3)
8= 7.427 (4.1); 7.263 (4.5); 6.995 (4.4); 6.993 (4.5); 5.278 (16.0); 1.792 (2.0); 1.782 (6.0); 1.775 (6.1); 1.765] \(2.5); 1.673 (0.5); 1.526 (2.4); 1.516 (6.0); 1.509 (6.2); 1.498 (2.1); 0.000 (4.3)
[Example XV II -2: 1 H-NMR (499.9 MHz, CDCI3) δ= 7.701 (5.1); 7.699 (5.3); 7.587 (4.7); 7.266 (3.7); 5.451 (16.0); 2.004 (2.6); 1.841 (2.1); 1.830 (6.2); 1.823] |(6.0); 1.813 (2.5); 1.643 (2.5); 1.575 (2.5); 1.565 (6.0); 1.558 (6.3); 1.547 (2.1); 0.000 (3.9)
|Example XVII-3: s H-NMR (499.9 MHz, CDCI3) δ= 7.688 (6.2); 7.627 (5.8); 7.267 (2.5); 5.299 (0.7); 5.067 (16.0); 1.998 (0.5); 1.989 (1.1); 1.982 (1.3); 1.973] (2.2); 1.965 (1.4); 1.958 (1.2); 1.949 (0.7); 1.259 (1.0); 1.251 (3.5); 1.243 (5.3); 1.235 (4.2); 1.228 (1.6); 1.207] (0.4); 1.134 (1.3); 1.127 (3.5); 1.120 (3.8); 1.112 (4.3); 1.105 (3.0); 1 097 (1.2); 0.000 (2.5)
(Example XVI!-4: 'H-NMR (499.9 MHz, CDCI3) δ= 7.715 (9.8); 7.622 (9.1); 7.264 (6.3); 5.383 (15.1); 5.378 (16.0); 1.641 (1.2); 1.634 (1.3); 1.623 (6.9); 1.620] (5.1); 1.610 (3.1); 1.606 (2.0); 1.599 (1.5); 1.590 (3.0); 1.583 (4.4); 1.575 (5.0); 1.566 (3.0); 1.557 (4.4); 1.549j (6.8); 1.542 (5.2); 1.535 (4.0); 1.519 (1.5); 0.006 (0.3); 0.000 (6.5) |Example XVII-5: ' H-NMR (300.2 MHz, CDC13): δ= 7.742 (0.9); 7.738 (1.3); 7.733 (0.6); 7.722 (0.4); 7.715 (1.7); 7.710 (1.5); 7.702 (0.9); 7.698 (1.3); 7.693 (0.6):
7.682 (0.4); 7.675 (1.7) 7.670 (1.5); 7.613 (0.3); 7.608 (0.4); 7.588 (0.9); 7.583 (0.9); 7.569 (0.5); 7.564 (1.1): 7.558 (1.0); 7.553 (0.4) 7.527 (1.3); 7.522 (0.9); 7.517 (1.4); 7.513 (0.7); 7.507 (1.0); 7.502 (1.6); 7.497 (1.3): 7.492 (1.6); 7.487 (0.5) 7.479 (0.7); 7.474 (0.6); 7.469 (0.6); 7.464 (0.4); 7.300 (4.6); 7.114 (3.8); 7.112 (3.8): 6.623 (2.1); 6.620 (2.1); 6.598 (2.1); 6.595 (2.1); 5.245 (16.0); 1.845 (2.0); 1.827 (4.9); 1.815 (5.6); 1.800 (2.7):
1.744 (0.4); 1.630 (0.4); 1.574 (2.6); 1.559 (5.5); 1.547 (5.0); 1.529 (2.0); 0.033 (4.7)
[Example XVII-6: H-NMR (300.2 MHz, CDCI3) δ= 7.796 (2.6); 7.793 (2.5); 7.567 (2.4); 7.300 (3.7); 5.647 (8.2); 3.847 (16.0); 3.521 (2.3); 1.828 (1.2); 1.810) (2.9); 1.798 (3.2); 1.782 (1.8); 1.727 (0.5); 1.560 (1.5); 1.545 (3.0); 1.533 (2.7); 1.515 (1.1); 0.105 (0.4); 0.033| (3.1)
jExample XVII-7: Ή-NMR (300.2 MHz. CDCI3)
5= 7.713 (1.2); 7.615 (1.3); 7.300 (1.2); 5.082 (5.5); 2.080 (0.4); 2.074 (0.8); 1.341 (7.2); 1.334 (16.0); 1.317j 1(0.5); 1.314 (0.4); 1.289 (0.5); 0.035 (0.5); 0.030 (0.7)
jExample XV! 1-8: 1 H-NMR (300.2 MHz, CDCI3)
§= 7.704 (1.9); 7.647 (1.8); 5.411 (5.6); 1.821 (16.0)
|Example XVII-9: H-NMR (300.2 MHz, CDCb): δ= 7.739 (8.8); 7.710 (9.5); 7.691 (0.5); 7.686 (0.4); 7.679 (0.5); 7.674 (0.4); 7.652 (0.3); 7.550 (0.9); 7.546 (0.9): 7.512 (0.3); 7.503 (1.3); 7.499 (1.0); 7.488 (0.4); 7.482 (0.4); 7.478 (0.4); 7.300 (2.7); 5.424 (0.5); 5.422 (0.4): 5.390 (0.4); 5.323 (1.4); 5.308 (0.5); 5.251 (0.6); 5.249 (0.6); 4.989 (16.0); 4.669 (6.5); 4.655 (0.5); 4.637 (12.1): 4.604 (7.1); 3.755 (0.8); 3.740 (1.0); 3.724 (0.8); 3.063 (4.1); 3.050 (0.5); 3.031 (7.3); 2.998 (3.9); 2.483 (0.5): 2.469 (0.6); 2.454 (0.5); 2.060 (0.8); 1.275 (0.5); 0.016 (2.2)
|Example XVII-10: 1 H-NMR (499.9 MHz, CDCI3):
5= 7.612 (2.6); 7.466 (0.6); 7.259 (116.3); 7.180 (3.6); 7.047 (0.7); 5.288 (16.0); 4.868 (0.8); 1.808 (2.1); 1.797] |(6.5); 1.790 (6.9); 1.781 (2.9); 1.747 (0.4); 1.552 (48.1); 1.536 (13.2); 1.525 (1 1.4); 1.518 (9.8); 1.508 (4.2): 1.476 (0.9); 1.436 (0.5); 1.255 (4.5); 1.186 (0.4); 1.178 (0.5); 1.170 (0.4); 1.161 (0.3); 1.140 (0.5); 1.035 (0.4): 10.894 (0.4); 0.880 (0.7); 0.866 (0.5); 0.856 (0.4); 0.837 (0.4); 0.116 (0.4); 0.069 (1.0); 0.000 (93.5); -0.120 (0.5)
|Example XVII- 1 1 : 1 H-NMR (400.1 MHz, de-DMSO):
5= 7.962 (3.7); 7.891 (4.0); 5.646 (5.5); 5.641 (5.5); 3.314 (4.0); 2.513 (8.3); 2.509 (10.9); 2.505 (8.2); 1.579) 1(16.0); 1.524 (16.0)
|Example XVII-13: 1 H-NMR (300.2 MHz, CDCI3):
5= 7.724 (1.2); 7.609 (1.0); 7.299 (1.0); 4.882 (3.1); 2.480 (3.0); 2.078 (0.8); 1.292 (0.5); 1.124 (16.0); 0.033| 1(1.0)
jExample XVII-14: 1 H-NMR (400.1 MHz, de-DMSO)
5= 7.918 (3.0); 7.860 (3.2); 7.858 (3.0); 5.381 (8.2); 3.331 (14.0); 2.867 (0.4); 2.850 (1.1); 2.833 (1.4); 2.816j |(1.1); 2.798 (0.4); 2.516 (2.1); 2.512 (3.9); 2.507 (5.1); 2.503 (3.7); 2.499 (1.8); 1.129 (16.0); 1.1 12 (15.7) jExample XVII-15: 1 H-NMR (300.2 MHz, de-DMSO) 5= 7.945 (5.5); 7.943 (5.5); 7.876 (6.1); 7.873 (5.4); 5.359 (16.0); 3.345 (1.2); 3.171 (0.5); 3.147 (1.1): 3.142
(1.1) 3.119 (2.2); 3.095 (1.3); 3.090 (1.2); 3.066 (0.6); 2.533 (1.1); 2.527 (2.2) 2.521 (3.1); 2.515 (2.2) 2.509 (1.0) 2.106 (9.6); 2.099 (0.5); 2.094 (2.3); 1.930 (0.4); 1.917 (1.0); 1.906 (0.6) 1.899 (1.0); 1.888 (1.5) 1.877 (1.5) 1.871 (1.6); 1.856 (1.3); 1.849 (1.4); 1.844 (1.3); 1.826 (0.7); 1.809 (0.5) 1.794 (0.6); 1.784 (1.8): 1.768 (1.1) 1.760 (2.1); 1.742 (1.2); 1.735 (1.3); 1.717 (1.1); 1.700 (0.5); 1.693 (0.6); 1.659 (0.4); 1.646 (1.0); 1.626| (4.9): 1.614 (4.4); 1.601 (6.3); 1.590 (3.5); 1.579 (2.1); 1.561 (0.6); 0.020 (3.3)
jExample XVII-16: 1 H-NMR (499.9 MHz, CDCI3)
5= 7.709 (10.1); 7.708 (10.5); 7.599 (9.6); 7.263 (8.7); 5.299 (0.4); 5.260 (15.5); 5.256 (16.0); 2.177 (3.0); 2.165 (6.5); 2.154 (3.9); 2.150 (4.1); 2.135 (0.5); 2.122 (3.3); 2.118 (2.9); 2.107 (6.3) , 2.099 (2.8); 2.095 (3.9); 1.968 (0.4); 1.959 (0.7); 1.950 (1.2); 1.943 (2.0); 1.937 (2.7); 1.934 (2.5); 1.926 (3.3) , 1.921 (2.4); 1.918 (2.5); 1.912 (2.8); 1.902 (1.1); 1.891 (1.6); 1.879 (1.4); 1.874 (1.3); 1.860 (3.2); 1.847 (3.7) , 1.838 (2.4); 1.832 (1.8); 1.813 (0.5); 1.607 (2.8); 0.006 (0.4); 0.000 (9.5); -0.007 (0.6)
jExample XVII-17: H-NMR (300.2 MHz, CDCb):
5= 7.716 (4.8); 7.631 (4.3); 7.298 (1.8); 5.326 (0.7); 4.875 (16.0); 3.462 (1.1); 3.434 (1.7); 3.406 (1.2): 3.379 (0.4); 3.376 (0.3); 2.458 (0.4); 2.430 (0.9); 2.426 (0.9); 2.421 (1.0); 2.416 (0.7); 2.395 (1.7); 2.389 (2.1) 2.361 (1.9); 2.360 (1.8); 2.339 (1.1); 2.332 (1.2); 2.325 (1.0); 2.310 (1.4); 2.303 (1.2); 2.296 (1.8); 2.288 (1.0) 2.281 (1.2); 2.275 (1.0); 2.267 (1.5); 2.261 (0.9); 2.247 (0.5); 2.240 (0.4); 2.233 (0.3); 2.231 (0.3); 2.227 (0.4): 2.173 (0.4); 2.147 (0.6); 2.142 (0.5); 2.136 (0.5); 2.1 16 (1.0); 2.109 (1.1); 2.106 (0.9); 2.088 (0.4); 2.079 (1.8) 2.051 (0.7); 2.022 (0.5); 2.012 (0.5); 2.009 (0.5); 1.997 (0.6); 1.994 (0.7); 1.985 (0.3); 1.980 (0.9); 1.977 (0.9) 1.971 (0.4); 1.964 (0.7); 1.961 (0.6); 1.957 (0.5); 1.944 (0.6); 1.940 (0.5); 1.927 (0.4); 1.790 (0.8); 0.024 (1.9) Example XVII-18: ! H-NMR (300.2 MHz, de-DMSO): δ= 8.103 (0.9); 8.099 (0.9); 8.040 (5.5); 8.038 (5.5); 7.952 (0.7); 7.926 (5.9); 7.923 (5.5); 7.876 (0.8); 7.873 (0.8); 7.854 (0.6); 7.819 (0.5); 5.710 (16.0); 5.572 (2.5); 4.238 (0.7); 4.183 (1.1); 3.499 (4.5); 2.972 (1.3); 2.962 (0.9); 2.954 (1.5); 2.948 (1.0); 2.943 (2.0); 2.933 (1.7); 2.926 (2.8); 2.915 (1.5); 2.908 (2.2); 2.897 (2.0); 2.891 (1.1); 2.885 (1.0); 2.879 (1.6); 2.607 (1.2); 2.596 (0.5); 2.582 (1.7); 2.575 (2.4); 2.562 (1.6); 2.549 (2.1); 2.533 (6.0); 2.527 (11.9); 2.521 (15.1); 2.515 (11.4); 2.509 (5.8); 2.360 (0.4); 2.334 (0.3); 2.237 (0.4); 2.219 (0.6); 2.202 (0.9); 2.186 (1.2); 2.183 (1.0); 2.166 (1.1); 2.150 (1.4); 2.134 (0.9); 2.117 (0.6); 2.109 (0.4); 2.099 (0.4); 1.911 (0.4); 1.903 (0.4); 1.866 (0.5); 1.840 (0.9); 1.828 (0.5); 1.811 (1.5); 1.803 (0.9); 1.799 (0.9); 1.786 (1.0); 1.781
(0.9); 1.774 (1.3); 1.756 (0.6); 1.748 (0.7); 0.031 (0.7); 0.020 (21.4); 0.009 (0.9)
Example XVII-19: ¾-NMR (300.2 MHz, CDC13): δ= 7.705 (5.6); 7.703 (5.5); 7.621 (5.1); 7.300 (1.3); 4.919 (16.0); 2.601 (3.8); 2.577 (6.6); 2.552 (4.3); 1.727 (0.9); 1.703 (2.7); 1.695 (0.9); 1.678 (3.4); 1.671 (1.4); 1.652 (2.5); 1.627 (1.2); 1.453 (0.6); 1.429 (1.9); 1.403 (2.7); 1.384 (1.3); 1.378 (2.9); 1.361 (0.6); 1.354 (1.8); 1.330 (0.6); 0.977 (6.9); 0.953 (13.5); 0.929 (5.4); 0.017 (13)
Use Examples:
Example A: in vivo preventive test on Atternaria hrassicae (leaf spot on radish) Solvent; 5% by volume of Dimethyl sulfoxide 10% by volume of Acetone
Emulsifier: 1 μΐ of Tween® 80 per mg of active ingredient
The active ingredients are made soluble and homogenized in a mixture of Dimethyl sulfoxide/Acetone/ /Tween® 80 and then diluted in water to the desired concentration.
The young plants of radish are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of Acetone/Dimethyl sulfoxide/ Tween® 80.
After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Altemaria hrassicae spores. The contaminated radish plants are incubated for 6 days at 20 °C and at 100% relative humidity.
The test is evaluated 6 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.
In this test the following compounds according to the invention showed efficacy between 70% and 79% at a concentration of 500 ppm of active ingredient: 1-04; 1-13; 1-18; 1-53; 1-66; 1-69; 1-70; 1-112; 1-155.
In this test the following compounds according to the invention showed efficacy between 80%o and 89%o at a concentration of 500 ppm of active ingredient: 1-01 ; 1-03; 1-19; 1-20; 1-22; 1-23; 1-40; 1-54; 1-55; 1-99. In this test the following compounds according to the invention showed efficacy between 90%o and 100%) at a concentration of 500 ppm of active ingredient: 1-02; 1-15; 1-16; 1-17; 1-27; 1-32; 1-33; 1-34; 1-114.
Example B: in wVo_Dreventive test on Botr & ci rea (grev mould) Solvent: 5% by volume of Dimethyl sulfoxide
10% by volume of Acetone Emulsifier: 1 μΐ of Tween® 80 per mg of active ingredient
The active ingredients are made soluble and homogenized in a mixture of Dimethyl sulfoxide/Acetone/ /Tween® 80 and then diluted in water to the desired concentration.
The young plants of gherkin are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of Acetone/Dimethyl sulfoxide/ Tween® 80.
After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Botrytis cinerea spores. The contaminated gherkin plants are incubated for 4 to 5 days at 17°C and at 90% relative humidity.
The test is evaluated 4 to 5 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.
In this test the following compounds according to the invention showed efficacy between 70% and 79% at a concentration of 500 ppm of active ingredient: 1-15; 1-66; 1-72; 1-98; 1-131; 1-137; 1-149. In this test the following compounds according to the invention showed efficacy between 80% and 89% at a concentration of 500 ppm of active ingredient: 1-13; 1-17; 1-42; 1-45; 1-69; 1-75; 1-125; 1-138; 1-142; 1-154.
In this test the following compounds according to the invention showed efficacy between 90% and 100% at a concentration of 500 ppm of active ingredient: 1-02; 1-04; 1-05; 1-06; 1-08; 1-14; 1-16; 1-18; 1-21; 1-25; 1-27; 1-29; 1-30; 1-32; 1-33; 1-34; 1-36; 1-38; 1-39; 1-40; 1-43; [-44; 1-54; 1-55; 1-59; 1-65; 1-71; 1-73; 1-76; 1-77; 1-79; 1-82; 1-99; 1-107; 1-108; 1-110; 1-112; 1-114; 1-118; 1-124; 1- 126; 1-128; 1-130; 1-133; 1-139; 1- 144; 1-146; I- 147; 1-155; 1-157; 1-158; 1-164; 1-167.
ExM Bie C: in vivo preventive test onj¾cdwia _¾eg^ on wheat)
Solvent: 5% by volume of Dimethyl sulfoxide
10% by volume of Acetone Emulsifier: Ιμΐ of Tween® 80 per mg of active ingredient
The active ingredients are made soluble and homogenized in a mixture of Dimethyl sulfoxide/Acetone/' /Tween® 80 and then diluted in water to the desired concentration.
The young plants of wheat are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of Acetone/Dimethyl sulfoxide' Tween® 80. After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Puccinia recondita spores. The contaminated wheat plants are incubated for 24 hours at 20°C and at 100% relative humidity and then for 10 days at 20°C and at 70-80%> relative humidity.
The test is evaluated 11 days after the inoculation. 0%> means an efficacy which corresponds to that of the control plants while an efficacy of 100%) means that no disease is observed.
In this test the following compounds according to the invention showed efficacy between 70% and 79 %o at a concentration of 500 ppm of active ingredient: 1-61 ; 1-68; 1-75; 1-105; 1- 132; 1-169.
In this test the following compounds according to the invention showed efficacy between 80%> and 89%) at a concentration of 500 ppm of active ingredient: 1-02; 1-03; 1-05; 1-07; 1-10; 1-11; 1-12; 1-13; 1-14; 1-15; I- 1 ; I- 17; 1-20; 1-21; 1-24; 1-25; 1-28; 1-33; 1-37; 1-38; 1-40; 1-44; 1-47; 1-48; 1-50; 1-52; 1-54; 1-56; 1-58; 1-59; 1-67; 1-69; 1-70; 1-72; 1-73; 1-77; 1-80; 1-89; 1-90; 1-92; 1-106; 1-107; 1-110; 1-113; 1- 121; 1-122; 1-123; 1-127; 1-137; 1-142; 1-151 ; 1- 155; 1-158; 1- 1 4; 1-167.
In this test the following compounds according to the invention showed efficacy between 90%o and 100%o at a concentration of 500 ppm of active ingredient: 1-01; 1-04; 1-06; 1-08; 1-18; 1-19; 1-22; 1-23; 1-26; 1-27; 1-29; 1-30; 1-31; 1-32; 1-34; 1-36; 1-39; 1-41; 1-42; 1-43; 1-45; 1-46; 1-49; 1- 1 ; 1-53; 1-55; 1-57; 1-62; 1-64; 1-65; 1-66; 1-71; 1-76; 1-79; 1-81; 1-82; 1-84; 1-85; 1-88; 1-91; 1-95; 1-96; 1-97; 1-98; 1-99; 1-101; 1-103; 1-104; 1-108; I- 109; 1-111; 1- 112; 1-114; 1-115; 1-117; 1-118; 1-120; 1-124; 1-125; 1-126; 1-128; 1-130; 1-131 ; 1-133; 1-136; I- 138; 1-139; 1-141 ; 1- 143; 1- 144; 1-146; 1-147; 1-148; 1-149; 1-152; 1-153; 1-154; 1-156; 1-157; 1- 165; 1-166.
Example I): in vivo preventive test on Pyrenophora teres (net blotch on barley)
Solvent: 5%. by volume of Dimethyl sulfoxide
10% by volume of Acetone
Emulsifier: 1 μΐ of Tween® 80 per mg of active ingredient
The active ingredients are made soluble and homogenized in a mixture of Dimethyl sulfoxide/Acetone/ /'Tween® 80 and then diluted in water to the desired concentration. The young plants of barley are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of Acetone/Dimethyl sulfoxide/ Tween® 80.
After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Pyrenophora teres spores. The contaminated barley plants are incubated for 48 hours at 20°C and at 100% relative humidity and then for 12 days at 20 °C and at 70-80%o relative humidity. The test is evaluated 14 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100%> means that no disease is observed. In this test the following compounds according to the invention showed efficacy between 70% and 79% at a concentration of 500 ppm of active ingredient: 1-07; 1-40; 1-42; 1-48; 1-53; Ϊ-56; 1-118; 1-120; 1-121 ; 1-130; I- 139; 1-143; 1-151 ; 1-152; 1-155.
In this test the following compounds according to the invention showed efficacy between 80% and 89% at a concentration of 500 ppm of active ingredient: 1-08; 1-11; 1-13; 1-14; 1-19; 1-22; 1-23; 1-25; 1-29; 1-32; 1-33; I- 38; 1-45; 1-50; 1-54; 1-55; 1-69; 1-72; 1-73; 1-75; 1-77; 1-80; 1-82; 1-84; 1-85; 1-89; 1-95; 1-97; 1-103; 1-112; I- 131 ; 1-142; 1-148; 1-153; 1-156; 1-164; 1-166; 1-167.
In this test the following compounds according to the invention showed efficacy between 90% and 100% at a concentration of 500 ppm of active ingredient: 1-01; 1-02; 1-04; 1-06; 1-12; 1-15; 1-16; 1-17; 1-18; 1-27; 1-30; 1-34; 1-36; 1-39; 1-43; 1-44; 1-49; 1-51; 1-62; 1-65; 1-66; 1-71 ; 1-76; 1-79; 1-88; 1-98; 1-99; 1-101; 1-107; 1-108; 1-109; 1-110; 1-114; 1-124; 1-126; 1-133; 1-144; 1-146; 1-147; 1-157; 1- 158.
Example EiH two^reventive test on Septoria tritici (le ∞LE l
Solvent: 5% by volume of Dimethyl sulfoxide
10 ) by volume of Acetone Emulsifier: Ιμΐ of Tween® 80 per mg of active ingredient
The active ingredients are made soluble and homogenized in a mixture of Dimethyl sulfoxide/'Acetone/ /Tween® 80 and then diluted in water to the desired concentration.
The young plants of wheat are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of Acetone/Dimethyl sulfoxide/ Tween® 80. After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Sep tor ia tritici spores. The contaminated wheat plants are incubated for 72 hours at 18°C and at 100% relative humidity and then for 21 days at 20 °C and at 90% relative humidity.
The test is evaluated 24 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed. In this test the following compounds according to the invention showed efficacy between 70% and 79% at a concentration of 500 ppm of active ingredient: 1-09; 1-21; 1-90; 1-105; 1-118; 1-120; 1-134; 1-142; 1-166; I- 169.
In this test the following compounds according to the invention showed efficacy between 80%o and 89% at a concentration of 500 ppm of active ingredient: 1-05; 1-20; 1-28; 1-58; 1-65; 1-69; 1-73; 1-78; 1-87; 1-110; 1-149. In this test the following compounds according to the invention showed efficacy between 90%> and 100% at a concentration of 500 ppm of active ingredient: 1-01; 1-02; 1-03; 1-04; 1-06; 1-07; 1-08; 1-11; 1-12; 1-13; 1-14; 1-15; 1-16; 1-17; 1-18; 1-19; 1-22; 1-23; 1-24; 1-25; 1-26; 1-27; 1-29; 1-30; 1-31; 1-32; 1-33; 1-34; 1-35; 1-36; 1-37; 1-38; 1-39; 1-40; 1-41 ; 1-42; 1-43; 1-44; 1-45; 1-48; 1-49; 1-50; 1-51; 1-52; 1-53; 1-54; 1-55; 1-56; 1-57; 1-59; 1-61 ; 1-62; 1-64; 1-66; 1-70; 1-71; 1-72; 1-74; 1-75; 1-76; 1-77; 1-79; 1-80; 1-81; 1-82; 1-84; 1-85; 1-88; 1-91; 1-92; 1-95; 1-96; 1-97; 1-98; 1-99: 1-101; 1-103; 1-104; 1-106; 1-107; 1-108; 1-109; 1- 111 ; 1-112; 1-113; 1-115; 1-116; 1-117; 1-121; 1-122; 1-123; 1-124; 1-125; 1-126; 1-127; 1-128; 1-130; 1-131; 1-132; Ϊ-133; 1-136; 1-137; 1-138; 1-139; 1-141 ; 1-143; 1-144; 1-146; 1-147; 1-148; 1-151 ; 1-152; 1-153; 1-154; Ϊ- 155; 1-156; 1-157; 1-158; Ϊ-164; 1- 165.
Figure imgf000112_0001
Solvent: 5% by volume of Dimethyl sulfoxide
10% by volume of Acetone Emulsifier: Ιμΐ of Tween® 80 per mg of active ingredient
The active ingredients are made soluble and homogenized in a mixture of Dimethyl sulfoxide/Acetone/ /Tween® 80 and then diluted in water to the desired concentration.
The young plants of gherkin are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution o f Acetone/Dimethyl sulfoxide/ Tween® 80. After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Sphaerotheca fuliginea spores. The contaminated gherkin plants are incubated for 72 hours at 18°C and at 100% relative humidity and then for 12 days at 20°C and at 70-80% relative humidity.
The test is evaluated 15 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed. In this test the following compounds according to the invention showed efficacy between 80% and 89% at a concentration of 500 ppm of active ingredient: 1-78.
In this test the following compounds according to the invention showed efficacy between 90% and 100%) at a concentration of 500 ppm of active ingredient: 1-01; 1-02; 1-03; 1-04; 1-05; 1-06; 1-07; 1-08; 1-09; 1-11; 1-12; 1-13; 1-14; 1- 15; 1-16; 1-17; 1-18; 1-19; 1-20; 1-21; 1-22; 1-23; 1-24; 1-25; 1-26; 1-27; 1-28; 1-29; 1-30; 1-31 ; 1-32; 1-33; 1-34; 1-36; 1-38; 1-39; 1-40; 1-41 ; 1-42; 1-43; 1-44; 1-45; 1-46; 1-47; 1-48; i-49; 1-50; 1-51 ; 1-52; 1-53; 1-54; 1-55; 1-56; 1-57; 1-58; 1-59; 1-61 ; 1-62; 1-64; 1-65; 1-66; 1-67; 1-69; 1-70; 1-71; 1-72; 1-73; 1-74; 1-75; 1-76; 1-77; 1-79; 1-80; 1-81; 1-82; 1-84; 1-85; 1-87; 1-88; 1-89; 1-90; 1-91 ; 1-92; 1-95; 1-96; 1-97; 1-98; 1-99; I- 101 ; 1-103; I- 104; 1-105; 1- 106; 1-107; 1-108; 1-109; 1- 1 10; 1-11 1; 1-112; 1-113; i- 1 14; 1-115; 1-116; 1-1 17; 1-118; 1-120; I- 121; 1-122; 1- 123; 1-124; 1-125; 1-126; 1-127; 1-128; 1-130; 1-131 ; 1-132; 1-133; I- 1 4; 1-136; 1-137; 1-138; I- 139; 1-141; 1- 142; 1-143; 1- 144; 1-146; 1-147; 1-149; 1-151 ; 1-152; 1-153; 1-154; 1-155; 1-156; 1-157; 1-158; I- 164; 1-165; 1-166; 1-167; 1-169.
Example G: in vivo preventive test on Uromyces appendiculatus (bean rust) Solvent: 5% by volume of Dimethyl sulfoxide
10% by volume of Acetone
Emulsifier: of Tween® 80 per mg of active ingredient
The active ingredients are made soluble and homogenized in a mixture of Dimethyl sulfoxide/Acetone/ /Tween® 80 and then diluted in water to the desired concentration.
The young plants of bean are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of Acetone/Dimethyl sulfoxide Tween® 80.
After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Uromyces appendiculatus spores. The contaminated bean plants are incubated for 24 hours at 20 °C and at 100% relative humidity and then for 10 days at 20 °C and at 70-80% relative humidity.
The test is evaluated 11 days after the inoculation.0% means an efficacy which corresponds to that of the control plants while an efficacy of 100%) means that no disease is observed.
In this test the following compounds according to the invention showed efficacy between 70%o and 79%) at a concentration of 500 ppm of active ingredient: 1-21; 1-28; 1-134; 1-169. In this test the following compounds according to the invention showed efficacy between 80%o and 89%o at a concentration of 500 ppm of active ingredient: 1- ! ; 1-107; 1-114; 1-123.
In this test the following compounds according to the invention showed efficacy between 90%o and 100%) at a concentration of 500 ppm of active ingredient: 1-01; 1-02; 1-03; 1-04; 1-05; 1-06; 1-07; 1-08; 1-09; 1-10; 1-11; 1-12; 1-14; I- 15; 1-16; 1-17; 1-18; 1-20; 1-22; 1-23; 1-24; 1-25; 1-26; 1-27; 1-29; 1-30; 1-31; 1-32; 1-33; 1-34; 1-36; 1-38; 1-39; 1-40; 1-41; 1-42; 1-43; 1-44; 1-45; 1-46; 1-47; 1-48; 1-49; 1-50; 1-52; 1-53; 1-54; 1-55; 1-56; 1-57; 1-58; 1-59; 1-61; 1-62; 1-64; 1-65; 1-66; 1-67; 1-68; 1-69; 1-70; 1-71; 1-72; 1-74; 1-75; 1-77; 1-79; 1-80; 1-81; 1-82; 1-84; 1-85; 1-88; 1-89; 1-90; 1-91; 1-92; 1-95; 1-96; 1-97; 1-98; 1-99; 1-101; 1-103; 1-104; 1-106; 1-109; I- 110; 1-111; I- 112; 1-113; 1-115; 1-117; 1-118; 1-120; 1-121; 1-122; 1-124; 1-125; 1-126; 1-127; 1-128; 1-130; 1-131; 1-132; I- 133; 1-136; 1-137; 1-138; 1-139; 1-141; 1-142; 1-144; 1-146; 1-147; 1-148; 1-149; 1-151; 1-152; 1-153; 1-154; I- 155; 1-156; 1-157; 1-158; 1-164; 1-165; 1-166; 1-167. j^yni^ prevcntivjHhcsto^^
Solvent: 24.5 parts by weight of acetone
24.5 parts by weight of dimethylacetamide
Emulsifier: 1 part by weight of alkylaryl polyglycol ether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for preventive activity, young plants are sprayed with the preparation of active compound at the stated rate of application. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension oiAlternaria solani. The plants are then placed in an incubation cabinet at approximately 20°C and a relative atmospheric humidity of 100%.
The test is evaluated 3 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control while an efficacy of 100% means that no disease is observed. In this test the following compounds according to the invention showed efficacy between 70% and 79% at a concentration of 100 ppm of active ingredient: 1-05; 1-42; 1-50; 1-96.
In this test the following compounds according to the invention showed efficacy between 80% and 89% at a concentration of 100 ppm of active ingredient: 1-26; [-43; 1-97; 1-103; 1- 133; 1-157.
In this test the following compounds according to the invention showed efficacy between 90% and 100% at a concentration of 100 ppm of active ingredient: 1-04; 1-06; 1-08; 1-16; 1-17; 1-18; 1-27; 1-29; 1-30; 1-32; 1-33; 1-34; 1-36; 1-38; 1-39; 1-40; 1-44; 1-65; 1-69; 1-95; 1-98; 1-99; 1- 101; 1-107; 1-112; 1-114; 1-125; 1-126; 1-146; I-
147; 1-153; 1-155; 1-158.
Example I: in vivo preventi test onj^opsorq test (soybeans)
Solvent: 24.5 parts by weight of acetone 24.5 parts by weight of dimethylacetamide
Emulsifier: 1 part by weight of aliylaryl polyglycol ether
To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration. To test for preventive activity, young plants are sprayed with the preparation of active compound at the stated rate of application. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of the causal agent of soybean rust ( P akopsora pachyrhizi) and stay for 24h without light in an incubation cabinet at approximately 24°C and a relative atmospheric humidity of 95 %.
The plants remain in the incubation cabinet at approximately 24°C and a relative atmospheric humidity of approximately 80 % and a day / night interval of 12h. The test is evaluated 7 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.
In this test the following compounds according to the invention showed efficacy between 70% and 79 %o at a concentration of 100 ppm of active ingredient: 1-26. In this test the following compounds according to the invention showed efficacy between 80% and 89%> at a concentration of 100 ppm of active ingredient: 1-50; 1-96; 1-107; 1-133.
In this test the following compounds according to the invention showed efficacy between 90% and 100% at a concentration of 100 ppm of active ingredient: 1-04; 1-05; 1-06; 1-08; 1- 16; 1- 17; 1- 18; 1-23 ; 1-27; 1-29; 1-30; 1-32; 1-33 ; 1-34; 1-36; 1-38; 1-39; 1-40; 1-42; 1-43; [-44; 1-65; 1-69; 1-95; 1-97; 1-98; 1-99; 1- 101 ; 1- 103; 1- 1 12; 1- 1 14; 1- 125; 1- 126; 1- 138; I- 1 46; 1- 147; 1- 1 53 ; 1- 1 55; 1- 1 57; 1-158. ! ilLMLltoM ^ test on Veniuria test (apples).
Solvent: 24.5 parts by weight of acetone
24.5 parts by weight of dimethylacetamide
Emulsifier: 1 part by weight of alkylaryl polyglycol ether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for preventive activity, young plants are sprayed with the preparation of active compound at the stated rate of application. After the spray coating has dried on, the plants are inoculated with an aqueous conidia suspension of the causal agent of apple scab (Venturia inaequatis) and then remain for 1 day in an incubation cabinet at approximately 20°C and a relative atmospheric humidity of 100%.
The plants are then placed in a greenhouse at approximately 21°C and a relative atmospheric humidity of approximately 90%.
The test is evaluated 10 days after the inoculation. 0%> means an efficacy which corresponds to that of the untreated control, while an efficacy of 100%o means that no disease is observed.
In this test the following compounds according to the invention showed efficacy between 70%i and 79% at a concentration of 100 ppm of active ingredient: 1- 133; 1- 138.
In this test the following compounds according to the invention showed efficacy between 80% and 89% at a concentration of 100 ppm of active ingredient: 1-06; 1-40; 1-42; 1-50; 1-65; 1-95: 1-96; 1-97; 1-99; 1- 101 ; 1- 103; 1- 107; 1- 1 12; 1- 1 14; 1- 153. In this test the following compounds according to the invention showed efficacy between 90% and 100% at a concentration of 100 ppm of active ingredient: 1-04; 1-08; 1-16; 1-17; 1-18; 1-26; 1-27; 1-29; 1-30; 1-32; 1-33; 1-34; 1-36; 1-38; 1-44; 1-69; 1-98; 1-125; 1-146; 1-147; 1-155; 1-157.
Example K: in vivo preventive Blumeria test (barley)
Solvent: 49 parts by weight of N,N-dimethylacetamide
Emulsifier: 1 part by weight of alkylaryl polyglycol ether
To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration. To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.
After the spray coating has been dried, the plants are dusted with spores of Blumeria graminis f.sp. hordei.
The plants are placed in the greenhouse at a temperature of approximately 18°C and a relative atmospheric humidity of approximately 80% to promote the development of mildew pustules. The test is evaluated 7 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.
In this test the following compounds according to the invention showed efficacy between 70% and 79% at a concentration of 500 ppm of active ingredient: 1-17; 1-25.
In this test the following compounds according to the invention showed efficacy between 80% and 89% at a concentration of 500 ppm of active ingredient: 1-43.
In this test the following compounds according to the invention showed efficacy between 90% and 100% at a concentration of 500 ppm of active ingredient: 1-01; 1-02; 1-04; 1-06; 1-08; 1-16; 1-18; 1-22; 1-26; 1-27; 1-29; 1-30; 1-32; 1-33; 1-34; 1-36; 1-38; 1-39; 1-40; 1-41; 1-42; 1-44; 1-49; 1-50; 1-62; 1-64; 1-65; 1-72; 1-75; 1-80; 1-84; 1-88; 1-92; 1-95; 1-96; 1-97; 1-98; 1-99; 1-101 ; 1-103; 1-109; 1-112; 1-114; 1-125; 1- 126; 1-133; 1-136; 1-138; I- 144; 1-146; 1-147; 1-152; 1- 154; 1-156; 1- 157; 1-164; 1-165.
ExampJe L: in vivo pi evenJive_Q<vam//w cu o. . ≤Ml£ l
Solvent: 49 parts by weight of Ν,Ν-dimethylacetamide Emulsifier: 1 part by weight of alkylaryl polyglycol ether To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application. After the spray coating has been dried, the pl ants are slightly injured by using a sandblast and afterwards they are sprayed with a conidia suspension of Fusarium culmorum.
The plants are placed in the greenhouse under a translucent incubation cabinet at a temperature of approximately 22°C and a relative atmospheric humidity of approximately 100%. The test is evaluated 5 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.
In this test the following compounds according to the invention showed efficacy between 70% and 79% at a concentration of 500 ppm of active ingredient: 1-02.
In this test the following compounds according to the invention showed efficacy between 80% and 89% at a concentration of 500 ppm of active ingredient: 1-18; 1-29; 1-36; 1-38.
In this test the following compounds according to the invention showed efficacy between 90% and 100% at a concentration of 500 ppm of active ingredient: 1-06; 1-16; 1-26; 1-34; 1-39; 1-65; 1-95; 1-97; 1-133; 1-157.
Example M: in vivo preventive Fmam t^wninearum tetjbarievj
Solvent: 49 parts by weight of N,N-dimethylacetamide Emulsifier: 1 part by weight of alkylaryl polyglycol ether
To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.
After the spray coating has been dried, the plants are slightly injured by using a sandblast and afterwards they are sprayed with a conidia suspension of Fusarium gmminearum.
The plants are placed in the greenhouse under a translucent incubation cabinet at a temperature of approximately 25 °C and a relative atmospheric humidity of approximately 100%. The test is evaluated 5 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.
In this test the following compounds according to the invention showed efficacy between 70% and 79%) at a concentration of 500 ppm of active ingredient: 1-04; 1-08; 1-32; 1-44; 1-49; 1-72; 1-112; 1-114; 1-152.
In this test the following compounds according to the invention showed efficacy between 80% and 89%o at a concentration of 500 ppm of active ingredient: 1-02; 1-16; 1-42; 1-64; 1-156.
In this test the following compounds according to the invention showed efficacy between 90 %> and 100% at a concentration of 500 ppm of active ingredient: 1-06; 1-18; 1-29; 1-34; 1-39; 1-41 ; 1-65; 1-88; 1-95; 1-96; 1-97; 1-98; 1-99; 1-103; 1-109; 1-125; 1-126; 1-133; 1-138; 1-144; 1-146; 1-147; 1-154; 1-157.
E am¾rie^J«_vrvp prevendve geto^aena nodorum testjwfaeatl
Solvent: 49 parts by weight of N,N-dimethylacetamide
Emulsifier: 1 part by weight of alkylaryl polyglycol ether
To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.
After the spray coating has been dried, the plants are sprayed with a spore suspension of Leptosphaeria nodorum. The plants remain for 48 hours in an incubation cabinet at approximately 20°C and a relative atmospheric humidity of approximately 100%.
The plants are placed in the greenhouse at a temperature of approximately 25 °C and a relative atmospheric humidity of approximately 80%o.
The test is evaluated 8 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.
In this test the following compounds according to the invention showed efficacy between 70% and 79 %o at a concentration of 500 ppm of active ingredient: 1-26; 1-39; 1-41 ; 1-152.
In this test the following compounds according to the invention showed efficacy between 80%o and 89%o at a concentration of 500 ppm of active ingredient: 1-11 ; 1-32; 1-36; 1-38; 1-44; 1-49; 1-65; 1-95; 1-125; 1-157. In this test the following compounds according to the invention showed efficacy between 90% and 100% at a concentration of 500 ppm of active ingredient: 1-02; 1-04; 1-06; 1-08; 1-16; 1-18; 1-27; 1-29; 1-30; 1-33; 1-34; 1-42; 1-72; 1-99; 1-133; Ϊ-146; 1-147; 1-154.
Example O: in vivo preventive Fusariutn nivale (var. niajus) iesi (wheat)
Solvent: 49 parts by weight of Ν,Ν-dimethylacetamide
Emulsifier: 1 part by weight of alkylaryl polyglycol ether
To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration. To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.
After the spray coating has been dried, the plants are slightly injured by using a sandblast and afterwards they are sprayed with a conidia suspension of Fusarium nivale (var. majus).
The plants are placed in the greenhouse under a translucent incubation cabinet at a temperature of approximately 10°C and a relative atmospheric humidity of approximately 100%.
The test is evaluated 5 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.
In this test the following compounds according to the invention showed efficacy between 70% and 79% at a concentration of 500 ppm of active ingredient: 1-01 ; 1-39. In this test the following compounds according to the invention showed efficacy between 80% and 89% at a concentration of 500 ppm of active ingredient: 1-11 ; 1-32; 1-41 ; 1-42; 1-49; 1-88; 1-109; 1-157; 1-164.
In this test the following compounds according to the invention showed efficacy between 90% and 100% at a concentration of 500 ppm of active ingredient: 1-02; 1-04; 1-06; 1-08; 1-16; 1-18; 1-26; 1-29; 1-34; 1-36; 1-38; 1-50; 1-65; 1-72; 1-95; 1-97; 1-99; 1-125; 1-133; 1- 146; 1-147; 1-152; I- 1 4. Example P: in vivo preventive Pyricularia oryzae test (rice)
Solvent: 49 parts by weight of N,N-dimethylacetamide
Emulsifier: 1 part by weight of alkylaryl polyglycol ether
To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration. To test for preventive activity, young plants are sprayed with the preparation of active compound or active compound combination at the stated rate of application.
After the spray coating has been dried, the plants are sprayed with a spore suspension of Pyricularia oryzae. The plants remain for 48 hours in an incubation cabinet at approximately 25 °C and a relative atmospheric humidity of approximately 100%.
The plants are placed in the greenhouse under a translucent incubations cabinet at a temperature of approximately 25 °C and a relative atmospheric humidity of approximately 100%.
The test is evaluated 8 days after the inoculation. 0% means an efficacy which corresponds to that of the control, while an efficacy of 100% means that no disease is observed. In this test the following compounds according to the invention showed efficacy between 70% and 79% at a concentration of 500 ppm of active ingredient: 1-02; 1-08; 1-25; 1-39; 1-40; [-44; 1-50; 1-84; 1-95; 1-97; I-l 12; Ι-Π4; 1-144; 1-146; 1-154; 1-164.
In this test the following compounds according to the invention showed efficacy between 80% and 89% at a concentration of 500 ppm of active ingredient: I-l 1; 1-22; 1-26; 1-42; 1-49; 1-92; 1-99; 1-125; 1-138; 1-147. In this test the following compounds according to the invention showed efficacy between 90% and 100% at a concentration of 500 ppm of active ingredient: 1-04; 1-06; 1-16; 1-17; 1-18; 1-27; 1-30; 1-36; 1-38; 1-65; 1-72; 1-98; 1-126; 1-133; 1-157; 1-165.
Examples Q:
The following examples Q l to Q4 provide comparative data of the efficacy of 5 -substituted imidazolylmethyl compounds according to the invention vs. an unsubstituted imidazolylmethyl compound against several pathogens. The data clearly demonstrate the superior properties of compounds according to the invention.
M ^QIIM vivo preventive lest on nML£ e∑ , Y mo d)
Solvent: 5% by volume of Dimethyl sulfoxide 10% by volume of Acetone
Emulsifier: 1 μΐ of Tween® 80 per mg of active ingredient
The active ingredients are made soluble and homogenized in a mixture of Dimethyl sulfoxide Acetone/ /Tween® 80 and then diluted in water to the desired concentration.
The young plants of gherkin are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of Acetone/Dimethyl sulfoxide/ Tween® 80. After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Botrytis cinerea spores. The contaminated gherkin plants are incubated for 4 to 5 days at 17°C and at 90% relative humidity.
The test is evaluated 4 to 5 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.
Table: results
Figure imgf000121_0001
Example Q2: in vivo preventive test on Pyrenophora teres (net blotch on barley)
Solvent: 5% by volume of Dimethyl sulfoxide
10% by volume of Acetone
Emulsifier: 1 μΐ of Tween® 80 per mg of active ingredient
The active ingredients are made soluble and homogenized in a mixture of Dimethyl sulfoxide/Acetone/ /Tween® 80 and then diluted in water to the desired concentration.
The young plants of barley are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of Acetone/Dimethyl sulfoxide/ Tween® 80. After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Pyrenophora teres spores. The contaminated barley plants are incubated for 48 hours at 20°C and at 100% relative humidity and then for 12 days at 20 °C and at 70-80% relative humidity.
The test is evaluated 14 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.
Table: results
Figure imgf000122_0001
ExamBje_Q3i tw riwjji eventivc test on Septoria tritici (ί ^Β ορ wheat)
Solvent: 5% by volume of Dimethyl sulfoxide
10% by volume of Acetone
Emulsifier: 1 μΐ of Tween® 80 per mg of active ingredient
The active ingredients are made soluble and homogenized in a mixture of Dimethyl sulfoxide/Acetone/ /'Tween® 80 and then diluted in water to the desired concentration.
The young plants of wheat are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of Acetone/Dimethyl sulfoxide/' Tween® 80. After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Sep tor ia tritici spores. The contaminated wheat plants are incubated for 72 hours at 18°C and at 100% relative humidity and then for 21 days at 20 °C and at 90% relative humidity.
The test is evaluated 24 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.
Table: results
Figure imgf000123_0001
Example Q4: in vitro test for the calculation of the ED50-value with microorganisms
Solvent: Dimethyl sulfoxide Culture medium: 14.6 g anhydrous D-glucose (VWR), 7.1 g Mycological Peptone (Oxoid),
1.4g granulated Yeast Extract (Merck), QSP 1 liter
Inoculum: Spore suspension
Fungicides were solubilized in DMSO and the solution used to prepare the required range of concentrations. The final concentration of DMSO used in the assay was < 1%. A spore suspension was prepared and diluted to the desired spore density.
Fungicides were evaluated for their ability to inhibit spore germination and mycelium growth in liquid culture assay. The compounds were added in the desired concentration to the culture medium with spores. After 4 to 7 days incubation, fungi-toxicity of compounds was determined by spectrometnc measurement of mycelium growth. Inhibition of fungal growth was determined by comparing the absorbance values in wells containing the fungicides with the absorbance in control wells without fungicides.
Table: results
Figure imgf000124_0001
Examples R:
The following examples R l to R7 provide comparative data of the efficacy of 5 -substituted imidazolylmethyl compounds according to the invention vs. substituted imidazolylmethyl derivatives bearing the substituent in another position against several pathogens. The data clearly demonstrate the superior properties of compounds according to the invention.
Example Rl : in vivo preventive test on Alternaria brassicae (leaf spot on radish)
Solvent: 5% by volume of Dimethyl sulfoxide
10% by volume of Acetone
Emulsifier: 1 μΐ of Tween® 80 per mg of active ingredient The active ingredients are made soluble and homogenized in a mixture of Dimethyl suifoxide/Acetone/' /Tween® 80 and then diluted in water to the desired concentration. The young plants of radish are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of Acetone/Dimethyl sulfoxide/' Tween® 80.
After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Altemaria brassicae spores. The contaminated radish plants are incubated for 6 days at 20°C and at 100% relative humidity.
The test is evaluated 6 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.
Results:
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 40 compound 100 0
According to the
invention:
1-04 500 70
100 20
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 0 co pound 100 0
According to the
invention:
1-03 500 83
100 0
Active compound Rate of application of Efficacy active compound in
ppm in% Comparison 500 0 compound 100 0
Comparison 500 0 compound 100 0
Figure imgf000126_0001
According to the
invention:
1-32 500 92
100 50
Figure imgf000126_0002
Figure imgf000126_0003
Example R2: In vivo preventive iesi on Botrytis cinerea (grey mould) The tested active ingredients are prepared by homogenization in a mixture of acetone/Dimethyl sulfoxide/tween® as disclosed above, and then diluted with water to obtain the desired active material concentration.
The young plants of gherkin are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of acetone/Dimethyl sulfoxide/tween®.
After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Botrytis cinerea spores. The contaminated gherkin plants are incubated for 4 to 5 days at 17°C and at 90% relative humidity.
The test is evaluated 4 to 5 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.
Results:
Figure imgf000127_0001
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 0 compound 100 0
According to the
invention:
1-06 500 97
100 80
Active compound Rate of application of Efficacy active compound in
ppm in% Comparison 500 0 compound 100 0
Figure imgf000128_0001
According to the
invention:
1-36 500 100
100 100
Figure imgf000128_0002
Figure imgf000128_0003
Active compound Rate of application of Efficacy active compound in
ppm in%
Figure imgf000129_0001
Figure imgf000129_0002
Figure imgf000129_0003
Example R3: In vivo preventive test on Puccinia recondita (brown rust on wheat)
The tested active ingredients are prepared by homogenization in a mixture of acetone Dimethyl sulfoxide/tween® as disclosed above, and then diluted with water to obtain the desired active material concentration. The young plants of wheat are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of acetone/Dimethyl sulfoxide/tween®.
After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Puccinia recondita spores. The contaminated wheat plants are incubated for 24 hours at 20°C and at 100% relative humidity and then for 10 days at 20°C and at 70-80% relative humidity.
The test is evaluated 11 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.
Results:
Figure imgf000130_0001
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 86 compound 100 29
According to the
invention:
1-03 500 86
100 86
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 83 compound 100 0 According to the
invention:
1-06 500 94
100 89
Figure imgf000131_0002
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 33 compound 100 0
Comparison 500 0 compound 100 0
Figure imgf000131_0001
According to the
invention:
1-32 500 94
100 78
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 94 compound ,ø· 100 0
C^Br
Figure imgf000132_0001
Figure imgf000132_0002
Figure imgf000132_0003
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 78 compound 100 11
According to the
invention:
Figure imgf000133_0001
Example R4: In vivo preventive test on Pyrenophom teres (net blotch on barley)
The tested active ingredients are prepared by homogenization in a mixture of acetone/Dimethyl sulfoxide/tween® as disclosed above, and then diluted with water to obtain the desired active material concentration.
The young plants of barley are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of acetone/Dimethyl sulfoxide/tween®.
After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Pyrenophom. teres spores. The contaminated barley plants are incubated for 48 hours at 20°C and at 100% relative humidity and then for 12 days at 20°C and at 70-80% relative humidity.
The test is evaluated 14 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.
Results:
Figure imgf000133_0002
Active compound Rate of application of Efficacy active compound in
ppm in%
Comp rison 500 0 conipound 100 0
According to the
invention:
Figure imgf000134_0001
Figure imgf000134_0002
Figure imgf000134_0003
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 38 compound 100 0
According to the
invention:
Figure imgf000135_0001
Figure imgf000135_0003
Figure imgf000135_0004
Figure imgf000135_0002
Example R5: in vivo preventive test on Septoria tritici (leaf spot on wheat)
The tested active ingredients are prepared by homogenization in a mixture of acetone/Dimethyl sulfoxide/tween® as disclosed above, and then diluted with water to obtain the desired active material concentration. The young plants of wheat are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of acetone/Dimethyl sulfoxide/tween®.
After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Septoria tritici spores. The contaminated wheat plants are incubated for 72 hours at 18°C and at 100% relative humidity and then for 21 days at 20°C and at 90% relative humidity. The test is evaluated 24 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.
Results:
Figure imgf000136_0001
Active compound Rate of application of
Efficacy active compound in
ppm in%
Comparison 500 33 compound 100 17
According to the
invention:
1-03 500 100
100 83
Figure imgf000137_0001
Figure imgf000137_0002
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 93 compound. x 100 0
Comparison 500 96 compound ■ X 100 20
" ra
According to the
invention:
1-32 500 100
100 71
4 ' Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 94 compound IT 100 38
According to the
invention:
1-30 500 98
100 94
Figure imgf000138_0001
Figure imgf000138_0002
Active compound Rate of application of Efficacy active compound in
ppm in%
Figure imgf000139_0001
Example R6: in vivo preventive test on Sphaerotheca fuliginea (powdery mi!dew on cucurbits)
The tested active ingredients are prepared by homogenization in a mixture of acetone/Dimethyl sulfoxide/tween® as disclosed above, and then diluted with water to obtain the desired active material concentration.
The young plants of gherkin are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of acetone/Dimethyl sulfoxide/tween®.
After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Sphaerotheca fuliginea spores. The contaminated gherkin plants are incubated for 72 hours at 18°C and at 100% relative humidity and then for 12 days at 20°C and at 70-80% relative humidity.
The test is evaluated 15 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.
Results:
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 30 compound 100 20
According to the
invention:
1-04 500 100
100 100
Active compound Rate of application of Efficacy active compound in
ppm in% Comparison 500 30 compound 100 0
According to the
invention:
1-03 500 100
100 85
Figure imgf000140_0001
Figure imgf000140_0002
Active compound Rate of application of Efficacy active compound in
ppm in%
Figure imgf000141_0001
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 80 compound 100 0
According to the
invention:
1-27 500 100
100 100
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 95 compound 100 95
Figure imgf000142_0001
Example R7: In vivo preventive lest on Uroinyces appendiculatus (bean rust)
The tested active ingredients are prepared by homogenization in a mixture of acetone/Dimethyl sulfoxide/tween® as disclosed above, and then diluted with water to obtain the desired active material concentration.
The young plants of bean are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of acetone/Dimethyl sulfoxide/tween®.
After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Uromyces appendiculatus spores. The contaminated bean plants are incubated for 24 hours at 20°C and at 100% relative humidity and then for 10 days at 20°C and at 70-80% relative humidity.
The test is evaluated 11 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.
Results:
Figure imgf000142_0002
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison ifY) 500 100 compound 100 0 According to the
invention:
1-03 500 100
100 81
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 50 compound 100 25
According lo the
invention:
1-06 500 100
100 100
Figure imgf000143_0001
Active compound Rate of apphcation of Efficacy active compound in
ppm in%
Comparison 500 0 compound 100 0
Comparison 500 0 compound 100 0
a X According to the
invention:
1-32 500 100
100 81
Figure imgf000144_0001
Figure imgf000144_0002
Active compound Rate of application of Efficacy active compound in
ppm in%
Comparison 500 0 compound \& 100 0
According to the
invention:
Figure imgf000145_0001

Claims

Claims
1. Imidazole derivatives of the formula (I)
Figure imgf000146_0001
wherein
R ! represents hydrogen, in each case optionally branched Ci-Cs-alkyl, Ci-Cs-haloalkyl, Ci- C6-alkenyl, C2-C7-haloalkenyl, C2-Cs-alkynyl, C2-Cs-haloalkynyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, C i -C4-haloalkoxy- , Ci-C4-alkylthio- or C i -C4-halo alky Ithio- sub stituted C3-C7-cycloalkyi, optionally halogen-, cyano-, C1-C4- alkyl-, C 1 - C4-haloalky 1- , Ci-C4-alkoxy-, C 1 -C4-haloalkoxy- , Ci-C4-alkylthio- or C1-C4- haloalkylthio-substituted bicycloalkyl, optionally halogen-, cyano-, Ci-C4-alkyi-, C1-C4- haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-alkylthio- or C 1 -C4-haloalkylthio- substituted C3-Cs-cycloalkyialkyl; optionally halogen-, cyano-, Ci-C4-alkyl-, C1-C4- haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-aikylthio- or C 1 -C4-haloalkylthio- substituted C3-C7-halocycloalkyl-C 1 -C4-alkyl; optionally halogen-, cyano-, Ci-C4-aikyl-, Ci-C4-haloalkyl-, Ci-C4-aIkoxy-, Ci-C4-haloaIkoxy-, Ci-C4-alkylthio- or C1-C4- haloalkyithio-substituted C3-C7-halocycloalkyl-Ci-C4-haloalkyl; optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-alkylthio- or Ci-C4-haloalkyithio-substituted C3-C7-cycloalkyl-C 1 -C4-haloalkyl; optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, C 1 -C4-haloalkoxy- , Ci-C4-alkylthio- or C 1 -C4-haloalkylthio-substituted C3-C7-cycloalkyl- C3-C7-cycloalkyl; optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haioalkoxy-, Ci-C4-alkylthio- or Ci-C4-haloaliylthio-substituted C3-C7-cycioalkenyl, optionally halogen-, cyano-, C1-C4- alkyl-, C 1 - C4-haloalky 1- , Ci-C4-alkoxy-, C 1 -C4-haloalkoxy- , Ci-C4-aikyithio- or C1-C4- haloalkylthio-substituted tri(Ci-C8-alkyl)silyl-Ci-C4-aikyl; optionally halogen-, cyano-, Ci- C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, C i-C4-haloalkoxy-, Ci-C4-alkylthio- or C1-C4- haloalkylthio-substituted tri(Ci-C8-alkyl)silyl-C3-C7-cycloalkyl;
R2 represents I I. Ci-Cs-alkyl, -Si(R3a)( R3b)( R3c), -P(0)(OH)2, -CH2-0-P(0)(OH)2, -C(0)-Ci- Cs-alkyl, -C(0)-C3-C7-cycloalkyl, -C(0)NH-Ci-C8-alkyl; -C(0)N-di-Ci-C8-alkyl; - C(0)0-Ci-Cs-alkyl; wherein the -C(0)-Ci-C8-alkyl, -C(0)-C3-C7-cycloalkyl, -C(0)NH- Ci-Cs-alkyl; -C(0)N-di-C 1 -Cs-alkyl or -C(0)0-Ci-C8-alkyl may be non- sub stituted or substituted by one or more group(s) selected from halogen or Ci-Cs-alkoxy; wherein
R3a, R3b, R3c represent independent from each other a phenyl or Ci-Cs-alkyl;
R ' represents halogen; hydro xyl; cyano; isocyano; nitro; amino; sulfanyl; pentafluoro-λ6- sulfanyl; carboxaldehyde, hydroxy carbonyl, Ci-Cs-alkyl; Ci-Cs-haloalkyl; Ci-Cs- cyanoalkyl; Ci-Cs-alkyloxy; Ci-Cs-halogenalkyloxy; tri(Ci-Cs-alkyl)silyi; tri(Ci-Cs- alkyl)silyi-Ci-Cs-alkyl; C3-C7-cycloalkyl; C3-C7-halogencycloalkyl; C3-C7-cycloalkenyl; C3-C7-halogencycloalkenyl; CU-Cio-cycloalkylalkyl; C4-Cio-halocycloalkylalkyl; Ce-Ci2- cycioalkyicycloalkyi; Ci-Cs-alkyl-C3-C7-cycloalkyl; Ci-Cs-alkoxy-C3-C7-cycloalkyl; tri(Ci-Cs-alkyl)silyl-C3-C7-cycloalkyl; C2-Cs-alkenyl; C2-Cs-alkynyl; C2-Cs-alkenyloxy; C2-C8-halogenalkenyloxy; C3-Cs-alkynyloxy; C3-Cs-halogenoalkynyloxy; Ci-Cs- alkylamino; Ci-Cs-halogenalkylamino; G-Cs-cyanoalkoxy; CU-Cs-cycloalkylalkoxy; C3 - C«- cy cloalkoxy ; Ci-Cs-aikylsulfanyl; Ci-Cs-halogenoalkylsulfanyl; Ci-Cs- alkyicarbonyl; Ci-Cs-haiogenoalkylcarbonyl; arylcarbonyl; aryl-Ci-Ce-alkylcarbonyl; C3- Cs-cycloalkylcarbonyl; C3-Cs-halogenoeycloalkylcarbonyl; Ci-Cs-alkylcarbamoyl; di-Ci- Cs-alkylcarbamoyl; N-Ci-Cs-alkyloxycarbamoyl; Ci-Cs-alkoxycarbamoyl; N-Ci-Cs-alkyl- C 1 -C8-alkoxy carbamoyl; aminothiocarbonyl; Ci-Cs-alkoxycarbonyl; Ci-Cs- halogenoalkoxycarbonyl; C3-Cs-cycloalkoxycarbonyl; C2-Cs-alkoxyalkylcarbonyl; C2-C8- halogenoalkoxyalkylcarbonyl; C3-C 10-cycloa koxya kylcarbonyl; Ci-Cs- alkylaminocarbonyl; di-Ci-Cg-alkylaminocarbonyl; Cs-Cs-cycloalkylaminocarbonyl; Ci-Cs-alkylcarbonyloxy; Ci-Cs-halogenoalkyicarbonyioxy; C3-Cs-cycloalkylcarbonyloxy; C 1 - C8-alkylcarbonylamino; C 1 -Cs-haiogenoalkylcarbonylamino ; Ci-Cs- alkylaminocarbonyloxy; di-C 1 -Cs-alkylaminocarbonyloxy ; C 1-Cg-alkyloxycarbonyloxy ; C 1-Cr alkylsulfinyl; Ci-Cs-halogenoalkylsulfinyl; C 1-Cg-alkylsulfonyl; Ci-Cs- halogenoalkylsulfonyi; Ci-Cs-alkylsulfonyloxy; Ci-Cs-halogenoalkylsulfonyloxy; Ci-Cs- alkylaminosulfamoyl; di-Ci-Cs-alkylaminosulfamoyl; (Ci-Cs-aIkoxyimino)-Ci-C8-alkyl; (C3-C7-cycloalkoxyimino)-Ci-C8-alkyl; hydroxyimino-C 1-Cs-alkyl; (C 1 -Cs-alkoxyimino)- Cs-Crcycloalkyl; hydroxyimino-C3-C7-cycloalkyl; (Ci-Cs-alkylimino)-oxy; (Ci-Cs- alkylimino)-oxy-Ci-C8-alkyl; (C3-C7-cycloalkylimino)-oxy-Ci-Cs-alkyl; (Ci-Ce- alkylimino)-oxy-C3-C7-cycloalkyl; (Ci-Cs-aLk;enyloxyimino)-Ci-Cs-alkyl; (Ci-Cs- ahcynyioxyimino)-Ci-Cs-alkyl; (benzyloxyimino)-C 1-C alkyl; Ci-Cs-alkoxyalkyl; Ci-Cs- alkylthioalkyl; Ci-Cs-alkoxyalkoxyalkyl; Ci-Cs-halogenoalkoxyalkyl; benzyl; phenyl; 5- membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; isocyano; amino; sulfanyl; pentafluoro- 6-sulfanyl; carboxaldehyde, hydroxycarbonyl, Ci-Cs-alkyl; Ci-Cs- haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs-alkyloxy; C 1 -Cs-halogenalkyloxy ; tri(Ci-Cs-alkyl)silyl; tri(Ci-Cs-alkyl)silyl-Ci-Cs-alkyl; C3-C7-cycloalkyl; C3-C7-halogencycloalkyl; C3-C7- cycloalkenyl; C3-C7-halogencycioalkenyl; CU-Cio-cycloalkylalkyl; C4-C10- halocycloalkylalkyl; Ce-Cn-cycloalkylcycloalkyl; C 1 -Cs-alkyl-Cs-C?- cy cloalkyl; Ci-Cs- alkoxy-C3-C7-cycloalkyl; tri(Ci-Cs-alkyl)silyl-C3-C7-cycloalkyl; C2-Cs-alkenyl; C2-C8- alkynyl; C2-Cg-alkenyloxy; C2-Cs-halogenalkenyloxy; Cs-Cs-alkynyloxy; C3-C8- halogenoalkynyioxy; Ci-Cs-alkylamino; Ci-Cs-halogenalkylamino; Ci-Cg-cyanoalkoxy; C4-C8-cycloalkylalkoxy; Cs-Ce-cycloalkoxy; C 1 -Cg-alkylsulfanyl; Ci-Cs- halogenoalkylsulfanyl; Ci-Cs-alkylcarbonyl; C Cs-haiogenoalkyicarbonyl; arylcarbonyl; aryl-Ci-Ce-alkylcarbonyl; C3 -C 8- cy cloalkylcarbonyl; Cs-Cg-halogenocycloalkylcarbonyl; Ci-Cs-alkylcarbamoyl; di-Ci-Cs-alkylcarbamoyl; N-C 1 -Cs-alkyloxy carbamoyl; Ci-Cs- alkoxy carbamoyl; N-Ci-Cg-alkyl-Ci-Cralkoxy carbamoyl; aminothiocarbonyl; Ci-Cs- alkoxycarbonyl; C 1 -Cs-halogenoalkoxy carbonyl; C3-Cs-cycloalkoxycarbonyl; C2-C8- alkoxyalkyicarbonyi; C2-C halogenoalkoxyalkylcarrx>nyl; C3-C10- cycloalkoxyalkylcarbonyl; Ci-Cs-alkylaminocarbonyl; di-Ci-Cs-alkylaminocarbonyl; C3- Cs-cycloalkyiaminocarbonyl; Ci-Cs-alkylcarbonyloxy; C 1 -Cs-halogenoalkylcarbonyloxy ; C3-C8-cycloalkylcarbonyloxy; Ci-Cs-alkylcarbonylamino; Ci-Cs- halogenoalkylcarrxmylamino; Ci-Cs-alkylaniinocarbonyloxy; di-Ci-Cs- alkylaminocarbonyloxy; C 1 -Cs-alkyloxy carbonyloxy; C 1 -Cs-alkylsulfinyl; Ci-Cs- halogenoalkylsulfmyl; C 1 -Cs-alkylsulfonyl; Ci-Cs-halogenoalkyisulfonyi; Ci-Cs- alkylsulfonyloxy; Ci-Cs-halogenoalkylsulfonyloxy; Ci-Cs-alkylaminosulfamoyl; di-Ci-Cs- alkylaminosulfamoyl; (Ci-Cs-alkoxyimino)-Ci-Cs-alkyl; (C3-C7-cycloalkoxyimino)-Ci-Cs- alkyl; hydroxyimino-C 1 -Cs-alkyl; (Ci-Cs-alkoxyimino)-C3-C7-cyeloalkyl; hydroxyimino- C3-C7-cycloalkyl; (Ci-Cs-alkylimino)-oxy; (Ci-Cs-alkylimino)-oxy-Ci-Cs-alkyl; (C3-C7- cycloalkylimino)-oxy-Ci-C8-alkyl; (Ci-C6-alkylimino)-oxy-C3-C7-cycioalkyl; (Ci-Cr alkenyloxyimino)-Ci-C8-alkyl; (Ci-Cs-alkynyloxyimino)-Ci-Cs-alkyl; (benzyloxyimino) - Ci-C8-alkyl; Ci-Cg-alkoxyalkyl; Ci-Cs-alkyithioalkyl; Ci-Cg-alkoxyalkoxyalkyl; Ci-Cr halogenoalkoxyalkyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino; represents hydrogen, fluorine, Ci-Cs-alkyl, Ci-Cs-haloalkyl or Ci-Cs-alkyloxy; represents hydrogen, fluorine, Ci-Cs-alkyl, Ci-Cs-haloalkyl or Ci-Cs-alkyloxy;
R5 form together with the carbon atom to which they are attached an optionally halogen-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, C i-C4-haloalkoxy-, C1-C4- alkylthio- or C 1 -C4-haloalkylthio-substituted C3-C7-cycloalkyl ring; represents a 6-membered aromatic cycle of formula (Q-I)
Figure imgf000149_0001
wherein
U1 represents CX1 or N; wherein X1 represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non- substituted carbaldehyde 0-(Ci-Cs-alkyl)oxrme, pentafluoro- 6-sulfenyl group, substituted or non-substituted G-Cs-alkyl, substituted or non-substituted G-G- cycloalkyl, substituted or non-substituted G-G-halogencycloalkyl having 1 to 5 halogen atoms; substituted or non- substituted C3-C?-cycloalkenyl; substituted or non-substituted G- G-halogenoalkyl having 1 to 5 halogen atoms, a substituted or non-substituted G-G- alkenyl, substituted or non- substituted G-Cs-alkynyl, substituted or non- substituted G-G- alkoxy, substituted or non- substituted C 1 -G-halogeno alkoxy having 1 to 5 halogen atoms, substituted or non-substituted C 1 -G-alkylsulfenyl, substituted or non-substituted G-G- alkenyloxy, substituted or non- substituted G-G-alkynyloxy, substituted or non-substituted G - G- cy cloalkoxy , substituted or non-substituted N-(G-G-alkoxy)-G-G-alkanimidoyl, substituted or non-substituted N-(G-G-alkoxy)-G-G-halogenoalkanimidoyl having 1 to 5 halogen atoms, Ci-Cs-alkylaminocarbonyl; di-G-G-alkylaminocarbonyl, substituted or non- substituted G-G-alkoxycarbonyl, substituted or non-substituted G-G- alkylcarbonyloxy, substituted or non-substituted C 1 -Cs-alkylsulfinyl, substituted or non- substituted G-G-alkylsulfonyl, substituted or non-substituted (G-G-alkoxyimino)-G-G- alkyl; substituted or non-substituted (C3-C7-cycloalkoxyimino)-Ci-C8-alkyl; substituted or non- substituted hydroxyimino-C 1 -G-alkyl, substituted or non-substituted phenyloxy, substituted or non-substituted phenyLsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(Ci-C8-alkyl)-silyloxy, substituted or non-substituted tri(Ci-C8-alkyl)-silyl, substituted or non- substituted heterocyclyl, substituted or non- substituted heterocyclyloxy;
U2 represents CX2 or N; wherein X2 represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non- substituted carbaldehyde 0-(Ci-Cs-alkyl)oxime, pentafluoro- 6-sulfenyl group, substituted or non-substituted G-Cs-alkyl, substituted or non-substituted C3-C8- cycloalkyl, substituted or non-substituted C3-C7-halogencycloalkyl having 1 to 5 halogen atoms; substituted or non- substituted Cs-CT-cycloalkenyl; substituted or non-substituted Ci- Cs-halogenoalkyl having 1 to 5 halogen atoms, a substituted or non-substituted C2-C8- alkenyl, substituted or non- substituted C2-Cs-aliynyl, substituted or non- substituted Ci-Cs- alkoxy, substituted or non-substituted C 1 -C 8-halogeno alkoxy having 1 to 5 halogen atoms, substituted or non-substituted G-Cs-alkylsulfenyl, substituted or non-substituted C2-C8- alkenyloxy, substituted or non- substituted Cs-Cs-alkynyloxy, substituted or non-substituted C3 - Ce- cy clo alkoxy , substituted or non-substituted N-(Ci-C8-alkoxy)-Ci-C8-alkanimidoyl, substituted or non-substituted N-(Ci-C8-alkoxy)-Ci-C8-halogenoalkanimidoyl having 1 to 5 halogen atoms, CrCs-alkylaminocarbonyl; di-Ci-Cs-alkylaminocarbonyl, substituted or non- substituted G-Cs-a koxyearbonyl, substituted or non-substituted G-Cs- alkylcarbonyloxy, substituted or non-substituted C 1 -Cs-alkylsulfmyl, substituted or non- substituted C 1 -Chalky Lsulfonyl, substituted or non-substituted (Ci-Cralkoxyimino)-Ci-Cr alkyi; substituted or non-substituted (C3-C7-cycloalkoxyimino)-Ci-Cs-alkyi; substituted or non- substituted hydroxyimino-C 1 -Cs-alkyl, substituted or non-substituted phenyioxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(Ci-Cs-alkyl)-silyloxy, substituted or non-substituted tri(Ci-Cralkyl)-silyl, substituted or non- substituted heterocyclyl, substituted or non- substituted heterocyclyloxy; U3 represents CX3 or N; wherein X3 represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non- substituted carbaldehyde 0-(Ci-Cs-alkyl)oxime, pentafluoro- 6-sulfenyl group, substituted or non-substituted G-Cs-alkyl, substituted or non-substituted C3-C8- cycioalkyl, substituted or non-substituted C3-C7-halogencycioalkyl having 1 to 5 halogen atoms; substituted or non- substituted C3-C7-cycloalkenyl; substituted or non-substituted G-
Cs-halogenoalkyl having 1 to 5 halogen atoms, a substituted or non-substituted G-G- alkenyl, substituted or non-substituted G-G-alkynyi, substituted or non-substituted G-G- alkoxy, substituted or non-substituted G-G-halogenoalkoxy having 1 to 5 halogen atoms, substituted or non-substituted Ci-Cs-alkylsulfenyl, substituted or non-substituted G-G- alkenyloxy, substituted or non- substituted Cs-Cs-alkynyloxy, substituted or non-substituted
C3 - C - cy cloalkoxy , substituted or non-substituted N-(Ci-C8-alkoxy)-Ci-Cs-alkanimidoyl, substituted or non-substituted N-(Ci-C8-alkoxy)-Ci-C8-halogenoalkanimidoyl having 1 to 5 halogen atoms, Ci-Cs-alkylaminocarbonyl; di-C i-Cs-alkylaminocarbonyl, substituted or non- substituted Ci-Cs-alkoxycarbonyl, substituted or non-substituted Ci-Cs- alkylcarbonyloxy, substituted or non-substituted C 1 -Cs-alkylsulfinyl, substituted or non- substituted Ci-Cs-alkylsulfonyl, substituted or non-substituted (C 1 -Cs-alkoxyimino) -C 1 -Cs- alkyl; substituted or non-substituted (C3-C7-cycloalkoxyimino)-Ci-Cs-alkyi; substituted or non- substituted hydroxyimino-C 1 -Cg-alkyl, substituted or non-substituted phenyioxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(Ci-Cs-alkyl)-silyloxy, substituted or non- substituted tri(Ci-C8-alkyl)-silyl, substituted or non- substituted heterocyclyl, substituted or non- substituted heterocyclyloxy; U4 represents CX4 or N; wherein X4 represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non- substituted carbaldehyde 0-(Ci-Cs-alkyl)oxime, pentafluoro- 6-suifenyl group, substituted or non-substituted G-Cs-alkyl, substituted or non-substituted C3-C8- cycloalkyl, substituted or non-substituted C3-C7-halogencycloalkyl having 1 to 5 halogen atoms; substituted or non- substituted C3-C?-cycloalkenyl; substituted or non-substituted G- C8-halogenoalkyl having 1 to 5 halogen atoms, a substituted or non-substituted G-G- alkenyl, substituted or non- substituted G-G-alkynyl, substituted or non- substituted G-G- alkoxy, substituted or non-substituted C 1 -G-halogeno alkoxy having 1 to 5 halogen atoms, substituted or non-substituted G-G-alkyisulfenyl, substituted or non-substituted G-G- alkenyloxy, substituted or non- substituted C3-C8-alkynyloxy, substituted or non-substituted G - G- cy clo alkoxy , substituted or non-substituted N-(G-G-alkoxy)-G-G-alkanimidoyl, substituted or non-substituted N-(G-C8-alkoxy)-G-C8-halogenoalkanimidoyl having 1 to 5 halogen atoms, Ci-Cs-alkylaminocarbonyi; di-G-G-aikylaminocarbonyl, substituted or non- substituted Ci-Cs-alkoxycarbonyl, substituted or non-substituted G-G- alkylcarbonyloxy, substituted or non-substituted C 1 -G-alkylsulfmyl, substituted or non- substituted C 1 -Chalky lsulfonyl, substituted or non-substituted (G-Cralkoxyimino)-G-Cs- alkyl; substituted or non-substituted (C3-C7-cycloalkoxyimino)-Ci-C8-alkyl; substituted or non- substituted hydroxyimino-C 1 -G-alkyl, substituted or non-substituted phenyloxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(G-G-alkyl)-silyloxy, substituted or non-substituted tri(Ci-Cralkyl)-silyl, substituted or non- substituted heterocyclyl, substituted or non- substituted heterocyclyloxy;
U5 represents CX5 or N; wherein X5 represents hydrogen, halogen, nitro, cyano, hydroxy, sulfanyl, carboxaldehyde, substituted or non- substituted carbaldehyde 0-(G-G-alkyl)oxime, pentafluoro- 6-sulfenyi group, substituted or non-substituted G-G-alkyl, substituted or non-substituted G-G- cycloalkyl, substituted or non-substituted C3-C7-halogencycloalkyl having 1 to 5 halogen atoms; substituted or non- substituted C3-C7-cycloalkenyl; substituted or non-substituted G- Cs-halogenoalkyl having 1 to 5 halogen atoms, a substituted or non-substituted C2-C8- alkenyl, substituted or non- substituted C2-Cg-alkynyl, substituted or non- substituted G-Cs- alkoxy, substituted or non- substituted C 1 -C 8-halogeno alkoxy having 1 to 5 halogen atoms, substituted or non-substituted G-Cs-alkylsulfenyl, substituted or non-substituted C2-C8- alkenyloxy, substituted or non- substituted Cs-Cs-alkynyloxy, substituted or non-substituted C3 - C«- cy cloalkoxy , substituted or non-substituted N-(Ci-Cs-alkoxy)-Ci-Cs-alkanimidoyl, substituted or non-substituted N-(Ci-C8-alkoxy)-G-C8-halogenoalkanimidoyl having 1 to 5 halogen atoms, G-Cs-alkylaminocarbonyl; di-G-Cs-alkylaminocarbonyl, substituted or non- substituted Ci-Cs-alkoxycarbonyl, substituted or non-substituted Ci-Cs- alkylcarbonyloxy, substituted or non-substituted Ci-Cs-alkylsulfinyl, substituted or non- substituted Ci -C8-alkyLsulfonyl, substituted or non-substituted (Ci-C8-alkoxyimino)-Ci-Cs- alkyl; substituted or non-substituted (C3-C7-cycloalkoxyimino)-Ci-C8-alkyl; substituted or non- substituted hydroxyimino-Ci-Cs-alkyl, substituted or non-substituted phenyloxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(Ci-Cs-alkyi)-silyloxy, substituted or non-substituted tri(Ci-Cs-alkyl)-silyl, substituted or non- substituted heterocyclyl, substituted or non- substituted heterocyclyloxy; and wherein at most two of U1, U2, U3, U4 or U5 can represent N; or
U1 and U2 or U2 and U3 or U3 and U4 form together an additional saturated or unsaturated 4 to 6-membered halogen- or Ci-Cs-a kyl-substituted or non-substituted ring; and its salts or N-oxides.
2. Imidazole derivatives of the formula (I) according to claim 1, wherein
R1 represents in each case optionally branched Ci-Cs-alkyl, Ci-Cs-haloalkyi, C2-C7-alkenyl, C?-C7-haloalkenyl, optionally halogen-, cyano, Ci-Cralkyl-, Ci-C4-haloalkyl-, C1-C4- alkoxy-, C 1 -C4-haloalkoxy-, Ci-C4-alkylthio- or Ci-C4-haloalkylthio-substituted C3-C7- cycloalkyl;
R2 represents I I, Ci-Cs-alkyl, halogen- or Ci-Cs-alkoxy-substituted or non-substituted -C(0)-
G-Cs-alkyl;
R3 represents halogen; hydroxyl; cyano; isocyano; nitro; carboxaldehyde, hydroxycarbonyl, Ci-Cs-alkyl; Ci-Cs-haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs-alkyloxy; C 1-Cs-halogenalkyloxy ; C3-C7-cycloalkyl; C3-C7-halogencycloalkyl; C2-Cs-alkenyl; C2-Cs-alkynyl; C2-C8- alkenyloxy; C2-C8-halogenalkenyloxy; C3-Cs-alkynyloxy; C3-Cs-haiogenoalkynyloxy; Ci- Cs-alkyisulfanyl; Ci-Cs-halogenoalkylsulfanyl; Ci-Cs-alkylcarbonyl; Ci-Cs- halogenoalkylcarbonyl; arylcarbonyl; aryl-Ci-C6-alkyicarbonyl; C3-Cs-cycloalkylcarbonyl; C3-C8-halogenocycloalkylcarbonyl; aminothiocarbonyl; Ci-Cg-alkoxycarbonyl; Ci-Cs- halogenoalkoxycarbonyl; C3-Cs- cy cloalkoxy carbony 1; Ci-Cs-alkyicarbonyloxy; Ci-Cs- halogenoalkylcarbonyloxy; Cs-Cs-cycloalkylcarbonyloxy; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; or phenyloxy; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; isocyano; amino; sulfanyl; pentafluoro^6-sulfanyl; Ci-Cg-alkyl; Ci-Cs-haloalkyl; Ci-Cg- alkyloxy; Ci-Cs-halogenalkyloxy; tri(Ci-Cs-alkyl)silyl; C3-C?-cycloalkyl; C2-Cs-alkenyl; Cz-Cs-alkynyl;
R" represents hydrogen, fluorine, Ci-C4-alkyl;
IV represents hydrogen, fluorine, Ci-C4-alkyl; or
R4 and R5 form together with the carbon atom to which they are attached an optionally halogen-, Ci- C4- alkyl- sub stituted C3-C6-cycloalkyl ring;
Figure imgf000153_0001
wherein X1, X2, X3, X4 or X5 independent from each other have the same definition as given in claim 1 ; preferably independent from each other represent hydrogen or halogen; and its salts or N-oxides.
Imidazole derivatives of the formula (I) according to claim 1 or 2, wherein
Q represents a, preferably substituted, phenyl, 3-pyridyl or 4-pyridyl of formula (Q-I-l) to (Q-
Figure imgf000153_0002
wherein X1, X2, X3, X4 or X5 independent from each other have the same definition as given in claim 1 or 2; preferably independent from each other represent hydrogen or halogen; and R1, R ,R :, R4 and R5 have the same definition as given in claim 1 or 2;
and its salts or N-oxides.
Imidazole derivatives of the formula (I) according to claim 1 or 2, wherein
R3 represents represents halogen; cyano; carboxaldehyde, hydroxy carbonyl, Ci-C4-alkyl; Ci- CVhaloalkyl; Ci-CVcyanoalkyl; Ci-C4-alkyloxy; Ci-CVhalogenalkyloxy; C3-C7- cycloaliyl; C3-C7-halogencycloaliyl; C2-C5-alkenyl; C2-C5-alkynyl; C 1 -C4-aLkylsulfanyl; C 1 -C4-halogenoaliylsulfanyl; C 1 -CValkylcarbonyl; Ci-C4-halogenoalkylcarbonyi; C1-C4- alkoxycarbonyl; C 1 -C4-halogenoalkoxycarbonyl; benzyl; phenyl; furyl; pyrrolyl; thienyl; pyridyl; benzyloxv; or phenyloxy; wherein the benzyl, phenyl, 5-membered heteroaryl, 6- membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; Ci-Cs-alkyl; Ci-Cs-haloalkyl; Ci-Cs-aliyloxy; Ci- Cg-halogenalkyloxy.
Q represents a, preferably substituted, phenyl, 3 -pyridyl or 4-pyridyl of formula (Q-I-l) to (Q-
Figure imgf000154_0001
wherein X1, X2, X3, X4 or X5 independent from each other have the same definition as given in claim 1 or 2; preferably independent from each other represent hydrogen or halogen; and R1, R , R4 and R5 have the same definition as given in claim 1 or 2;
and its salts or N-oxides.
Method for controlling harmful microorganisms in crop protection and in the protection of materials, characterized in that compounds of the formula (I) according to Claim 1, 2, 3 or 4 are applied to the harmful microorganisms and/or their habitat.
Method for controlling phytopathogenic harmful fungi in crop protection and in the protection of materials, characterized in that compounds of the formula (I) according to Claim 1, 2, 3 or 4 are applied to the phytopathogenic harmful fungi and/or their habitat.
Composition for controlling harmful microorganisms, preferably for controlling phytopathogenic harmful fungi , characterized by a content of at least one compound of the formula (I) according to Claim 1, 2, 3 or 4, in addition to extenders and/or surfactants.
8. Composition according to Claim 7 comprising at least one further active ingredient selected from the group of the insecticides, attractants, stenlants, bactericides, acaricides, nematicides, fungicides, growth regulators, herbicides, fertilizers, safeners and semiochemicals.
9. Use of compounds of the formula (I) according to Claim 1, 2, 3 or 4 for control of harmful microorganisms, preferably phytopathogenic harmful fungi, in crop protection and in the protection of materials.
10. Process for producing compositions for controlling harmful microorganisms, preferably for controlling phytopathogenic harmful fungi, characterized in that compounds of the formula (I) according to Claim 1, 2, 3 or 4 are mixed with extenders and/or surfactants.
11. Use of compounds of the formula (I) according to Claim 1, 2, 3 or 4 for treatment of transgenic plants.
12. Use of compounds of the formula (I) according to Claim 1, 2, 3 or 4 for treatment of seed and of seed of transgenic plants.
13. Compounds of formula (XVII)
Figure imgf000155_0001
(XVII)
wherein
R1 represents hydrogen, in each case optionally branched Ci-Cs-alkyl, Ci-Cs-haloalkyl, C2- C7-alkenyl, C2-C7-haloaLkenyl, C2-Cs-alkynyi, Ci-Cg-haioalkynyl, optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-Crhaloalkyl-, Ci-C4-alkoxy-, C 1 -C4-haloalkoxy- , Ci-C4-alkylthio- or Ci-C4-haloalkylthio-substituted C3-C?-cycloalkyl, optionally halogen-, cyano-, C1-C4- alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-alkylthio- or C1-C4- haloalkylthio-substituted bicycloalkyi, optionally halogen-, cyano-, Ci-C"4-alkyl-, C1-C4- haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haioalkoxy-, Ci-C4-alkylthio- or Ci-C4-haloalkylthio- substituted Cs-Cs-cycloalkylalkyl; optionally halogen-, cyano-, Ci-C4-alkyl-, C1-C4- haloalkyl-, Ci-C -alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-alkylthio- or Ci-C4-haloalkylthio- substituted C3-C7-halocycloalkyl-Ci-C4-alkyl; optionally halogen-, cyano-, Ci-C4-alkyl-, C 1 - Ct-haloalky 1- , Ci-C -alkoxy-, C 1 -C -haloalkoxy-, Ci-C4-alkylthio- or C1-C4- haloalkylthio-substituted C3-C7-halocycloaIkyl-Ci-C4-haloalkyl; optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C -alkoxy-, C 1 -C4-haloalkoxy- , Ci-C -alkylthio- or C 1 -C4-haloalkylthio-substituted C3-C7-cycloalkyl-Ci-C4-haloaLkyl; optionally halogen-, cyano-, Ci-C4-alkyl-, C 1 -C4-haloalkyl-, Ci-C4-alkoxy-, C 1 -C4-haloalkoxy- , Ci-C4-alkylthio- or C i-C4-haloalkylthio-substituted Cs-Crcycloalkyl- C3-C6-cycloalkyl; optionally halogen-, cyano-, Ci-C4-alkyl-, Ci-C4-haloalkyl-, Ci-C4-alkoxy-, C i -C4-haloalkoxy- , Ci-C4-alkylthio- or Ci-C4-haloalkylthio-substituted C3-C7-cycloalkenyl, optionally halogen-, cyano-, C1-C4- aliyl-, C 1 - C4-haloalky 1- , Ci-C4-alkoxy-, C i-C -haloalkoxy-, Ci-C -alkylthio- or C1-C4- haloalkylthio-substituted tri(CrC8-alkyl)silyl-Ci-C4-alkyl; optionally halogen-, cyano-, Ci- C4-alkyl-, C 1 -C4-haloalkyl-, Ci-C4-alkoxy-, Ci-C4-haloalkoxy-, Ci-C4-alkylthio- or C1-C4- haloalkylthio-substituted tri(Ci-C8-alkyl)silyl-C3-C7-cycloalk i;
R ' represents halogen; hydro xyl; cyano; isocyano; nitro; amino; sulfanyl; pentafluoro-λ6- sulfanyl; carboxaldehyde, Ci-Cs-alkyl; Ci-Cs-haloalkyl; Ci-Cs-cyanoalkyl; Ci-Cs-alkyloxy; Ci-Cs-halogenalkyloxy; tri(Ci-C8-alkyl)silyl; tri(Ci-C8-alkyl)silyl-Ci-Cs-alkyl; C3-C7- cycloalkyl; C3-C7-halogencycloalkyl; C3-C7-cycloalkenyl; C3-C7-halogencycloalkenyl; C4- Cio-cycloalkylalkyl; C4-C 10-halocycloalkylalkyl; C«-C 12-cycloalkylcycloalkyl; G-Cs-alkyl- C3-C7-cycloalkyl; Ci-Cs-alkoxy-C3-C7-cycloalkyl; tri(Ci-Cs-alkyl)silyl-C3-C7-cycloalkyl; C2-C8-alkenyl; C2-Cs-alkynyl; C2-Cs-alkenyloxy; C2-Cs-halogenalkenyloxy; C3-C8- alkynyloxy; C3-Cs-halogenoalkynyloxy; Ci-Cs-alkylamino; C 1 -Cs-halogenalkylamino; Ci- Cg-cyanoalkoxy; C4-C8-cycloalkylalkoxy; C3-C6-cycloalkoxy; C 1 -Cs-alkylsulfanyl; G- Cs-halogenoalkylsulfanyl; C 1 -Cs-alkylcarbonyl; C 1 -Cg-halogenoalkylcarbonyl; arylcarbonyl; aryl-Ci-Ce-alkylcarbonyl; C3-Cs-cycloalkylcarbonyl; C3-C8- halogenocycloalkylcarbonyl; C 1 -Cs-alkylcarbamoyl; di-C Cs-alkylcarbamoyl; N-G-Cs- alkyloxycarbamoyl; C 1 -Cs-alkoxy carbamoyl; N-Ci-Cs-alkyl-Ci-Cs-alkoxycarbamoyi; aminothiocarbonyl; C2-C5-alkoxycarbonyl; G-Cs-halogenoalkoxycarbonyi; C3-C8- cycloalkoxycarbonyl; C2-C8-alkoxyalkylcarbonyl; C2-C8-halogenoalkoxyalkylcarbonyl; C3- Cio-cycloalkoxyalkylcarbonyl; Ci-Cs-alkylaminocarbonyl; di-Ci-Cs-alkylaminocarbonyl; C3-Cs-cycloaltylaminocarbonyl; Ci-Cs-alkylcarbonyloxy; G-Cs- halogenoalkylcarbonyloxy; Cs-Cs-cycloalkylcarbonyloxy; Ci-Cs-alkylcarbonylamino; Ci-Cs-halogenoalkylcarbonylamino; Ci-Cs-alkylaminocarbonyloxy; di-G-Cs- alkylaminocarbonyloxy; C 1 -Cs-alkyloxycarbonyloxy ; Ci-Cs-alkylsulfinyl; G-Cs- halogenoalkylsulfinyl; C 1 -Cs-alkylsulfonyl; Ci-Cs-halogenoalkylsulfonyl; G-Cs- alkylsulfonyloxy; C Cs-halogenoalkylsulfonyloxy; G-Cs-alkylaminosulfamoyl; di-G-Cg- alkylaminosulfamoyl; (Ci-Cs-alkoxyimino)-Ci-Cralkyl; (G-G-cycloalkoxyimino^G-Cs- alkyl; hydroxyimino-C 1 -Cs-alkyl; (G-Cs-alkoxyimiiK^-G-G-cycloalkyl; hydroxyimino- C3-C7-cycloalkyl; (CrCs-alkylimino)-oxy; (Ci-C8-alkylimino)-oxy-Ci-Cs-alkyl; (C3-C7- cycloalkylimino)-oxy-G-Cs-alkyl; (Ci-C6-alkyUrnino)-oxy-C3-C7-cycloalkyl; (G-Cs- alkenyloxyimino)-G -Cs-alkyl; (G-Cs-alkynyloxyimino)-G-Cralkyl; (benzyloxyimino) - Ci-Cs-alkyl; G-Cs-alkoxyalkyl; G-Cs-alkylthioalkyl; G-Cs-alkoxyalkoxyalkyl; G-Cs- halogenoalkoxyalkyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino; wherein the benzyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, benzyloxy or phenyloxy may be optionally substituted by one or more group(s) selected from halogen; hydroxyl; cyano; isocyano; amino; sulfanyl; pentafluoro- 6-sulfanyl; carboxaldehyde, hydroxycarbonyl, Ci-Cs-alkyl; Ci-Cs-haloalkyi; Ci-Cs-cyanoalkyi; Ci-Cs-alkyloxy; Ci-Cs- halogenalkyloxy; tri(Ci-C8-alkyi)silyl; tri(Ci-C8-alkyl)silyl-Ci-C8-alkyl; C3-C7-cycloaIkyl; C3-C7-haiogencycloalkyl; C3-C7-cycloalkenyl; C3-C7-halogencycloalkenyl; C4-C10- eycloalkylalkyl; C4-C1o-halocycloalkylalkyl; Ce-Cn-cycloalkylcycloalkyl; Ci-Cs-alkyl-C3- Cv-cycloalkyl; Ci-Cs-alkoxy-Cs-CT-cycloalkyl; tri(Ci-C8-alkyl)siiyl-C3-C7-cycloalkyi; C2- C8-alkenyi; C2-C8-alkynyl; C2-C8-alkenyloxy; C^-Cs-halogenalkenyloxy; C3-CV alkynyloxy; C3-C8-halogenoalkynyloxy; Ci-Cs-alkylamino; Ci-Cs-halogenalkyiamino; Ci- C8-cyanoalkoxy; G^-Cs-cycloalkylalkoxy; C3-C6-cycloalkoxy; C1-C8-alkylsulfanyl; Ci- Cs-halogenoalkylsuifanyl; C 1 -Cs-alkyicarbonyl; C 1 -Cs-halogenoalkylcarbonyl; arylcarbonyl; aryl-Ci-C6-alkylcarbonyl; Cs-Cs-cycloalkylcarbonyl; C3-C8- halogenocycloalkylcarbonyl; Ci-Cs-alkylcarbamoyl; di-Ci-Cs-alkylcarbamoyl; N-Ci-Cg- alkyloxycarbamoyl; C1-Cs-alkoxy carbamoyl; N-Ci-Cs-alkyl-Ci-Cs-alkoxycarbamoyl; aminothiocarbonyl; C1-Cs-alkoxy carbonyl; Ci-Cg-halogenoalkoxycarbonyl; C3-CV cy cloalkoxy carbonyl ; C2-C8-alkoxyalkylcarbonyl; C2-C8-halogenoalkoxyalkylcarbonyl; C3- Cio-cycloalkoxyalkylcarbonyl; Ci-Cg-alkylaminocarbonyl; di-Ci-Cs-alkylaminocarbonyl; C3-C8-cycloalkyiaminocarbonyl; Ci-Cs-alkylcarbonyloxy; Ci-Cs- halogenoalkylcarbonyloxy; C3-Cs- cy cloalkylcarbonyloxy ; Ci-Cg-alkylcarbonylamino; C1-Cs-halogeno alkylcarbonylamino ; Ci-Cs-alkylaminocarbonyloxy; di-Ci-Cs- alkylaminocarbonyloxy; C1-Cs-alkyloxycarbonyloxy ; C1-C8-alkylsulfinyl; Ci-C8- halogenoalkylsulfmyl; C1-C8-alkylsulfonyl; Ci-C8-halogenoalkylsulfonyl; G-C8- alkylsulfonyloxy; C1-Cs-halogenoalkylsulfonyloxy ; Ci-C8-alkylaminosulfamoyl; di-G-Cs- alkylaminosulfamoyl; (Ci-C8-alkoxyimino)-Ci-C8-alkyi; (C3-C7-cycloalkoxyimino)-Ci-Cs- alkyl; hydroxyimino-C1-Cs-alkyl; (Ci-C8-alkoxyimino)-C3-C7-cycloalkyl; hydroxyimino- C3-C7-cycloalkyl; (Ci-Cs-alkylimino)-oxy; (Ci-C8-alkylimino)-oxy-Ci-C8-alkyl; (C3-C7- cycloalkylimino)-oxy-Ci-Cs-alkyl; (Ci-C6-alkylimino)-oxy-C3-C7-cycloalkyl; (G-C8- alkenyloxyimino)-Ci-Cs-alkyl; (Ci-Cs-alkynyloxyimino)-Ci-Cs-alkyl; (benzyloxyimino) - Ci-Cs-alkyl; G-C8-alkoxyalkyi; Ci-Cs-alkylthioalkyl; Ci-Cs-alkoxyalkoxyalkyl; Ci-Cg- halogenoalkoxyalkyl; benzyl; phenyl; 5-membered heteroaryl; 6-membered heteroaryl; benzyloxy; phenyloxy; benzylsulfanyl; benzylamino; phenylsulfanyl; or phenylamino; salts or N-oxides.
PCT/EP2016/056764 2015-04-02 2016-03-29 Novel 5-substituted imidazole derivatives WO2016156290A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
MX2017012709A MX2017012709A (en) 2015-04-02 2016-03-29 Novel 5-substituted imidazole derivatives.
JP2017551271A JP2018516237A (en) 2015-04-02 2016-03-29 Novel 5-substituted imidazole derivatives
CA2981379A CA2981379A1 (en) 2015-04-02 2016-03-29 Novel 5-substituted imidazole derivatives
AU2016239067A AU2016239067A1 (en) 2015-04-02 2016-03-29 Novel 5-substituted imidazole derivatives
EP16711859.5A EP3277666A1 (en) 2015-04-02 2016-03-29 Novel 5-substituted imidazole derivatives
CN201680027971.2A CN107635968A (en) 2015-04-02 2016-03-29 The imdazole derivatives of 5 new substitutions
CR20170445A CR20170445A (en) 2015-04-02 2016-03-29 NEW DERIVATIVES OF IMIDAZOLILMETILO 5-SUBSTITUTES
BR112017021183A BR112017021183A2 (en) 2015-04-02 2016-03-29 new 5-substituted imidazolylmethyl derivatives
EA201792151A EA201792151A1 (en) 2015-04-02 2016-03-29 NEW 5-SUBSTITUTED IMIDAZOLE DERIVATIVES
KR1020177031654A KR20170132315A (en) 2015-04-02 2016-03-29 New 5-substituted imidazole derivatives
US15/563,414 US10231453B2 (en) 2015-04-02 2016-03-29 5-substituted imidazole derivatives
IL254773A IL254773A0 (en) 2015-04-02 2017-09-28 Novel 5-substituted imidazole derivatives
PH12017501808A PH12017501808A1 (en) 2015-04-02 2017-09-29 Novel 5-substituted imidazole derivatives
CONC2017/0010006A CO2017010006A2 (en) 2015-04-02 2017-10-02 New 5-substituted imidazolylmethyl derivatives
ZA2017/07424A ZA201707424B (en) 2015-04-02 2017-11-01 Novel 5-substituted imidazole derivatives
US16/190,285 US10568326B2 (en) 2015-04-02 2018-11-14 5-substituted imidazole derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15162437.6 2015-04-02
EP15162437 2015-04-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/563,414 A-371-Of-International US10231453B2 (en) 2015-04-02 2016-03-29 5-substituted imidazole derivatives
US16/190,285 Continuation US10568326B2 (en) 2015-04-02 2018-11-14 5-substituted imidazole derivatives

Publications (1)

Publication Number Publication Date
WO2016156290A1 true WO2016156290A1 (en) 2016-10-06

Family

ID=52807717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/056764 WO2016156290A1 (en) 2015-04-02 2016-03-29 Novel 5-substituted imidazole derivatives

Country Status (23)

Country Link
US (2) US10231453B2 (en)
EP (1) EP3277666A1 (en)
JP (1) JP2018516237A (en)
KR (1) KR20170132315A (en)
CN (1) CN107635968A (en)
AR (1) AR104178A1 (en)
AU (1) AU2016239067A1 (en)
BR (1) BR112017021183A2 (en)
CA (1) CA2981379A1 (en)
CL (1) CL2017002480A1 (en)
CO (1) CO2017010006A2 (en)
CR (1) CR20170445A (en)
EA (1) EA201792151A1 (en)
EC (1) ECSP17065502A (en)
GT (1) GT201700210A (en)
IL (1) IL254773A0 (en)
MX (1) MX2017012709A (en)
PE (1) PE20180175A1 (en)
PH (1) PH12017501808A1 (en)
TW (1) TW201702229A (en)
UY (1) UY36603A (en)
WO (1) WO2016156290A1 (en)
ZA (1) ZA201707424B (en)

Cited By (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3292762A1 (en) 2016-09-13 2018-03-14 Bayer CropScience Aktiengesellschaft Active compound combinations comprising a 5-substituted imidazole derivative
WO2018060075A1 (en) 2016-09-29 2018-04-05 Bayer Cropscience Aktiengesellschaft 1 -[2-(1 -chlorocyclopropyl)-2-hydroxy-3-(3-phenyl-1,2-oxazol-5-yl)propyl]-1h-imidazole-5-carbonitrile derivatives and related compounds as fungicides for crop protection
WO2019091898A1 (en) 2017-11-09 2019-05-16 Bayer Aktiengesellschaft Process for the preparation of 5-substituted imidazole derivatives and manganese compounds useful therefor
WO2019115338A1 (en) 2017-12-12 2019-06-20 Bayer Aktiengesellschaft Process for the preparation of (5-cyano-imidazol-1-yl)ethanone derivatives and intermediates useful therefor
WO2019162228A1 (en) 2018-02-21 2019-08-29 Bayer Aktiengesellschaft 1-(5-substituted imidazol-1-yl)but-3-en derivatives and their use as fungicides
WO2020025807A1 (en) 2018-08-03 2020-02-06 Syngenta Crop Protection Ag Microbiocidal 1,2,5-oxadiazol-3(2h)-one derivatives
WO2020053365A2 (en) 2018-09-13 2020-03-19 Syngenta Participations Ag Pesticidally active azole-amide compounds
WO2020053364A1 (en) 2018-09-13 2020-03-19 Syngenta Participations Ag Pesticidally active azole-amide compounds
WO2020070050A1 (en) 2018-10-01 2020-04-09 Bayer Aktiengesellschaft Fungicidal 5-substituted imidazol-1-yl carbinol derivatives
WO2020079111A1 (en) 2018-10-18 2020-04-23 Syngenta Crop Protection Ag Microbiocidal compounds
WO2020079198A1 (en) 2018-10-19 2020-04-23 Syngenta Participations Ag Pesticidally active azole-amide compounds
WO2020094363A1 (en) 2018-11-05 2020-05-14 Syngenta Participations Ag Pesticidally active azole-amide compounds
WO2020109509A1 (en) 2018-11-30 2020-06-04 Syngenta Participations Ag Microbiocidal thiazole derivatives
WO2020109511A1 (en) 2018-11-30 2020-06-04 Syngenta Crop Protection Ag Microbiocidal 2-acylamino-thiazole-4-carboxamide derivatives
WO2020165403A1 (en) 2019-02-15 2020-08-20 Syngenta Crop Protection Ag Phenyl substituted thiazole derivatives as microbiocidal compounds
WO2020169526A1 (en) 2019-02-18 2020-08-27 Syngenta Crop Protection Ag Pesticidally-active cyanamide heterocyclic compounds
WO2020169445A1 (en) 2019-02-18 2020-08-27 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
WO2020182649A1 (en) 2019-03-08 2020-09-17 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
WO2020188027A1 (en) 2019-03-20 2020-09-24 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
WO2020188014A1 (en) 2019-03-20 2020-09-24 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
WO2020193618A1 (en) 2019-03-27 2020-10-01 Syngenta Crop Protection Ag Microbiocidal thiazole derivatives
WO2020193341A1 (en) 2019-03-22 2020-10-01 Syngenta Crop Protection Ag N-[1-(5-bromo-2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-2-cyclopropyl-6-(trifluoromethyl)pyridine-4-carboxamide derivatives and related compounds as insecticides
WO2020193387A1 (en) 2019-03-22 2020-10-01 Syngenta Crop Protection Ag Fungicidal compounds
WO2020201079A1 (en) 2019-03-29 2020-10-08 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
WO2020201398A1 (en) 2019-04-05 2020-10-08 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
WO2020208095A1 (en) 2019-04-10 2020-10-15 Syngenta Crop Protection Ag Microbiocidal picolinamide derivatives
WO2020208096A1 (en) 2019-04-10 2020-10-15 Syngenta Crop Protection Ag Fungicidal compositions
WO2020208036A1 (en) 2019-04-11 2020-10-15 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
WO2020239856A1 (en) 2019-05-29 2020-12-03 Syngenta Crop Protection Ag Microbiocidal derivatives
WO2020239855A1 (en) 2019-05-29 2020-12-03 Syngenta Crop Protection Ag Microbiocidal derivatives
WO2020239854A1 (en) 2019-05-29 2020-12-03 Syngenta Crop Protection Ag Microbiocidal derivatives
WO2020239853A1 (en) 2019-05-29 2020-12-03 Syngenta Crop Protection Ag Microbiocidal derivatives
WO2020254530A1 (en) 2019-06-18 2020-12-24 Syngenta Crop Protection Ag 7-sulfonyl-n-(1,3,4-thiadiazol-2-yl)-quinoxaline-6-carboxamide derivatives and the respective -benzimidazole-5-, -imidazo[4,5-b]pyridine-5-, -3h-furo[3,2b]pyridine-5-, -quinoline-2-, and -naphthalene-2-carboxamide derivatives as pesticides
WO2021004968A1 (en) 2019-07-05 2021-01-14 Syngenta Crop Protection Ag Microbiocidal picolinamide derivatives
WO2021009026A1 (en) 2019-07-12 2021-01-21 Syngenta Crop Protection Ag Methyl 2-[(4-methoxyimino-tetralin-6-yl]prop-2-enoate derivatives, chromane, isochromane, 6,7,8,9-tetrahydrobenzo[7]annulene, 1h-isobenzofurane and indane analogues thereof, and similar compounds, as agrochemical fungicides
WO2021032634A1 (en) 2019-08-21 2021-02-25 Syngenta Participations Ag Apparatus and method for reducing dust development in precision drill sowing
WO2021032633A1 (en) 2019-08-21 2021-02-25 Syngenta Participations Ag High precision greenhouse seed and seedling treatment
WO2021032632A1 (en) 2019-08-21 2021-02-25 Syngenta Participations Ag Apparatus and method for converting existing sowing equipment
WO2021032631A1 (en) 2019-08-21 2021-02-25 Syngenta Participations Ag Precision treatment and sowing or planting method and device
WO2021032630A1 (en) 2019-08-21 2021-02-25 Syngenta Participations Ag Sowing device and method for treating seeds during planting
WO2021037614A1 (en) 2019-08-23 2021-03-04 Syngenta Crop Protection Ag Pesticidally active pyrazine-amide compounds
WO2021043616A1 (en) 2019-09-02 2021-03-11 Syngenta Crop Protection Ag Strigolactone derivatives as plant growth regulator compounds
WO2021053161A1 (en) 2019-09-20 2021-03-25 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
WO2021053110A1 (en) 2019-09-20 2021-03-25 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents
WO2021083936A1 (en) 2019-11-01 2021-05-06 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2021110891A1 (en) 2019-12-04 2021-06-10 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic amino compounds
WO2021122645A1 (en) 2019-12-20 2021-06-24 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
WO2021136722A1 (en) 2019-12-31 2021-07-08 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2021140122A1 (en) 2020-01-06 2021-07-15 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2021144354A1 (en) 2020-01-15 2021-07-22 Syngenta Crop Protection Ag Pesticidally-active bicyclic heteroaromatic compounds
WO2021148639A1 (en) 2020-01-24 2021-07-29 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2021148643A1 (en) 2020-01-23 2021-07-29 Syngenta Crop Protection Ag Fungicidal compositions
WO2021151926A1 (en) 2020-01-30 2021-08-05 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic amino compounds
WO2021160680A1 (en) 2020-02-11 2021-08-19 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
WO2021170830A1 (en) 2020-02-27 2021-09-02 Syngenta Crop Protection Ag Fungicidal compositions
WO2021170881A1 (en) 2020-02-27 2021-09-02 Syngenta Crop Protection Ag Pesticidally active diazine-bisamide compounds
WO2021176007A1 (en) 2020-03-05 2021-09-10 Syngenta Crop Protection Ag Fungicidal compositions
WO2021175822A1 (en) 2020-03-02 2021-09-10 Syngenta Crop Protection Ag Pesticidally amidine-substituted benzoic acid amide compounds
WO2021176057A1 (en) 2020-03-05 2021-09-10 Syngenta Crop Protection Ag Fungicidal compositions
WO2021180975A1 (en) 2020-03-13 2021-09-16 Syngenta Crop Protection Ag Methods of controlling or preventing infestation of plants by the phytopathogenic microorganism corynespora cassiicola
WO2021180592A1 (en) 2020-03-13 2021-09-16 Syngenta Crop Protection Ag Methods of controlling or preventing infestation of plants by the phytopathogenic microorganism corynespora cassiicola
WO2021180598A1 (en) 2020-03-13 2021-09-16 Syngenta Crop Protection Ag Methods of controlling or preventing infestation of plants by the phytopathogenic microorganism corynespora cassiicola
WO2021180976A1 (en) 2020-03-13 2021-09-16 Syngenta Crop Protection Ag Methods of controlling or preventing infestation of plants by the phytopathogenic microorganism corynespora cassiicola, cercospora sojina and/or cercospora kikuchii
WO2021180974A1 (en) 2020-03-13 2021-09-16 Syngenta Crop Protection Ag Methods of controlling or preventing infestation of plants by the phytopathogenic microorganism corynespora cassiicola
WO2021180596A1 (en) 2020-03-13 2021-09-16 Syngenta Crop Protection Ag Methods of controlling or preventing infestation of plants by the phytopathogenic microorganism corynespora cassiicola
WO2021204857A1 (en) 2020-04-08 2021-10-14 Syngenta Crop Protection Ag Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives
WO2021204822A1 (en) 2020-04-08 2021-10-14 Syngenta Crop Protection Ag Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives
WO2021204855A1 (en) 2020-04-08 2021-10-14 Syngenta Crop Protection Ag Microbiocidal quinoline dihydropyrrolopyrazine derivatives
WO2021213929A1 (en) 2020-04-20 2021-10-28 Syngenta Crop Protection Ag Pesticidally active substituted 1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives with sulfur containing substituents
WO2021219775A1 (en) 2020-04-30 2021-11-04 Syngenta Crop Protection Ag Microbiocidal compounds
WO2021219778A1 (en) 2020-04-30 2021-11-04 Syngenta Crop Protection Ag Microbiocidal compounds
WO2021219810A1 (en) 2020-04-30 2021-11-04 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2021219780A1 (en) 2020-05-01 2021-11-04 Syngenta Crop Protection Ag Microbiocidal compounds
WO2021224409A1 (en) 2020-05-06 2021-11-11 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2021224102A1 (en) 2020-05-05 2021-11-11 Syngenta Crop Protection Ag Microbiocidal compounds
WO2021244950A1 (en) 2020-06-03 2021-12-09 Syngenta Crop Protection Ag Fungicidal compositions
WO2021244952A1 (en) 2020-06-03 2021-12-09 Syngenta Crop Protection Ag Microbiocidal derivatives
WO2021244951A1 (en) 2020-06-03 2021-12-09 Syngenta Crop Protection Ag Fungicidal compositions
WO2022013417A1 (en) 2020-07-17 2022-01-20 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022017975A1 (en) 2020-07-18 2022-01-27 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022043576A2 (en) 2020-08-31 2022-03-03 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022049146A1 (en) 2020-09-02 2022-03-10 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022048988A1 (en) 2020-09-02 2022-03-10 Syngenta Participations Ag Plant growth regulator compounds
WO2022049144A1 (en) 2020-09-02 2022-03-10 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022049141A1 (en) 2020-09-01 2022-03-10 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022053567A1 (en) 2020-09-09 2022-03-17 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022058580A1 (en) 2020-09-21 2022-03-24 Syngenta Crop Protection Ag Microbiocidal compounds
WO2022084346A1 (en) 2020-10-22 2022-04-28 Syngenta Crop Protection Ag Zealactone derivatives as plant growth regulators
WO2022101265A1 (en) 2020-11-13 2022-05-19 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2022157188A2 (en) 2021-01-23 2022-07-28 Syngenta Crop Protection Ag Pesticidally active heteroaromatic compounds
WO2022157334A1 (en) 2021-01-21 2022-07-28 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022157122A1 (en) 2021-01-22 2022-07-28 Syngenta Crop Protection Ag Method for the control or suppression of phytopathogenic bacteria
WO2022207462A1 (en) 2021-03-30 2022-10-06 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
WO2022207479A1 (en) 2021-03-27 2022-10-06 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives
WO2022207665A1 (en) 2021-03-31 2022-10-06 Syngenta Crop Protection Ag Microbiocidal quinoline/quinoxaline benzothiazine derivatives
WO2022219146A2 (en) 2021-04-16 2022-10-20 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
WO2022223376A1 (en) 2021-04-20 2022-10-27 Syngenta Crop Protection Ag Microbiocidal quinoline/quinoxaline isoquinoline derivatives
WO2022233869A1 (en) 2021-05-04 2022-11-10 Syngenta Crop Protection Ag Use of clethodim for insect control
WO2022253841A1 (en) 2021-06-02 2022-12-08 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfoximine containing substituents
WO2022253645A1 (en) 2021-06-01 2022-12-08 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline derivatives
WO2022258481A1 (en) 2021-06-09 2022-12-15 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
WO2022268648A1 (en) 2021-06-24 2022-12-29 Syngenta Crop Protection Ag 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides
WO2023275116A1 (en) 2021-07-02 2023-01-05 Syngenta Crop Protection Ag Use of fluazifop-p-butyl for insect control
WO2023006634A1 (en) 2021-07-27 2023-02-02 Syngenta Crop Protection Ag Method for controlling diamide resistant pests & compounds therefor
WO2023006789A1 (en) 2021-07-29 2023-02-02 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2023012081A1 (en) 2021-08-05 2023-02-09 Syngenta Crop Protection Ag Method for controlling diamide resistant pests & compounds therefor
WO2023012044A1 (en) 2021-08-02 2023-02-09 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2023017016A1 (en) 2021-08-10 2023-02-16 Syngenta Crop Protection Ag Fungicide mixture
WO2023017094A1 (en) 2021-08-10 2023-02-16 Syngenta Crop Protection Ag 2,2-difluoro-5h-[1,3]dioxolo[4,5-f]isoindol-7-one derivatives as pesticides
WO2023021020A1 (en) 2021-08-19 2023-02-23 Syngenta Crop Protection Ag Method for controlling diamide resistant pests & compounds therefor
WO2023061838A1 (en) 2021-10-14 2023-04-20 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives
WO2023072785A1 (en) 2021-10-29 2023-05-04 Syngenta Crop Protection Ag Fungicidal compositions
WO2023072945A1 (en) 2021-10-25 2023-05-04 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2023072849A1 (en) 2021-10-27 2023-05-04 Syngenta Crop Protection Ag Pesticidally active pyridazinone compounds
WO2023072784A1 (en) 2021-10-29 2023-05-04 Syngenta Crop Protection Ag Fungicidal compositions comprising fludioxonil
WO2023089049A2 (en) 2021-11-19 2023-05-25 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives
WO2023094303A1 (en) 2021-11-25 2023-06-01 Syngenta Crop Protection Ag Microbiocidal heterobiaryl amide derivatives
WO2023094304A1 (en) 2021-11-25 2023-06-01 Syngenta Crop Protection Ag Microbiocidal heterobiaryl amide derivatives
WO2023099460A1 (en) 2021-12-02 2023-06-08 Syngenta Crop Protection Ag Fungicidal compositions
WO2023104714A1 (en) 2021-12-10 2023-06-15 Syngenta Crop Protection Ag Pesticidally active pyridazinone compounds
EP4197333A1 (en) 2021-12-15 2023-06-21 Syngenta Crop Protection AG Method for controlling diamide resistant pests & compounds therefor
WO2023111215A1 (en) 2021-12-17 2023-06-22 Syngenta Crop Protection Ag Microbiocidal pyridine-substituted benzothiazine derivatives
WO2023110871A1 (en) 2021-12-17 2023-06-22 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2023110710A1 (en) 2021-12-13 2023-06-22 Syngenta Crop Protection Ag Method for controlling diamide resistant pests & compounds therefor
WO2023110869A1 (en) 2021-12-15 2023-06-22 Syngenta Crop Protection Ag Microbiocidal bicycle heterocyclic derivatives
WO2023110928A1 (en) 2021-12-17 2023-06-22 Syngenta Crop Protection Ag Fungicidal compositions
WO2023118434A1 (en) 2021-12-22 2023-06-29 Globachem Nv Pesticidally active amide compounds
WO2023117625A1 (en) 2021-12-22 2023-06-29 Syngenta Crop Protection Ag Fungicidal compositions
WO2023118011A1 (en) 2021-12-22 2023-06-29 Syngenta Crop Protection Ag Microbiocidal aza-heterobiaryl derivatives
WO2023139166A1 (en) 2022-01-19 2023-07-27 Syngenta Crop Protection Ag Methods for controlling plant pathogens
WO2023148368A1 (en) 2022-02-07 2023-08-10 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2023148206A1 (en) 2022-02-02 2023-08-10 Syngenta Crop Protection Ag Microbiocidal n-amide derivatives
WO2023148369A1 (en) 2022-02-07 2023-08-10 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2023166067A1 (en) 2022-03-02 2023-09-07 Syngenta Crop Protection Ag Microbiocidal pyridazinone amide derivatives
WO2023187191A1 (en) 2022-04-01 2023-10-05 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2023209238A1 (en) 2022-04-29 2023-11-02 Syngenta Crop Protection Ag Fungicidal compositions
WO2023217989A1 (en) 2022-05-12 2023-11-16 Syngenta Crop Protection Ag Alkoxy heteroaryl- carboxamide or thioamide compounds
WO2023247552A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Microbiocidal bicyclic heterocyclic carboxamide derivatives
WO2023247360A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2024008567A1 (en) 2022-07-07 2024-01-11 Syngenta Crop Protection Ag Precision application devices and compositions
WO2024017788A1 (en) 2022-07-22 2024-01-25 Syngenta Crop Protection Ag Solid form of a heterocyclic amide derivative
WO2024018016A1 (en) 2022-07-21 2024-01-25 Syngenta Crop Protection Ag Crystalline forms of 1,2,4-oxadiazole fungicides
WO2024022910A1 (en) 2022-07-26 2024-02-01 Syngenta Crop Protection Ag 1-[1-[2-(pyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]-3-[2,4-dichloro-5-phenyl]urea derivatives and similar compounds as pesticides
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024038053A1 (en) 2022-08-16 2024-02-22 Syngenta Crop Protection Ag New use of pydiflumetofen
WO2024056732A1 (en) 2022-09-16 2024-03-21 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
WO2024068947A1 (en) 2022-09-30 2024-04-04 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2024068656A1 (en) 2022-09-28 2024-04-04 Syngenta Crop Protection Ag Fungicidal compositions
WO2024068655A1 (en) 2022-09-28 2024-04-04 Syngenta Crop Protection Ag Fungicidal compositions
WO2024068950A1 (en) 2022-09-30 2024-04-04 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2024068838A1 (en) 2022-09-28 2024-04-04 Syngenta Crop Protection Ag Fungicidal compositions

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519391A1 (en) * 2016-09-29 2019-08-07 Bayer CropScience Aktiengesellschaft Novel 5-substituted imidazolylmethyl derivatives
CN109943410B (en) * 2017-12-21 2022-05-31 丰益(上海)生物技术研发中心有限公司 Method for reducing zearalenone in oil
CN108913698B (en) * 2018-07-25 2021-10-26 安徽农业大学 CAPS marker related to wheat ear germination resistance/sensibility and application thereof

Citations (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1155529A (en) * 1965-07-07 1969-06-18 Merck & Co Inc Imidazole derivatives, their Preparation and Compositions containing them
US4085209A (en) 1975-02-05 1978-04-18 Rohm And Haas Company Preparation and safening effect of 1-substituted imidazole metal salt complexes
DE3111238A1 (en) 1981-03-21 1982-10-07 Bayer Ag, 5090 Leverkusen SUBSTITUTED TRIAZOLYL METHYL OXIRANES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS INTERMEDIATE PRODUCTS
DE3202604A1 (en) 1982-01-27 1983-08-04 Bayer Ag, 5090 Leverkusen ETHER DERIVATIVES OF SUBSTITUTED 1-HYDROXYALKYL-AZOLES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS FUNGICIDES AND PLANT GROWTH REGULATORS
DE3235935A1 (en) 1982-09-29 1984-03-29 Bayer Ag, 5090 Leverkusen AZOLYLBUTANOLE
DE3307217A1 (en) 1983-03-02 1984-09-06 Bayer Ag, 5090 Leverkusen SUBSTITUTED 1,3-DIAZOLYL-2-PROPANOLS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS AN ANTIMYCOTIC AGENT
DE3315681A1 (en) 1983-04-29 1984-10-31 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING OXIRANES
EP0225739A2 (en) 1985-12-10 1987-06-16 Imperial Chemical Industries Plc 2-2-Dimethyl-3-hydroxy-3-propargyl-4-(1,2,4-triazole-1-yl -butane derivatives as plant growth regulators
EP0291797A2 (en) 1987-05-18 1988-11-23 Bayer Ag Hydroxyalkyl triazol derivatives
JPH02101067A (en) 1988-10-07 1990-04-12 Kureha Chem Ind Co Ltd Novel acylated triazole derivative, production thereof and germicide for agricultural and horticulture containing the same derivative as active ingredient
EP0461502A2 (en) 1990-06-13 1991-12-18 Bayer Ag Azolyl propanol derivatives
DE4027608A1 (en) 1990-08-31 1992-03-05 Bayer Ag METHOD FOR PRODUCING 1-CHLOR-2- (1-CHLORO-CYCLOPROPYL) -3- (2-CHLORO-PHENYL) -PROPAN-2-OL AND / OR 2- (1-CHLORO-CYCLOPROPYL) -2- (2 -CHLORINE-BENZYL) -OXIRANE
WO1993002086A1 (en) 1991-07-16 1993-02-04 Imperial Chemical Industries Plc Process for the preparation of aryl and aralkyl magnesium halides
WO1993012121A1 (en) 1991-12-11 1993-06-24 Zeneca Limited Process for the preparation of ether solutions of grignard compounds
EP0557967A1 (en) 1992-02-26 1993-09-01 Central Glass Company, Limited Method of side-chain chlorination of 2-chloro-methylpyridine
EP0679634A2 (en) * 1994-04-27 1995-11-02 Fuji Photo Film Co., Ltd. Method for producing a 3-oxo-propionic acid amide compound and substituted acetyl compound used therein
WO1995029901A1 (en) 1994-04-28 1995-11-09 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
FR2802772A1 (en) 1999-12-22 2001-06-29 Agronomique Inst Nat Rech USE OF AN ELICITINE-LIPID COMPLEX FOR PLANT PROTECTION AGAINST PATHOGENS
WO2003026663A1 (en) 2001-09-25 2003-04-03 Pharmacia Corporation Process for making substituted pyrazoles
WO2005027837A2 (en) 2003-09-18 2005-03-31 Merck & Co., Inc. Substituted sulfonamides
WO2005044785A1 (en) 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
WO2005111003A1 (en) 2004-04-29 2005-11-24 Abbott Laboratories Amino-tetrazoles analogues and methods of use
WO2008003622A1 (en) 2006-07-05 2008-01-10 Basf Se Azolylmethyloxiranes, their use for controlling phytopathogenic fungi and agents containing said compounds
WO2008147544A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
WO2009153554A1 (en) 2008-06-19 2009-12-23 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
WO2010029066A1 (en) 2008-09-10 2010-03-18 Basf Se Imidazole and triazole compounds, use thereof and agents containing said compounds
CN101824002A (en) 2010-05-13 2010-09-08 南京华威医药科技开发有限公司 Water soluble triazole compound and synthesis method thereof
WO2010132999A1 (en) 2009-05-21 2010-11-25 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2011042389A2 (en) 2009-10-09 2011-04-14 Bayer Cropscience Ag Phenylpyri(mi)dinylazoles
US20120010190A1 (en) 2010-07-12 2012-01-12 Caterina Bissantz 1-hydroxyimino-3-phenyl-propanes
WO2012055942A1 (en) 2010-10-27 2012-05-03 Proximagen Limited Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
WO2012087784A1 (en) 2010-12-23 2012-06-28 Amgen Inc. Heterocyclic compounds and their uses
WO2012085815A1 (en) 2010-12-21 2012-06-28 Novartis Ag Bi-heteroaryl compounds as vps34 inhibitors
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
WO2012175119A1 (en) 2011-06-22 2012-12-27 Isochem Process for the preparation of solifenacin and salts thereof
WO2013076228A1 (en) 2011-11-25 2013-05-30 Bayer Intellectual Property Gmbh 2-iodo imidazole-derivatives
WO2014076228A1 (en) 2012-11-15 2014-05-22 Ruag Ammotec Gmbh Projectile having a soldered project core
EP2746259A1 (en) * 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
WO2014118170A1 (en) * 2013-02-04 2014-08-07 Syngenta Participations Ag Novel microbiocides

Patent Citations (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1155529A (en) * 1965-07-07 1969-06-18 Merck & Co Inc Imidazole derivatives, their Preparation and Compositions containing them
US4085209A (en) 1975-02-05 1978-04-18 Rohm And Haas Company Preparation and safening effect of 1-substituted imidazole metal salt complexes
DE3111238A1 (en) 1981-03-21 1982-10-07 Bayer Ag, 5090 Leverkusen SUBSTITUTED TRIAZOLYL METHYL OXIRANES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS INTERMEDIATE PRODUCTS
DE3202604A1 (en) 1982-01-27 1983-08-04 Bayer Ag, 5090 Leverkusen ETHER DERIVATIVES OF SUBSTITUTED 1-HYDROXYALKYL-AZOLES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS FUNGICIDES AND PLANT GROWTH REGULATORS
DE3235935A1 (en) 1982-09-29 1984-03-29 Bayer Ag, 5090 Leverkusen AZOLYLBUTANOLE
DE3307217A1 (en) 1983-03-02 1984-09-06 Bayer Ag, 5090 Leverkusen SUBSTITUTED 1,3-DIAZOLYL-2-PROPANOLS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS AN ANTIMYCOTIC AGENT
DE3315681A1 (en) 1983-04-29 1984-10-31 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING OXIRANES
EP0225739A2 (en) 1985-12-10 1987-06-16 Imperial Chemical Industries Plc 2-2-Dimethyl-3-hydroxy-3-propargyl-4-(1,2,4-triazole-1-yl -butane derivatives as plant growth regulators
EP0291797A2 (en) 1987-05-18 1988-11-23 Bayer Ag Hydroxyalkyl triazol derivatives
JPH02101067A (en) 1988-10-07 1990-04-12 Kureha Chem Ind Co Ltd Novel acylated triazole derivative, production thereof and germicide for agricultural and horticulture containing the same derivative as active ingredient
EP0461502A2 (en) 1990-06-13 1991-12-18 Bayer Ag Azolyl propanol derivatives
DE4027608A1 (en) 1990-08-31 1992-03-05 Bayer Ag METHOD FOR PRODUCING 1-CHLOR-2- (1-CHLORO-CYCLOPROPYL) -3- (2-CHLORO-PHENYL) -PROPAN-2-OL AND / OR 2- (1-CHLORO-CYCLOPROPYL) -2- (2 -CHLORINE-BENZYL) -OXIRANE
WO1993002086A1 (en) 1991-07-16 1993-02-04 Imperial Chemical Industries Plc Process for the preparation of aryl and aralkyl magnesium halides
WO1993012121A1 (en) 1991-12-11 1993-06-24 Zeneca Limited Process for the preparation of ether solutions of grignard compounds
EP0557967A1 (en) 1992-02-26 1993-09-01 Central Glass Company, Limited Method of side-chain chlorination of 2-chloro-methylpyridine
EP0679634A2 (en) * 1994-04-27 1995-11-02 Fuji Photo Film Co., Ltd. Method for producing a 3-oxo-propionic acid amide compound and substituted acetyl compound used therein
WO1995029901A1 (en) 1994-04-28 1995-11-09 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
FR2802772A1 (en) 1999-12-22 2001-06-29 Agronomique Inst Nat Rech USE OF AN ELICITINE-LIPID COMPLEX FOR PLANT PROTECTION AGAINST PATHOGENS
WO2003026663A1 (en) 2001-09-25 2003-04-03 Pharmacia Corporation Process for making substituted pyrazoles
WO2005027837A2 (en) 2003-09-18 2005-03-31 Merck & Co., Inc. Substituted sulfonamides
WO2005044785A1 (en) 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
WO2005111003A1 (en) 2004-04-29 2005-11-24 Abbott Laboratories Amino-tetrazoles analogues and methods of use
WO2008003622A1 (en) 2006-07-05 2008-01-10 Basf Se Azolylmethyloxiranes, their use for controlling phytopathogenic fungi and agents containing said compounds
WO2008147544A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
WO2009153554A1 (en) 2008-06-19 2009-12-23 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
WO2010029066A1 (en) 2008-09-10 2010-03-18 Basf Se Imidazole and triazole compounds, use thereof and agents containing said compounds
WO2010132999A1 (en) 2009-05-21 2010-11-25 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2011042389A2 (en) 2009-10-09 2011-04-14 Bayer Cropscience Ag Phenylpyri(mi)dinylazoles
CN101824002A (en) 2010-05-13 2010-09-08 南京华威医药科技开发有限公司 Water soluble triazole compound and synthesis method thereof
US20120010190A1 (en) 2010-07-12 2012-01-12 Caterina Bissantz 1-hydroxyimino-3-phenyl-propanes
WO2012055942A1 (en) 2010-10-27 2012-05-03 Proximagen Limited Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease
WO2012085815A1 (en) 2010-12-21 2012-06-28 Novartis Ag Bi-heteroaryl compounds as vps34 inhibitors
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
WO2012087784A1 (en) 2010-12-23 2012-06-28 Amgen Inc. Heterocyclic compounds and their uses
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
WO2012175119A1 (en) 2011-06-22 2012-12-27 Isochem Process for the preparation of solifenacin and salts thereof
WO2013076228A1 (en) 2011-11-25 2013-05-30 Bayer Intellectual Property Gmbh 2-iodo imidazole-derivatives
WO2014076228A1 (en) 2012-11-15 2014-05-22 Ruag Ammotec Gmbh Projectile having a soldered project core
EP2746259A1 (en) * 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
WO2014118170A1 (en) * 2013-02-04 2014-08-07 Syngenta Participations Ag Novel microbiocides

Non-Patent Citations (61)

* Cited by examiner, † Cited by third party
Title
"Comprehensive Heterocyclic Chemistry H", vol. 5, 1996, PERGAMON PRESS, pages: 37 - 243
"Comprehensive Heterocyclic Chemistry I", vol. 2, 1984, PERGAMON PRESS, pages: 395 - 510
"COMPREHENSIVE HETEROCYCLIC CHEMISTRY I", vol. 3, 1984, PERGAMON PRESS, pages: 1 - 197
"Comprehensive Heterocyclic Chemistry I", vol. 4, 1984, PERGAMON PRESS, pages: 155 - 376
"COMPREHENSIVE HETEROCYCLIC CHEMISTRY I", vol. 5, pages: 167 - 498
"COMPREHENSIVE HETEROCYCLIC CHEMISTRY I", vol. S, 1984, PERGAMON PRESS, pages: 167 - 498
"Comprehensive Heterocyclic Chemistry II", vol. 2, 1996, PERGAMON PRESS, pages: 39 - 257
"Comprehensive Heterocyclic Chemistry II", vol. 2, 1996, PERGAMON PRESS, pages: 39 - 2S7
"COMPREHENSIVE HETEROCYCLIC CHEMISTRY II", vol. 3, 1996, PERGAMON PRESS, pages: 1 - 220
"Comprehensive Heterocyclic Chemistry II", vol. 5, 1996, PERGAMON PRESS, pages: 37 - 243
"COMPREHENSIVE HETEROCYCLIC CHEMISTRY II", vol. 6, 1996, PERGAMON PRESS, pages: 1 - 278
"Comprehensive Heterocyclic Chemistry III", vol. 3, 2008, PERGAMON PRESS, pages: 45 - 388
"COMPREHENSIVE HETEROCYCLIC CHEMISTRY III", vol. 4, 2008, PERGAMON PRESS, pages: 1 - 364
"COMPREHENSIVE HETEROCYCLIC CHEMISTRY III", vol. 5, 1984, PERGAMON PRESS,, pages: 167 - 498
"COMPREHENSIVE HETEROCYCLIC CHEMISTRY III", vol. 6, 1996, PERGAMON PRESS, pages: 1 - 278
"Comprehensive Heterocyclic Chemistry III", vol. 7, 2008, PERGAMON PRESS, article "pages 101-169; 217-308"
"COMPREHENSIVE HETEROCYCLIC CHEMISTRY III", vol. 7, 2008, PERGAMON PRESS, pages: 1 - 331
"Comprehensive Heterocyclic Chemistry III", vol. 7, 2008, PERGAMON PRESS, pages: 101 - 169
"Comprehensive Heterocyclic Chemistry III", vol. 7, 2008, PERGAMON PRESS, pages: 101 - 169,217-
"COMPREHENSIVE HETEROCYCLIC CHEMISTRY", vol. 6, 1996, PERGAMON PRESS,, pages: 1 - 278
ACTA CHEMICA SCANDINAVICA, vol. 44, no. 1, 1990, pages 1050 - 1057
ALBRECHT METZER, DISSERTATION, 2010
ANGEW. CHEM. INT. ED., vol. 50, 2011, pages 9205 - 9209
BELLER ET AL., CHEM. ASIAN J., vol. 7, no. 1, 2011, pages 40 - 44
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, pages 2634 - 2640
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, pages 7207 - 7213
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 22, 2012, pages 901 - 906
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 16, 1996, pages 2031 - 2036
CHEM. EUR. J., vol. 12, 2006, pages 4743 - 4748
CHEMCOMM, 2008, pages 5824 - 5826
CHEMICAL & PHARMACEUTICAL BULLETIN, 1970, pages 1457 - 1464
CHEMICAL & PHARMACEUTICAL BULLETIN, 1980, pages 337 - 342
CHEMICAL BIOLOGY & DRUG DESIGN, vol. 75, no. 1, 2010, pages 68 - 90
CHEMISCHE BERICHTE, 1986, pages 2995 - 3026
DALTON TRANSACTION, 2011, pages 2366 - 2374
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 February 2014 (2014-02-17), "1H-Imidazole-5-carboxylic acid, 1-(2-oxopropyl)-, methyl ester", XP002740396, Database accession no. 1547109-85-2 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 19 December 2013 (2013-12-19), "1H-Imidazole-5-carboxylic acid, 1-(2-oxoethyl)-", XP002740397, Database accession no. 1499007-61-2 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 23 February 2014 (2014-02-23), "1H-Imidazole-5-carboxylic acid, 1-(2-oxoethyl)-, methylester", XP002740395, Database accession no. 1552535-35-9 *
DISSERTATION ALBRECHT METZER, 2010
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, 2011, pages 1570 - 1574
HETEROCYCLES, 1998, pages 2103 - 2109
J. LI; G. GRIBBLE: "Palladium in heterocyclic chemistry", 2000, PERGAMON PRESS
J. ORG. CHEM., vol. 57, 1992, pages 5425 - 5431
JOURNAL OF MEDICINAL CHEMISTRY, 1963, pages 205 - 207
JOURNAL OF ORGANIC CHEMISTRY, 2001, pages 2149 - 2153
JOURNAL OF ORGANIC CHEMISTRY, 2004, pages 908 - 914
JOURNAL OF ORGANIC CHEMISTRY, 2012, pages 9458 - 9472
JOURNAL OF ORGANIC CHEMISTRY, vol. 78, 2013, pages 12220 - 12223
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1937, pages 1494 - 1497
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1955, pages 3858 - 3860
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2011, pages 11194 - 11204
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2012, pages 15556
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2012, pages 19358 - 19361
LOVE; JONES, J. ORG. CHEM., vol. 64, 1999, pages 3755
ORG. LETT., vol. 18, no. 1, 2016, pages 16 - 19
ORGANIC LETTERS, 2009, pages 1773 - 1775
ORGANIC LETTERS, 2013, pages 554 - 557
SEDITION, J. LI; G. GRIBBLE: "Palladium in heterocyclic chemistry", 2000, PERGAMON PRESS
SYNTHESIS, vol. 18, 2008, pages 2996
T. GREENE & P. WUTS: "Protective groups in organic synthesis, 3rd edition", 1999, WILEY INTERSCIENCE, pages: 615 - 632
TODOROKI Y ET AL: "Abscinazole-F1, a conformationally restricted analogue of the plant growth retardant uniconazole and an inhibitor of ABA 8'-hydroxylase CYP707A with no growth-retardant effect", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 17, no. 18, 15 September 2009 (2009-09-15), PERGAMON, GB, pages 6620 - 6630, XP026545201, ISSN: 0968-0896, [retrieved on 20090803], DOI: 10.1016/J.BMC.2009.07.070 *

Cited By (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3292762A1 (en) 2016-09-13 2018-03-14 Bayer CropScience Aktiengesellschaft Active compound combinations comprising a 5-substituted imidazole derivative
WO2018050456A1 (en) 2016-09-13 2018-03-22 Bayer Cropscience Aktiengesellschaft Active compound combinations comprising a 5-substituted imidazole derivative
WO2018060075A1 (en) 2016-09-29 2018-04-05 Bayer Cropscience Aktiengesellschaft 1 -[2-(1 -chlorocyclopropyl)-2-hydroxy-3-(3-phenyl-1,2-oxazol-5-yl)propyl]-1h-imidazole-5-carbonitrile derivatives and related compounds as fungicides for crop protection
WO2019091898A1 (en) 2017-11-09 2019-05-16 Bayer Aktiengesellschaft Process for the preparation of 5-substituted imidazole derivatives and manganese compounds useful therefor
WO2019115338A1 (en) 2017-12-12 2019-06-20 Bayer Aktiengesellschaft Process for the preparation of (5-cyano-imidazol-1-yl)ethanone derivatives and intermediates useful therefor
WO2019162228A1 (en) 2018-02-21 2019-08-29 Bayer Aktiengesellschaft 1-(5-substituted imidazol-1-yl)but-3-en derivatives and their use as fungicides
WO2020025807A1 (en) 2018-08-03 2020-02-06 Syngenta Crop Protection Ag Microbiocidal 1,2,5-oxadiazol-3(2h)-one derivatives
WO2020053365A2 (en) 2018-09-13 2020-03-19 Syngenta Participations Ag Pesticidally active azole-amide compounds
WO2020053364A1 (en) 2018-09-13 2020-03-19 Syngenta Participations Ag Pesticidally active azole-amide compounds
WO2020070050A1 (en) 2018-10-01 2020-04-09 Bayer Aktiengesellschaft Fungicidal 5-substituted imidazol-1-yl carbinol derivatives
WO2020079111A1 (en) 2018-10-18 2020-04-23 Syngenta Crop Protection Ag Microbiocidal compounds
WO2020079198A1 (en) 2018-10-19 2020-04-23 Syngenta Participations Ag Pesticidally active azole-amide compounds
WO2020094363A1 (en) 2018-11-05 2020-05-14 Syngenta Participations Ag Pesticidally active azole-amide compounds
WO2020109509A1 (en) 2018-11-30 2020-06-04 Syngenta Participations Ag Microbiocidal thiazole derivatives
WO2020109511A1 (en) 2018-11-30 2020-06-04 Syngenta Crop Protection Ag Microbiocidal 2-acylamino-thiazole-4-carboxamide derivatives
WO2020165403A1 (en) 2019-02-15 2020-08-20 Syngenta Crop Protection Ag Phenyl substituted thiazole derivatives as microbiocidal compounds
WO2020169526A1 (en) 2019-02-18 2020-08-27 Syngenta Crop Protection Ag Pesticidally-active cyanamide heterocyclic compounds
WO2020169445A1 (en) 2019-02-18 2020-08-27 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
WO2020182649A1 (en) 2019-03-08 2020-09-17 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
WO2020188027A1 (en) 2019-03-20 2020-09-24 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
WO2020188014A1 (en) 2019-03-20 2020-09-24 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
WO2020193341A1 (en) 2019-03-22 2020-10-01 Syngenta Crop Protection Ag N-[1-(5-bromo-2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-2-cyclopropyl-6-(trifluoromethyl)pyridine-4-carboxamide derivatives and related compounds as insecticides
WO2020193387A1 (en) 2019-03-22 2020-10-01 Syngenta Crop Protection Ag Fungicidal compounds
WO2020193618A1 (en) 2019-03-27 2020-10-01 Syngenta Crop Protection Ag Microbiocidal thiazole derivatives
WO2020201079A1 (en) 2019-03-29 2020-10-08 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
WO2020201398A1 (en) 2019-04-05 2020-10-08 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
WO2020208095A1 (en) 2019-04-10 2020-10-15 Syngenta Crop Protection Ag Microbiocidal picolinamide derivatives
WO2020208096A1 (en) 2019-04-10 2020-10-15 Syngenta Crop Protection Ag Fungicidal compositions
WO2020208036A1 (en) 2019-04-11 2020-10-15 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
WO2020239856A1 (en) 2019-05-29 2020-12-03 Syngenta Crop Protection Ag Microbiocidal derivatives
WO2020239855A1 (en) 2019-05-29 2020-12-03 Syngenta Crop Protection Ag Microbiocidal derivatives
WO2020239854A1 (en) 2019-05-29 2020-12-03 Syngenta Crop Protection Ag Microbiocidal derivatives
WO2020239853A1 (en) 2019-05-29 2020-12-03 Syngenta Crop Protection Ag Microbiocidal derivatives
WO2020254530A1 (en) 2019-06-18 2020-12-24 Syngenta Crop Protection Ag 7-sulfonyl-n-(1,3,4-thiadiazol-2-yl)-quinoxaline-6-carboxamide derivatives and the respective -benzimidazole-5-, -imidazo[4,5-b]pyridine-5-, -3h-furo[3,2b]pyridine-5-, -quinoline-2-, and -naphthalene-2-carboxamide derivatives as pesticides
WO2021004968A1 (en) 2019-07-05 2021-01-14 Syngenta Crop Protection Ag Microbiocidal picolinamide derivatives
WO2021009026A1 (en) 2019-07-12 2021-01-21 Syngenta Crop Protection Ag Methyl 2-[(4-methoxyimino-tetralin-6-yl]prop-2-enoate derivatives, chromane, isochromane, 6,7,8,9-tetrahydrobenzo[7]annulene, 1h-isobenzofurane and indane analogues thereof, and similar compounds, as agrochemical fungicides
WO2021032634A1 (en) 2019-08-21 2021-02-25 Syngenta Participations Ag Apparatus and method for reducing dust development in precision drill sowing
WO2021032633A1 (en) 2019-08-21 2021-02-25 Syngenta Participations Ag High precision greenhouse seed and seedling treatment
WO2021032632A1 (en) 2019-08-21 2021-02-25 Syngenta Participations Ag Apparatus and method for converting existing sowing equipment
WO2021032631A1 (en) 2019-08-21 2021-02-25 Syngenta Participations Ag Precision treatment and sowing or planting method and device
WO2021032630A1 (en) 2019-08-21 2021-02-25 Syngenta Participations Ag Sowing device and method for treating seeds during planting
WO2021037614A1 (en) 2019-08-23 2021-03-04 Syngenta Crop Protection Ag Pesticidally active pyrazine-amide compounds
WO2021043616A1 (en) 2019-09-02 2021-03-11 Syngenta Crop Protection Ag Strigolactone derivatives as plant growth regulator compounds
WO2021053161A1 (en) 2019-09-20 2021-03-25 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
WO2021053110A1 (en) 2019-09-20 2021-03-25 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents
WO2021083936A1 (en) 2019-11-01 2021-05-06 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2021110891A1 (en) 2019-12-04 2021-06-10 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic amino compounds
WO2021122645A1 (en) 2019-12-20 2021-06-24 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
WO2021136722A1 (en) 2019-12-31 2021-07-08 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2021140122A1 (en) 2020-01-06 2021-07-15 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2021144354A1 (en) 2020-01-15 2021-07-22 Syngenta Crop Protection Ag Pesticidally-active bicyclic heteroaromatic compounds
WO2021148643A1 (en) 2020-01-23 2021-07-29 Syngenta Crop Protection Ag Fungicidal compositions
WO2021148639A1 (en) 2020-01-24 2021-07-29 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2021151926A1 (en) 2020-01-30 2021-08-05 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic amino compounds
WO2021160680A1 (en) 2020-02-11 2021-08-19 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
WO2021170830A1 (en) 2020-02-27 2021-09-02 Syngenta Crop Protection Ag Fungicidal compositions
WO2021170881A1 (en) 2020-02-27 2021-09-02 Syngenta Crop Protection Ag Pesticidally active diazine-bisamide compounds
WO2021175822A1 (en) 2020-03-02 2021-09-10 Syngenta Crop Protection Ag Pesticidally amidine-substituted benzoic acid amide compounds
WO2021176007A1 (en) 2020-03-05 2021-09-10 Syngenta Crop Protection Ag Fungicidal compositions
WO2021176057A1 (en) 2020-03-05 2021-09-10 Syngenta Crop Protection Ag Fungicidal compositions
WO2021180975A1 (en) 2020-03-13 2021-09-16 Syngenta Crop Protection Ag Methods of controlling or preventing infestation of plants by the phytopathogenic microorganism corynespora cassiicola
WO2021180592A1 (en) 2020-03-13 2021-09-16 Syngenta Crop Protection Ag Methods of controlling or preventing infestation of plants by the phytopathogenic microorganism corynespora cassiicola
WO2021180598A1 (en) 2020-03-13 2021-09-16 Syngenta Crop Protection Ag Methods of controlling or preventing infestation of plants by the phytopathogenic microorganism corynespora cassiicola
WO2021180976A1 (en) 2020-03-13 2021-09-16 Syngenta Crop Protection Ag Methods of controlling or preventing infestation of plants by the phytopathogenic microorganism corynespora cassiicola, cercospora sojina and/or cercospora kikuchii
WO2021180974A1 (en) 2020-03-13 2021-09-16 Syngenta Crop Protection Ag Methods of controlling or preventing infestation of plants by the phytopathogenic microorganism corynespora cassiicola
WO2021180596A1 (en) 2020-03-13 2021-09-16 Syngenta Crop Protection Ag Methods of controlling or preventing infestation of plants by the phytopathogenic microorganism corynespora cassiicola
WO2021204857A1 (en) 2020-04-08 2021-10-14 Syngenta Crop Protection Ag Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives
WO2021204822A1 (en) 2020-04-08 2021-10-14 Syngenta Crop Protection Ag Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives
WO2021204855A1 (en) 2020-04-08 2021-10-14 Syngenta Crop Protection Ag Microbiocidal quinoline dihydropyrrolopyrazine derivatives
WO2021213929A1 (en) 2020-04-20 2021-10-28 Syngenta Crop Protection Ag Pesticidally active substituted 1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives with sulfur containing substituents
WO2021219775A1 (en) 2020-04-30 2021-11-04 Syngenta Crop Protection Ag Microbiocidal compounds
WO2021219778A1 (en) 2020-04-30 2021-11-04 Syngenta Crop Protection Ag Microbiocidal compounds
WO2021219810A1 (en) 2020-04-30 2021-11-04 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2021219780A1 (en) 2020-05-01 2021-11-04 Syngenta Crop Protection Ag Microbiocidal compounds
WO2021224102A1 (en) 2020-05-05 2021-11-11 Syngenta Crop Protection Ag Microbiocidal compounds
WO2021224409A1 (en) 2020-05-06 2021-11-11 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2021244950A1 (en) 2020-06-03 2021-12-09 Syngenta Crop Protection Ag Fungicidal compositions
WO2021244952A1 (en) 2020-06-03 2021-12-09 Syngenta Crop Protection Ag Microbiocidal derivatives
WO2021244951A1 (en) 2020-06-03 2021-12-09 Syngenta Crop Protection Ag Fungicidal compositions
WO2022013417A1 (en) 2020-07-17 2022-01-20 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022017975A1 (en) 2020-07-18 2022-01-27 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022043576A2 (en) 2020-08-31 2022-03-03 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022049141A1 (en) 2020-09-01 2022-03-10 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022049144A1 (en) 2020-09-02 2022-03-10 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022048988A1 (en) 2020-09-02 2022-03-10 Syngenta Participations Ag Plant growth regulator compounds
WO2022049146A1 (en) 2020-09-02 2022-03-10 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022053567A1 (en) 2020-09-09 2022-03-17 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022058580A1 (en) 2020-09-21 2022-03-24 Syngenta Crop Protection Ag Microbiocidal compounds
WO2022084346A1 (en) 2020-10-22 2022-04-28 Syngenta Crop Protection Ag Zealactone derivatives as plant growth regulators
WO2022101265A1 (en) 2020-11-13 2022-05-19 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2022157334A1 (en) 2021-01-21 2022-07-28 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022157122A1 (en) 2021-01-22 2022-07-28 Syngenta Crop Protection Ag Method for the control or suppression of phytopathogenic bacteria
WO2022157188A2 (en) 2021-01-23 2022-07-28 Syngenta Crop Protection Ag Pesticidally active heteroaromatic compounds
WO2022207479A1 (en) 2021-03-27 2022-10-06 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives
WO2022207462A1 (en) 2021-03-30 2022-10-06 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
WO2022207665A1 (en) 2021-03-31 2022-10-06 Syngenta Crop Protection Ag Microbiocidal quinoline/quinoxaline benzothiazine derivatives
WO2022219146A2 (en) 2021-04-16 2022-10-20 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
WO2022223376A1 (en) 2021-04-20 2022-10-27 Syngenta Crop Protection Ag Microbiocidal quinoline/quinoxaline isoquinoline derivatives
WO2022233869A1 (en) 2021-05-04 2022-11-10 Syngenta Crop Protection Ag Use of clethodim for insect control
WO2022253645A1 (en) 2021-06-01 2022-12-08 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline derivatives
WO2022253841A1 (en) 2021-06-02 2022-12-08 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfoximine containing substituents
WO2022258481A1 (en) 2021-06-09 2022-12-15 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
WO2022268648A1 (en) 2021-06-24 2022-12-29 Syngenta Crop Protection Ag 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides
WO2023275116A1 (en) 2021-07-02 2023-01-05 Syngenta Crop Protection Ag Use of fluazifop-p-butyl for insect control
WO2023006634A1 (en) 2021-07-27 2023-02-02 Syngenta Crop Protection Ag Method for controlling diamide resistant pests & compounds therefor
WO2023006789A1 (en) 2021-07-29 2023-02-02 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2023012044A1 (en) 2021-08-02 2023-02-09 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2023012081A1 (en) 2021-08-05 2023-02-09 Syngenta Crop Protection Ag Method for controlling diamide resistant pests & compounds therefor
WO2023017016A1 (en) 2021-08-10 2023-02-16 Syngenta Crop Protection Ag Fungicide mixture
WO2023017094A1 (en) 2021-08-10 2023-02-16 Syngenta Crop Protection Ag 2,2-difluoro-5h-[1,3]dioxolo[4,5-f]isoindol-7-one derivatives as pesticides
WO2023021020A1 (en) 2021-08-19 2023-02-23 Syngenta Crop Protection Ag Method for controlling diamide resistant pests & compounds therefor
WO2023061838A1 (en) 2021-10-14 2023-04-20 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives
WO2023072945A1 (en) 2021-10-25 2023-05-04 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2023072849A1 (en) 2021-10-27 2023-05-04 Syngenta Crop Protection Ag Pesticidally active pyridazinone compounds
WO2023072784A1 (en) 2021-10-29 2023-05-04 Syngenta Crop Protection Ag Fungicidal compositions comprising fludioxonil
WO2023072785A1 (en) 2021-10-29 2023-05-04 Syngenta Crop Protection Ag Fungicidal compositions
WO2023089049A2 (en) 2021-11-19 2023-05-25 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives
WO2023094303A1 (en) 2021-11-25 2023-06-01 Syngenta Crop Protection Ag Microbiocidal heterobiaryl amide derivatives
WO2023094304A1 (en) 2021-11-25 2023-06-01 Syngenta Crop Protection Ag Microbiocidal heterobiaryl amide derivatives
WO2023099460A1 (en) 2021-12-02 2023-06-08 Syngenta Crop Protection Ag Fungicidal compositions
WO2023104714A1 (en) 2021-12-10 2023-06-15 Syngenta Crop Protection Ag Pesticidally active pyridazinone compounds
WO2023110710A1 (en) 2021-12-13 2023-06-22 Syngenta Crop Protection Ag Method for controlling diamide resistant pests & compounds therefor
EP4197333A1 (en) 2021-12-15 2023-06-21 Syngenta Crop Protection AG Method for controlling diamide resistant pests & compounds therefor
WO2023110869A1 (en) 2021-12-15 2023-06-22 Syngenta Crop Protection Ag Microbiocidal bicycle heterocyclic derivatives
WO2023111215A1 (en) 2021-12-17 2023-06-22 Syngenta Crop Protection Ag Microbiocidal pyridine-substituted benzothiazine derivatives
WO2023110871A1 (en) 2021-12-17 2023-06-22 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2023110928A1 (en) 2021-12-17 2023-06-22 Syngenta Crop Protection Ag Fungicidal compositions
WO2023118434A1 (en) 2021-12-22 2023-06-29 Globachem Nv Pesticidally active amide compounds
WO2023117625A1 (en) 2021-12-22 2023-06-29 Syngenta Crop Protection Ag Fungicidal compositions
WO2023118011A1 (en) 2021-12-22 2023-06-29 Syngenta Crop Protection Ag Microbiocidal aza-heterobiaryl derivatives
WO2023139166A1 (en) 2022-01-19 2023-07-27 Syngenta Crop Protection Ag Methods for controlling plant pathogens
WO2023148206A1 (en) 2022-02-02 2023-08-10 Syngenta Crop Protection Ag Microbiocidal n-amide derivatives
WO2023148368A1 (en) 2022-02-07 2023-08-10 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2023148369A1 (en) 2022-02-07 2023-08-10 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2023166067A1 (en) 2022-03-02 2023-09-07 Syngenta Crop Protection Ag Microbiocidal pyridazinone amide derivatives
WO2023187191A1 (en) 2022-04-01 2023-10-05 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2023209238A1 (en) 2022-04-29 2023-11-02 Syngenta Crop Protection Ag Fungicidal compositions
WO2023217989A1 (en) 2022-05-12 2023-11-16 Syngenta Crop Protection Ag Alkoxy heteroaryl- carboxamide or thioamide compounds
WO2023247552A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Microbiocidal bicyclic heterocyclic carboxamide derivatives
WO2023247360A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2024008567A1 (en) 2022-07-07 2024-01-11 Syngenta Crop Protection Ag Precision application devices and compositions
WO2024018016A1 (en) 2022-07-21 2024-01-25 Syngenta Crop Protection Ag Crystalline forms of 1,2,4-oxadiazole fungicides
WO2024017788A1 (en) 2022-07-22 2024-01-25 Syngenta Crop Protection Ag Solid form of a heterocyclic amide derivative
WO2024022910A1 (en) 2022-07-26 2024-02-01 Syngenta Crop Protection Ag 1-[1-[2-(pyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]-3-[2,4-dichloro-5-phenyl]urea derivatives and similar compounds as pesticides
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024038053A1 (en) 2022-08-16 2024-02-22 Syngenta Crop Protection Ag New use of pydiflumetofen
WO2024056732A1 (en) 2022-09-16 2024-03-21 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
WO2024068656A1 (en) 2022-09-28 2024-04-04 Syngenta Crop Protection Ag Fungicidal compositions
WO2024068655A1 (en) 2022-09-28 2024-04-04 Syngenta Crop Protection Ag Fungicidal compositions
WO2024068838A1 (en) 2022-09-28 2024-04-04 Syngenta Crop Protection Ag Fungicidal compositions
WO2024068947A1 (en) 2022-09-30 2024-04-04 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2024068950A1 (en) 2022-09-30 2024-04-04 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives

Also Published As

Publication number Publication date
AU2016239067A1 (en) 2017-10-19
US20190082691A1 (en) 2019-03-21
PE20180175A1 (en) 2018-01-22
MX2017012709A (en) 2017-11-23
US20180084780A1 (en) 2018-03-29
EA201792151A1 (en) 2018-04-30
CA2981379A1 (en) 2016-10-06
US10231453B2 (en) 2019-03-19
TW201702229A (en) 2017-01-16
AR104178A1 (en) 2017-07-05
CR20170445A (en) 2018-02-06
BR112017021183A2 (en) 2018-07-03
KR20170132315A (en) 2017-12-01
IL254773A0 (en) 2017-12-31
JP2018516237A (en) 2018-06-21
US10568326B2 (en) 2020-02-25
UY36603A (en) 2016-10-31
ZA201707424B (en) 2019-07-31
EP3277666A1 (en) 2018-02-07
CO2017010006A2 (en) 2018-01-05
PH12017501808A1 (en) 2018-04-23
ECSP17065502A (en) 2017-10-31
GT201700210A (en) 2018-12-06
CL2017002480A1 (en) 2018-05-11
CN107635968A (en) 2018-01-26

Similar Documents

Publication Publication Date Title
US10568326B2 (en) 5-substituted imidazole derivatives
WO2016156282A1 (en) Novel triazole compounds for controlling phytopathogenic harmful fungi
WO2017029179A1 (en) Triazole derivatives, intermediates thereof and their use as fungicides
CA2909213A1 (en) Novel triazole derivatives
US10246420B2 (en) Pyrazole derivatives
AU2016239175A1 (en) Triazole derivatives as pesticides and plant growth regulators
EP3519391A1 (en) Novel 5-substituted imidazolylmethyl derivatives
WO2016156311A1 (en) Triazole derivatives as pesticides and plant growth regulators
EP3277674B1 (en) Triazol derivatives as fungicides
WO2016050769A1 (en) Novel triazole derivatives useful as fungicides
CA3038401A1 (en) 5-substituted imidazolylmethyloxirane derivatives as fungicides
AU2017327356A1 (en) Active compound combinations comprising a 5-substituted imidazole derivative
WO2016156284A1 (en) Novel pyridine compounds for controlling phytopathogenic harmful fungi
OA18593A (en) Triazole derivatives, intermediates thereof and their use as fungicides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16711859

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 254773

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2981379

Country of ref document: CA

Ref document number: 2017551271

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2016711859

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15563414

Country of ref document: US

Ref document number: 12017501808

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: NC2017/0010006

Country of ref document: CO

Ref document number: 001646-2017

Country of ref document: PE

Ref document number: MX/A/2017/012709

Country of ref document: MX

Ref document number: CR2017-000445

Country of ref document: CR

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017021183

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2016239067

Country of ref document: AU

Date of ref document: 20160329

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201792151

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20177031654

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201710618

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 112017021183

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20171002